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Abstract 
 
The aim of this thesis was to understand the process of reproductive decision-
making in women with maternally inherited mitochondrial disease. It 
demonstrates the uncertainty fundamental to the experiences of women with 
mitochondrial DNA mutations (a subsection of women with mitochondrial 
disease). This uncertainty manifests in the personal accounts of their condition, 
as well as in relation to their reproductive decision-making.  
Twenty semi-structured qualitative interviews were conducted with eighteen 
women with mitochondrial DNA mutations, sampled via their connection to a 
mitochondrial disease specialist service in North East England. Retrospective, 
prospective and hypothetical questions were utilised in data collection. The data 
generated from the study, which was informed by constructivist grounded theory, 
can be organised into two central areas, both of which can be related back to 
uncertainty. The first area relates to how women harbour the desire for a healthy 
biologically related child. The second area features decision-making, which within 
the context of maternally inherited mitochondrial disease, is essentially the 
process by which women consolidate their desires for healthy children, and how 
they negotiate risk. The women’s accounts highlight social aspects of uncertainty 
that features in their reproductive decision-making, in contrast to the current 
literature that focuses on more clinical aspects of uncertainty. In addition, they 
also demonstrate how educational and employment institutions struggle to 
manage the uncertainty inherent in mitochondrial disease.  
An important outcome of this thesis, therefore, has been the adaptation of a 
sociological conceptual model to address this inconsistency. The model can be 
utilised by clinicians in discussions with women to comprehensively explore the 
process of decision-making in the face of uncertainty. This thesis demonstrates 
how the decision-making process is necessarily social, and highlights the 
importance of sociological understanding of uncertainty in the mitochondrial 
disease reproductive advice clinic.  
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Chapter 1. Introduction  
 
This thesis explores the experiences of women with mitochondrial DNA (mtDNA) 
mutations. Findings from the study are structured across this thesis in a broadly 
chronological order, reflecting the women’s accounts of their journey to diagnosis, 
their experiences of being diagnosed and the impact of that diagnosis. This 
structure allows for the exploration of the embodied, clinical and social 
experiences women have of their condition and enables the development of a 
reproductive decision-making conceptual model.  
In particular, this thesis illuminates how uncertainty underpins women’s 
experiences of mtDNA mutations. In doing so, it illustrates how the biomedical 
model of illness struggles to incorporate the full scope of this uncertainty, as do 
important social institutions relating to education and employment. This thesis 
advocates taking a more sociological approach to uncertainty in mitochondrial 
disease, by demonstrating how the reproductive decision-making process is 
necessarily social and extends beyond the scope of more clinical conceptions of 
uncertainty. 
This chapter presents an overview of current understandings of mtDNA mutations 
as a rare disorder that has no curative treatment pathway and, in terms of family 
planning, has an extensive but finite set of reproductive options. It also outlines 
elements of the social, emotional and financial consequences of experiencing a 
rare disorder. The research aims and main research questions are followed by a 
short statement reflecting on the originality and potential impact of the conceptual 
model developed in the process of conducting this research. This chapter 
concludes with a summary of each of the remaining chapters. 
1.1 Mitochondria, Mitochondrial Function  
Mitochondria are double membrane structures found in all nucleated cells and 
their principal function is the production of adenosine triphosphate (ATP) through 
oxidative phosphorylation (OXPHOS), or more simply termed, the production of 
cellular energy. Mitochondria are a cell organelle and comprise of an outer 
membrane, inner membrane, inter-membrane space, cristae space and the 
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matrix in which many cellular processes occur (Taylor & Turnbull, 2005). During 
the process of OXPHOS  a series of chemical reactions take place within the 
inner membrane where electrons are transferred across a number of complexes 
that result in the transformation of adenosine diphosphate (ADP) to ATP and H20 
(water) generation (Gorman et al., 2016) (Figure 1.1). To compare ATP 
generation from the mitochondrial respiratory chain to that of glucose 
metabolism, the mitochondrial respiratory chain produces 38 molecules of ATP to 
the 2 molecules produced via glycolysis (Berg et al., 2002). In addition to 
OXPHOS , mitochondria play a fundamental role in normal cellular function; 
hence dysfunctional mitochondria can have devastating consequences 
(Schapira, 2006). The density of mitochondria found within a cell denotes its 
energy requirements, with more mitochondria in high energy demanding tissues 
such as the heart, brain and skeletal muscle (Schapira, 2006).   
 
 
Figure 1.1 Schematic representation of oxidative phosphorylation showing 
complex I-IV of the respiratory chain and complex V and ATP synthase (Gorman 
et al., 2016) Used with permissions.  
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1.2 Mitochondrial Genetics  
Mitochondria are the only other source of extra-chromosomal deoxyribonucleic 
acid (DNA) in a cell (with the exception of plant chloroplasts) and are under dual 
genetic control, that is controlled by their own DNA (mtDNA) and DNA from the 
nucleus (nDNA) (Taylor & Turnbull, 2005). Mitochondrial genetics is unlike 
Mendelian patterns of inheritance, exhibiting uniparental inheritance with mtDNA 
being inherited from mothers only, leading to the term maternally inherited 
mitochondrial disorders that I will use throughout this thesis. The predominant 
and accepted theory is of maternal inheritance only, although there has been a 
single case report of paternal inheritance of mitochondria in an affected individual 
(Schwartz & Vissing, 2002) which has never been duplicated. 
1.2.1 Mitochondrial Genome 
Human mtDNA is a double stranded circular DNA composed of ~16.6-kb (16,569 
kilo-bases) with a total of 37 genes. This is in comparison to the nucleus, which 
has 3.3 billion base pairs and codes for between 20,000 and 30,000 genes 
(Taylor & Turnbull, 2005). Mitochondrial DNA encodes for 13 essential 
polypeptides for the OXPHOS system, 2 ribosomal RNA’s and 22 transfer RNAs 
(Gorman et al., 2016; Taylor & Turnbull, 2005) (Figure 1.2). 
 4 
 
 
 
Figure 1.2 Human mitochondrial genome. Comprising of ~16.6-kb circular double 
stranded DNA molecule including annotated coding regions (Gorman et al., 2016) 
Used with permissions.  
 
1.2.2 Heteroplasmy  
Given the variation in the number of mitochondria present in a single cell, there 
can be thousands of copies of mtDNA. The mtDNA copy number in mature 
human oocytes is reported to be between 15,000 (Wai et al., 2010) and 
1,600,000 (Greggains et al., 2014). Homoplasmy is the term given when all 
copies of the mitochondrial genome are identical. Heteroplasmy is the term used 
to denote the mixture of mutated and wild-type mtDNA, this percentage can 
determine whether or not the cell functions correctly (Gorman et al., 2016). Some 
mitochondrial mutations can be homoplasmic, in that they affect all copies of the 
mitochondrial genome whereas others are heteroplasmic, in that the mutation 
only affects a proportion of copies (Taylor & Turnbull, 2005). The higher the 
heteroplasmy level or percentage the higher the number of mutated mtDNA in a 
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cell, the lower the percentage of heteroplasmy, the higher the wild-type or 
‘normal’ mtDNA. Women who carry a homoplasmic mutation will therefore pass 
their mutation onto their child at a similarly high level, whilst those women with a 
heteroplasmic mutation face greater uncertainty with regards to inheritance 
(Taylor & Turnbull, 2005). This is further complicated by the concept of ‘threshold 
effect’, that determines both the clinical phenotype and biochemical defect 
expression and is typically in the range of 60-90% mutant to wild type 
mitochondrial mtDNA (see section 1.2.3). 
Mitochondrial function or disturbances in function are also linked with numerous 
other illnesses including cancer and neurodegenerative disorders including 
Parkinson’s and Alzheimer’s diseases. Variations in mtDNA mutation copy 
number have been observed in human malignancies although the exact 
mechanisms involved are not yet fully understood (Yu, 2011). Links to 
neurodegenerative conditions are complex and thought to be related to 
mitochondrial dynamics (which relates to mitochondria size, shape, movement 
alongside others) as well as the role of mitochondria in aging and the net 
production of reactive oxygen species (ROS) (Reeve et al., 2012; Lin & Beal, 
2006).  
1.2.3 Threshold Effect 
There is a general rule that the more mutated mtDNA present the more severe 
the resultant symptoms. However this is complicated by the concept of ‘threshold 
effect’, which shows that not all tissues are affected in the same way by the same 
level/type of mutation. The threshold effect is observed when a certain 
percentage of heteroplasmy is required for both the presence of clinical and 
biochemical expression of disease (Figure 1.3). The threshold effect can range 
from mutation percentages of 60% to 90% depending on the type of mutation and 
the tissue (Alston et al., 2010; Rossignol et al., 2003; Sciacco., 1994; Tuppen., 
2010) 
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Figure 1.3 Mitochondrial DNA (mtDNA) heteroplasmy and the threshold effect. 
The percentage of mutant mitochondria determines the heteroplasmy level of a 
cell. Wild-type (green circles) maintain normal cellular function until the number of 
mutant mitochondria (red circles) compromises this. This number is the individual 
cell threshold level and is determined by the type of mutation.  
 
1.2.4 Genetic Bottleneck 
The phenomenon of the ‘mitochondrial genetic bottleneck’ accounts for the rapid 
alterations in the heteroplasmy levels in one generation. The prevailing theory is 
that this occurs in early embryonic development where rapid amplification of 
mtDNA during oocyte maturation results in mature oocytes with differing levels of 
mutations (Gorman et al., 2016) (Figure 1.4).  
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Figure 1.4 Mitochondrial genetic bottleneck showing how varied levels of mutant 
and wild-type (normal) mitochondria occur between mature oocytes during oocyte 
maturation and the potential outcomes relating to affectedness of offspring 
(Gorman et al., 2016). Used with permissions.  
 
In relation to this thesis, it is important to understand that both the threshold effect 
and the genetic bottleneck of mtDNA mutations mean that counselling women 
with a known mtDNA mutation is especially complex. The level of uncertainty 
around the, almost impossible, predication of an offspring’s mutation load and 
affectedness is a predominant issue for women interviewed in this study. I will 
now move onto describe how pathogenic mtDNA mutations manifest clinically.  
1.3 Medical Implications of Mitochondrial Disease  
Mitochondrial disease is a group of disorders that are clinically heterogeneous 
and are caused by defects in mtDNA or in the nuclear DNA (nDNA) of a cell that 
affects mitochondrial maintenance (Gorman et al., 2016; Smits et al., 2010; 
Taylor & Turnbull, 2005). They are a clinically and genetically diverse group of 
disorders that are progressive and can be fatal in some circumstances. They are 
essentially the result of insufficient OXPHOS or put more simply, ‘defective 
batteries’ within a cell. I will dedicate the majority of this section to mtDNA 
mutations, but for the clarity understanding of mitochondrial disease as a whole I 
included a summary of nDNA mutations and their clinical presentations.  
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1.3.1 Mitochondrial Mutations  
The incidence of adults with mitochondrial disease due to a pathogenic mtDNA 
mutation is estimated at 9.6 cases per 10,000 with another 10.8 individuals 
thought to be risk of developing mitochondrial disease (Gorman et al., 2015). 
mtDNA mutations can cause varying phenotypes amongst individuals and their 
family members. We will come to see within this thesis (discussed in Chapter 7 
and 8) how the variation in affectedness impacts upon women and their lived 
experiences of mitochondrial disease and how this coupled with uncertainty 
regarding affectedness of children or future children, impacts upon reproductive 
decision making. I will outline briefly the most common mtDNA mutations as they 
also encompass the sample included in this study. I have chosen not to link 
women included in the study to their mtDNA mutation or self-described syndrome 
to protect their anonymity. Also, where not relevant to the context of the particular 
argument, I have chosen not to disclose their individual symptoms or symptoms 
of their relatives. We will also see how the variation in presentation of mtDNA 
mutations results in complex diagnostic pathways for a proportion of participants 
and their relatives (discussed in Chapter 5). The diverse phenotypes and clinical 
presentations resulting from mtDNA mutations are shown in Figures 1.5 and 
Figure 1.6. 
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Figure 1.5 Human mitochondrial genome showing common mtDNA mutations 
and related clinical symptoms (Tuppen et al., 2010). Used with permissions.  
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Figure 1.6 Common clinical presentations of mtDNA mutations divided into 
neurological and non- neurological origins (Gorman et al, 2016). Used with 
permissions.  
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a. Point Mutation m.3243 A>G 
A mutation arising from the nucleotide change A to G at position 3243 in the MT-
TL1 gene is one of the most common mtDNA mutations in the patient population 
and this is reflected in the sample of women who took part in this study (11 of the 
18 women). This point mutation is heteroplasmic and maternally inherited. The 
phenotype of m.3243 A>G is extremely varied although a number of symptoms 
and combined syndromes have been recorded. Clinical syndromes linked to the 
m.3243 A>G mutation include ‘MELAS’ (mitochondrial encephalopathy with lactic 
acidosis and stroke like episodes), ‘MIDD’ (maternally inherited diabetes and 
deafness) and ‘PEO’ (progressive external ophthalmoplegia) (Mancuso et al., 
2013). However not all patients experience symptoms as severe as these 
syndromes, making these definitions troublesome to patients (see Chapter 5 for 
further information). Other clinical symptoms associated with m.3243 A>G 
mutations include gastro-intestinal dysmotility, cognitive impairment, ataxia, 
migraine, seizures and cardiomyopathy with links to sudden adult death 
syndrome; muscle weakness and pain, exercise intolerance and neuropathy 
(Chapman et al., 2014; Finsterer & Frank, 2017; Mancuso et al., 2015; Nesbitt et 
al., 2013; Ng et al., 2016a; Ng et al., 2016b).  
b. Point Mutation m.8344 A>G 
A mutation arising from the nucleotide change A to G at position 8344 in the MT-
TK gene is referred to as m.8344A>G- related mitochondrial disease and 
associated with the clinical phenotype ‘MERRF’ (myoclonic epilepsy with ragged 
red fibres), although it is important to note that pathogenic variants on other 
genes are also attributed to this phenotype (Gorman et al., 2016; Taylor & 
Turnbull, 2005). This point mutation is heteroplasmic like m.3243 A>G. The 
MERRF phenotype includes primarily epilepsy, ataxia, weakness and dementia 
but has been linked with myoclonus (brief involuntary twitching), muscle 
weakness, pain and muscle wasting, hearing loss, cognitive impairment, multiple 
lipomatosis, neuropathy, migraines, exercise intolerance, optic atrophy, short 
stature and cardiomyopathy (Shoffner et al., 1990; Mancuso et al., 2013).  
c. Point Mutation m.11778 G>A and m.3460 G>A 
Both point mutations m.11778 G>A and m.3460G>A are linked to the clinical 
phenotype of optic neuropathy and the clinical syndrome of ‘LHON’ (Leber’s 
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Hereditary Optic Neuropathy).  These mutations are found on two separate 
genes, with m.11778 G>A located on the MT-ND4 gene whereas the m.3460 
G>A is located on the MT-ND1 gene. LHON has also been associated with a 
third mutation on MT-ND6 gene, m.14484 T>G. All three mutations are 
considered both homoplasmic and heteroplasmic. (Gorman et al., 2016; Taylor & 
Turnbull, 2005). As noted above, children of women with a homoplasmic mutation 
are guaranteed to pass their mutation onto their child, although this transmission 
does not denote the affectedness of a child at the same high level, with males 
being considered to be at greater risk of visual loss then females (50 % in males 
verses 10 % in females) (Yu-Wai-Man et al., 2009).  Symptoms associated with 
these mutations may also include bilateral painless vision loss, dystonia, cardiac 
pre-excitation syndromes and multiple sclerosis- like syndrome (Harding 
Syndrome) (Gorman et al., 2016; Pfeffer et al., 2013; Yu-Wai-Man et al., 2008).  
d. Single Large Scale Deletions  
Single large scale mtDNA deletions are commonly referred to as ‘single deletions’ 
and are often described as sporadic in their nature with the risk of maternal 
inheritance thought to be the lowest of any other mitochondrial mutation, with the 
risk to children of affected mothers recorded as 4.11 % (Chinnery et al., 2004).  
These deletions are just that, in that a proportion of the mitochondrial genome is 
deleted or rearranged and can result in varied phenotypes, including clinical 
syndromes ‘Person Syndrome’ in children and ‘Kearns-Sayer Syndrome (KSS)’ in 
adults (Gorman et al., 2016). Symptoms linked to single deletions include 
progressive external ophthalmopelgia (PEO), pigmentary retinopathy 
(progressive visual impairment), increased cerebrospinal fluid protein levels, 
cerebellar ataxia, cardiac conduction abnormalities, myopathy, diabetes, 
deafness, bulbar weakness (due to impaired function of cranial nerves) and 
dementia in adults with additional symptoms (Gorman et al., 2016; Holt et al., 
1989; Kearns & Sayer, 1958). Symptoms observed in children include 
sideroblastic anaemia (related to impaired bone marrow function to produce 
‘normal’ red blood cells) that is associated pancreatic dysfunction, 
pantocytopenia (reduced blood cell count of red, white and platelet cells) and 
renal tubulopathy (impaired renal tubule function in the kidneys) (Gorman et al., 
2016; Rotig et al., 1989; Rötig et al., 1995).  
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1.3.2 Nuclear Mutations  
Mutations and clinical symptoms arising from nDNA mutations are not the focus 
of this study. However to enable a more complete view of mitochondrial disease I 
provide a brief overview. The difference between the aetiology of mutations is 
naturally very important to treating clinicians although we will come to see that 
upon initial diagnosis and information seeking activities patients often confuse 
their mutations origin (discussed further in Chapter 5).  
Identification of nDNA mutations had been especially difficult up until the 
introduction of next-generation sequencing, which allowed for proteins that were 
previously thought not to be involved in mitochondrial function to be linked with 
disease (Lightowlers et al., 2015). These disorders, which are also referred to as 
Mendelian mitochondrial disorders, include but are not limited to; mutations that 
affected structure and assembly of the protein complexes involved in OXPHOS, 
mtDNA maintenance genes, mitochondrial translation, lipid metabolism, 
mitochondrial homeostasis, apoptosis, and mitochondrial metabolism 
(Lightowlers et al., 2015). Additional information on genotype and phenotype of 
nDNA disorders can be found in Gorman et al., 2016.  
1.3.3 Pregnancy in Mitochondrial Disease  
There is limited data available on pregnancy and mitochondrial disease, but a 
summary has shown that the most common complications are threatened 
preterm labour and preeclampsia (a condition that includes high blood pressure, 
high levels of protein in urine and swelling of the hands, feet and legs) (Say et al., 
2011). Alongside these, Say and colleagues reported that women experienced 
variation in pregnancy experiences, ranging from asymptomatic, mild symptoms 
that resolved once the child was born and severe symptoms that included issues 
surrounding cardiac conduction (Wolff-Parkinson-White syndrome), persistent 
paraesthesia (a persistent sensation of tickling, tingling, numbness or burning or 
the skin) and focal segmental glomerulosclerosis (a condition that affects the 
kidneys’ filtering units- glomueruli- resulting in cortical scarring) (Say et al.,2011). 
More recently the risk of both threatened preterm labour and preeclampsia have 
also been supported in a patient case study by Nakamura and colleagues 
(Nakamura et al., 2016). The incidence of pregnancy complications were asked 
of women in this study, although these were not notable experiences for the 
 14 
 
 
women and appeared to influence decision making only in exceptional 
circumstances (discussed further in Chapter 8 section 8.6). 
1.3.4 Treatments in Mitochondrial Disease  
Due to the complexity of mitochondrial disease aetiology and clinical variations, 
pharmacological treatments are still in early research phases. Mitochondrial 
disease therapeutic strategies face common challenges associated with rare 
disease drug development including funding barriers, insufficient homogenous 
patient population to power studies and the development of robust assessments 
to measure clinically meaningful outcomes. Treatments for mitochondrial patients 
are predominantly symptom management approaches.  
Treatments targeting specific complications and research treatments are 
summarised by Gorman and colleagues (2016) and include the use of 
compounds that ‘scavenge’ toxins, allogeneic haematopoietic stem cell 
transplantation as well as enzyme replacement and gene therapies.   
There are a number of surgical options available to sub-sets of patients that 
include organ transplantation (although this may be prohibited by the multi-
system presentation of disease but may be beneficial in particular 
mutations/organs), the placement of vagus nerve stimulators to help reduce 
seizure activity in children who are non-responsive to antiepileptic drugs, 
cochlear implants in those patients with hearing impairment and the positioning of 
cardiac pacemakers and defibrillators (Parikh  et al., 2009). 
High doses of dietary supplements are often routinely provided to patients, who 
collectively refer to them as ‘mito cocktails’ (mitoACTION, 2008). These include 
supplements that play multiple roles in energy production within a cell such as  
Coenzyme Q10 (CoQ10 or ubiquinone), Riboflavin (B2 vitamin), creatinine, L-
Arginine, L- Carnitine and Folic acid (El-Hattab et al., 2017; Goldstein & Wolfe, 
2013; Parikh et al., 2009). In most cases their efficacy has not been tested in a 
clinical trials with mitochondrial disease patients (with exception of small studies 
of creatinine and L Arginine), with optimal dose regimes remaining unknown 
(Parikh et al., 2009). 
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Advances in understanding the natural history of specific mutations can allow 
counselling of patients in relation to their lifestyle such as diet and exercise. 
Increased understanding of gut dysmotility can lead to patient specific dietary 
advice as well as the use of pharmacological treatments of constipation for 
example, although dietary interventions requires further investigation in the 
human setting (Gorman et al., 2016).  
Despite the above approaches and on-going research into specific treatments 
many patients remain frustrated with the lack of specific treatment available to 
them; the uncertainty surrounding the availability of future targeted treatments is 
highlighted by one woman in particular in this study (discussed further in Chapter 
6 section 6.2.1). Such uncertainty, as well as that faced by patients in relation to 
how their disease burden may alter in the future, underpins their experience of 
mitochondrial disease. Concerns relating to women’s ability to parent in the future 
also feature in their reproductive decision-making. I will now move on to discuss 
the social implications of mitochondrial disease.  
1.4 Social Implications of Mitochondrial Disease   
Very little is found in the literature in relation to the experiences of those living 
with a mitochondrial disorder and its impact. Although the primary focus of this 
study was to examining the impact of mtDNA disease on reproductive decision-
making, data highlighted that the uncertainty posed by the disorder influenced 
other areas of women’s lives (discussed further in Chapter 6).  
1.4.1 Work and Education  
Explicit investigation into the impact of mitochondrial disease on work and 
education is not present in the literature. Challenges facing those with 
mitochondrial disease are the variations in symptom type and severity. Some 
people experience symptoms that can have major impact upon their ability to 
complete every day tasks meaning that they require devices such as wheelchairs 
and hearing aids, which clearly mark them as having some form of illness or 
disability. Others may have symptoms that are less obvious or ‘invisible’ to others 
as well as those that are mildly affected and describe marginal or no impact on 
daily living. For those managing symptoms such as severe fatigue, hearing loss, 
ataxia, syncope, visual disturbances and diabetes this study highlights their 
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disruptive nature and how they have impacted upon work and education. The 
impact of illness both acute and chronic has been shown to affect key life 
trajectories such as education, with the notion of ‘lives interrupted’ at key 
transition points such as school exams (Grinyer, 2007). Disability, poor physical 
and mental health have also been shown to correlate with financial stress (Jeon 
et al., 2009). With rare disease and chronic illness said to have a significant 
negative impact on a sufferers finances (Barlow et al., 2007). Drawing on 
sociological theories of the impact of chronic illness on an individual (see Bury 
(1991) and Williams (2000) for review of key concepts), women’s experiences of 
mitochondrial disease can be viewed as a biographical disruption, which is 
discussed further Chapter 6.  
1.4.2 Family Relationships  
The predominant evaluations of the impact of mitochondrial disease on families 
has been conducted via quantitative or clinical descriptive assessment of parents, 
in particular mothers, around caregiving to affected children (Kim et al., 2010; 
Read & Calnan, 2000; Senger et al., 2016). In one study, mothers of children 
affected by mitochondrial disease were compared with those with intractable 
epilepsy; it was found mothers of children with mitochondrial disease had 
significantly higher caregiver burden, a poorer quality of life, and higher levels of 
depression and anxiety than those with intractable epilepsy (Kim et al., 2010). It 
is postulated that this may result from the maternal inheritance of the disorder, 
with calls for accurate information to be provided to caregivers to help combat 
anxiety (Kim et al., 2010). Investigation into the impact of caring for a child 
affected by a mitochondrial disorder (aetiology not specified) has also been 
conducted by Senger et al (2016) through an online survey of parents, where 
respondents were 95% mothers and 5% fathers. Respondents to the survey 
reported that children had multi-organ involvement, visited several specialists and 
were subjected to periods of hospitalisation resulting in increased stress indictors 
in parents attempting to manage their child’s disease outweighing those levels 
seen in other chronic childhood illnesses. The authors suggest that stress 
experienced by parents may result from the uncertainty involved in the prolonged 
diagnostic pathways from symptom onset to diagnosis (Senger et al., 2016). The 
impact of uncertainty and its link to emotional distress, anxiety and depression is 
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discussed further in Chapter 2 section 2.3. Identifying specific stressors for 
parents may assist clinicians in supporting families with an affected child and 
provide care to the entire family unit (Senger et al., 2016).  
1.4.3 Social Relationships  
Empirical research examining the impact of mitochondrial disease on social 
relationships, such as friendships has not been discussed in the literature to date. 
Lack of high quality relationships has been associated with both physical and 
psychological ill health (Landsford et al., 2005). The impact of illness on 
friendships networks has been shown to leave those affected feeling isolated as 
peers continue with life as normal, whereas the affected person may struggle to 
maintain social contact (Grinyer, 2007). Although this study did not set out to 
explore the impact of mitochondrial disease on these relationships, accounts of 
women’s relationships outside their immediate family were negatively affected 
due to the uncertainty of their disease burden (Chapter 6). 
1.5 Reproductive Options in Maternally Inherited Mitochondrial Disease  
Thorburn and Dhal (2001) argue that the ‘ultimate’ reproductive choice made by 
couples with a known mtDNA mutation will ‘depend on the attitudes of the couple 
influenced by cultural and religious traditions’ (p105). There are a number of 
reproductive options available to women with maternally inherited mitochondrial 
disease, which are discussed in detail in Chapter 3. Options include genetic 
counselling, conception without medical intervention, voluntary childlessness, 
adoption, ovum (egg) donation, surrogacy (both partial and complete), prenatal 
testing, pre-implantation genetic diagnosis (PGD) and newly licenced 
mitochondrial donation. An aim of this study was to provide an in-depth 
exploration of the ideas and preferences of women with whom these of 
reproductive options are available, in contrast to the professional discourse that 
dominates existing literature.  
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1.6 Research Aims  
1.6.1 Primary Objective  
The main objective of this qualitative study was to interview women with 
maternally inherited mitochondrial disease and investigate their experiences of 
reproductive decision-making.  
This study sought to specifically explore the following: 
• Women’s experiences of living with a diagnosis of maternally inherited 
mitochondrial disease  
• Women’s knowledge about the risk of transmission to their children, 
genetic testing and reproductive techniques. 
• The impact of health professionals, family and other information sources 
on reproductive decision-making 
• Women’s information needs  
1.6.2 Primary Outcome  
The primary outcome of this study was to inform the development of a patient 
pathway and provide a conceptual model of decision-making (Figure 1.7) to 
support discussions of reproduction with women who have maternally inherited 
mitochondrial disease. The conceptual model may also be helpful in the 
discussion with couples with known nuclear mitochondrial disorders.  
1.7 Contribution of Study   
As outlined above there is limited data on patient experiences of living with 
mitochondrial disease and scarce empirical data on the views of women with 
maternally inherited mitochondrial disease regarding available reproductive 
options. In exploring women’s ideas and preferences of these options and the 
development of a conceptual model of reproductive decision-making it became 
evident that women’s social, everyday, experiences of mitochondrial disease 
were fundamentally important to their decision-making. This thesis offers insight 
into women’s diagnostic journeys and their complex nature from a woman’s 
perspective as well as offering an understanding of the impact of mitochondrial 
disease on their lives. This provides important context to women’s lives, which in 
turn contributes to reproductive decision-making. This work has allowed for the 
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adaptation of an existing sociological model of decision-making (Downing, 2005). 
The adapted model shows how risk is made sense of and negotiated by women 
with a known pathological mtDNA mutation. The attribution of risk into three 
domains - acceptance, modification and avoidance - determines how women 
proceed in their reproductive decision-making. Those women who choose to 
accept their individual risk continue with conceiving a child without engaging in 
interventional options, those who wish to modify risk have a preference to engage 
in interventional options, where as those who are risk averse choose not to have 
a child or have further children.  
 
 
 
 
 
 
 
 
 
 
 
 
 20 
 
 
 
 
Figure 1.7 Conceptual Model of Reproductive Decision Making In Maternally Inherited Mitochondrial Disease (adapted from 
Downing (2005)) 
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1.8 Chapter Summaries  
This thesis is centred on uncertainty as fundamental to the experiences of 
women with maternally inherited mitochondrial disease. Uncertainty occurs in 
relation to their own or their family members’ experience of the disease and in 
their own reproductive decision-making. The introduction has provided an 
overview of mitochondria, their functions and their genetics that result in the 
(biomedical) uncertainty of predicting inheritance risk. I have discussed the 
known medical implications of mitochondrial disease and highlighted the gaps in 
knowledge surrounding the social implications of mitochondrial disease. I have 
also outlined the research aims and the primary unique contribution of this thesis 
a conceptual model of reproductive decision-making in maternally inherited 
mitochondrial disease.  
Chapter 2 Literature Review  
In this chapter I present an overview of the key issues that this thesis interacts 
with. These include decision-making in the clinic, understandings of risk and 
uncertainty in reproduction, reproductive decision making in the context of a 
known genetic disorder, notions of kinship, parenthood and genetic relatedness 
and the implication that assisted reproductive technologies are purposed to have 
on these.  
Chapter 3 Reproductive Options  
In this chapter I present each of the available reproductive options, providing 
where relevant, the clinical technique involved as well a summary of the key legal 
and social considerations of each option. This chapter highlights how there is 
limited empirical research on the views and preferences of women with a known 
pathological mitochondrial mutation regarding each option and their subsequent 
reproductive decision-making. 
Chapter 4 Methodology and Methods 
In this chapter I outline the methodology used within this study, as well as the 
practical approach to conducting the study. I explore the ethical issues that 
presented prior to and during the course of study and how these were addressed 
and managed. I introduce the women who took part in the study, how purposive 
sampling was employed within the study and the practicalities of study interviews. 
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I describe my approach to maintaining the anonymisation of women, their family 
members and the health professionals they encountered. A key strength of this 
study is that 20 semi-structured interviews were collected over a period of three 
years, in which the political and regulatory landscape changed in regards to 
mitochondrial donation as an option for women with maternally inherited 
mitochondrial disease. I discuss how data was collected, analysed and 
interpreted using aspects of grounded theory and show a step-by-step process of 
how data was organised into codes and categories. I also reflect on my position 
as a researcher and how my personal and research backgrounds have shaped 
elements of the collection and analysis of data. Finally I show the developmental 
process that led to the proposed conceptual model of reproductive decision-
making (Figure 1.7) specific to women with maternally inherited mitochondrial 
disease, showing early versions of the model and how these were super imposed 
into Downing's (2005) existing model of responsibility in reproductive decision-
making in Huntington’s disease.  
Chapter 5 Diagnostic Pathways: Women’s Practical Experiences  
In this chapter I show the complex and varied diagnostic pathways experienced 
by women. These pathways were experienced directly by women presenting with 
symptoms that resulted in them seeking medical assistance, where as others 
were diagnosed via an affected family member. I show that experiences of 
mitochondrial disease can pre-exist diagnosis for women and their family 
members, with symptoms often manifesting from childhood as well as being 
multi-generational.  I discuss that delays in diagnosis prevent women who have 
had symptoms from the legitimisation that the ‘sick role’ (Parsons, 1951) affords 
them and how women experience a sense of relief upon receiving a diagnosis. I 
present the experiences of mothers whose children are affected by mitochondrial 
disease and how their child’s diagnosis led to their own as well as highlighting 
that not all women experienced symptoms prior to diagnosis. Throughout the 
chapter I discuss the relevance of Andersen’s model of total patient delay 
(Andersen et al.,1995) and how it can be applied to the aspects of diagnosis 
delay in mitochondrial disease but that it cannot address the complexities 
experienced by all women.  
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Chapter 6 Social Implications of Diagnosis 
In this chapter I discuss the short and long-term social impacts that receiving a 
diagnosis has on women. I first discuss the initial response to receiving a 
diagnosis and how for some women the uncertainty posed by limited information 
about their prognosis can lead to the fear that they or their family member have a 
life-limiting condition. I examine women’s information seeking activities and how 
they disclose (or choose not to disclose) their diagnosis. Following this I describe 
the long-term impact of their diagnosis on social relationships, emotional support, 
education and work. I conclude with how receiving a diagnosis affects the nature 
of some women’s relationships with health care professionals.   
Chapter 7 Reproductive Options: Searching for the Healthy and Biologically 
Authentic Child  
In this chapter I discuss the core preference for most, but not all women is for ‘my 
healthy child’. This results in mitochondrial donation being the most favourable 
reproductive option for many women. Mitochondrial donation enables biological 
parenthood for both parents whist combating uncertainty related to the child –
centred risks, the potential affectedness of a future child. Other reproductive 
options were either not considered or considered as an interim or last option, with 
ideas of social and biological kinship and parenthood key issues in women’s 
ideas and preferences for reproductive options. This chapter highlights that 
reproductive decision-making for these women sits in a wider framework, in 
which values and preferences are one of a number of influential factors.  
Chapter 8 Reproductive Decision Making in Maternally Inherited 
Mitochondrial Disease: Conceptual Model  
In this chapter I consolidate the findings from this study, organising them into 
influential factors and elements that make up the proposed conceptual model. 
These factors include women’s awareness of inheritance risk, made up of their 
lived experience, factual awareness and women’s assessment of risk, most 
notably child-centred risk as well as risks relating to parenting ability and 
pregnancy complications. Additional elements of consideration include women’s 
preferences towards reproductive options, their thoughts surrounding feelings of 
guilt and responsibility in the context of the maternal inheritance of mtDNA 
mutations and for some their religious beliefs. This chapter discusses how 
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consideration of these enables women to establish themselves as responsible 
decision makers, which in turn impacts upon their reproductive decisions. 
Chapter 9 Discussion, Recommendations and Conclusion  
This final chapter begins with a summary of the main findings presented in this 
thesis and discusses the implications for women with mtDNA mutations. 
Implications are divided between those relating to reproductive decision-making 
and wider social implications in reference to existing literature. Within this chapter 
I critically assess the strengths and limitations of the study whilst discussing 
areas of interest that merit future research, in both reproductive decision-making 
and the broader experience of living with mitochondrial disease. Finally I make 
recommendations to clinical practice and commissioning policy as a result of 
these findings.
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Chapter 2. Literature Review 
 
2.1 Introduction 
This chapter presents an overview of the literature that surrounds key issues 
pertinent to this thesis. At the core of this thesis is the impact of uncertainty on 
women with mtDNA mutations, both in living with the disorder and in relation to 
their reproductive decision-making. Uncertainty surrounding predicting the 
affectedness of children conceived by mothers with a known mtDNA mutation 
means that women are faced with making reproductive decisions with limited 
clinical information; therefore decision-making is largely informed by social 
elements. In the first section of this chapter I outline the principals of decision-
making in the clinic and how risk and uncertainty is defined and understood in 
reproduction and decision-making. I discuss reproductive decision-making in the 
context of genetic disorders, drawing on comparisons in the literature surrounding 
Mendelian genetic disease. In the final section I review kinship, parenthood and 
genetic relatedness and how assisted reproductive technologies (ART) have 
been said to impact upon these.   
2.2 Perspectives of Decision Making in the Clinic 
Over the last 300 years, relationships between a doctor and patient were 
considered to be paternalistic, rooted in the belief that doctors are best placed to 
make decisions for their patient and dates back to Hippocratic traditions (Miles, 
2009; Truog, 2012). This doctor–patient relationship has been compared to that 
of a parent and child and by upholding this perspective it enabled doctors to 
retain their social status as indispensible (Chin, 2002). Chin (2002) notes that 
although the transition was slow in medicine, movement away from this 
perspective can be attributed to the rise in Western libertarianism, whereby many 
areas of society began to denounce decision-making made by those in a position 
of authority such as religious and political institutions. The paternalistic belief that 
a doctor has overriding authority in the treatment of their patient is evident in 
Chin’s (2002) comparison between physicians’ code of ethics documents from 
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1847 and 1990, which showed that the prompt and implicit obedience of a patient 
was later replaced with a patients right to make a decision and their right to 
refuse or accept treatment.  
Truog (2012) notes that the shift in medicine to an idea of an autonomous patient 
can be linked to the right-based movements of the 1960’s, with Veatch describing 
a social revolution through the idea that everyone should be treated equally, that 
healthcare should be for all and not only those who are able to afford access 
(Veatch, 1972 cited by Stiggelbout et al., 2015: p1173), whilst Charles and 
colleagues argue that this shift occurred in the 1980’s (Charles et al., 1999: 
p652). However, general agreement exists on the reasons as to why the 
paternalistic approach in medicine was dominant for so long: doctors were seen 
as best placed to assess ‘risk’ versus ‘benefit’ of treatment; there were limited or 
small number of available existing treatments for particular concerns; they had 
access to the most up to date knowledge of an illness; that they were invested in 
restoring the health of their patient and were working within a professional code 
of ethics (Charles et al., 1999). Although largely considered out-dated and an 
unethical approach in medicine as a whole, the paternalistic custom is still 
practiced in situations where a patient is not considered to have capacity to make 
a medical decision. These paternalistic acts are debated in cases of patients 
refusing life saving treatment (Bingham, 2012), end of life care (McNamara, 
2004), emergency care (Erbay et al., 2014; Clarke et al.,1980), compulsory 
admission or detention for psychiatric illness (Fistein et al., 2016) and dementia 
and Alzheimer’s disease (McBrien, 2007).  
Emanuel and Emanuel (1992) described three other types of doctor-patient 
relationships in addition to the paternalistic model. These included the 
‘informative model’, where a physician provides technical detailed information 
relating to the patients medical concern, potential treatment pathways and 
associated risks. The patient is then said to be able to make a decision that is 
most closely aligned to their values and does not take into consideration the 
physician’s values. The next model is the ‘interpretative model’, whereby a 
physician provides technical detailed information but also helps a patient ‘to 
elucidate or articulate their values’ and choose the course of action that 
corresponds with these (p2222).  
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Their final model is entitled the ‘deliberative model’, where physicians provide 
information to patients and offer advice as to what they would consider the most 
suitable course of action. Like paternalism these approaches have received 
criticism, with the informative model being considered too distant from the caring 
relationship expected of doctors and that it does not consider uncertainty 
experienced by patients. It is thought that the interpretative model is flawed due 
to the practicalities of time restraints and training of clinicians who may 
subconsciously impose their own values in consultation. Mismatched values 
between the patient and clinician are cited as the primary weakness of the 
deliberative model, as well a variation in values held by different clinicians 
towards a potential course of treatment. These models have largely been 
superseded by the proposal of shared decision-making (SDM); first defined by 
Charles et al (1997) but can be traced back to concept of sharing decision 
making by Veatch 1972 (Veatch, 1972 cited by Stiggelbout et al.,, 2015:p 1172).   
2.2.1 Shared Decision Making  
Those invested in exploring the best approach and practices to decision-making 
in the clinic have reached a general consensus that a shared decision-making 
process enables the right balance of patient autonomy and physician input 
(Stiggelbout, et al., 2015). This concept purports that in order to manage illness 
successfully patients and health care professional should work together. It 
acknowledges the expertise of the physician but also that the patient is the expert 
on their ‘experience of illness, social circumstances, habits and behaviours, 
attitudes to risk, values and preferences’ (Coulter, 1999: p719). The process of 
shared decision-making (SDM) is made up of four key components (Figure 2.1), 
which can be further separated into six elements (situation diagnosis, choice 
awareness, option clarification, discussion of harms and benefits, deliberation of 
patient preference and making a decision) (Stiggelbout et al., 2015; Wieringa et 
al., 2017). The practice of all four components in reality however is said to be 
limited (Stiggelbout et al.,, 2015; Couët et al., 2015). A broader approach to SDM 
and its components has also been proposed by Elwyn and colleagues (2012) and 
is discussed further in Chapter 6 section 6.4, in relation to a participant’s specific 
reproductive decision-making consultation.  
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Figure 2.1 Shared- Decision Making (SDM). Informed by Stiggelbout et al 2015.  
 
By using a SDM approach, relationships between a health professional and their 
patient is said to be strengthened, with patients reporting an increase in physician 
satisfaction and relationship quality when implemented (Sullivan et al, 2006; Shay 
and Lafata, 2015). Despite widespread acknowledgement of the positives of SDM 
by professionals and patients, Shay and Lafata (2015) note there are limited data 
and also methodological issues that complicate assessing the impact of SDM on 
patient behaviour and health outcomes.  
In this section I have described the changing perspectives of decision-making in 
clinical encounters, with emphasis now placed in the active participation of 
patients in deciding what course of action is appropriate for them. Decision-
making in the context of this study is related to the reproductive options available 
to women and includes retrospective, current and hypothetical accounts of 
reproductive decision-making. Women are faced with assessing risk of 
affectedness of future children based on limited clinical information due to the 
complexities of mitochondrial inheritance discussed in Chapter 1. They also have 
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to consider a broad array of reproductive options that include a range of 
emotional, physical and social factors (discussed below in Chapter 3). As a result 
of this, their reproductive decision-making can be seen as largely within the social 
realm, reliant on assessing a number of social factors (Figure 1.7). In the 
following section I will describe an overview of the concepts of risk and 
uncertainty, before introducing reproductive decision-making in the context of 
genetic disorders (section 2.4). 
2.3 Understanding Risk and Uncertainty  
2.3.1 Risk  
Historically concepts of risk where tied to probabilities and the process of losses 
and gains. In recent decades however the term has become linked with concepts 
of danger (Lupton, 1999). Beck (1992) notes that this may have occurred as a 
result of changing society and that risk could be ‘defined as a systemic way of 
dealing with hazards and insecurities induced and introduced by modernisation’ 
(p21). For Beck (1992), risk can only exists when there is knowledge of it. 
In practical terms, Slovic et al (2005) note that risk perception and subsequent 
actions of individuals can depend on their preference for a specific activity or 
outcome. Those who are said to judge the activity or outcome as favourable will 
evaluate the risk as low but the benefits as high. In contrast, those who do not 
find the activity or outcome as favourable will evaluate the risk as high and the 
benefits low, a process defined as affect heuristic. However, such risk perception 
and assessment does not occur in a social vacuum, it is shaped by an 
individual’s culture or subculture (Lupton, 1999). Centrally, definitions of risk are 
under constant revision within an individual, they are influenced by a persons 
core values, societal norms and societal institutions (Parsons and Clarke, 1993). 
There is also debate about the role of emotion in risk perception and assessment.  
For example, Sjöberg (1998) notes that when communicating risk there should 
not be an assumption that an individual’s response will be based on emotions.  
They argue that emotional responses can be superficial and that judgements 
should be based on values and beliefs.  However, Slovic et al (2005) suggest the 
risk can be considered as both a feeling and analysis, the former being rapid and 
instinct driven and the later being grounded in logic and reason. There are many 
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definitions of risk within the literature (Haimes, 2009; Kaplan & Garrick, 1981; 
Renn, 1998; Yates & Stone, 1992) but in the context of this thesis I found the 
inconsistent accounts between risk as ‘emotional’ or ‘void of emotion’ interesting 
due to the factors found to be influential in the reproductive decision-making in 
women interviewed, such as feelings of guilt and responsibility and the impact of 
their lived experience (Chapter 8).  
2.3.2 Risk and Reproduction    
Despite declining mortality rates associated with pregnancy, society has become 
increasingly concerned with risks posed to not only pregnant women, but to all 
women even those who may never become pregnant (Possamai-Inesedy, 2006; 
Ruhl, 1999). The experiences of women and pregnancy in Western societies can 
be described as shaped by the social constructs of risk in which they live. In 
modern day society women are bombarded with information relating to risk 
surrounding reproduction and pregnancies, such as their weight or BMI (Body 
Mass Index), their diet, their alcohol consumption and smoking (Possamai-
Inesedy, 2006; Cedergren, 2004; Torloni et al., 2009; Wisner et al., 2000; 
Lindqvist et al., 1999; Chatenoud et al., 1998; Thorne et al., 2006; Kravetz and 
Federman, 2005; Abel, 1982). With increased pre-natal monitoring, especially in 
those mothers who are at increased risk, pregnancy can now been seen to be a 
continuous analysis of what is normal and what is defective, with a child’s birth 
being reliant on meeting a specified criteria (Remennick, 2006). Pregnant women 
or women attempting to conceive who ‘fail’ to respond to risk appropriately could 
end up being labelled as irresponsible, not only to her own health but that of her 
unborn or planned child (Possamai-Inesedy, 2006).   
Conflicts between clinicians and mothers over risk(s) posed to them and/or their 
unborn child are not uncommon, disagreements can include prenatal activities 
such as smoking or consuming alcohol, treatment regimes for mother and the 
foetus, and labour and delivery methods (Oberman, 2000). Escalation of conflicts 
beyond disagreement can result in pregnant women being the subject of a court 
order to comply with the treatment directed by their doctor, leading to incidents 
known as maternal-foetal conflicts (Epstein, 2013; Oberman, 2000). Despite 
agreement existing that it is ‘impermissible to infringe upon pregnant women's 
autonomy rights’ (Oberman, 2000: p452), maternal-foetal conflict remains highly 
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debated in areas of medicine, bioethics and law (Epstein, 2013; Johnsen, 1986; 
Oberman, 2000). Amongst the large number of prosecutions of women who have 
been said to have caused harm to their unborn child, there are women who have 
had these charges overturned, with women’s autonomy being a key instrument of 
their defence (Epstein, 2013; Johnsen, 1986; Oberman, 2000). It has been 
argued that cases such as these, underpinned by the belief that foetal rights 
outweigh that of the mother could result in the ideas of pregnancy becoming a 
crime (Robertson & Paltrow, 1989), whereby all women are vulnerable to 
prosecution as no one woman is able to provide the ‘perfect womb’ (Paltrow, 
1990 cited by Epstein, 2013: p145).  
The notion of the ‘irresponsible’ or ‘responsible’ mother can be also been seen in 
the context of prenatal diagnostic testing. Some women believe that in order to 
fulfil the role of a ‘good mother’ they must act responsibly and undergo prenatal 
testing, to avoid having an ill child who may suffer in the future (Remennick, 
2006) - parental testing and motherhood is discussed below in Chapter 3 and 2.5 
respectively. Feelings of responsibility to children and other family members is an 
influential factor in the proposed conceptual model of reproductive decision-
making in maternally inherited mitochondrial disease and is discussed in Chapter 
8 section 8.7.2.  
2.3.3 Uncertainty  
Uncertainty in illness has been defined as the ‘inability to determine the meaning 
of illness-related events’ (Mishel, 1988) and can be applied to acute, life-limiting 
and chronic illness (Smith & Lieher, 2014). Uncertainity experienced in illness 
includes the period prior to diagnosis, diagnosis, considerations of treamtents 
and their outcomes (Mishel, 1988). McCormick’s (2002) review of the literature 
provides explanations of the five charteristics that can be viewed as situations of 
uncertainity: ambiguity, vagueness, unpredicatbility, lack of information and 
unfamiliartiy. They note that these are situations in which uncertainty can arise 
from but that uncertainity is the result of a persons reaction to these situations. 
These reactions can be further seperated into three areas: probability, 
temporaility and perception (McCormick, 2002).  
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Providing information relating to the probabilities of outcomes in illness is an 
attempt to address uncertainity and can assist with decision-making. The lack of 
probabilistic information can contribute to uncertaintiy. The temporality of chronic 
illness is also defined as biographical temporality, whereby patients are unable to 
plan for the future and unsure of how their disease burden may 
increase,decrease or fluctate in the future. Perception of events or situtations as 
uncertain is required by the individual, if the person does not see their situation 
as ambigiuos or vague uncertainity does not present itself (Mishel, 1984).  
The presence of high level uncertainty has been linked with high levels of 
emotional distress, anxiety and depression (Carpentier et al., 2007; Chaney et 
al., 2016; Giammanco & Gitto, 2016; Haisfield-Wolfe et al., 2012; McCormick, 
2002; Parker et al., 2016; Reich et al., 2006). Eliminating uncertainty can be seen 
as ‘the solution’, although for many people an unlikely situation. McCormick 
(2002) notes that emphasising the possible postives of uncertainity may be an 
approach for health care professionals to support a patient faced with uncertainty. 
Ideas of ambiguity, vagueness, unpredicatbility, lack of information and 
unfamiliartiy aswell as probability, temporaility and perception echo the 
experience of women with maternally inherited mitochondrial disease. This is 
especially in relation to areas such as their diagnosis, their family members 
diagnosis and reproductive decision-making. As a result, it is uncertainty that 
underpins this thesis due to its prevalence in the many areas of women lives and 
in reproductive decision-making. 
2.3.4 Risk, Reproduction and Decision Making 
Within medicine, negotiating risk of initiation, deferring or refusing treatment is 
complicated by the unpredictability of outcomes. Addressing the inherent 
uncertainty and complexity of decision-making in healthcare has led to the 
development of various approaches to risk analysis, including risk modelling 
(Hunink et al., 2014). Decision diagrams and balance sheets are said to enable 
the individuals to assess the impact of multiple factors that may occur at different 
time points in the context of the bigger picture that the ‘unaided human cannot 
possibly accomplish’ (Hunink et al., 2014 p:ix). Decision-making, predicting and 
negotiating risk in reproduction, pregnancy and parenthood has an extensive 
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literature base. Within this literature is a number of decision-making models and 
aids have been developed and reviewed in areas such as teenage pregnancy 
(Hoskins & Simons, 2015), fertility treatment (McLernon et al., 2014), mode of 
delivery (Schoorel et al., 2014), midwifery care (Noseworthy et al., 2013) general 
obstetric and maternity care (Dugas et al., 2012; Stevens et al., 2016) and 
breastfeeding (Martens & Young, 1997). This thesis argues that the assessment 
of risk for women with maternally inherited mitochondrial disease is 
predominantly informed by social factors due to uncertainty imposed upon them 
by the complex inheritance of mitochondria and therefore inheritance risk, as well 
potential risks in pregnancy and parenting ability. The proposed conceptual 
model of reproductive decision-making (see Figure 1.7) therefore includes 
aspects of risk as socially constructed, dependent on women’s cultures and 
environment, lived experience, emotions, beliefs and values. I will now move on 
to discuss reproductive decision-making in the context of a known genetic 
disorder.  
2.4 Reproductive Decision Making  
Reproductive decision-making in the context of a known Mendelian genetic 
disorder has been extensively researched (see Sivell et al., 2008 for review) but 
reproductive decision making in the context of a known mtDNA mutation less so. 
Complexities surrounding predicting affectedness of a future child/children makes 
the process of decision-making difficult for women, their partners, family 
members and the clinical teams involved (Gorman et al, 2016). Comparisons in 
the literature of reproductive decision-making can be made in part between X-
linked genetic conditions such as certain muscular dystrophies and those that are 
categorised as late onset genetic disorders such as Huntington Disease. Prior 
studies into risk perception, it’s interpretation and retention in genetics can also 
assist understanding how an individual responds to risk including carrier and 
inheritance risk (Sivell et al., 2008; Gigerenzer and Edwards, 2003; Edwards et 
al, 2001; Meiser et al., 2001; Dommering et al., 2010; Parsons and Clarke, 1993). 
Literature surrounding reproductive decision-making processes is also helpful in 
understanding how individuals with a known genetic inheritance risk contemplate 
decisions (Downing, 2005; Lippman-Hand & Fraser, 1979; Myring et al., 2011).  
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2.4.1 Lived Experience  
Lived experiences of a genetic disorder are complex and can be attributed to 
many different aspects of life including relationships with one’s self and those 
around them. Lived experience has been reported to be a major influential factor 
in reproductive decision-making, with a large majority of accounts being of 
negative experiences impacting on decision-making although positive accounts 
are also present in the literature. This experience can also be referred to as an 
‘experiential knowledge’, whereby those making reproductive decisions draw on 
either their own embodied experience of disability or via the close relationship 
they have with an affected individual (Boardman, 2017; Boardman, 2014). Lived 
experiences can be divided into those of closely affected relatives 
(parents/siblings) and the lived experiences of people having an affected 
pregnancy or child/children. Experience of growing up with an affected relative 
can result in individuals wanting to avoid having a child who may also be 
affected. Kay & Kingston (2002) described reports from women who were known 
to be carriers for an X-linked condition, where the experience of living with an 
affected brother strengthened their desire to avoid have an affected child. For 
some people, negative experiences of living with an affected parent (or relative) 
with Huntington’s disease (HD) as a child meant that they not only wish to avoid 
having a child but also distanced themselves from entering into relationships 
(Decruyenaere et al., 2007; Klitzman et al., 2007). 
Lived experience as a parent of an affected child has various influences on 
reproductive decision-making. Parents of affected children are said to remain 
undecided about future reproductive decision-making and have unresolved doubt 
surrounding decisions (Frets et al., 1991). A national survey of reproductive 
issues and carrier screening in cystic fibrous (CF) conducted in the Netherlands 
showed that in 53% (154/288) of couples sampled plans for future pregnancies 
had been influenced by having an affected child, 40% of couples had not been 
influenced and 7% reported not knowing (Henneman et al., 2002). For those that 
reported being influenced 70% did not want to have another affected child, 14% 
were undecided about future pregnancies, 8% reported it easier to decide not to 
have any more children, with the remaining not providing an answer/other 
(Henneman et al., 2002). Myring et al's (2011) study into reproductive decision 
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making also in CF showed that couples in which both the male and the female 
carried a recessive gene for cystic fibrosis (resulting in a 25% chance of an 
affected child) were heavily influence by already having one child with a 
diagnosis of CF or by an affected family member. Finally, Dommering et al's 
(2010) study into retinoblastoma parents showed how they where influenced by 
the burden of disease on their children, wanting to avoid another child undergoing 
painful treatment. 
Parents of affected children are mindful that having another child (affected or 
unaffected) may negatively effect their existing child and so impact that child’s 
requirements (Dommering et al., 2010; Myring et al., 2011). Myring et al’s (2011) 
participants recall opting to have a prenatal test result in subsequent pregnancies 
as they worried about the impact that another affected child may have on their 
existing affected child and the care they are able to provide them, with one 
couple reporting that they would have had a termination had they found out they 
were having another affected child. Couples have also reported worrying about 
the impact an ill sibling would have on their healthy child/children, taking them 
away from that child to meet the demands of a new ‘sick child’ (Dommering et al., 
2010; Myring et al., 2011). Personal experience for these individuals helped them 
to determine if they could parent a sick child or multiple sick children. Parents 
who did feel that they would be able to cope with another child who was affected 
showed a sense of empowerment from their experience (Myring et al., 2011).   
The desire to have a healthy child was stronger in the couples who had had an 
affected child which resulted in them being more likely to have another 
pregnancy, whereas those who had had healthy child were described as content 
and were less likely to have another child (Myring et al., 2011). They reported 
that seven of 13 influential factors in reproductive decision making were attributed 
to lived experience. These could be divided between those with an affected child 
and those without, these included: relational issues - love and loyalty towards first 
child and love of affected family member(s) – health issues - the health of child 
with CF and concerns of cross-infection – external sources of information - 
genetic counselling; internet and other media and issues around ability to cope 
with their first child 
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Lived experience of a genetic disorder, either their own embodied experience or 
that of a family member, including children is an important factor in reproductive 
decision-making in a number of genetic disorders. This is also the true of the 
women interviewed in this study, with lived experience featuring in the proposed 
conceptual model of reproductive decision-making in maternally inherited 
mitochondrial disease.  
2.4.2 Guilt and Responsibility  
Guilt and responsibility are often discussed together in relation to reproductive 
decision-making and although guilt is different from responsibility they seem to be 
intrinsically linked in this context. Feelings of guilt and responsibility surrounding 
the idea of pregnancy and inheritance are well established within the literature 
(Barlevy et al., 2012; Decruyenaere et al., 2007; Dimond, 2013, 2014; Donnelly et 
al., 2013; Downing, 2005; Frets et al., 1991; Hallowell et al., 2006; Kay & 
Kingston, 2002; Klitzman et al., 2007; Raspberry & Skinner, 2011). 
Kiltzman and colleagues (2007) presented a comprehensive list of emergent 
themes surrounding reproductive decision-making in couples with a known HD 
risk. Included amongst these were feelings of ‘guilt’ and ‘blame’. Participants 
stated that they would feel guilt by having a child who was at-risk and that they 
believed that they may feel guilty in the future even if such feelings were illogical. 
They note that such feelings of guilt may be overwhelming with parents feeling 
that they may be blamed in the future. They were also concerned they may be 
blamed if prenatal testing and pre-implantation diagnosis (PGD) (see Chapter 3) 
became common techniques in HD in the future but that the decision to not 
undergo these was taken. However it was also noted that some individuals would 
feel no blame (Klitzman et al., 2007). We see here that change over time is a 
concern both for the potential to feel guilt in the future but also in relation the 
development and acceptance of technologies; change over time is further 
discussed in section 2.4.4. Guilt has also been linked to declining pre-natal 
testing, in that by choosing not to undergo prenatal testing, parents may have 
future feelings of guilt and regret at having had the chance to avoid having a 
affected child (Decruyenaere et al., 2007 p458). Couples making reproductive 
decisions can sometimes be faced with relatives who disapprove of their chosen 
decision with reactions of others being a known influencer on decision making 
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(Frets et al., 1991). Having such disapproving relatives also adds additional 
pressure onto couples (Frets et al., 1991). 
In addition to reports surrounding guilt and blame, the notion of ‘responsibility’ in 
reproductive decision making in HD has also been explored. Responsibility 
towards others was said to constitute considerations to the individuals own 
interest, others’ sense of the individuals responsibilities, input from family and 
health care professionals, costs, and wider ‘moral, religious and political 
obligations’ (Klitzman et al., 2007 p352). This thesis adapts a model of 
responsibilities proposed by Downing (2005), which shows the process in which 
participants in their  study in HD progressed through in order to establish 
themselves as a ‘responsible’ decision maker. Downing’s (2005) full model is 
shown in Chapter 4, section 4.7. Their model incorporates factors and elements 
influential in reproductive decision-making in HD, some of which have been 
retained in the model of decision making in maternally inherited mitochondrial 
disease where as others have been were replaced (see Chapter 4, section 4.7). 
Responsibility in reproductive decision-making has however been shown to be 
transferred outwardly from the individual, with beliefs of predestination or 
predestiny being seen in relation to risk and genetics. This is where an individual 
with a known risk believes that a health outcome is destined or fated to happen. 
The application of this belief in genetics has been termed ‘genetic determination’ 
and has been said to be used by those with knowledge of their genetic risk to free 
them from the responsibility of passing on a genetic condition (Hallowell et al., 
2006 p979). In Hallowell et al’s (2006) study of male BRAC1/2 carriers, some 
men adopted this belief which allowed them to believe that their status as a 
carrier was an ‘unavoidable fact of life’ and to ‘construct themselves and others 
as blameless’ (Hallowell et al., 2006 p979). Understanding guilt, blame and 
responsibility in the context of reproductive decision-making in maternally 
inherited mitochondrial disease is important not only for reproductive counselling 
but also in diagnostic setting for women who may have a child/children and who 
may go on to suffer from these feelings post diagnosis (Chapter 6 section 6.3.2).  
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2.4.3 Perception, Interpretation and Retention of Genetic Risk  
Literature examining how individuals perceive genetic risk is extremely valuable 
in the context of reproductive decision making in maternally inherited 
mitochondrial disease, when risk of affectedness can be complex to make sense 
of for both clinicians and patients. As noted above, definitions of risk are said to 
be under constant revision within an individual and are influenced by a persons 
core values, societal norms and societal institutions (Parsons and Clarke, 1993). 
In this section I will highlight key literature on perception and interpretation of 
genetic risk followed by studies discussing retention of genetic risk.  
2.4.3.a Perception and Interpretation of Genetic Risk  
Understanding one’s genetic risk is said to ‘influence risk management decisions’ 
(Sivell et al., 2008 p30). Couples who are said to perceive their inheritance risk 
as high have been reported to have struggled more with decision-making than 
others (Frets et al., 1991).  Myring et al (2011) reported that a numerical 
inheritance risk of 25% was clearly understood amongst their participants. 
However complex inheritance risks are not always retained, understood or 
interpreted, with some individuals perceiving their risk to be higher than it is 
(Sivell et al., 2008; Gigerenzer and Edwards, 2003; Edwards et al., 2001; Meiser 
et al., 2001). In a study of retinoblastoma patients, who had between <1% and 
50% risk of inheritance, opinions divided over what percentage would be 
considered above the risk threshold (Dommering et al., 2010). Some couples 
were happy to accept 50% whereas one woman who was pregnant at the time 
reported feeling that 2% was too high (Dommering et al., 2010 p338).  
Parsons and Clarke (1993) investigated the difference in perceptions of risk 
between female carriers of the X-linked genetic neuromuscular disorder 
Duchenne Muscular Dystrophy (DMD) and health professionals. They found that 
health professionals cited numerical values from the literature, which were made 
up of numerous percentages relating to carrier and reproductive risk. Whereas 
mothers and female siblings of affected males with DMD used descriptive terms 
of ‘high or low’, ‘bad, not so bad and high’ (Parsons and Clarke, 1993 p563). 
Women appeared to confuse their carrier and reproductive risk and interpreted 
certain percentage risks as ‘high’ when health professionals considered these 
‘low’ (Parsons and Clarke, 1993). Potential reasons for this where thought to be 
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related to women not understanding the differences between the two risks, as 
well as health professionals not imparting information clearly enough or defining 
the differences between carrier and reproductive risk.  Also arbitrary “high” and 
“low” understandings were associated with certain percentages, with some 
women cautiously assessing their individual risk (Parsons and Clarke, 1993).  
Gender difference in risk perception is especially important when considering that 
reproductive decisions often (but not exclusively) are made within heterosexual 
couples. In this thesis, I focused mostly on interviewing women with mtDNA 
mutations. I need to note that Newman et al (2002) showed that males and 
females differed in their perception of carrier risk in cystic fibrosis. They reported 
that men were more likely to assume that they were carriers and that any children 
they had may also be carriers compared to women, however the authors were 
unable to provide further explanation as to why this was the case.  
There are also arguments that some couples believe that they may be able to 
‘beat the odds’ surrounding reproductive risk. Myring et al (2011) described 
couples that had a 25% chance of having an affected child believing that ‘the 
odds maybe in their favour’ in their next pregnancy (p412) or that they had taken 
‘a gamble’ in their first pregnancy (Klitzman et al., 2007 p358). In contrast to this, 
couples who have not yet had an affected child believe they may not be so lucky 
in their next pregnancy. The notion of being ‘lucky next time’ in a couple’s 
subsequent pregnancy was observed in retrospective study of reproductive 
decision-making in HD. Couples who had experienced previous terminations of 
affected pregnancies lived in hope that that a future pregnancy would result in an 
unaffected foetus and that that pregnancy would make up for their ‘pain and 
sorrow’ (Decruyenaere et al., 2007 p458). Hope in particular relation to 
reproductive decision-making in mitochondrial disease has been discussed by 
Herbrand and Dimond (2017), who report that women who had themselves 
received a mitochondrial disease diagnosis or cared for an affected child viewed 
mitochondrial donation as offering hope to women making reproductive decisions 
now, their female family members in the future and to society in general. Ideas of 
‘luck’ and ‘hope’ are clearly important notions when considering risk perception in 
reproductive decision-making.  
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2.4.3.b Retention of Genetic Risk  
Sivell and colleagues (2008) reviewed existing qualitative and quantitative 
literature showing a large body of evidence that over time risk perceptions may 
become more accurate compared to initial perceptions. Retention of numerical 
risk after genetic counselling has also shown to be poor, with women diagnosed 
with breast and ovarian cancer showing experienced difficulty in recalling risk six 
weeks after genetic counselling (Hallowell et al., 1997). In a qualitative study, 
some couples found it difficult to remember all of the information given to them 
(Dommering et al., 2010).  
Critiques of genetic counselling and retention of information have argued that that 
there should be a focus on genetic counsellors practicing more ‘effective risk 
communication strategies’ (Sivell et al., 2008 p31). Counselling methods 
employed by clinicians and genetic counsellors have also been questioned in 
relation to how risk is presented to an individual. The presentation of risk has 
been shown to impact upon responses to information (Marteau, 1989). Non-
directive counselling methodologies used seek to influence a person’s ‘thinking 
processes’ whereas directive counselling is the process of ‘influencing 
behaviours’, with arguments existing that both forms have a place in genetic 
counselling (Kessler, 1992). 
2.4.4 Existing Models and Processes of Reproductive Decision Making  
Reproductive decision making processes with knowledge of a genetic condition 
are said to be imbued with ‘conflict and ambivalence’ both ‘consciously and 
unconsciously processed’ (Decruyenaere et al., 2007 p460). Early work 
conducted by Lippman-Hand and Fraser (1979:73) into reproductive decision-
making in the knowledge of genetic risk was said to occur in four ways:   
1) ‘binarisation of risk’: decision making on the basis that something 
happens or it does not  
2) ‘diffusing the burden of responsibility’: finding an outward reason to 
make a decision  
3) ‘reproductive roulette’: avoiding making an explicit decision by leaving 
‘contraception to chance’ and finally  
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4) ‘scenario – based’ thinking: that allows for a decision to be managed 
Myring et al (2011) investigated retrospective reproductive decision-making and 
described that decision-making began in couples with CF towards the end of the 
phase of adaption to their child’s diagnosis. They describe their participants 
engaging in scenario-based thinking - as described by Lippman-Hand and Fraser 
(1979) - which included parents thinking of all the possible outcomes of a 
decision.  
A model of reproductive decision-making for couples considering undergoing 
PGD (see Chapter 3) was developed by Hershberger et al (2012) and includes 
four specific phases of decision-making. The decision-making process is said to 
be iterative and includes multiple decisions (see Figure 2.2). The first phase is 
entitled the identify phase were parents acknowledge their at-risk status; 
contemplate is the phase of exploring reproduction options and parenthood and 
is said to be the longest; third is resolve where couples accept, decline or 
oscillate (neither for or against PGD) and finally, engagement (Hershberger et al., 
2012). 
 
 
 
Figure 2.2 Decision-making process for at-risk genetic couples considering pre-
implantation genetic diagnosis (PGD)(Hershberger et al., 2012). Used with 
permissions. 
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Some of the processes included in the Hershberger et al (2012) model mirror 
those proposed in this thesis regarding overall reproductive options decision-
making in mtDNA mutations, which are discussed in Chapter 8.  
Myring et al (2011) provided a model of decision-making in CF (see Figure 2.3), 
that include three main stages - shock, adjustment and decision - which where 
significantly influenced by personal experiences and time pressures if the woman 
was already pregnant which they label as ‘forced’. Noticeably this model includes 
the decision ‘to not decide’, that women had the final decision (due to their role as 
primary care giver and the pregnancy implications) and that decisions were 
subject to change over time. 
 
 
Figure 2.3 Reproductive Decision Making in Cystic Fibrosis Carrier Couples.  
The process includes 1) Shock 2) Adjust 3) Decide, were ‘Forced’ represents 
finding out carrier status and risk whilst pregnant in accelerated decision-making 
conditions. Reproduced from (Myring et al., 2011) 
 
Change over time is a significant process in reproductive decision-making. The 
perception of risk, which is not always related to health risk, can be seen to 
change over time. For example, Dommering et al (2010) reports that parents 
whose children were no longer receiving treatment, and who were living a 
relatively normal life, no longer wished to avoid having more children. 
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In addition to the above models and processes, some researchers have reviewed 
existing models of behaviour for their appropriateness in understanding decision- 
making in genetic disorders. In considering change over time in the context of 
reproductive decision-making, Klitzman et al (2007) refers to the Health Belief 
Model and how its application in reproductive decision-making in HD may be 
beneficial.  The Health Belief Model is a theory that largely reflects the actions of 
adults and how ways of knowing (or beliefs) and their behaviour change over 
time based on temporal, linear and rational decision-making, as a result of 
interactions with other and environmental factors (Rosenstock et al., 1988; 
Kirscht, 1974, Finfgeld et al., 2003). Although this model does not take into 
account emotional factors or the impact of morals, unconscious and imagined 
elements of decision-making (Klitzman et al 2007). In an attempt to understand 
the suitability of Prochaska and DiClemente (1983) ‘stages of change’ model 
Houlihan (1999) applied the model to individuals undergoing pre-natal testing in 
HD. The ‘stages of change’ model was originally developed to understand 
smoking cessation and is reported to be primarily a linear process in which 
people cease to engage in harmful behaviours. The initial stage is termed pre-
contemplation (unwilling/unaware of change), followed by contemplation (to 
consider the possibility), action and maintenance of change. Although the result 
was that the model was too simplistic and placed judgement values on 
undergoing prenatal testing or not, Houlihan concluded that it was usefull in 
assisting nurses to provide stage matched interventions such as counseling, 
ensuring effective communication and ultimately decision-making.  
2.5 Kinship, Parenthood and Genetic Relatedness  
Issues of kinship – social relationships between people – and how they are 
defined are also central to the experience of reproductive decision-making.  We 
need to consider two types of kinship, ‘biological’ kinship (e.g. genetically-related 
child) and ‘social’ kinship (e.g. adopted child). Genealogically constructed kinship 
are relationships formed with those who are biologically related to an individual; 
this idea is also described as ‘descent’, ‘lineage’, ‘biological’ and ‘bio-essentialist’ 
kinship. However, socially constructed kinship is also central.  Biological kinship 
focuses on a ‘state of being’, they either ‘exist or they do not’ whereas social 
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kinship focuses on social relationship formed by actions and interactions, on 
‘doing’ (Schinder.,1984:p165).  
2.5.1 Parenthood  
Traditional western theories of parenthood were built upon married male and 
female couples having children. This restricted view is no longer representative of 
modern day families, with many families comprising of step-parents and half 
siblings. Contemporary varieties of parenthood such as gay parenthood also 
exist, facilitated by assisted reproductive technologies (ART), adoption and 
surrogacy (Murphy, 2013). I will discuss below the impact of ART on parenthood, 
but I will first outline perspectives on what constitutes a ‘parent’ and ‘parenthood’.  
Berman (2014) argues that parenthood is a form of possession, whereby the birth 
mother primarily, and those around her, have control over the child. Steinbock 
(2005) summarised four of the key positions on defining legal parentage, which 
included: genetic relatedness, contract or intent-based parenthood via an 
agreement, social parenting, and the best interest approach whereby an adults 
interests are replaced by what is best for the child. These positions encompass 
the majority of reproductive options available to women with maternally inherited 
mitochondrial disease (with the exception of voluntary childlessness), which are 
described in more detail below (see Chapter 3). Taking the best interest 
approach idea of parenthood is said to move away from the perspective that 
children are possessions. However it is not without it’s critics whom argue that 
after eliminating the risk of neglect or abuse, how is it possible to deem which 
parent (the biological or social) is best. It is therefore said to be ‘too vague, too 
difficult to apply and reflects social prejudices’ (Steinbock 2005:p302).   
When investigating the reasons as to why people want to become parents, 
Murphy (2013) found that for some, parenthood was rooted in a feeling that they 
had always wanted to be a parent; they where pre-destined to be (Chatjouli et al., 
2017). Rabin and Greene (1968) noted that respondents to their survey listed 
motivations of parenthood as being fatalistic, the purpose in which men and 
women where ‘brought into the world’ (p:39) to procreate as well as altruistic 
motivations, born from affection for children and the desire to nurture. Some 
people go on to enter into grandparenthood, whereby they take an active role in 
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the parenting of their grandchildren, either formally (by court order) or as social 
contracts with parents (Werner et al., 1998). 
Issues pertaining to parenthood have been largely examined in relation to gender 
roles historically, with researchers examining the role of mothers and fathers 
often as discrete roles as opposed to in conjunction with one another (Fox, 2001; 
Rossi, 1984; Sanchez & Thomson, 1997; Song, 2012; Starrels, 1994; Thompson 
& Walker, 1989). Becoming a parent is often discussed as a transition into 
parenthood, which is said to be more stressful for prospective mothers than 
fathers, in part due to the woman’s role as primary care givers (Pinquart and 
Teubert, 2010 cited in Widarsson et al., 2013), although it has been argued that 
couples experience equal stress which manifests in different ways (Widarsson et 
al., 2013). With the introduction of ART, traditional ‘natural’ theories of 
parenthood have been challenged.  
2.5.2 Assisted Reproductive Technologies and Parenthood  
Jones (2015) draws on Aristotle and the work of William Harvey (1651) when 
describing what constitutes a woman’s role in reproduction. He lists women’s 
roles as providing equal contribution of inherited material, providing the ‘bulk’ of 
the embryo and thirdly, gestation and labour.  We will see below, in Chapter 3, 
that advancements in ART have led to these three roles no longer being 
restricted to one woman, and could in theory be played by three separate women 
(not forgoing the social mother after the delivery of a child). These advancements 
have led to parenthood no longer being confined by genetic relatedness, albeit, it 
could be argued that adoption has challenged this idea for centuries. Emerging 
reproductive and genetic technologies have allowed for reproduction, which was 
considered to be concerned with biology only, to be questioned. McKinnon (2015 
p 462-464) argues that assisted reproductive technologies have the ‘quality of 
procreative sex’ in that they produce something natural (a child) and therefore a 
‘seemingly natural kinship’ but that this is achieved by different means.  
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ART has been described as denaturalising conception, pregnancy and the idea of 
nature1 (McKinnon, 2015) and dislocating the ‘natural fact’ of motherhood and 
family (Strathern, 1992, cited in Teman 2010 p8). 
The introductions of ART that allows for a donor sperm or egg to be used to form 
an embryo means that the resultant child will not be genetically linked to one or 
both of the intending parents (see Chapter 3). As we have seen above, 
parenthood can be depicted by some as a form of possession of children. This 
can be further reinforced by the concept that genetic parents have a claim to the 
children because they ‘own’ the genetic material of which their children consist of. 
This belief originates from a criticised interpretation of the theorists Locke who 
wrote of children being the product of bodily labour (Franklin-Hall, 2012). This 
perspective of genetic ownership of children is therefore challenged by 
techniques that involve egg or sperm donation. Another approach to the 
prioritisation of genetic relatedness in parenthood can be linked back to 
anthropological debates on kinship and the notion of ‘blood is thicker then water’ 
(Schinder, 1984 p165).  Schinder disagreed with this perspective and argued that 
by assuming that this is true, all other kinship relationships, including social 
parenthood were weaker than those created through a biological link, (Schinder, 
1984). In addition to manipulation of genetics, surrogacy conflicts with ideas of 
the role of the mother as someone who gestates; providing nourishment and 
safety to the growing child. The role of the gestational mother has been 
considered as a form of ‘sweat equity’, whereby the gestational connection is said 
to lead to stronger claim to parenthood then genetics alone (Steinbock 
2005:p298). I will go on to explore surrogacy in more detail in Chapter 3. 
2.6 Summary   
This chapter provides a summary of the literature surrounding the key issues in 
which this thesis interacts with. I have outlined the historical perspectives of 
decision-making in the clinic, showing that in large, the paternalistic approach is 
no longer considered an ethical practice in medicine (with certain exceptions). I 
                                            
1 Questions of ‘nature’ or ‘nurture’ have been central to debates around adoption. Parents whom 
seek to be reunited with the children that they relinquished parental rights for have campaigned 
for recognition of their biological bond to their unknown children and protest to end the automatic 
assumption that the social parent is ‘superior’ in this context (Modell, 1986 p646). In some 
cultures the importance of gestational motherhood and genetic relationships with those who 
conceived a person are irrelevant, (Bamford, 1998; cited by Sahlins, 2011 p3). 
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have shown that changes in medical practices now strongly emphasises patient 
autonomy in decision-making regarding their care. I have detailed how SDM has 
become the gold standard approach to clinical decision-making, improving 
reported patient satisfaction and patient-doctor relationships. Despite these 
benefits the implementation of SDM in the clinic and its role in improved health 
outcomes has proven difficult to measure. Central to SDM are discussions with 
patients surrounding risk and uncertainty of treatment options. To understand this 
further I have discussed the premises of risk, risk in reproduction and how in 
today’s culture women are bombarded with various potential risks in relation to 
planned or actual reproduction. I have highlighted briefly existing decision-making 
models or aids that have been developed to assist women in areas including 
contraception, fertility treatments and obstetric care. Uncertainty underpins this 
thesis, with women directly experiencing uncertainty due to their illness or that of 
their family members as well as in their own or their female family members 
reproductive decision-making. Uncertainty is made up of five keys areas, 
including ambiguity, vagueness, unpredictability, lack of information and 
unfamiliarity. High levels of uncertainty have been linked to high levels of 
emotional distress, anxiety and depression.  
A central objective of this study is to understand reproductive decision-making in 
maternally inherited mitochondrial disease, from the women’s perspective is 
missing from the literature. However by utilising empirical research into 
Mendelian genetic conditions, including X-linked and late on-set disorders I have 
been able to show core components of reproductive decision-making. These 
included lived experience, feelings of guilt and responsibility, the retention of 
genetic risk and existing models/process of reproductive decision-making. Finally 
this chapter includes an overview of kinship, parenthood and genetic relatedness, 
as well as highlighting how ART have been said to denaturalise conception, 
pregnancy and ideas of nature. A number of the reproductive options are 
available to women present challenges to the traditional thoughts of kinship and 
parenthood, which I will now go on to discuss further in Chapter 3. 
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Chapter 3. Reproductive Options 
3.1 Introduction 
This chapter presents a summary of the reproductive options available to women 
with mtDNA mutations. Women’s ideas and preferences to these options are 
routed in their values, these values can then been see an influential in 
reproductive decision-making in maternally inherited mitochondrial disease. The 
thesis explores how reproductive options that enable a genetically related child 
are compared against those that restrict genetic relatedness or provide 
parenthood via a social kinship relationship are presented in Chapter 8. I will 
detail the biological procedures (where relevant) and key social perspectives of 
each option and where possible their already known application in mitochondrial 
disease. Due to the constraints of this thesis and the number of options available 
to women, these summaries will serve to inform the reader of the primary issues 
relating to each option and I recognise that the debates on each option are more 
extensive than provided here.  
3.2 Genetic Counselling  
The National Society for Genetic Counsellors (NSGC), an American organisation 
define genetic counselling as ‘the process of helping people understand and 
adapt to the medical, psychological and familial implications of genetic 
contributions to disease’ (Resta et al., 2006 p77). With ever increasing advances 
in genetic technologies and screening, there is a greater need to address the 
support required by the recipients of genetic information, especially those 
individuals who may be more vulnerable than others (Lerman et al., 2002). The 
distinct roles of genetic counsellors have been summarised as the ‘interpretation 
of family and medical histories to enable risk assessment’, provide ‘education 
relating to inheritance, preventative options including genetic testing and personal 
risk’ and to ‘facilitate informed decision making and adaption of personal risk’ 
(Trepanier et al., 2004 cited in Smerecnik et al.,2009 p 217) .  
As described in Chapter 1, the complexities of mtDNA can be challenging to 
impart and understand for all those involved (Poulton et al., 2017; Gorman et al., 
2015; Nesbitt et al., 2014; Vento and Pappa, 2013; Taylor and Turnbull, 2005; 
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Burgstaller et al., 2015; Read and Calnan, 2000; Thorburn and Dahl, 2001).  
When asked about these challenges, 20 mitochondrial specialists from across 
Europe who took part in Bredenoord et al (2010) qualitative study of 
professionals views and experiences of decision-making in mtDNA disorders 
discussed four distinct themes surrounding their reproductive counselling 
experiences. The themes included: how ethically and biologically different 
mitochondrial genetics were to that of Mendelian disorders; their discomfort and 
doubt posed by the uncertainty of disorders even after testing; the struggle 
between patient autonomy and their own role and responsibilities in complex 
decision-making; and lastly, the strategies employed to attempt to control 
uncertainty. Professional’s described anxiety and discomfort in communicating 
ambiguous results with patients and describing ‘heated discussions’ with 
colleagues about such results (Bredenoord et al., 2010:p11). The mitochondrial 
professionals included agreed in patient autonomy in decision-making, however 
they were less certain, due to the levels of complexity and uncertainty posed by 
the disorder, whether or not couples could make autonomous decisions, with a 
certain ‘intellectual capacity’ required (Bredenoord et al., 2010:p14).  In relation to 
clinical strategies to tackle uncertainty, some clinics avoided testing certain 
mutations whereas others described large collaborative networks in which 
diagnostic and genetic expertise from multiple centres could be accessed. Finally 
professionals appear to question the difficulty in defining and explaining risk to 
patients and whether or not the desire to seek accuracy is asking too much, 
conflicting with their role as the provider of expert knowledge (Bredenoord et al., 
2010).  Women’s experiences of reproductive and genetic counselling, both from 
a genetic counsellor and mitochondrial specialists are discussed in Chapter 7 
section 7.2. 
3.3 Conception without Medical Intervention  
Conception without medical intervention in the context of this thesis is defined as 
conceiving a child through sexual intercourse and choosing to not engage with 
any prenatal tests above those offered as standard care to all women. For a large 
number of women with mtDNA mutations they do not show signs or symptoms or 
receive a diagnosis until after they have had an affected child/children, that 
translates into many women having had pregnancies without the knowledge of a 
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potential risk. Some women who are in receipt of their diagnosis may also assess 
their risk and decide to become pregnant without engaging in any medical 
intervention. This study seeks to understand the reason behind this decision and 
the risk assessment processes that women conduct and is discussed further in 
Chapter 7 and Chapter 8.  
3.4 Voluntary and Involuntary Childlessness   
The concept of ‘just not having any children’ was raised by women themselves in 
this study. Prior to this, voluntary childlessness was not a reproductive option that 
was included in the list of those presented to women either in the original scope 
of this study (discussed further in Chapter 4 section 4.3.5) or those generally 
offered to women in the clinic. This may be that reproductive options are 
considered to be those available or offered to women after women are believed 
to have already made the choice between having a child and childlessness. 
Research into voluntary childlessness gathered pace in the mid 1970’s and 
Houseknecht’s 1987 review of the literature on the topic set out clear definitions 
of childlessness. Involuntary childlessness is defined as those who want to have 
children but are unable to due to ‘medical, physical, behavioural conditions’ whilst 
voluntary childlessness is termed as those who would ‘prefer to have no children’ 
and that both the intent and degree of commitment of these choices should be 
ascertained before assignment (Houseknecht, 1987 p369-370). Houseknecht 
(1987) also defined permanent and temporary childlessness, with temporary 
childlessness being a significant ‘state’ in which women with mtDNA mutations 
appear to occupy (discussed further in Chapter 7 section 7.6) (Houseknecht, 
1987 p369). Caution is given to researchers in this area that attempt to 
distinguish between voluntary and involuntary childlessness, in that the former is 
‘the combination of choice and permanence’ whilst the later is ‘due to impaired 
fecundity, delayed childbearing and uncertainty’ (Houseknecht, 1987 p370).  
More recent definitions of voluntarily childlessness are  
women of childbearing age who are fertile and state that they do not intend 
to have children, have chosen sterilisation or women who are past 
childbearing age but when fertile chose not to have children (Kelly, 2009 
p157).  
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There have also been investigations into the sub-groups of women who choose 
childlessness, which can see women further divided into ‘transitional, postponers, 
ambivalent and passive decision makers’ (Kelly, 2009 p158) all of whom may 
have made a different choice in different circumstances. Women who choose to 
not mother in a biological or social capacity are often stereotyped as selfish or 
desperate (Letherby, 2002), with the most significant demographic stated as the 
older, European American, unmarried woman with a high socioeconomic status, 
with a long history of employment and little or no religious beliefs (Kelly, 2009).  
Negative attitudes and stigma have been associated with voluntary childlessness 
because it is seen to deviate from society’s norms that couples should want to 
have children with many negative perceptions attributed to these couples, such 
as being unhappily married, career driven, selfishness, psychologically 
maladjusted and emotionally immature (Lapham et al., 1996). Those who have 
chosen to not have children face ‘social pressures to alter or justify their status’ 
and find themselves developing strategies that help them do ‘identify work’ to 
combat this negativity (Park, 2002 p21). This study seeks to offer a unique 
contribution to the ideas and preferences of women with mtDNA mutations 
towards voluntary childlessness as a reproductive option (discussed in Chapter 7 
section 7.6). 
3.5 Adoption   
Adoption as a reproductive option has been traditionally associated with infertile 
couples (also referred to as involuntary childless in adoption literature) that seek 
a child to bring into their family, but it is also an option for parents who have a 
known genetic condition that they may wish to avoid transmitting to a biological 
child. Advances in reproductive technologies and the techniques available are 
said to be centred on the wants of the intending parents; whereas those services 
that manage adoption are seen to assess what intending parents can provide to a 
child (McGlaughlin & Grayson, 2001). It is important to note that the view of 
adoption presented in this thesis is one of Western societies reflections, with the 
practices of adoption also referred to as child circulation (Berman, 2014) in other 
cultures, excluded. 
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In the UK, governmental regulations state that to be eligible for adoption the 
adoptee must be under the age of 18 and must not be or have ever been married 
or in a civil partnership. For a child to be eligible for adoption both biological 
parents have to provide consent unless they cannot be found, do not have 
capacity to consent or if the child is deemed to be at risk if they were not adopted. 
The intending parent(s) must be over the age of 21, have a permanent address in 
the UK and have lived in the UK for at least one year. Intending parent(s) can 
include people who are single, married, in civil partnership, an un-married couple 
or the partner to the biological parent. It is cautioned that there may be different 
specifications in place for private adoptions or for a ‘looked after child’ (those 
placed under the care of local or national authorities) (GOV.UK, accessed 06.09 
2017).  
Adoption is commonly associated with lengthy and intrusive processes that are 
stressful for intending parents (Bird et al., 2002). In the UK the process of 
adoption is listed as the following: an initial meeting before being provided the 
application form, the application form, preparation classes, assignment of a social 
worker to review suitability, police checks on the person and adult family 
members, collection of three references and a full medical examination (GOV.UK, 
accessed 06.09 2017). Adoption in the UK has changed over the years, with less 
and less infants being given up for adoption, in their place there are a number of 
children who are unable to live with their biological parents, who tend to be older 
and have siblings also in need. Leading UK adoption organisation ‘Adoption UK’ 
outline on their website that there are more than 4000 children living in foster 
care who have had an ‘unsettled start to their lives’ and may have suffered from 
abuse or neglect (adoptionUK, accessed 06.09.2017).  
Routes to adoption for the intending parent(s) are said to have started once a 
couple have failed to achieve the societal norm of a biological child and during 
this process are required to come to terms with the loss of hope to become a 
biological parent and identify as an adoptive parent (Daly, 1990; cited in van den 
Akker, 2001 p148). A study of 131 infertile couples showed that 80% had sought 
medical options to enable them to have a child and were motivated by the need 
to understand the reasons behind their infertility, whereas adoption and fostering 
were considered secondary to medical options and considered much later (van 
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Balen et al., 1995). In another study, when asked about the importance of a 
genetic link, 81.4% (48/59) of adopted parents/prospective adoptive parents 
recorded that they did not believe a genetic link was important, with the remaining 
believing it was (van den Akker, 2001). Within this sample 100 people responded 
the a question regarding their motive for adoption which included; altruism 
(40.8%), wanting a family (35.7%), adoption as a permanent solution (11.2%), 
other options failed (8.2%), the only remaining option (3.1%) and that one person 
was an adopted child themselves (1%) (van den Akker, 2001). Stages involved 
for families who adopt a child are said to include welcoming of the child into the 
family and community, disclosing information to the child and dealing with the 
child’s responses and managing social stigma, which are also argued to apply to 
conception via donation and surrogacy (van den Akker, 2001).  
Although discussed in debates surrounding mitochondrial donation below, 
adoption as a reproductive option for women with mtDNA mutations has not been 
investigated empirically. This study offers a unique contribution to both 
mitochondrial disorders and adoption literature (Chapter 7 section 7.5).   
3.6 Ovum Donation  
It is argued that the most ‘obvious and reliable method’ (Thorburn & Dahl, 2001 
p105) to ‘completely eliminate the risk’ (Burgstaller et al., 2015 p13) of 
transmitting the pathogenic mutation to their offspring, for women with mtDNA 
mutations would be ovum/egg donation. This is the process in which a donated 
ovum is used in place of the at-risk woman’s ovum, it is important to note that this 
ovum should not be that of a maternal relative who might also be at-risk. Ovum 
donation is the process in which a donor ovum/egg is fertilised with the intending 
father’s sperm through in vitro fertilisation (IVF) and transferred into the intending 
mother’s uterus, with the first record of a successful procedure being in 1984 in 
California (Bustillo et al, 1984). In this thesis I used the term ovum and egg 
interchangeably. When discussing this technique with women I used the term egg 
donation as opposed to ovum to prevent potential confusion, as all women 
understood the term egg. 
Predominant issues in gamete (ovum/sperm) donation include 
disclosure/anonymity, payment for gametes, exploitation of donors (centering on 
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egg donors and less so on sperm donors), parent-child relationships in ovum 
donation and the overarching sentiment of the meaning of motherhood (Kirkman, 
2003). As of April 2005 in the UK, donor anonymity was replaced with donor 
identity release, which means that individuals conceived through gamete 
donation, can seek identifying information about their donor from the age of 18. 
However this is only possible if the procedure is done at a licenced clinic (which 
does not take into account informal arrangements seen in sperm donation or 
treatments conducted abroad). Issues surrounding disclosure to children about 
their conception are complex and are at the centre of donor conception studies, a 
primary reason cited is that heterosexual couples utilising gamete donation are 
able to ‘adopt the mantel of a traditional family’ and therefore are able to conceal 
their use of gamete donation (Nordqvist & Smart, 2014 p7).  
In the UK it is illegal to pay for gametes, but expenses to the donor are provided, 
limited to £35 per visit up to a maximum of £750 for a ‘course of donation’ (HFEA 
accessed 07.09.2017). It has been argued that the practice of ‘payment’ for 
sperm and not eggs (in some clinics) implies that eggs are not an entity that can 
be ‘sold’ and that there is a maternal attachment placed on them (Braverman, 
1993; Murray & Golombok, 2000 cited in Kirkman, 2003 p3). The availability and 
choice of donors available to women is more limited in the UK compared to some 
parts of Europe and elsewhere in the world and so some intending parents 
choose to access gametes from outside the country, contributing to the 
multibillion dollar industry that has developed from reproductive tourism 
(Nahman, 2016) also known as ‘fertility tourism’ and ‘cross border reproductive 
care’ (Deonandan, 2015). Beliefs regarding exploitation of egg donors (and 
surrogates) centring around this ‘tourism’ are complex and each ‘destination’ 
country can be viewed individually by it’s political, economic and religious past 
(Pfeffer, 2011).  
Issues relating to legal parentage in the UK are however more simpler for women 
who conceive via egg donation than in surrogacy (discussed below) as in the UK 
the gestational mother is recognised as the legal parent of a children born 
through egg donation. Kirkman (2003) argues that disengaging from genetic 
continuity can be seen as a threat to motherhood. Parent-child relationships have 
been investigated in gamete recipient parents in comparison to natural 
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conception parents by Golombok and colleagues (2002) who found that parent-
child relationships were more positive in the gamete recipient group than those in 
the natural conception group and that gamete recipient parents had greater 
emotional involvement with their child. Gamete recipient mothers have also been 
shown to take greater pleasure in their children but also perceive them to be 
more vulnerable (Golombok et al., 2005). Both studies conclude that although a 
genetic link may not exist between the parent and child this does not negatively 
impact on the relationships (Golombok et al., 2005; Golombok et al., 2002).  
Although ovum donation can be seen to be a very simple solution for women with 
mtDNA mutations, qualitative investigations of its suitability for women is 
unknown. This study seeks to provide insight into women’s ideas and 
preferences surrounding ovum donation as a reproductive option (Chapter 7 
section 7.4). 
3.7 Surrogacy  
There is an extensive base of literature surrounding surrogacy, with primary 
perceptions being on issues pertaining to how contentious it is within social, 
moral, ethical and legal frameworks around the world (Nahman, 2016). For 
women with mtDNA mutations surrogacy offers an option to women who may be 
physically unable to carry a child to term due to their disease burden, taking into 
account the potential risk to mother and baby as well as offering the option to use 
a donor ovum/egg to avoid transmission of their mtDNA mutation.  
Surrogacy is traditionally described by the link in which the surrogate mother has 
to the resultant child and includes two forms of surrogate parenting, 1) genetic or 
partial surrogacy in which the surrogate mother and the intended or 
commissioning father are the genetic parents of the child and 2) non-genetic or 
full surrogacy in which the intending or commissioning mother and father are the 
genetic parents (HFEA, accessed 04.09.2017). The usual routes of conception in 
genetic surrogacy is artificial insemination, whilst with non-genetic surrogacy is 
in-vitro fertilization  (IVF) (Golombok et al, 2004). There are also circumstances in 
which there can be up to three potential ‘mother’ roles, including biological, 
gestational and social mothers. For the purpose of this thesis I choose to use the 
term ‘intending’ parent as opposed to ‘commissioning’ parent as I believe 
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commissioning is more suited to legislative aspects of surrogacy whilst I aim to 
present surrogacy as a mode of enabling parenthood.   
Surrogacy laws differ dramatically across the globe with some countries or states 
outlawing surrogacy outright, while others allow altruistic surrogacy (no financial 
gain to the surrogate) but prohibit commercial surrogacy (a debated term but 
general consensus is that this describes payment to the surrogate above 
reasonable expenses), to some countries or states having no legislation in favour 
or in opposition (Teman, 2010). Many viewpoints can be linked to the thinking 
that surrogacy is a ‘cultural anomaly’, especially in western society and said to be 
in relation to beliefs surrounding ‘nature’ and motherhood as a ‘natural fact’ 
(Teman, 2010 p6-8). This is coupled with stigma of the woman who relinquishes 
her child, disturbing societies views of motherly commitments (Teman, 2010).  
In the UK commercial surrogacy arrangements are illegal and surrogacy 
arrangements are not enforceable (Surrogacy Arrangements Act 1985 c49). 
There are many criticisms of this act and subsequent amendments and reports in 
which the UK government has been said to have had a knee-jerk reaction to 
‘cash for babies’ scandals that had emerged in the 1980’s, moving to a more 
altruistic approach of a ‘gifting relationship’ (Fenton-Glynn, 2016 p 60-61). As a 
result it is only legal in the UK to cover the expenses of the surrogate, such as 
loss of earnings and transport to and from hospital visits. In the UK surrogacy 
may be legislated against but is not a regulated activity and fertility clinics are 
unable to assist with the ‘matching’ of a surrogate to intending parents. In 
addition to expenses paid to the surrogate, intending parents can face preliminary 
costs to register with not-for-profit organisations that assist with ‘matching’ them 
to a suitable surrogate.  
Organisations in the UK that aim to assist intending parents include Surrogacy 
UK and Brilliant Beginnings; agencies that claim to offer ‘surrogacy through 
friendship’ (Surrogacy UK, accessed 04.09.2017) and support during the ‘family 
building process’ (Brilliant Beginings, accessed 04.09.2017).  Surrogacy UK 
reported via the HFEA that the process of surrogacy can cost intending parents 
from £7,000 to upwards of £15,000, although it is cautioned that this can increase 
depending on the type of clinical procedure utilised to achieve pregnancy (HFEA,  
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accessed 04.09.2017).  In addition to these costs intending parents face issues 
relating to who is considered the legal parent at birth and whose names are 
added to the birth certificate.  
In the UK, the surrogate or gestational mother is recorded on the child’s birth 
certificate even if the child is not genetically related to her (i.e. is genetically 
related to the intending mother). In order for intending parents to be granted 
parental rights, they must apply and be granted a parental order; once this is in 
place the surrogate and the named second parent (if not the intending parent) will 
have no further rights or obligations to the child, although parental orders 
themselves are not simple to obtain (Fenton-Glynn, 2016). This remains a 
complex process (Fenton-Glynn, 2016) and although appropriate forms regarding 
legal parenthood are provided by the HFEA on their website, seeking legal advice 
is strongly encouraged regarding their completion and later application for the 
Parental Order (HFEA, accessed 04.09.2017).   
Reproductive tourism is common amongst for not only ovum/egg donation but 
also within surrogacy due to the variation in legislation and commercial surrogacy 
practices available in some countries. This is compounded further with supply 
and demand principals, in that the demand for surrogates outweighs the number 
available in the UK (Fenton-Glynn, 2016). There are many ethical debates 
surrounding reproductive tourism and surrogacy which are outside the scope of 
this thesis (Nahman, 2016,; Fenton-Glynn, 2016), but UK parents are cautioned 
that if they consider this option that they take expert legal advice around the 
transfer of legal parenthood and parental rights in relation to the nationality of the 
surrogate and the country of birth of the child (HFEA, accessed 04.09.2017).  
Intending parents in the UK live with uncertainty during their surrogacy journeys 
in that there is no legal contract that ensures their planned child will be 
relinquished by the surrogate mother after birth as well as anxiety over 
establishing the ‘right’ type of relationship with the surrogate (Golombok et al., 
2004). Golomok and colleagues (2004) summarised the impact of surrogacy on 
intending parents, which included effects on psychological wellbeing (including 
parental anxiety, depression) marital conflict as well as interference in the quality 
of parenting due to feelings of inferiority compared to other parents.  
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From a social perspective surrogacy is said to differ from gamete donation in that 
it separates the role of biological and social motherhood (Golombok et al., 2004). 
Jones (2015) argues that even in consideration of advancing techniques ‘it 
cannot seriously be disputed’ (p101) that the woman who carries a child to term 
and gives birth is not the biological mother. Surrogacy raises issues about identity 
and how embodied experience of pregnancy can construct a new self-identity for 
some women (although for some this happens after birth) (Teman, 2009). In the 
case of the intending mother this change in self-identity must be managed by 
their access and desire to undergo this change (Teman, 2009). Teman (2009) 
highlights the blurred physical boundaries experienced by surrogates who are 
said to do a lot of ‘classification work’ (p52) to distance themselves from 
experiences that may elicit emotional ties to the growing foetus such as ‘kicks’ 
and other fetal movements, whereas intending mothers appear to take on the 
surrogates body as an ‘appendage’ (p54). The embodied experiences of 
pregnancy in surrogacy described by Teman (2009: p47) include ‘initiating, 
challenging, validating, shifting, merging and birthing of the shifting body’.  
There have been no empirical studies detailing experiences of surrogacy in 
patients with mitochondrial disease, nuclear or mitochondrial in origin. 
References to surrogacy alongside mitochondrial disease are included in debates 
surrounding the introduction of mitochondrial donation as an alternative option to 
undergoing the novel technique. The original contribution that this work adds to 
the field is that it presents the views and preferences of women with mtDNA 
mutations regarding surrogacy as a reproductive option (discussed in Chapter 7 
section 7.4).  
3.8 Prenatal Diagnosis and Prenatal Testing  
Prenatal diagnosis (PND) or prenatal testing are techniques that permit the 
genetic testing of a foetus before birth and include chorionic villus 
sampling/biopsy (CVS/CVB) or amniocentesis. Chorionic villus sampling is the 
process in which placental tissue is sampled for chromosomal abnormalities and 
is the earlier of the two tests, taking place between approximately 10-14 weeks 
gestation. The procedure can be done by the percutaneous transabdominal 
approach (needle puncture procedure through the abdomen) or as a transcervical 
approach (via the uterine cervix) (Bhatt, 2017) (Figure 3.1).  Amniocentesis is a 
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later prenatal test, which can be performed between 16-20 weeks gestation and 
includes the withdrawing of amniotic fluid from around the foetus which contains 
fetal exfoliate cells, urine and secretions by a transabdominal approach (Dimri & 
Baijal, 2016 p131). Test results are available between 1-7 days post procedure 
depending on diagnostic tests performed on the sample (Bhatt, 2017 p81; Dimri 
& Baijal, 2016 p134). 
 
 
Figure 3.1 Prenatal testing techniques a) Amniocentesis testing procedure and 
b) Chorionic Villus Sampling procedure. Reproduced from (Byer, Shainberg, & 
Galliano, 1999).  
 
Prenatal testing is offered to women in a number of different scenarios such as 
when there is a known genetic risk to a future child, when an earlier diagnostic 
test has raised concerns or when the mother will be over the age of 35 at time of 
delivery. Both procedures carry a risk of fetal loss or fetal injury; the percentages 
however vary from one report to another. Bhatt (2017) review of 16 cohort studies 
reports that the risk of fetal loss 14 days post transabdominal CVS is 0.7%, 1.3% 
30 days post transabdominal CVS and 2% loss at any time during pregnancy 
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(Bhatt, 2017). Dimri and Baijal (2016) review of nine studies showed that 
miscarriages post-midtrimester after amniocentesis ranges from 0.75% to 3.3% 
(Dimri & Baijal, 2016). Nesbitt et al (2014) stated that the ‘aim of prenatal testing 
in mitochondrial disease is to identify fetuses harbouring mutations that will cause 
severe disease and offer termination at a relatively early stage’ (p1257).   
Chorionic villus sampling was first offered to women with mtDNA mutations in 
1992 but reservations surrounding the sensitivity of tests continued for a number 
of years after. These concerns were related to whether heteroplasmy levels 
tested at these time points were predictive of mutation load in other tissues or at 
birth (Thorburn & Dahl, 2001). These tests depended on heteroplasmy levels 
found in the cells taken during prenatal testing to be largely representative of all 
cells in the fetus and that they remain at these levels as the pregnancy 
progresses. As with predicting inheritance risk, understanding heteroplasmy 
results from prenatal tests in relation to the affectedness of a future child is 
especially difficult (Nesbitt et al., 2014). Prenatal testing is not advised for women 
with a known homoplasmic mtDNA mutation, as the foetus will also be 
homoplasmic and therefore the test will not offer any beneficial information 
(Poulton et al., 2017). The so called ‘grey zone’ can make it difficult for a clinician 
to counsel parents and for parents to decide whether to continue with or 
terminate the pregnancy (Nesbitt et al., 2014; Smeets et al., 2015). Thorburn and 
Dhal (2001) argue that interpretation of results proves difficult, with heteroplasmy 
below 30% considered low risk, whilst those over 90 % are considered high risk 
(Thorburn & Dahl, 2001).  
Nesbitt and colleagues (2014) reviewed data on prenatal tests offered within their 
combined clinical services from April 2007 to January 2013, totalling 62 
procedures of which 17 were mtDNA mutations, the remaining 45 were nDNA 
mutations. These tests were offered to women who already had an affected child, 
were a known carrier of a mtDNA mutation or who had a severely affected sibling 
(Nesbitt et al., 2014). Of these 62 procedures, 59 were CVS (gestation time 
between 8-15 weeks) and 3 were amniocentesis (gestation time of 15-17 weeks) 
(Nesbitt et al., 2014). The findings of this study are said to have shown that 
prenatal testing in mitochondrial disease is ‘reliable and informative for nuclear 
mutations and selected mtDNA mutations’ and that the provision of appropriate 
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reproductive counselling is important for patients considering all their 
reproductive options (Nesbitt et al., 2014 p 1255).  
Social perspectives of prenatal diagnosis include the view that individuals 
presented with genetic information that may then require them to choose 
between continuing with a pregnancy and termination may be focusing only on 
the disability and show little regard for the fetus and to disabled people 
(Boardman, 2014). This leads into the belief of ‘expressivist objection’ or EO 
which is the belief that there is focus on correcting and preventing disability rather 
than the value of a disabled person (Buchanan, 1996 cited by Boardman, 2014). 
Boardman (2014) highlights that genetic testing and selective termination in 
families with experience of the condition is however very different to that of 
decision-making in the general public or with those with no experience of the 
condition (Boardman, 2014). There has been critique of what constitutes 
‘balanced’ information in consultations with women who have screened positive 
for Down’s syndrome, where physicians and midwives have only practical 
‘textbook’ knowledge. This can lead to a focus on the medical problems 
associated with the syndrome as opposed to providing information of the broader 
subject of living with disability (Williams et al, 2002). There are however those 
who believe that EO is too simple an idea and does not represent the complexity 
of reproductive decision-making for intending parents in these situations, being 
overly critical of them and not taking into account broader arguments surrounding 
reproductive technologies (Shakespeare, 2006 cited in Boardman, 2014).  
Although studies have been conducted into prenatal testing in mitochondrial 
disease, little is known about the patients and their partners opinions of these 
test, this study seeks to add to this literature with unique insight in to views of 
women with mtDNA mutations of CVS and amniocentesis as reproductive options 
(discussed in Chapter 7 section 7.3) 
3.9 Pre-implantation Genetic Diagnosis  
Pre-implantation genetic diagnosis (PGD) is the process in which embryos 
created via in-vitro fertilisation are biopsied and tested for genetic abnormalities 
the outcome of which can enable decision-making between the clinician and 
intending parents about whether to transfer the embryo(s) or not (included in 
Figure 3.2a). As well as having a mutation load thought to be below the threshold 
 62 
 
 
level for clinical affectedness the embryo(s) must also meet standard IVF grading 
standards to be considered suitable for implantation. The first report of PGD as 
an option in human disease was in 1989, for X-linked conditions and was 
reported in 2006 to have been used successfully in mitochondrial disease, 
namely in the m.8993 T>G mutation, associated with NARP (Neurogenic Muscle 
Weakness Ataxia Retinis Pigmentosa) phenotype ( Steffann et al., 2006 cited in 
Brown et al., 2006). The HFEA website lists the mitochondrial conditions for 
which license has been to allow for PGD, these include NARP, MELAS, MERRF, 
Leigh Syndrome, PEO, Mitochondrial DNA Depletion Syndrome 2 (myopathic 
type), Mitochondrial Complex 1 Deficiencies (multiple gene origins) and LHON 
(HFEA, accessed 08.09.2017). The primary advantage of PGD is that it can 
prevent intending parents from facing possible termination of their pregnancy, as 
is the possibility with prenatal testing. 
In PGD embryos are tested at either blastomere (an eight–cell embryo, or Day 3) 
or blastocyst (approximately 70-100 cells or Day 5) stage (Smeets et al., 2015; 
Poulton et al., 2017). There are however conflicting reports about the accuracy of 
PGD in mitochondrial disorders due to difficulties in confirming if the results are 
indicative of mutations loads of the whole embryo. These concerns centre largely 
on the stage at which the embryo has developed at the time of the biopsy 
(Smeets et al., 2015; Poulton et al., 2017). PGD is reported to raise issues of 
uncertainty for parents and is intensely emotional due to the strong desire to 
avoid having an unhealthy child or experience another unsuccessful pregnancy- 
in couples accessing nuclear genome PGD (Roberts & Franklin, 2004). Roberts 
and Franklin (2004) conducted an in-depth ethnographic study of two PGD 
clinic’s in the UK over 18 months, they found that those women who took part in 
the study reported that finding out that they were candidates for PGD was ‘an 
enormous relief’ (p228) and that for some their decision to undergo the technique 
was a ‘choice of necessity’ (p228) and not really a free choice due to prior 
experience.  
As noted above, the complexities of counselling patients with heteroplasmic 
mutations and being able to indicate what levels of mutation may result in an 
affected child is especially difficult. It is advised to counsel these women and their 
partners on a case-by-case basis, with Smeets and colleagues including parental 
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perceptions of risk as an important factor to be considered alongside the 
biological concerns (Smeets et al., 2015). This study seeks to understand how 
women with mtDNA mutations perceive PGD as a reproductive option (discussed 
in Chapter 7 section 7.4). 
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Figure 3.2 a) Pre-implantation Genetic Diagnosis (PGD) procedure involves IVF 
of all oocytes harvested from the intending mother; these are then biopsied and 
analysed for mutation. Embryos that meet IVF grading criteria and acceptable 
mutation percentage (to parents and clinicians) are implanted b) Metaphase II 
Spindle Transfer involves the removal of the spindle from donor oocyte, which is 
replaced by the intending mothers spindle; this oocyte is then fertilised with 
intending fathers sperm c) Pronuclear Transfer involves of the removal of the 
pronuclei from both the donor and intending parents zygote and inserting the 
intending parents pronuclei into the enucleated donor zygote (Gorman et al., 
2016). Used with permission  
 
 
3.10 Mitochondrial Donation  
Mitochondrial Donation is the term used to described two reproductive techniques 
that have been at the centre of international scrutiny for a number of years, with 
intensive biological, ethical, legal, moral and religious debates emerging in 
advance of UK parliamentary debates and licensing of the techniques.  The two 
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techniques include pronuclear transfer (PNT) and metaphase II spindle transfer 
(MST). Figure 3.2 (b and c) shows the difference between the two techniques, 
which are sometimes also referred to as mitochondrial replacement. In 
pronuclear transfer the pronuclei from the fertilised donor oocyte is removed and 
replaced with that of the pronuclei from the intending parents (the pronculei  from 
the early stages of the nucleus that contains chromosomes from the egg and 
sperm). In metaphase II spindle transfer the transfer occurs before fertilisation 
and involves the replacement of the donor spindle complex with that of the 
intending mothers spindle (the spindle is a microtubule apparatus that is involved 
with the movement of chromosomes during cell division- the complex includes 
the nuclear chromosomal material). Both techniques result in the nuclear genetic 
material from the intending parents being incorporated into a zygote that contains 
mitochondria from the donor and therefore free from the mtDNA mutation 
(Gorman et al., 2016).  
Research into the potential of these techniques to prevent mitochondrial disease 
transmission dates back to 1995 (Rubenstein et al., 1995 cited in Craven et al., 
2015) eventually cumulating in the award of the first licence to practice these 
techniques being granted to Newcastle Fertility Centre, Newcastle Upon Tyne, 
UK in March 2017 as an amendment to the Centre’s existing Treatment and 
Storage license. Milestones encountered and required to facilitate this 
amendment to licence are summarised in Figure 3.3. During this period, clinical 
use of mitochondrial donation, specifically MST was first reported by Zhang et al 
(2016) and later described in full by Zhang et al (2017). The team reported the 
birth of a male child, whose percentage of mtDNA mutation ranged from 
undetectable to 9.23% across a range of tissues after the use of MST (Zhang et 
al 2017). News of the first clinical application of mitochondrial donation was met 
with controversy due to the clinical team having been said to have purposively 
travelled to Mexico where no legalisation exists against such IVF techniques 
(Palacios-González and Medina-Arellano, 2017; Chan et al, 2017). The team 
involved in this pregnancy have also reported the potential use of MST in a 
further 20 pregnancies in the first half of 2017 (New Scitentist, 2016). In addition 
to this announcement, clinical teams in the Ukraine announced the birth of a child 
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born through mitochondrial donation, for the treatment of infertility as opposed to 
the prevention of transmitting mitochondrial disease (Coghlan, 2016). 
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Figure 3.3 Timeline of Mitochondrial Donation UK approval process (1998-2017). Green boxes denote regulator activity, orange 
demote political activity. HFEA: Human Fertilisation and Embryology Association. NCFL: Newcastle Fertility Centre. Informed by 
(Craven et al., 2015) and extended with recent advance. 
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Mitochondrial donation has attracted worldwide attention and with it many varied 
opinions on its suitability as a technique. Controversy has centred on 1) 
introduction of a third persons DNA (donor mtDNA) and implications for the 
identity of children born via mitochondrial donation 2) that it is a germline 
technique that will see donor mtDNA passed onto the children of females born of 
this technique 3) safety and efficacy of the techniques to prevent mitochondrial 
disease and also the proposed surveillance of children 4) status and welfare of 
the mitochondrial donor 5) the wider societal impact of the techniques as well as 
6) investigation of the debates themselves (Castro, 2016; Haimes & Taylor, 
2017). Critiques have also centred on the misleading terminology of 
mitochondrial donation and mitochondrial replacement (Jones, 2015; Lane & 
Nisker, 2016; Nisker, 2015). Worries were that these may be heard by some to 
mean that the mitochondria ‘travel’, where it is the pronuclei or the spindle 
complex that is inserted into the donor oocyte or zygote. On this basis it has been 
suggested that ‘nuclear DNA hosting’ would be a more accurate description 
(Haimes & Taylor, 2015 p364).  
As outlined above mtDNA account for a very small proportion of DNA present in a 
single cell, approximately 0.1% (Taylor & Turnbull, 2005). The introduction of this 
small percentage of DNA resulted in media tag lines of ‘3 parent babies’ ‘3 
person IVF’ that then made their way into scholarly debates and public 
consciousness surrounding these techniques (Baylis, 2013; Dimond, 2015; 
Haimes and Taylor, 2015; Turkmendag., 2017; Dimond and Stephens, 2017). 
Claims that children born via mitochondrial donation would have three parents or 
two mothers was not supported by the Nuffield Council of Bioethic’s review of the 
techniques. The Council concluded that this should not be considered the case 
from a biological or legal perspective (Nuffield Council on Bioethics, 2012). The 
emphasis of healthy biologically related children were criticised by some in that 
they lacked information relating to other options available to women and 
‘valorising genetic connection’ (Haimes & Taylor, 2017 p5) a point at which this 
study addresses by deliberately seeking the opinions of women on all 
reproductive options available to them. In recognition of the intensive debates 
surrounding mitochondrial donation as a reproductive option for women with 
maternally inherited mitochondrial disease I sought to add a patient’s perspective 
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of these techniques to the body of literature via this study, which I believe is 
lacking in comparison to other commentaries. 
A consideration by the Nuffield Council included potential identity issues for a 
child conceived via mitochondrial donation, that he/she may have ‘confused or 
conflicted’ self-identity. In response to this query key research stakeholders 
responded that genes present on mtDNA were not linked with those responsible 
for identify-forming characteristics (Nuffield Council on Bioethics, 2012). The 
many different facets of identity and how mitochondrial donation may or may not 
impact upon them are discussed in-depth by the working group within the Nuffield 
Council and others (Watts et al., 2012; Dimond, 2015; Wrigley et al., 2015) 
Mitochondrial donation is what is termed a germline technique because female 
children born of mitochondrial donation will pass the donor’s mitochondria on to 
their children, therefore genetic modification will occur in future generations and 
further down the maternal line, the unknowns of which underpin safety concerns 
relating to the technique. Safety and efficacy of these techniques have been 
investigated over a number of years directed by the core research team and in 
alignment with the calls for additional testing by the HFEA over the course of their 
scientific reviews (Figure 3.3) (Craven et al., 2015; Wise, 2014). During the 
consultation process it was advised that mitochondrial donation be offered to 
couples as part of a research study only and that couples accessing 
mitochondrial donation should commit to long term follow-up of their child 
(Nuffield Council on Bioethics, 2012). Common critiques of the introduction of 
mitochondrial donation in parliament were in relation into the breach of the EU 
Clinical Trials Directive if mitochondrial donation were to be approved, despite 
this directive only being applicable to medicines and medical devices and would 
having no place in the implementation of reproductive technologies (HC Deb 
2015-02 col.163.169. 171.177.181.183.185). To address concerns of safety, 
efficacy and long term survilaance, in advance of the licensing application, a 
study to assess the fetal and postnatal development of children concieved using 
mitocohndrial donation was approved by a UK Research Ethics Committee as 
well as the preparation of a dedicated Mitocohndrial Donation Clinical Care 
Pathway for long term follow-up of children.  
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The role of the mitochondrial donor has been heavily debated, with many 
preferring the term egg providers as a more adequate description of their 
contribution (Baylis, 2013; Haimes & Taylor, 2015). For the purpose of this thesis 
I have decided to use the term mitochondrial donor. For those proposing 
mitochondrial donation the status of the mitochondrial donor was that of a tissue 
donor, whilst critics questioned if donors should be afforded the same status as 
gamete donors (Brandt, 2016; Turkmendag., 2017; Appleby, 2016) The 
implications of gamete status would mean that children born via mitochondrial 
donation would be able to contact the donor once they reached 18 years of age. 
In addition to contacting their mitochondrial donor, theoretically they would also 
be able to contact any siblings born via mitochondrial donation also (HFEA, 
accessed 08.09.2017). The rights of the mitochondrial donor would also be that 
of an egg donor, enabling them to access information regarding the outcomes of 
their donation as well as being restricted in the number of donations they can 
make (HFEA accessed 08.09.2017). The defence of the status as tissue donor 
was argued that although the genetic contribution of the donor was significant 
enough to prevent disease, it did not compare to that of a gamete and therefore 
should not be placed in the same category (HFEA, accessed 08.09.2017).  As 
above in the case of surrogacy, UK law does not recognise ‘genetic motherhood’ 
but only that of gestational motherhood (Nuffield Council on Bioethics, 2012 p46).  
In addition to donor rights, concerns relating to the donor and the process in 
which eggs are collected were debated. In order to become an egg donor, 
women must undergo controlled ovarian hyper stimulation (COH) of their ovaries 
in order to produce a significant number of eggs to harvest at their collection date 
(this is also the case in IVF). Those campaigning against the introduction of 
mitochondrial donation raised concerns over the possible dangers of this (Baylis, 
2013; Dickenson, 2013; Palacios-González, 2016). Ovarian hyperstimulation 
syndrome (OHSS) is caused by an excessive response to gonadotropins used to 
stimulate ovaries. Symptoms can range from the mild to the severe. It is 
estimated that 1% of women who undergo COH will experience moderate or 
severe symptoms (Royal College of Obstetricians and Gynaecologists, 2016). 
Serious complications such as venous thromboembolism (VTE) –the 
development of significant clots –are rare. Baylis (2013) writes that mitochondrial 
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donation poses a risk to egg providers, paying specific attention to the physical 
and psychological risks involved in providing eggs, and that these risks have to 
be considered by women regarding their role in ‘some else’s reproductive project’ 
(Baylis, 2013 p533). Haimes and Taylor (2015) argue that despite the 
essentialness of donors for both the development (research) and application 
(therapeutic) of the techniques they were ‘rendered invisible’ (p:360) from the 
debates surrounding them and that this was a conscious decision as part of the 
‘strategy of persuasion’ (p:361) to obscure and diminish the role of egg donor. 
3.11 Summary  
This chapter presents a summary of the nine reproductive options available to 
women. Women with maternally inherited mitochondrial disorders have, if they so 
wish, the option to access genetic counselling, provided by mitochondrial 
specialists and/or genetic counsellors. Genetic counselling aims to provide 
women with information on their individualised inheritance risk to facilitated 
informed decision-making. Providing genetic counselling to patients about 
inheritance of mtDNA mutations is troublesome to trained mitochondrial 
specialists, who find imparting complex information, which cannot be considered 
accurate, particularly discomfiting. To combat this, specialists work in large 
networks enabling access to expertise and technologies. For a number of women 
with mtDNA mutations, their reproductive decision-making precedes their 
diagnosis, therefore resulting in a proportion of women who had little or no 
reason to consider another option other than natural conception without 
intervention. There are also women who choose this option after receiving their 
diagnosis. Understanding this process is a unique contribution of this study.  
With the knowledge that they harbour about a pathogenic mutation, women may 
decide that they do not want to raise children, which is termed voluntary 
childlessness, where others may find themselves in a temporary state of 
childlessness. Adoption is an option for women, enabling them to fulfil a 
mothering role to a child, but is strictly regulated by authorities and can be 
perceived as a difficult and challenging process. Ovum or egg donation has been 
said to be the most logical ART to prevent the transmission of mtDNA mutations, 
but no empirical evidence is present in the literature around womens views and 
perceptions of this method in maternally inherited mitochondrial disorders. 
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Surrogacy provides women who are unable to carry a child the opportunity to 
have a biologically related child, which may be related to both intending parents 
or if used alongside ovum donation, related to the intending father. Surrogacy 
splits the role of intending mother and gestational mother whereby both women 
are required to work at their role, the gestational mother in distancing herself from 
the growing fetus and the biological/intending mother in establishing the desired 
relationship with the gestational mother and taking on her body as an appendage. 
Surrogacy however brings with it levels of uncertainty surrounding the 
relinquishing of the resultant child to the intending parents in which UK law 
cannot assist.  
Prenatal diagnosis and PGD techniques allow for parents to be informed of 
potential mutation loads of their growing child or their fertilised embryos 
respectively. Both offer women and their partners the opportunity to obtain 
information that could be important in establishing clinical affectedness of their 
future children, however PGD allows for the discarding of embryos in place of 
pregnancy termination. Although both techniques are available, little is known of 
women’s ideas and preferences surrounding these techniques for mitochondrial 
mutations. The newest clinically available option is mitochondrial donation. 
Although the two techniques involved differ in the point at which the nDNA is 
removed from oocyte or zygote, both techniques result in an embryo that has 
donated mitochondria, and therefore preventing the transmission of mutated 
mitochondria. Due to the germline implications of these procedures, lengthy 
debates in numerous areas have taken places over decades. This thesis 
explores how women, who themselves may be eligible for this treatment (as well 
as their daughters and maternal family members) view mitochondrial donation 
techniques.   
Throughout this chapter, key components that make up uncertainty present 
amongst reproductive options especially in relation to ambiguity, vagueness, 
unpredictability, and unfamiliarity. In the following chapter I will detail the 
methodological approach that was taken to conduct this study and the practical 
methods of designing, setting up, conducting the study and analysis of study 
results. 
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Chapter 4. Methodology and Methods 
4.1 Introduction 
Within this chapter I address the theoretical and practical issues that presented 
throughout the conduct of this study. Initially, I outline the methodological framework 
that was chosen for this work and the underpinning theories behind this framework. I 
then move on to the ethical and institutional approvals required to initiate the study. I 
describe the research population, sampling methods and introduce the participants 
along with the key health professionals they encountered. I further define how 
interviews were conducted and recorded and provide a step-by-step guide to the 
data analysis methods used throughout the study and how the resultant themes 
were revealed. I will show in detail how the proposed conceptual model of 
reproductive decision-making in maternally inherited mitochondrial disease evolved 
across a number of different versions. I will, throughout each section, include my 
personal reflective practice and where applicable any amendments to processes and 
reasons why they were implemented.  
4.2 Methodology  
Qualitative methodology was chosen to examine the experiences of women with 
mtDNA mutations and reproductive decision-making as it allows for rich and varied 
data to be collected. However qualitative research is commonly associated with a 
lack of scientific rigor. This criticism is often based on ideas that data is only 
anecdotal, subjective to the researcher and therefore open to bias and that findings 
lacks reproducibility (Mays and Pope., 1995). Ways in which to address the reliability 
and validity of qualitative research is discussed in Section 4.8. 
In this section I will detail the methodology used in this research. Krauss, (2005: 
p758) defines methodology as identifying ‘the particular practice used to attain 
knowledge’. Guba and Lincoln (1994: p108) note that ‘inquiry paradigms define for 
inquirers what it is they are about’ and within this, the limits of legitimate enquiry are 
set out. They believe that a researcher’s response to three fundamental questions 
can define an inquiry paradigm, these being the ontological question, the 
epistemological question and the methodological question. I will therefore outline the 
theoretical approaches used and how aspects of constructivist grounded theory was 
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employed throughout fieldwork and interpretation. To begin, I will discuss the 
ontological and epistemological stance taken in this study.   
4.2.1 Ontological Approach  
It is argued that ontology and epistemology sit alongside one another and that 
ontology informs the theoretical perspective as, ‘Ontology is the study of being’ 
(Crotty, 1998:p10). Paradigms or a person’s set of beliefs can be charted on a 
spectrum ranging from positivism, the belief that enquiry enables you to know exactly 
what something is or how it works through to constructivism where there is an 
assumption that knowledge is created between the researcher and the respondent 
during inquiry (Guba and Lincoln 1994). Positivism as a theoretical perspective is 
underpinned by objectivism (Crotty, 1998) and has been described as dominating 
science, focusing on the quantitative analysis of phenomena, independent of social 
relationships or encounters and ‘providing a single apprehensible reality’ (Perry et 
al.,1999: p16). 
Differing from positivism, realism is an ontological perspective that acknowledges 
multiplicity of realities and goes further by suggesting that each reality has equal 
validity (Krauss et al., 2005 p761) and that a difference exists between reality and a 
person’s perception of reality (Bisman 2002 cited in Krauss et al, 2005: p761). This 
understanding is grounded in the phenomenon described as ‘multiple realities’ 
(Krauss et al., 2005), where each person experiences life from their own perspective 
and therefore has multiple different realities. 
As we have seen in Chapter 2, decision-making is complex and can be dependent 
on an individual’s lived experience, beliefs and values, meaning that each person’s 
views on an issue or decision renders them in their own internal reality. The study 
described in this thesis is primarily concerned with woman’s experiences of 
reproductive decision-making, understanding women’s multiple realities and how 
these are influenced by their experiences and what meanings are placed on them. 
Acceptance of these multiple realities is essential in order to be open to emergent 
phenomena not previously described in this study group. Taking this approach also 
accepts that social conditioning of a researcher impacts on their knowledge of reality 
and is not independent of social actors (Dobson, 2002). 
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The ontological approach taken in this study was one of ‘subtle realism’ 
(Hammersley, 1992; Seale, 2006) where I acknowledge that realties discussed in 
this thesis are only known via my own interpretation of accounts constructed by 
others. By adopting this approach, I am attempting to explore and represent these 
realities as opposed to ‘truth’. I seek to compare these multiple realties to one 
another and to existing literature on associated topics. 
4.2.2 Epistemology  
It is argued that knowing the lens in which a researcher approaches an inquiry is an 
important step in understanding the study design methodology employed within a 
study (Dobson, 2002). Choosing the appropriate theoretical approach to take to 
examine decision-making as opposed to a set paradigm was an important step in the 
design of this study. For this I see myself as adopting an epistemological approach 
of social constructionism, which is in harmonisation with ontological perspective of 
subtle realism. Crotty (1998) defines constructionism as an epistemology where 
  ‘Truth or meaning comes into existence in and out of our engagement with 
 the realities in our world. There is no meaning without a mind. Meaning is not 
 discovered, but constructed’ (Crotty, 1998:p 8-9) 
 
In this, Crotty (1998) tells us that people construct meaning differently to one another 
and that an object or a phenomenon does not have an existing meaning already 
attributed to it, simply waiting to be discovered. Social constructivism states that it is 
a person’s culture that dictates how they see or don’t see an object or a meaning 
(Crotty, 1998). In taking this approach, I have actively considered the culture in 
which I have been part of prior to and during the course of this project and how this 
is reflected in the meaning that I have attributed to the phenomena I seek to present 
in this thesis.  
4.2.3 Symbolic Interactionism  
Blumer (1969) notes that every individual has the capacity for thought, which is 
shaped by our social interactions (as cited in Crooks, 2010:p14). This capacity lends 
itself to the ability to associate meanings and symbols with the expression of 
thought, which is further modified by interactions with others and with one’s self 
(Crooks, 2010). These interactions go on to enable a person to understand a 
 76 
 
situation they find themselves in and to make choices. Symbolic interactionism is an 
established theory in health and illness research (Crooks, 2010). 
4.2.4 Constructivist Grounded Theory  
The research strategy for this study was fundamentally informed by Constructivist 
Grounded theory. Constructivist grounded theory requires no defined hypothesis of 
the phenomenon under study but for the phenomenon to emerge from the data as it 
develops. It originates from the work of Glaser and Strauss (Glaser, 1978; Glaser & 
Stauss, 1967) and informs recruitment, sampling, method and analysis.  
Grounded theory was first introduced when positivist epistemology was dominant, in 
response to claims that qualitative inquiry was not ‘scientific enough’. Defining 
components of the practice of grounded theory included the simultaneous 
involvement of data collection and analysis, developing analytical codes from the 
data, memoing, comparing data throughout the inquiry to permit the development of 
theory, using sampling methods that sought to construct theory as opposed to 
representing a population and to conduct literature searches after analysis (Glaser, 
1978; Glaser & Stauss, 1967). 
The original form of grounded theory received criticism from other qualitative 
researchers over time in that it assumed that the researchers performing the analysis 
did not bring their own interpretation to the data, echoing the positivist approach to 
inquiry. In its earliest form Glaser and Strauss had provided strategies to be applied 
to data analysis in an attempt to reflect the language and tone of quantitative 
methodologies. Over time grounded theory has been developed. Constructivist 
grounded theory, developed by Charmaz (2006) is the methodology that was applied 
to this study. Charmaz (2006) not only acknowledges the researcher in the process 
of data analysis but that their approach ‘assumes that any theoretical rendering 
offers interpretative portrayal of the studied world not an exact picture of it’ (Charmaz 
2006:p10). Charmaz (2006) writes that unlike traditional grounded theory  
 ‘Neither data nor theories are discovered. Rather we are part of the world we 
 study and the data we collect. We construct our grounded theories throughout 
 past and present involvements and interactions with people, perspectives 
 and research practices’ (Charmaz 2006:p10) 
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A feature of constructivist grounded theory then, is how it frames the interviewee-
interviewer interaction as collaborative (Crooks, 2010). Crooks (2010) notes that 
selecting grounded theory the ‘researcher-participant relationship becomes the 
interactive context’, this relationship allows for the researcher ‘to understand the 
perspectives of women, women’s ways of coming to know their health issues’ 
including ‘strategies and processes to help them through a situation’ (p24). Rapley 
(2004) states that qualitative interviews are collaboratively produced between the 
interviewer and the interviewee and that the interviewers are active participants in 
the construct of the interview.  
In addition to the above grounded theory methodologies of data analysis, Charmaz 
(2006) also included mapping of data as part of memo writing. Mapping or clustering 
of data allows for a visual perspective of data and can assist with analysis of 
complex and overlapping codes and relationships.  
This approach has shaped both data collection, analysis and interpretation of data in 
this study. Throughout this thesis I aim to be transparent with regards to my 
worldview, my concurrent role as a member of the ‘sometimes known’ research 
team, which can be seen in my field notes and memos (omitted from the appendix to 
prevent patient identification but available upon request).  
Interactions with my participants as a researcher led to changes in the interview 
schedule and most notably the interview aid relating to reproductive options (see 
section 4.5). 
4.3 Data Collection  
4.3.1 Ethical Approvals  
National ethical approval for this study was obtained from North East Newcastle and 
North Tyneside NRES Committee 1 in June 2014 (14/NE/0144). Two substantial 
amendments were notified to and approved by the Committee (Amendment 01 
28.03.2015 and Amendment 02 11.03.2016). Details of these amendments are 
described below. I attended the review meeting and received favourable opinion 
after one minor typographical change was made to the Partner/Relative and Close 
Friend Information Sheet. 
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The ethical challenges foreseen within this study included  
a) The emotive nature of the topic in both study arms (retrospective and current 
and prospective decision-making groups) 
b) The potential of clinical questions being directed to the non-clinical researcher  
c) Discussions on topics that raised safety concerns for the women or others 
d) Data Protection and Confidentiality  
e) Managing and supporting the emotional needs of the researcher. 
4.3.1.a Emotive Nature of Reproductive Decision Making  
Women who suffer from or who harbour a mtDNA mutation may face difficult 
decisions regarding their reproductive options, complicated further by the difficulty in 
predicting risks to both the mother and future child. Researching topics of this nature 
requires a sensitive approach and study design. Discussion around what constitutes 
a sensitive topic has been discussed by a number of authors, including Siber and 
Stanley (1988) who state that sensitive research is that which can be harmful to the 
participant and/or the research team investigating it. Lee and Renzetti (1990) explore 
the meaning of sensitive topics and they consider the costs incurred by the 
participant during the process, these costs may include psychological costs such a 
guilt or shame but also consequential costs of prosecution if disclosing an illegal act. 
Lee and Renzetti (1990) define a sensitive topic as  
 one which potentially poses for those involved a substantial threat, the 
 emergence of which renders problematic for the researcher and/or the 
 researched the collection, holding, and/or dissemination of research data
 (Lee and Renzetti 1990:p513) 
 
This approach believes that the topic itself is of less concern but when introduced 
into the context of the research interview, it becomes sensitive. Cassell(1980) and 
Ramos (1989) both argue that by assuming that a research topic is harmful you exert 
power over the participant, taking away their own ability to control how and what is 
said during the interview process. I approached interviews with an understanding 
that the topic may be more sensitive to some women than others, which was in fact 
what was observed. To address the potential of distress at the outset of this study, 
detailed information sheets for each study group were provided (along with a specific 
information sheet for potential interview attendees - Appendix A2). These information 
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sheets outlined that the topic of reproductive decisions would be covered in the 
interview, which may cause some distress to some women, and that their 
participation was voluntary.  
Eighteen women were interviewed as part of this project; they were offered a choice 
of locations in which to take part in the study. Women were informed that on the day 
of the scheduled interview or at any point during the interview they felt distressed or 
upset they could cancel, postpone, pause or terminate the interview. Women were 
offered a choice of interview location to reduce the inconvenience of taking part in 
the study, nine interviews took place at the participant’s home, one interview took 
place in a public space (coffee house), four at their place of work (meeting room), 
two in the outpatient clinic at Data Collection Centre 1 and two at a clinical research 
facility at Data Collection Centre 1. Interviews conducted at Data Collection Centre 1 
occurred in private consultation or meeting rooms and were arranged before or after 
the woman’s scheduled clinical review. The interview conducted in a public space 
was at the request of the participant, when asked if confidentiality of the location 
would pose an issue, the woman was happy to conduct the interview without 
concern. Two follow-up interviews were conducted over the telephone. 
Participants in qualitative enquiry are said to have more control of the research they 
are taking part in than in other biomedical research (Cassell, 1980) often having the 
control over the research setting and the context especially in unstructured 
interviews. Elwood and Martin (2000) suggest that allowing research participants the 
choice of interview location may enable them to feel more empowered with their 
interaction with the researcher and that this permits the researcher to observe the 
social geographies of the participant (Larossa et al 1981 cited in Corbin and Morse 
2003). Corbin and Morse (2003) claim that research conducted in the homes of 
participants is more likely to elicit information that may not have been offered had the 
interview been conducted elsewhere. Whereas other writers believe that interviews 
in the homes of participants may disrupt power hierarchies, they do not erase power 
differences (Oberhauser (1997) and Falconer-Al Hindi (1997) cited in Elwood and 
Martin 2000). I do not believe the location of the interviews necessarily affected the 
topics discussed by women but providing a choice permitted women to be able to 
choose the space in which they shared their experiences. This choice of location 
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was commented on by participants as helpful and convenient and enabled them to 
take part in the study more easily. 
Information sheets and consent forms were provided to any attendees who 
accompanied women during the interview. No questions were directed to attendees, 
however it was felt that to best support women they should be given the option for 
their partner/ relative or close friend to be present. Three of the twenty interviews 
included the woman’s male partner - these were all in the clinical setting - in two 
interviews conducted at home, male partners were in an adjoining room with an open 
door.  
Finally to support the women further, it was arranged with them that I would contact 
them by their preferred method (telephone/email) approximately seven to ten days 
following the interview. Smith (1992) states that leaving a participant in distress 
following an interview is ‘morally wrong’ and to ensure that this was not the case I 
purposively enquired as to whether they had been left feeling upset of distressed by 
any topics covered. Women were advised if at any point following the interview 
(immediately after/the weeks or months following) they felt distressed that they could 
contact me directly. With this information I could inform their clinical care team, who 
could then send a review appointment to the woman taking part or make a referral to 
the appropriate NHS service.  
It was not uncommon during the interviews for women to become upset and there 
were often tears when discussing topics, especially the topic of inheritance risk and 
feelings of guilt. At these moments I asked women if they wished to suspend or 
terminate the interview. Only one interview was suspended with the tape recorder 
turned off to allow for composure before recommencing (at the request of the 
participant). The majority of the women wanted to continue to discuss the topic and 
afterwards told of how they felt better having had a chance to think and reflect on 
their feelings. This is seen also in the work of Elmir et al (2011) who described their 
participants experiences as cathartic and providing a sense of relief. Initially I felt 
uncomfortable in these circumstances but over the course of the study I felt better 
able to deal with these incidents, with support of the study support team (see section 
4.3.1.e).  
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4.3.1.b Clinical Questions from Women and Attendees  
As a non-clinical researcher it was a personal concern of mine during the design of 
the study that I might be misinterpreted as a clinician or someone with medical 
training. This raised the potential of participants asking clinical questions or 
clarifications and also women may not have felt able to give critiques of Data 
Collection Centre 1 to which I was associated by means of my employment. The 
potential impact of being known or being perceived as a medically trained individual 
performing qualitative interviews has been explored, with Hoddinott and Roisin 
(1997) comparing disclosure of professional training versus withholding in research 
interviews. Richards and Emslie (2000) reported the differences between the 
experiences of a GP’s fieldwork compared to a sociologist researching the same 
patient population. Participants perceived the GP as having a high status and her 
profession over shadowed perception of her personal characteristics, whereas the 
sociologist was often asked if she was a student (which she was not) and identified 
as ‘the girl from the university’ (p74). Differences in interview content was also 
observed, with those interviewed by the sociologist discussing broader and not 
always health related issues, whereas topics in the interview with the GP remained 
predominately health based (Richards and Emslie 2000).  
To try to prevent this I introduced myself to women as a member of the research 
group and that the project was to inform my PhD thesis. If at any stage a clinical 
question was asked, or they sought clarification of previously given clinical 
information I informed women that I was unable to answer or clarify but would feed 
any queries they had back to the clinical care team with their permission. This was 
acceptable to the women and did not raise an issue for them. I addressed the 
potential of women feeling that they could not provide a critique of the service 
provided by Data Collection Centre 1 by purposely asking for ways in which their 
experience could have been improved.  
4.3.1.c Discussions on Topics that Raised Safety Concerns from Women and 
Others 
As part of the informed consent process women and attendees (if applicable) were 
informed that their personal information and discussions would only be shared 
(without their consent) with their clinical team or other appropriate services if they 
raised safety concerns of the researcher. Two interviews raised concerns that were 
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discussed with supervisors and wider team, following transcription (Sarah) and 
immediately following the interview (Wendy).   
Whilst transcribing Sarah’s digitally recorded interview it became evident that she 
may have misunderstood a clinical diagnostic test. This was discussed with a 
supervisor and it was agreed that this should be fedback to her mitochondrial 
clinician. Sarah was then contacted to further explore her understanding of this 
particular test and the issue was confirmed resolved.  
The second incident occurred in the hours following Wendy’s interview. Wendy was 
evidently distressed at the outset of the interview (the interview was paused and only 
continued in accordance with her wishes) this distress was centred on her struggle to 
come to terms with her diagnosis and how she had received this. With her consent 
this incident and her request for specific counselling was communicated with the 
whole supervisory team, and then directed to her mitochondrial clinician. 
4.3.1.d Data Protection and Confidentiality  
The confidentiality of women, attendees and any other persons discussed during the 
course of interviews (clinicians/ family members) was of utmost importance 
throughout the lifetime of the study. As mitochondrial disease is a rare disorder care 
has been taken when discussing potentially traceable identifiers, use of quotations 
and tabulated participant information (Table 4.3). Where important to maintain 
confidentiality, aspects of the data have been amended to prevent potential 
identification, such as specific relationships to family members. 
The mitochondrial research nurse contacted potential participants and obtained their 
consent that I may contact them, this was sought in advance of me being informed of 
their details. Women and their interview attendees were reassured that data 
collected would be anonymised when reported. As described to participants, all 
those who took part in the interviews were assigned a pseudonym, a conscious 
decision, as I did not feel that study numerical identifiers alone were appropriate. Any 
family member, friend or colleagues discussed in the interview were also provided 
with a pseudonym.  
Care has been taken when participants have identified clinical professionals, not only 
from within the mitochondrial clinical community but across a multitude of medical 
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specialities. All medical doctors have been referred to as male to prevent the 
identification of female doctors who are easily identifiable in the UK mitochondrial 
and reproductive medicine community (see also section 4.4.6). Male gender was 
chosen as both a practical consideration, to avoid the amendment of large sections 
of data and out of concern that identifying all clinicians as female may lead to 
subconscious association to female clinicians by future readers. I decided to retain 
the gender of the nursing staff but there has been no distinction between nursing 
roles (clinical or research) when discussed by women to prevent identification of 
individuals. I have also removed NHS Trust Logos, names and contact details 
provided in appendices (Appendix A2) 
Newcastle University requires that primary research data from this study be held for 
10 years after study end. Newcastle Upon Tyne Hospitals NHS Foundation Trust 
acted as Sponsor for this study. In accordance with their policies, regulatory data 
from this study will be held for 5 years after the study end. Storage of research data 
and regulatory data will continue to be in line with the Department of Health’s 
Research Governance Framework, Newcastle University’s Policies and Procedures, 
the Data Protection Act 1998 and International Conference for Harmonisation Good 
Clinical Practice (ICH GCP) principles.  
All paper-based data is stored in a locked cabinet in a locked office, behind access 
controlled entry doors in the Medical School at Newcastle University. All electronic 
data (including digital audio recordings) are stored on file servers, which are 
password protected and backed up regularly. Digital audio recordings will be deleted 
from file servers 6 months after final data analysis. 
4.3.1.e Managing and Supporting the Emotional Needs of the Researcher  
Lee and Renzetti (1990) tell us that research may also be harmful to the researcher. 
During the design of this study I prepared for interview conduct by attending training 
events about qualitative research. Identified early on in this process was the 
provision of emotional support for myself through the study. There is a great body of 
research which also documents the need to protect the researcher conducting 
interviews which are sensitive in nature (Dickson-Swift et al., 2006 ; Dickson-Swift et 
al., 2008). To try to minimise this, a support team comprising of study supervisors 
and nursing staff was formed, to allow for confidential discussions about topics 
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discussed in interviews. This was provided consistently through the study and on an 
ad-hoc basis when required. This was especially important for a particular interview 
that resembled personal experiences of my own family members. Thompson (1995) 
writes that a shared traumatic experience between the researcher and participant 
can benefit the research process, I felt that this particular interview analysis and 
subsequent data analysis was enriched by this experience. I managed the emotions 
that were raised at this time by discussing them with the support team, which was 
most important to me during the analysis and re-analysis of interview transcripts and 
associated memos. I am also grateful to fellow PhD researchers within the Institute 
of Health and Society who provided support with coping mechanisms for handling 
emotive topics during data analysis.  
4.3.2 Institutional Approvals   
The study was sponsored by Newcastle Upon Tyne Hospitals NHS Foundation Trust 
(NuTH). Sponsorship included indemnity for the conduct and management of the 
study. Insurance for the design of the study was provided by Newcastle University.  
In advance of the study start date I was required to update my research passport 
with Data Collection Centre 1 that permitted me to access clinical information for my 
position as clinical research manager. This allowed me the opportunity to include 
conducting patient interviews in my approved activities; this amended approval was 
provided in June 2014.  
Research and Development (R and D) approval was obtained in July 2014, which 
enabled research interviews to physically take place at Data Collection Centre 1 if 
preferred by the woman. Additional clinical research department approval was 
granted May 2014.  
National Institute for Health Research (NIHR) adoption for the study was granted in 
August 2014. This status permitted access to service support costs to aid with study 
recruitment.  
Described below in section 4.3.4 patient recruitment was facilitated by approval from 
the MRC Mitochondrial Patient Cohort - A Natural History Study and Patient Registry 
(13/NE/0326) Oversight Committee (MDOC). As the research manager of the 
Mitochondrial Cohort (MitoCohort), who processed all approvals I removed myself 
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from this role and was deputised by the Chief Investigator and mitochondrial 
research nurse. I was temporarily removed from the MDOC universal email address 
that provided national review of my application to contact potential patients (via 
research nurse as gatekeeper) and subsequently I refrained from accessing any of 
these documents when reinstated. MDOC approval was granted in May 2014. 
Although approved, postal invitation via the MitoCohort was not tested, as all 
participants who took part were approached in outpatients or via their family 
members. 
4.3.3 Informed Consent  
Informed consent to participate in research has throughout my research career been 
extremely important to me and I felt this was even more so in this research setting. 
As described above, care was taken to inform the women of the potential for distress 
given the interview topic and the support mechanisms in place to minimise any 
distress to participants. I had attended previous NIHR Informed Consent training for 
my Masters research project and have continually renewed by ICH GCP certificates 
in research since 2008 to ensure up to date training in research conduct. Potential 
participants in the study were given a minimum of 24-hour period to consider taking 
part, but in most cases exceeded 7 days (Figure 4.1). 
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Figure 4.1Recruitment and Informed Consent Flowchart 
 
4.3.4 Research Population  
In line with the research objectives I wanted to interview women who had previous 
experience of reproductive decision-making (retrospective group) and women who 
were currently or prospectively considering their reproductive options (current and 
prospective group). It was evident from the outset that these groups could also 
include sub-groups of women (Table 4.1). Gathering the experiences and opinions of 
these women would allow for a more detailed understanding of how reproductive 
decision-making has been and is being viewed by this patient population. An attempt 
was made to include women from each sub group within the study sample.  
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Retrospective Group Current and Prospective Group 
Affected women (diagnosis 
unknown) who went on to have an 
affected child/children 
Women who are making imminent 
reproductive decisions (<2 years) 
Affected women (diagnosis known) 
who went on to have a child/children 
who were affected/unaffected 
Women who may be looking to make 
a reproductive decision in the near 
future (<5 years) 
Affected women (diagnosis known) 
who did not go on to have a 
child/children 
 
Table 4.1 Study Groups and potential patient sub-groups. 
 
Inclusion Criteria 
1. Females with a known mtDNA mutation between 16 and 65 years of age 
2. Capable of giving informed consent  
3. Able to read and converse in English (to ensure informed consent as funding 
for an interpreter was not available) 
Additional Inclusion Criteria (Retrospective Group) 
1. Females with a known mtDNA mutation who have made a reproductive 
decision in the last 212 years 
Additional Inclusion Criteria (Current and Prospective Group) 
1. Females with a known mtDNA mutation who were currently or who may be 
looking to make a reproductive decision in the near future (<5 years) 
                                            
2 *Amendment 1 permitted the increase in age of 5 years (see section 4.4.2) 
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During the design of the study, the purposeful inclusion of partners (male or female) 
was discussed, although the investigation of this additional group was thought to be 
too difficult to accommodate within the scope of this PhD thesis. Their inclusion, if 
wished by the participant was included into the design, with specific consent to use 
any contributory data (Appendix A2). Their inclusion at the request of the woman, so 
that they could offer additional support to them, was especially important given the 
topic of the interview. 
Analysis has not focused specifically on the attendee’s data unless in direct relation 
to the topic being discussed by the woman (all 3 attendees were male partners of 
women interviewed). The study did not exclude homosexual couples, during 
sampling the inclusion of homosexual partners were discussed with the clinical team 
but there were no women known to be in a same sex relationship.  
Inclusion to the study was also controlled for by geographical location. During the 
course of design and study set up, the MitoCohort had two other applications 
(Studies A and B) to interview women with a mitochondrial diagnosis regarding their 
reproductive options. In order to accommodate three similar studies and in the best 
interests of patients, the decision to split the country into three separate geographical 
areas (taking into account patient populations) was made by the MitoCohort Chief 
Investigator.  
This study was assigned the North East, Yorkshire, North West of England and 
Scotland. The geographical split is illustrated in Figure 4.2; each allocated area was 
equal in the proportion of eligible patients. Study A recruited women with a single 
mtDNA mutation (m.3243 A>G) and Study B recruited women with either nDNA or 
mtDNA mutations. 
 89 
 
 
Figure 4.2. Geographical sampling locations superimposed onto population map of 
reported mitochondrial disease patients. Red Area: local project, Blue Areas: Study 
A and Green Area: Study B 
 
A study initiation meeting was conducted in which all those involved in eligibility 
review were invited and training on the protocol given when all approvals were 
received (July 2014). Eligibility screening was conducted by the clinical team, which 
included consultants in neurology and reproductive medicine, speciality training 
registrars, mitochondrial specialist nurses and research nurses. It was especially 
important that those who conducted eligibility were familiar with the women to take 
into account potential scenarios where approach to take part may cause distress, 
such as recent bereavement or personal or family members declining health. 
This eligibility review included consideration of physical and emotional status before I 
was informed of their potential inclusion. This enabled the clinical and research 
teams to select women who were assessed to be emotionally stable to take part. 
Two potentially eligible patients where not contacted to take part in an interview 
when assessed due to their then current emotional distress surrounding dealing with 
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their progressing condition or still processing their diagnosis. A key benefit of the use 
of gatekeepers in this study was their expertise in the very specific and rare patient 
population (Arcury & Quandt, 1999). A criticism of this method of gatekeeping was 
that at times there were internal differences about the appropriateness of certain 
women to be approached to participate. This may have meant that some potentially 
interesting individuals were not included in this study. The roles of these gatekeepers 
were key to the study and to those who took part.  
4.3.5 Sampling  
Purposive sampling was used in this study, in order to understand the wide range of 
experiences of reproductive decision-making in maternally inherited mitochondrial 
disease. Patton (1990) tells us that ‘qualitative inquiry typically focuses in depth on 
relatively small samples selected purposively’ (p169), where logic and power is 
based on selecting information rich cases that allow for in-depth study. Charmaz 
(2006) supports this by writing that a study ‘based upon rich, substantial and relevant 
data stands out’ (p18). This approach allowed for me to adapt questions asked 
throughout the study and focus on emerging themes.  
To include as many experiences as possible, those women who fell into the sub 
groups above (Table 4.1) were sought out. The purpose of which was to allow for in-
depth illumination and explanation (Patton 1990).  
Sampling occurred over three distinct time periods (Table 4.2) and included in Round 
One ‘typical’ case patients identified in outpatients at Data Collection Centre 1 (n=6). 
Round Two included mixed purposive sampling methods, ‘extreme/deviant case’ 
‘identification’, ‘convenience’, ‘chain identification’ and ‘stratified purposeful’ 
(Patton1990) (n=9). Round Three was a final analysis checking round that included 
approaching former current and prospective women interviewed in Round One and 
Two for a follow-up interview (n=2). This was specifically to investigate the notion of 
change over time presented in the conceptual model of reproductive decision-
making and was part of Amendment 2 to the study. A targeted sampling approach 
was used to recruit new participants into the current and prospective group (n=3), 
this was deliberate to address the imbalance between the two study groups 
previously observed and to interview women who in theory may have access to the 
then newly licenced mitochondrial donation technique. Women who were known to 
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have expressed a recent interest in discussing their reproductive options with their 
mitochondrial clinician were approached to participate in Round Three.  
What is important to note is that Round One occurred before final parliamentary 
debates occurred in February 2015, in which both Houses of Parliament approved 
mitochondrial donation techniques for women at risk of transmitting a mtDNA 
mutation to their child. Therefore these first six interviews took place before anyone 
could be sure that these techniques could be developed further.  
Round Two occurred in the months preceding the favourable vote and amendment in 
The Human Fertilisation and Embryology (Mitochondrial Donation) Regulations 
2015.  It was felt by many in the clinical and research communities that mitochondrial 
donation would be available within 12 months of this legislation, however the license 
required by the regulators (HFEA) for the introduction of this techniques was not 
granted until March 2017.  
Round Three took place from May-June 2017, following the award of the license and 
after the introduction of a specific reproductive choices clinic at Data Collection 
Centre 1. 
The timing of each round is important when assessing the context of the interviews, 
specifically relating to the political and regulatory landscapes governing access to 
the mitochondrial donation, as well as the intense focus on reproductive decision-
making for these women from many different perspectives, including bio-ethical, 
religious and legal communities discussed previously in Chapter 3. Conducting study 
interviews over the last three years considering the above and in conjunction with 
grounded theory supports the research conclusions and recommendations. 
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Round One Two Three 
Political/ 
Regulatory 
Landscape 
Prior HFEA MD 
Donation 
Amendment 
Post HFEA MD 
Donation 
Amendment 
Post MD Licence 
Award. Initiation of 
Reproductive Choices 
Clinic 
Type Typical case 
sampling 
Mixed purposeful 
sampling  
Opportunistic sampling 
(follow-up) and theory 
based sampling (new 
interviewees)  
Total Number of 
Women and 
Attendees 
6 (1 Attendee) 
 
9 (2 Attendee’s) 
 
5  
Retrospective 
Group 
3 6 0 
Current or 
Prospective 
Group 
2  3 3 
Pregnant Group *  *1 0 0 
Follow Up  
(Current or 
Prospective Group) 
N/A N/A 2 
Table 4.2 Sampling methods and recruitment table. * (included in retrospective 
group during analysis- see section 4.6) 
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Data from transcripts and field notes from Round One were analysed between 
October 2014 and March 2015 in which emergent categories and themes were 
identified and the interview schedule amended (Appendix B2). These categories 
centred on discovery of their diagnosis, when/how and who women spoke to 
regarding their diagnosis and inheritance risk (termed disclosure), relationships with 
clinical care teams and their own reproductive pathway. During this period of 
analysis, I was able to look critically at the data and to identify those women who had 
not yet been included in the sample. This included women who had continued to add 
to their family many years after diagnosis and what drove them, multiple family 
member perspectives and those who were extremely proactive in seeking future 
access to mitochondrial donation as their preferred option. Actively seeking out these 
groups lead to the mixed sampling approach of Round Two, which included 
participants identifying female members who met some of the above criteria (chain 
identification).  
In addition, data from Round One was restricted with regards to what women thought 
about all available reproductive options. Instead only those options that they had 
personally considered were discussed. This lack of information meant that those 
options, which appeared, be the ‘least popular’ such as ovum donation, surrogacy or 
adoption were not included. This lead to the introduction of a specific Interview Aid 
(Appendix B2) into Round Two.  
This interview aid listed available options and a short explanation of each option. The 
information provided was reviewed and approved by supervisors for accuracy and 
appropriateness. This aid was amended following the first interview, when Wendy 
identified that the option to ‘just not have children’ was not listed. This was added to 
version 2, which was used throughout the remaining interviews.  
4.3.5.a Sample Size 
In total, twenty interviews were conducted in this study, sixteen people were 
interviewed once (n=16 interviews), and two were interviewed twice (n=4 interviews). 
I collected data until I was satisfied that it was rich and sufficient (Charmaz, 2006), 
evaluated by assessing my data against Charmaz (2006), recommendations of  
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a. Has enough data been gathered to understand the context of the 
study? 
b. Have detailed descriptions of a range of participant’s views been 
obtained? 
c. Does the data expose what is happening under the surface?  
d. Does the data reveal change over time? 
e. Have multiple accounts of data (in this case decision making) been 
obtained?  
f. Has the data allowed for the development of analytical categories?  
g. Has the data provided the ability to make comparisons and how do 
these comparisons generate and inform ideas?  
The third and final round of interviews (n=5) allowed for me to address the key codes 
and categories discovered further and to test the proposed conceptual model of 
reproductive decision-making in maternally inherited mitochondrial disease making 
(see section 4.7).  
4.3.5.b Recruitment Challenges  
An initial limitation of the sample included in this study was that the clinical team at 
Data Collection Centre 1, whom were acting as gatekeepers were familiar with more 
women who would be categorised in the retrospective group. Familiarity was built 
over a number of years caring for these women and may have already included their 
assistance in the reproductive histories of these women. The number of women 
actively seeking advice regarding their current and prospective reproductive options 
were fewer and this lead to the initial imbalance between the two study groups. This 
disparity was addressed by specifically approaching women in the third sampling 
round who would be considered in the current or prospective arm.  
4.4 Participants   
As specified above I refer to those who took part in this study as ‘women’ or 
‘participants’. I have assigned all those interviewed and the individuals discussed in 
their accounts with pseudonyms, I use these names throughout this thesis. I have 
chosen to do this to highlight the personal nature of this work.  
In total I conducted 20 interviews, 18 of which were primary interviews and two 
follow-up interviews. Travel and accommodation costs incurred from participating in 
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the study were reimbursed. In total there were 10 women who were categorised as 
in the retrospective decision-making group and eight women categorised as in the 
current and prospective for data analysis. One woman was pregnant at the time of 
the interview, and was included in the retrospective group as she was actively trying 
to conceive at the time of her diagnosis. The number of pregnancies and the number 
of children were not specifically asked alongside the demographic information but 
were included in the Interview Schedule. This information has been excluded in 
Table 4.3 to maintain the anonymity of the women.   
Demographic information was collected from participants directly at the outset of the 
interviews, outlined below. I did not ask participants directly, but only two of the 
participants were non-white British. All participants spoke English as a first language 
or were fluent in English as a second language. As previously outlined all 
participants accessed via the MitoCohort lived in the North of England and Scotland, 
with the exception of one participant accessed outside the scope of the MitoCohort 
who lived in South East England. Women represented a range of occupational class 
groups as defined by the ONS, 2010 (with the exception of group 8) and working in 
public, private and charitable sectors3. Educational attainment ranged from school 
leavers to those with postgraduate qualifications.   
Giving the rarity of maternally inherited mitochondrial disease and the geographically 
restricted sample I have chosen to provide limited information on the participants in 
this thesis when not relevant to the issues explored. I have been cautious with the 
potential identification of participants to professionals who by the nature of the 
specialised care provided to women may recognise patients based on diagnostic 
pathways, family and reproductive histories.  
The following demographic information was included in the interview schedule, 
considered initially to be potential influential factors.  
 
                                            
3 Office of National Statistics Standard Occupational Classification (ONS, 2010) has 
been used as an objective tool to describe relevant participant demographics, based 
on information that was made available during the interviews. 
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1. Disease Mutation  
2. Age  
3. Religion 
4. Relationship Status  
5. Educational Attainment  
6. Employment status and sector 
4.4.1 Disease Mutation   
All women identified as eligible to participate had a known mtDNA mutation, but 
women were asked at the start of their interview whether they knew what type of 
mitochondrial disease they had and if they knew their particular mutation (see 
Chapter 5). As was expected, the most common mutation m.3243 A>G was most 
prominent in the study sample (n=11), with others including m.8344 A>G (n=2), 
single large-scale deletions (n=2), m.11778 G>A (n=1), m.3460G>A (n=1), and one 
other rare mtDNA mutation not yet defined at the time of the interview. The numbers 
of each mutation have purposively been included here but otherwise omitted from 
Table 4.3 and throughout this thesis to prevent potential identification.  
4.4.2 Age  
The age of the women in both study groups ranged from 24 to 63 years of age, the 
age range in the current and prospective group was 24-39 years and the 
retrospective group, 34-63 years. Original ethical approval included women from 16-
60 years of age, Amendment 01 included an increase in the age of eligible 
participants to permit the inclusion of potential grandmothers whose daughters faced 
current decision-making, increasing the maximum age to 65. Age ranges of 4 years 
have been included in Table 4.3 to minimise the risk of potential identification.  
4.4.3 Relationship Status  
Relationship status was gathered to understand the position of each participant at 
the time of the interview. Within the sample, 12 women were married, two were 
engaged, two were cohabiting with a partner and two women who were single. All of 
those in the retrospective group were married, with the current and prospective 
group including married, cohabiting, engaged or single.  
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4.4.4 Religion  
Women were asked at the start of each interview if they followed a particular faith. 
For the majority of women their faith and beliefs were not discussed any further in 
the context of impacting reproductive decision-making. However the faith of three 
women was discussed in greater detail, these women self described themselves as 
Muslim, Methodist/Church of England and Church of Scotland. Other women 
described themselves as being christened or brought up within the Church of 
England but did not consider themselves as having a faith-based belief. One woman 
believed in ‘something bigger’ but did not describe this as any religion. This 
information has not been included in Table 4.3 but religious beliefs are discussed 
further in Chapter 8 section 8.7.3.  
4.4.5 Educational Attainment, Employment Status and Sector  
Initial literature reviews of inheritance risk assessments had shown that those 
women with a lower educational attainment had difficulties in understanding risk 
probabilities and recurrences (Grimes & Snively, 1999). For this reason, I enquired 
into the level of education within my sample of women. A large proportion of women 
went on to further study or employment schemes that led to skilled or professional 
positions. I also enquired into as to their employment status and sector. This 
provided helpful context to the interview both during the process of conducting the 
interview and data analysis, especially with women whose background was in 
healthcare or healthcare provision. 
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Pseudonym Study Group Age Range Relationship Status 
Sally  Retrospective 34-38 Married  
Sarah  Retrospective  34-38 Married  
Joanna and Gary  Current/Prospective  34-38 Engaged 
Emma Current/Prospective 24-28 Cohabiting  
Jenny  Retrospective  49-53 Married  
Lisa Retrospective  34-38 Married  
Wendy and Mark  Current/Prospective 34-38 Married  
Lesley  Retrospective  54-58 Married  
Andi Retrospective  44-48 Married 
Alice  Retrospective  49-53 Married  
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Mandy  Current/Prospective 24-28 Single  
Maggie  Retrospective  49-53 Married  
Holly and Edward Current/Prospective 29-33 Cohabiting  
Pauline  Retrospective 44-48 Married  
Miriam  Retrospective  59-63 Married 
Lucy  Current/Prospective 24-28 Single 
Zoe  Current/Prospective 38-42 Married  
Ashley  Current/Prospective 38-42 Married 
Table 4.3 Demographic information on participants. mtDNA mutation, educational attainment, employment, religion, number of 
pregnancies & children omitted
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4.4.6 Health Professionals  
As outlined above in Data Protections and Confidentiality (section 4.3.1) the 
protection of the health professionals discussed in the course of the interviews was 
also important. Women discussed professionals encountered in often complex and 
lengthy diagnostic pathways across multiple primary, secondary and tertiary settings. 
This resulted in the removal of potential identifiers about a large number of 
professionals and their location/healthcare settings. Anonymisation of staff members 
occurred in interview transcripts, field notes, memos and in this thesis.  
I have approached anonymisation in the following ways  
1. For individuals encountered at primary care settings I have referred to them as 
‘GP’ only. The rationale for this is, women did not routinely give the individual’s 
name and referred to them only by their role.   
2. For individuals encountered at secondary care settings I have distinguished 
them as Consultant or Registrar in their specific medical speciality at District  
(DH) or Regional Hospitals (RH). Given the large number of district and 
regional hospitals attended across the sample, providing the seniority and 
gender of these individuals was not considered as a potential identifier.   
3. Physicians encountered at Data Collection Centre 1 were link anonymised to a 
numerical code in transcriptions and memoing. I do not make reference to this 
code in the thesis; I instead use Dr X. For professors, consultants and 
registrars I have identified them all with the prefix of Dr, in order not to 
distinguish between seniority that could lead to identification. I have 
purposively not distinguished between adult and paediatric training to protect 
the paediatric-trained members of staff amongst a larger number of adult 
trained colleagues. I have assigned all doctors as male gender to prevent the 
identification of female physicians who are in the minority. I chose to use male 
gender, both from practical perspective to avoid amending large sections of 
data and out of concern that future readers might subconsciously link quotes 
citing female doctors to a limited number of women practicing in the 
mitochondrial community. The majority of the time women interviewed referred 
to doctors with their professional prefix, in rare circumstances using their first 
names only. When specific identification was not relevant to the section in 
discussion within this thesis I have referred to staff as ‘mitochondrial 
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specialist(s)’, ‘reproductive medicine specialist(s)’ or ‘mitochondrial and 
reproductive medicine specialist(s)’. 
4. For nursing staff, past or present encountered at Data Collection Centre 1, I 
have not distinguished between their individual roles (specialist or research) to 
prevent identification of a limited number of nursing staff that provide care to 
mitochondrial patients at the centre. Nurses were also link-anonymised and 
assigned a numerical code, this included past and present nursing staff. The 
gender of nurses is referenced as female in transcripts, memos and in this 
thesis. Other professionals were prefixed by their role, such as allied health 
professionals that could include specialised genetic counsellors or speech and 
language therapists. 
4.5 Conducting Study Interviews  
Conducting study interviews with participants gave me the opportunity to enter into, 
at times, a very private and intimate space and share with them not only their 
experiences surrounding reproductive decision-making but also other personal 
stories about a range of topics. Over time I shared my related stories with some 
women, ranging from trivial to the more personal and relationships were formed, if 
only briefly. Corbin and Morse (2003) write that despite the number of times a 
participant may have told their story, the first time an interviewee and interviewer talk 
together ‘it marks the beginning of a new relationship’ and the course of the interview 
cannot always be predicted (p341). 
A primary interview schedule for both study groups was constructed during regulatory 
submissions (Appendix B1) based on study objectives and initial literature review. As 
anticipated this document changed throughout the lifetime of the study in response to 
the emergent codes and categories and their importance to the women. Interviews 
were semi-structured and in some circumstance not all topics were discussed in 
order or at all. The issues important to the women participants guided the interviews 
following introductory questions. I reverted back to the schedule when the natural 
course of those topics came to a close. This approach was important to ensure that 
as a researcher I listen to stories and issues intrinsic to the participant, without 
restricting them to a predetermined set of ideas informed by other work or 
researcher’s ideas.  
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As discussed above, interviews took place in a mixture of locations chosen by the 
women, the most popular choice was their home followed by their work place 
(meeting room) and then at their convenience before or after their clinical review or 
procedure.  
Introductory question centred around risk and how, when and who made them aware 
of the risk of inheritance to their child/future child, ‘Do you remember where you were 
when you were told about the potential risk of passing on your condition to a child?’ 
The response to this question, provided by nearly all women was the story of their or 
their family members diagnosis, highlighting the often lengthy and complex patient 
journeys these women or their family members had already experienced (see 
Chapter 5).  We will come to see how the lived experience of these women is crucial 
to their reproductive decision-making (see Chapter 8). 
As discussed above in section 4.3.5, an interview aid listing reproductive options 
applicable to women with maternally inherited mitochondrial disease was introduced 
in Round Two. This aid was found to be invaluable and allowed for new discussions 
on reproductive options previously omitted by women in Round One. Options that did 
not naturally emerge in the first round included most notably adoption, ovum donation 
and surrogacy.  With the introduction of the aid, and explanation of each given, 
women were able to consider how they felt about all the options and ordered them 
with regards to which they would consider the most appropriate or would completely 
discard.  
Follow-Up interviews were conducted in Round Three during the final data analysis 
stage of the study, with an emphasis to test the proposed conceptual model of 
reproductive decision-making. Of the five women eligible for a follow-up interview 
(those in the current and prospective group), four women were approached to take 
part in a follow- up interview. One woman was not approached out of concern for her 
emotional wellbeing after her original interview. Two of the four women contacted for 
a follow-up interview did not respond. Of those two women who took part, both 
interviews were conducted by telephone interview. Follow-up interviews centered on 
the reproductive journeys of the women since their initial interview, the time between 
their initial interview and their follow-up interview was 23 months and 32 months.  
Interviews and field notes were digitally recorded, this enabled easy transfer to 
secure password protect server following the interview. The recorder was used to 
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provide accurate transcription and analysis of data and allowed for me to be 
responsive to the women during the interview as opposed to note taking. Digital 
recordings of initial interviews lasted between 17 minutes and 120 minutes. Follow-
up interviews lasted 10 and 34 minutes. Before the recordings were started, I 
confirmed informed consent. Written Informed Consent was obtained for interviews 
conducted face to face, for follow-up telephone interviews consent was confirmed on 
the audio recording and recorded in their medical notes. After the interview had 
ended and the digital recorder stopped, I engaged in informal conversation with the 
women, offering them another chance to ask any questions. In some circumstances 
additional relevant information was given after the digital recorder was stopped, this 
information was recorded in field notes. As soon as possible and in a confidential 
setting I recorded field notes directly onto the recorder. These included details of 
non-recorded conversations, areas of interest and my observations during the whole 
interview process (Rapley, 2004). These field notes were used alongside interview 
transcripts to form the complete data set analysed as part of this thesis.  
4.5.1 Clinical Observations  
Throughout the process of gaining project approvals to initiate recruitment I attended 
mitochondrial and fertility clinics at Data Collection Centre 1. These observations 
have not been included in data collection as ethnography was not a planned method 
of data collection, instead these opportunities provided me with an understanding of 
the experiences of mitochondrial patients, general fertility patients and more 
specifically mitochondrial patients and their reproductive journeys.   
Whilst observing assessments in the mitochondrial outpatient clinic, I witnessed 
patients from all over the UK who had travelled for their clinical review. Patients who 
attended the clinic (all of whom were female) showed varying differences in disease 
burden from one another, highlighting the phenotypic variations, which presents 
amongst different mtDNA and nDNA mutations.   
Whilst observing standard fertility clinics, I was able to observe couples that were 
experiencing a number of barriers to achieving ‘natural’ conception, including medical 
conditions affecting the female and/or male and homosexual couples. Observations 
included initial assessment visits, visits where couples received their individual test 
results and clinics specifically to consent couples to their chosen treatment 
procedure. 
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I also observed a PGD clinical consultation with a couple considering PGD as a 
potential option to reduce the risk of transmission of the intending mothers mtDNA 
mutation. Topics discussed included the disease burden of the patient, their 
immediate and extended family, present and past medical history of both prospective 
parents, the technique and its required medical and emotional commitments.  
4.5.2 Reflecting on Personal Position as a Researcher  
Briefly addressed in section 4.3.1, I considered my position as researcher from the 
outset of this study and the ways in which my personal and research background 
might shape the collection and analysis of the data.  
Krauss (2005) states that qualitative researchers are ‘encouraged to record their own 
biases, feelings and thoughts and to state them explicitly in the research report’ 
(Krauss 2005:p764). Ambert et al (1995) write that a researcher should reflect upon 
class, ethnicity and gender when considering what influence the researcher, the 
interviewee and setting has on the data. 
I have throughout this process examined my own relationship to the study. When this 
study was first discussed in April 2013 I had been employed as the clinical research 
coordinator (and later manager of clinical research) in the mitochondrial group at 
Data Collection Centre 1 for two years. This role at that time had also included 
supporting other rare neuromuscular conditions, with the design, approval and 
implementation of studies ranging from patient registries to clinical trials of new drug 
therapies.  Prior to this I had spent three years managing Phase 1 (first in human) 
through to Phase 3 oncology drug studies in a tertiary hospital setting similar to Data 
Collection Centre 1. My academic background had included a degree in 
Pharmacology and a Masters in Clinical Research. The Masters included taught 
modules as well as a self-directed clinical research project. In this project I consented 
chemotherapy naive patients to take part in a biomarker study in which I studied the 
appropriateness of a novel enzyme assay to help determine the role of personalised 
medicine in cancer treatment. Prior to this study my research experience had been 
based on a positivist epistemology. It was this master project in particular that was 
the driving force behind my interest in qualitative research methods, discovering 
during the consent process of that study, the intricacies of patient journeys and their 
resultant behaviours.  
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Before this study was initiated, I gave a lot of thought as to how I would be perceived 
by future participants, for some time I focused on how ‘not being a mother’ or how 
being myself a child of ‘assisted reproductive technologies’ might impact on how I 
presented myself or was perceived by the women in my study. I now realise that this 
did not require concern. I now know that perceptions and interactions with each 
individual could not be controlled, and as stated above these interactions were 
enriched by the social worlds that interviewees and I myself constructed before, 
during and after the interview process. I felt I established different relationships with 
every participant, some of which were of the same age, relationship status, even 
similarities in studying part time as I was, whereas others were at a different stage in 
their life course. Research has shown that taking part in research interviews can 
prove beneficial to patients in a number of ways, it can be (a) cathartic, (b) provide 
self-acknowledgment and validation, (c) contributes to a sense of purpose, (d) 
increase sense of awareness, (e) grant a sense of empowerment, (f) promote healing 
and (g) give a voice to the voiceless and disenfranchised (Hutchinson et al., 1994: 
p161).   
At times, participants told me stories that they had not spoken about with any other 
person in their family, often asking if I agreed with their chosen actions. This was 
complicated further by the inclusion of multiple members of the same family, whereby 
women asked me what their family member had thought or said about a particular 
issue. I overcame this by reminding patients that I did not judge or have an opinion 
on their actions and that I was bound by confidentiality to not disclose other 
interviewees’ responses. All participants accepted this. 
4.6 Data Analysis  
Analysis of data was based on Charmaz (2006) constructivist grounded theory, which 
provides a framework to manage data, which included concurrent data collection and 
analysis, the assignment of ‘codes’ to the small fragments of data. The accumulation 
of these codes would in turn become the emergent categories that could then be 
compared to future data sets. Categories would then become ‘memos’, which would 
derive the phenomena directly from the data as opposed to a predefined hypothesis 
and where researchers were prompted to conduct their literature review after 
analysis. 
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Data were collected between August 2014 and July 2017, which included semi-
structured interviews with women and researcher field notes. Data collection and 
analysis occurred concurrently, so that issues that arose in earlier rounds of 
interviews could be explored in subsequent ones. Analysis of data was a continual 
process, often returning to transcripts months and years later to re-investigate codes, 
categories and memos further. To illustrate the steps taken throughout the study I 
have summarised the process in Figure 4.3. As proficiency of data analysis 
increased some aspects such a line by line coding and mind mapping were required 
less but detailed patient specific memos and conceptual memos existed throughout 
the study. 
Figure 4.3 Data analysis flow chart 
 
4.6.1 Familiarisation with Data  
Ten of the eighteen interviews were transcribed verbatim by myself (ID001- ID009 
and ID011). These included detailed non-speech tokens (Rapley, 2004) whilst the 
others (ID010 and ID’s 012 - 015) were transcribed by a professional transcription 
service. Follow up interviews and interviews conducted in the confidence round 
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(Round Three) were partially transcribed by myself, transcribing data that was 
supportive or in conflict with existing ideas.  
For the interviews I transcribed, this included listening to the interviews multiple 
times, often replaying sections to determine accurate transcription. For the interviews 
that I did not transcribe, I familiarised myself with the data by listening to each 
interview multiple times and reviewed transcripts twice for accuracy. I repeated this 
for field notes recorded and transcribed by myself following each interview. All 
transcripts and fields notes were edited during transcription to ensure anonymity of 
the participant and those family members and clinicians who may have featured in 
the interview as described above. Although these methods were time consuming this 
allowed for me to become immersed in my data and has led to a very detailed 
recollection of all the interviews conducted in the study (Rapley, 2004).  
4.6.2 Line by Line Focused Coding  
All analysis was conducted according to the standard procedures of rigorous 
qualitative analysis (Rapley, 2010). Once transcribed, I reviewed the data using first 
and second line coding (Charmaz, 2006). This meant that I conducted focused line-
by-line coding throughout the interview (see examples, Figure 4.4 and 4.5). This 
approach was especially useful to me as a novice qualitative researcher and allowed 
for me to capture extremely large numbers of codes grounded in the data that could 
be further define or discarded as categories emerged and developed.  
Coding was carried out manually, with sporadic use of qualitative collation and 
management software (NVivo Software). I, however preferred manual coding and 
reverted to this method in the majority of the analyses. 
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Figure 4.4 Example of line-by-line focused coding. 
 
Figure 4.5 Example of line-by-line focused coding  
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4.6.3 Patient Specific Analytical Memoing  
For every patient, I wrote extremely detailed patient specific analytical memo’s 
ranging from 15 pages to 38 pages long. These covered each pre-identified or 
individually emergent codes and categories relevant to women as individuals. I was 
then able to order their interview into large categories such as diagnosis pathways, 
impact of diagnosis, clinical relationships, disclosure and reproductive decisions. I 
further interrogated these by re-coding the memos, so that ideas could be collected 
across each category (see Figure 4.6 for example).  
Figure 4.6 Coding of patient specific analytical memos 
 
4.6.4 Category Specific Mind Mapping  
In order to make sense of codes for each emergent category, I mapped individual 
codes, allowing for issues to be better identified, that then ultimately made up the 
large main category components (Charmaz, 2006). I did this first manually (see 
Figure 4.7 for example) and then entered a selection of these into mind mapping 
software MindView 5.0.  
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Figure 4.7 Manual mind mapping of disclosure category 
 
4.6.5 Category Specific Analysis  
After identifying the main codes of a category in Round One, I was able to produce 
Category Specific Memo’s that then underwent further revisions. For example, Figure 
4.9 is the third version of sub-code ‘speed of disclosure’ of the larger category 
Disclosure.  
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Figure 4.8 Category specific memo of disclosure: sub-code speed of disclosure 
(Version 3)  
 
The sub-codes and were then entered into an Excel spread sheet that allowed for 
future participants to be plotted against the existing memo version (Kraman & Hamm, 
1999; Mays & Pope, 1995; Seale, 1999). Over time the overall category memos were 
amended and updated in accordance with the new data collected and analysed. 
Figure 4.10 highlights Version 4 of the Disclosure sub-category emerging when new 
information led to the amendment relating to script use; the boxes that remain white 
are in agreement with the data collected already in Round One, those highlighted 
represent areas that new participants have changed the sub-category or are not 
applicable.
Disclosure: How do characters within the story of known diagnosis increase? V3 
• The speed of disclosure of ‘some kind of genetic condition’ to those socially 
significant from the person receiving news of a potential diagnosis is 
relatively fast, even in circumstances when diagnosis not confirmed or even 
when told by a relative (with inherited significance) in the first instance. 
o The prognosis over the specific mutation is important to establish as 
soon as possible (linked to information provision and use of the 
internet!) to establish if fatal, life altering or mild (002) 
o This can be complicated by the lack of understanding and complexity 
of the disease. Bare minimum of information or learnt scripts/stories 
are used to assist disclosure and can also be a way in which to modify 
the level of disclosure to others (full or partial)  
o Frustration arises due to the lack of the individuals understanding and 
inability to answer/explain to others 
o The speed of disclosure ‘of some kind of genetic condition’ to others 
may legitimise their symptomatic illness to family, friends and 
employers 
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Figure 4.9 Redacted analytical induction category workbook: Disclosure sub category: speed of disclosure (Version 4)
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4.6.6 Data Clinics  
In addition to discussing analytical outputs at regular supervisory meetings, sub-
sections of interview transcripts were reviewed at Data Clinics and included research 
associates, assistants and other PhD researchers based in the Institute of Health 
and Society. This allowed for a proportion of my data to be analysed collectively, 
where the researchers shared and exchanged interpretations of key issues emerging 
from the data (Rapley, 2010). 
4.7 Conceptual Model Development  
Data collected and analysed over the course of the study allowed for the 
development of a disease specific conceptual model of reproductive decision-
making. The process included three specific developmental stages, each resulting in 
an updated version of the conceptual model. Discussions of the final version are 
covered specifically in Chapter 8, but developmental stages are included here to 
show how this came in to being. The first two conceptual model versions were 
mapped from emergent study categories. Upon recognising the similarities between 
prior work by Downing (2005), categories were then super-imposed into their existing 
framework of responsible decision-making in HD. Similarities and differences are 
present between the Downing (2005) model and the proposed maternally inherited 
mitochondrial disease model and these were revealed through a process of 
refinement. 
4.7.1 Conceptual Model Version 1 
The following model was developed from categories discovered in interviews that 
showed three distinct time points throughout the process of reproductive decision-
making. Initially these were broken down into time point zero (T0) which included 
pre- and post-diagnosis considerations, time point one (T1) that was response to 
T0’s considerations and time point two (T2) where women experience a changed or 
altered perception of risk. A response to risk was framed as being accepting or 
adverse to risk, which dictated what reproductive options they engaged with.  
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Figure 4.10 Maternally inherited mitochondrial disease reproductive decision-making 
conceptual model (Version 1) 
 
4.7.2 Conceptual Model Version 2 
The second version on the model shows more clearly the differences amongst those 
women who were considered to be risk adverse and their reproductive decisions. 
This was done by dividing these into those who sought to modify their risk by 
engaging in reproductive options, which included a form of intervention and those 
who avoided further risk by having no further pregnancies. It also showed more 
clearly that those women whose perception of risk had changed or been altered 
sought ways in which to modify future risks.   
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Figure 4.11 Maternally inherited mitochondrial disease reproductive decision-making 
conceptual model (Version 2) 
 
4.7.3 Conceptual Model Version 3  
The model was then reviewed against Downing's (2005) model of responsibility in 
HD (Figure 4.12) and configured to the same framework. The refined model is 
outlined in the Chapter 1 (Figure 1.7) and discussed in detail in Chapter 8 (Figure 
8.1) and 9 (Figure 9.1).  
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Figure 4.12 Model of Responsibility of Huntington’s disease (Downing, 2005) 
 
With my refined model, factors and elements that corresponded with emergent 
categories in this study remained, but those that did not were replaced with elements 
specific to the study data (see Chapter 8). The novel time point, time point two (T2) 
was included into the model representing change over time in relation to risk 
perception, attributed to a change in personal circumstances or witnessing the 
impact of progressing disease or fatality in the family. Interviews in Round Three 
(post-licensing of mitochondrial donation) were specifically conducted to enable the 
categories of the final proposed model to be tested. The proposed conceptual model 
can be applied to the experiences of women in both the retrospective and current 
and prospective decision-making groups. 
4.8 Reliability and Validity   
As introduced earlier, qualitative research is often criticised for lack of scientific rigor, 
therefore ensuring reliability and validity of these methods is not only key within the 
wider social science field but also within this study.  Mays and Pope (1995) suggest 
that in order to ensure rigor in qualitative research a ‘systematic and self-conscious 
research design, data collection, interpretation and communication’ should be 
applied as would be in quantitative research (pp 110).  In addition to this, clear 
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accounts of the methods of data collection and analyses should be included in the 
dissemination of research, an area which Mays and Pope (1995) describe as 
neglected in some articles. 
When assessing reliability and validity in qualitative research Guba and Lincoln 
(1989) established the following as precedent of quality 1) credibility 2) 
transferability, 3) dependability and 4) conformability as well as the creation of a 
reflexive journal. Over time there has been suggestions that not all of the these 
recommendations are required in every study, Morse (2015) concluded that reliability 
and validity are intertwined and recommended strategies to enable them both to be 
achieved within a study. The strategies of thick and rich description of data, negative 
case analysis, peer review and debriefing, coding systems and acknowledging 
potential researcher biases have all been employed in this thesis.  
4.9 Summary    
In this chapter I have outlined the methodological framework and theoretical 
approach taken for this work, detailing the practicalities of data collection and 
analysis employed throughout the study. I have shown the step-by-step 
developmental process of the proposed conceptual model of reproductive decision-
making in maternally inherited mitochondrial disease. It is important to reiterate that 
although these processes are presented here in a linear form, in reality these 
activities took place in overlapping cycles throughout the three years in which data 
was collected and analysed.  
In total 20 interviews were conducted with 18 women with a known mtDNA mutation, 
allowing for a rich data set to enable integration and the formation of the results 
presented in this thesis. I am confident that the data, analysis, conclusions and 
recommendations to clinicians from this work are grounded in the data. They provide 
a solid foundation to support the disease specific conceptual model of reproductive 
decision-making, therefore informing the patient pathway for women with maternally 
inherited mitochondrial disease making reproductive decisions now and in the future,
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Chapter 5. Diagnostic Pathways: Women’s Practical Experiences  
 
5.1 Introduction 
This short chapter is the first of four findings chapters; it sets the scene for the 
remainder of this thesis and provides important context. It prioritises the experiences 
of women with maternally inherited mitochondrial disease and their diagnosis. This 
Chapter centres women’s description of their illness unlike the bulk of the literature 
that views their condition via a clinical perspective. The focus of this thesis is 
reproductive decision-making for women with maternally inherited mitochondrial 
disease. However, to do this it is necessary to situate their experience of the 
conditions as an important feature of their life so far, as for many it has had important 
and long-term impacts on their life prior to being diagnosed. In some cases women 
were entirely asymptomatic whereas others negotiated a complex and varied 
collection of symptoms that they did not always attributed to having any particular 
condition. For some women the onset of symptoms and delay in diagnosis resulted in 
uncertainty. They didn’t know why they were getting the symptoms, how they would 
develop or if they were related to a specific condition. Therefore their experience of 
living with maternally inherited mitochondrial disease pre-existed diagnosis and in 
some cases women’s reproductive decision-making. For this reason, this chapter 
explores in particular how women understood and made sense of their embodied 
experiences, in combination with illness experienced by family members, including in 
some instances their own children, and how this in turn influenced their individual 
journeys to diagnosis. Interview data collected from women featured accounts of 
delay in terms of their diagnosis. In the literature this is referred to as diagnostic 
delay and can represent the time between them becoming symptomatic, or the 
diagnosis of a family member and the diagnosis of the woman herself. To further 
explore this I use two models of diagnostic pathways to explain the accounts of 
women.  
5.2 Diagnostic Delay in Rare Disease 
Of the many challenges facing rare disease patients, delay in diagnosis and access 
to appropriate health care are a common problem across the many thousands of 
known rare disorders (Dharssi et al., 2017; Elliott & Zurynski, 2015; Zurynski et al., 
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2017). The diagnosis of mitochondrial disease is no different, complicated by its dual 
genome origins and its complex and varied phenotypes that result in a number of 
investigations and expert interpretation required to obtain a diagnosis (Haas et al., 
2008). Countries across the globe have established individual or collaborative 
strategies to address these along with other challenges facing rare disease patients 
(Dharssi et al., 2017). The UK Strategy for Rare Disease published a number of 
commitments to improve the lives of those living with rare disease by 2020, in which 
the eleventh commitment was to ‘work to achieve reduced time for diagnosis’ and to 
‘ensure that undiagnosed patients have appropriate access to coordinated care’ 
(Department of Health & UK Government, 2013 p 32-33) 
It is recognised that general practitioners in the UK health care system can play a 
role in ‘spotting the zebra from the horses’ and will play a bigger role in the long-term 
management of people with rare disease (Evans & Rafi, 2016 p550). However, 
delays can sometimes occur before patients have even made contact with health 
care professionals. Women in the study tell us about specific periods of delays 
between them first noticing an unexplained symptom(s) and making the first 
appointment with their GP. The Andersen Model of Health Care Utilisation provides a 
conceptual structure of seeking medical attention for a specific illness concern, which 
can be seen to be relevant to both the women and their family members in this study 
(Andersen et al., 1995). The general model of ‘total patient delay’ as proposed by 
Andersen includes 1) appraisal delay: time between detection of unexplained 
symptoms and concluding illness 2) illness delay: time between inferring illness and 
deciding to seek medical help 3) behavioural delay: time between a person deciding 
an illness requires medical care and deciding to act on this 4) scheduling delay: time 
between deciding to act on the decision to seek help and actually attending an 
appointment and 5) treatment delay: time between the first appointment with a health 
care professional and the onset of treatment (Andersen et al., 1995; Walter et al., 
2012).  
Throughout the section that follows, I will show how women experienced aspects of 
the Andersen model, as well as difficulties in being ‘believed’ and therefore accessing 
appropriate care services before finally receiving their diagnosis of a mtDNA 
mutation.  
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5.3 Accounts of Diagnosis as a Direct Result of Women’s Symptoms  
Of the 18 women included in the study, five women were diagnosed with their mtDNA 
mutation as a result of their own ill health. The length of time in which women had 
experienced symptoms ranged from approximately 12 months to over 30 years 
before receiving a diagnosis. I will describe their diagnostic journeys by first outlining 
the initial noticing of symptoms, their experiences of visiting health care professionals 
in primary, secondary and tertiary care settings and how they came to be diagnosed 
with a mtDNA mutation.   
Throughout the data women report experiences of initial ‘noticing’ of unexplained 
symptom(s). Personal accounts of noticing symptoms which led to concern can be 
seen to be experienced throughout the life course of some of the women interviewed, 
some dating back to when they were at school. Given the historical context, Dimond 
(2013) notes that many patients lived with symptoms of mitochondrial disease before 
the development of the necessary diagnostic techniques. We see this in Jenny’s 
accounts of her childhood fatigue and how it noticeably affected her when taking part 
in school sports, ‘I’d known … since I was a kid there was something wrong' (Jenny: 
74-75), unfortunately for Jenny her GP had told her mother that she was ‘just lazy’, 
which meant that she remained undiagnosed for over 30 years. Difficulty participating 
in physical school or social activities was also true for Holly and Lucy, having both 
experienced symptoms since their childhood. Holly struggled to hold her arms in their 
air whilst dancing ‘I was always getting into trouble for not keeping my hands up high 
enough’ (Holly: 372-374) in activities outside of school whilst Lucy suffered anxiety 
when faced with her PE classes. When discussing how she was relieved to have 
received her diagnosis she tells us that: 
Aw 100% because for years I’ve been poorly, first school, middle school, 
always tired, always, I hated PE with a passion, couldn’t run, teachers used to 
shout at me, they used to call me lazy. I would make myself sick thinking 
about PE the next day, cause it was just, so now that I’ve got something it’s 
good to say there is a reason why I am feeling like this (Lucy: 34-38) 
 
For Lucy, her diagnosis now allowed her to understand why she had struggled for so 
many years, that this was not a product of being ‘lazy’. Having a diagnosis enabled 
her to re-position her past experiences as emerging from her ‘sick role’ (Parsons, 
1951) and so other’s responses to her as somehow malingering where illegitimate. 
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Other accounts of noticing include deterioration in health over a number of years. 
Women noticed changes such as the onset of extreme fatigue, weight changes, loss 
of hearing, myoclonic jerks and episodes of syncope. Women commonly refer to 
‘something not being quite right’, ‘something is wrong’, ‘getting worse’ or ‘I’ve felt it for 
years’. Andi can be seen to have experienced appraisal delay (Andersen et al., 1995) 
at the initial onset of fatigue, as she did not believe that this may be of a medical 
aetiology but a sign that she had ‘just taken on too much’ (Andi: 86-87). She was 
working full time, headed a number of community and charity committees/events as 
well as having a young family ‘I just thought arh I’ve just taken on too much’. To 
address this, she reduced her working hours and stepped down from some of the 
organisations she had been supporting. The first symptoms that prompted Andi to 
seek medical advice were visual inconsistencies that she described as ‘getting worse 
and it was just getting weird’ (Andi: 43).  
Some women were conscious of physical changes over time, especially symptoms 
that they could not associate with any other cause. Maggie described being ‘really 
concerned that I was losing my hearing’ (Maggie: 217) in her early to mid-thirties. 
There was a period of time for Maggie where this concern had been delayed - 
described as behavioural delay (Andersen et al., 1995) - until she finally decided to 
make an appointment with her GP. She was told however that ‘you’re far too young it 
can’t possibly be’ (Maggie: 218-219). Like many of the women interviewed Maggie 
was told that it was ‘something that you’ve got in your head’ (Maggie: 220) or for 
those who experienced fatigue, that they were just ‘lazy’. Muir (2016) argued that the 
experience of not being believed was not uncommon amongst patients with rare 
disorders, with many experiencing issues with persuading medical professionals to 
believe their symptoms and their condition often being written off as psychological in 
origin. Living with medically unexplained symptoms can leave sufferers unable to 
achieve society’s sick role as a result of not having a medical diagnosis, access to 
the appropriate medical care, and often a lack of visible illness. This leaves them 
facing accusations of malingering, hypochondria and mental illness (Glenton, 2003). 
Some of these women also experienced treatment delay (Andersen et al., 1995), 
which in Maggie’s case was the eventual placing of two hearing aids. It took a 
number of years and the onset of an additional symptom, initially spotted at a high 
street optician, before Maggie would be diagnosed and receive appropriate advice, 
support and care.  
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Women who received a diagnosis as a direct result of their ill health saw a number of 
health professionals over the course of their diagnostic pathway. After navigating a 
referral from a primary care setting to their local hospital they were seen by a 
specialist in the major symptom that they were exhibiting. None were seen by a 
neurologist in the first instance. Specialities encountered included audiology, 
ophthalmology, cardiology and diabetology, with subsequent referral times to 
neurology ranging from a matter of months to 16 years. In three cases, 
ophthalmology specialists at regional hospitals made the potential link to a 
mitochondrial disorder and made a referral to a regional neurologist or directly to a 
mitochondrial specialist. For two of these women, they were told that they might have 
‘mitochondrial disease’ or ‘myasthenia gravis’, an autoimmune disease that causes 
muscle weakness and fatigue. They were informed that the latter would be the worse 
of the two.  
Sarah experienced a very lengthy and traumatic diagnostic pathway, undergoing a 
number of invasive operations and emergency admissions. At one point, she 
received advice from a specialist that suggested a procedure that would leave her 
with sight in one eye only, at the prospect of which Sarah described feeling 
‘absolutely like devastated’ (Sarah: 195) by the prospect of. Shortly after this 
encounter she had an appointment with another ophthalmologist who suspected a 
neurological explanation. The onset of recurrent infections prior to Sarah’s eventual 
referral was described as a ‘traumatic 18 months leading up to that diagnosis’ 
(Sarah: 148). Sarah was referred a regional neurologist who performed a muscle 
biopsy. 
Sarah: They thought it might have been something called myasthenia 
  gravis 
Int:   Ok yeah 
Sarah:  But the neurologist wasn’t convinced so did the muscle biopsy 
  that was sent to [mitochondrial specialist centre], suspected  
  mitochondria, then the biopsy came back, I got the results, when 
  I was given the information I was told that it was a more positive 
  diagnosis then myasthenia gravis (Sarah: 112-114) 
 
Sarah had read about both potential diagnoses before returning to receive her 
results, where she reports being told in a very hectic, rushed clinic that she had 
mitochondrial disease. Like many women in the study, Sarah was not able to recall if 
she had a mtDNA mutation or nDNA mutation when asked, but she did recall the 
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specific mutation. What was important to Sarah was establishing the seriousness of 
her condition first for herself and then if it would have any impact on her plans to start 
a family (see section 7.4.1). The complexities of Sarah’s diagnostic pathway are 
shown in Figure 5.1, highlighting the number of clinical referrals she experienced 
after the onset of severe symptoms and how she actively sought advice from a 
mitochondrial specialist to understand her diagnosis more and to undergo additional 
testing and health assessments.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 124 
 
 
Figure 5.1 Example of primary complex diagnostic pathway in maternally inherited mitochondrial disease. HCP: Health Care 
Professionals. DH: District Hospital. RH1: Regional Hospital. 
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In this section I have termed these women’s experiences of diagnosis as the ‘primary 
complex diagnostic pathway of maternally inherited mitochondrial disease’, in which 
they themselves have experienced both symptoms and multiple encounters with 
health care professionals. For these women their experiences of ill health, 
unnecessarily prolonged due to delayed diagnosis, is a factor of consideration with 
regards to reproductive decision-making, which I explore further in Chapter 8. 
5.4 Accounts of Diagnosis as a Result of a Childs Symptoms  
The majority of the women interviewed in this study were diagnosed as a result of a 
family member’s ill health. This could be a product of their own child’s diagnosis, 
which will be discussed here, or as a result of their parent or sibling’s diagnosis, 
which I will discuss below. Three women who took part in the study received their 
own diagnosis of a mtDNA mutation as a result of their child’s diagnostic pathway.  
Again, these where lengthy, taking place over approximately three to seven years. 
Like the women above there was a period of ‘noticing’ of symptoms that went onto to 
initiate their child’s pathway at first and then their own.   
For one woman their own mother had initially ‘noticed’ symptoms. Historically, 
Jenny’s mother had noticed her own daughter’s abnormal level of fatigue but, at that 
time, was unable to progress further than their GP. However, Jenny went on to 
recognise the same symptoms in her child years later, ‘I could see it happening 
when [child] was younger’ (Jenny: 103) and described the situation as ‘history 
repeating itself’ (Jenny: 105). Jenny delayed seeking medical advice ‘you try to (0.2) 
ignore it’ (Jenny: 107), demonstrating a period of illness delay before seeking a 
referral when she saw her child’s symptoms worsening (Andersen et al., 1995). 
Jenny reflects on the delay as ‘which rightly or wrongly you do, but it just got to the 
stage where [child] was getting worse then what I was’ (Jenny: 109-110). It could be 
inferred that Jenny delayed seeking advice given her own experience of not being 
believed. Only when her child became noticeably worse than she had been, she 
acted to seek medical advice.   
Jenny does not provide a description of her child’s diagnostic pathway but that all 
three generations of her family gave blood for a DNA test. Whist’s Jenny’s mother’s 
test came back ‘minutely’, Jenny and her child’s results were ‘just like you’d think 
that someone had just got a big black dabber [marker] and just went duhh’ (Jenny: 
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118-119). Jenny made an action with her hand indicating heavy highlighting of an 
imagined piece of paper, this relates to a type of diagnostic test where the absence 
or presence of a protein is measured by the appearance of a protein band on a film. 
Heavy thick bands denote a high concentration and in comparing these across family 
members showed that both Jenny and her child had the same concentrations as 
each other, resulting in them both having the same diagnosis.  
For women who described themselves as having no prior experience of ill health that 
they could relate and compare their child’s symptoms to, they described noticing 
symptoms including vomiting, weight lost, ‘failure to thrive’, ‘walking wobbly or oddly’, 
‘wobbly eyes’ and myoclonic jerks. Mothers of affected children experienced delays 
in accessing the appropriate care or prolonged treatment delays (Andersen et al., 
1995). Notably, the mothers interviewed did not appear to experience the other 
delays (appraisal, illness, behavioural or scheduling) described by Andersen, with 
these women making contact with their GPs at the outset, unlike in the personal 
accounts above. Sally observed symptoms in her youngest child when they were 
very young. She described experiencing a complication at her GP initially, ‘we went 
to our local GP and there was a bit complication’ (Sally: 39-40), that we can take to 
understand as a delay. After ‘eventually’ being referred to a local hospital, Sally was 
told that they would implement a ‘kinda watching and waiting’ (Sally: 41) approach. It 
went on to take a number of years, three referrals to three different hospital settings 
along with many blood tests, multiple MRI’s and a muscle biopsy before Sally’s child 
would be diagnosed with a mtDNA mutation. Sally was told of the inheritance link 
when she and her husband were told of their child’s diagnosis, the impact of which is 
described in Chapter 6 and Chapter 8.  
Miriam was diagnosed after the eventual diagnosis of her middle child who had 
experienced symptoms for almost seven years before receiving a mtDNA diagnosis. 
Miriam and her family experienced many difficult, emotional and frustrating 
encounters with medical professionals during this time.  
So I kept going back, as mothers do, this isn’t right, [they] not just got that 
[they have] got something else (Miriam: 148-150).  
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Muir (2016) also reported that alongside adult rare disease patients being 
considered to experience psychosomatic illness, parents of children with rare 
disease were considered to be neurotic.  
Women of affected children in the study expressed concern, anger and frustration 
that their child was not being seen by the right kind of specialist. Delayed diagnosis 
of children suffering from a rare disorder due to the perceived lack of knowledge 
amongst health professionals has been shown to have serious consequences to 
both parents and children, including stress, worry and frustration (Zurynski et al., 
2017).  Miriam and her family had seen a number of doctors over the seven years 
before their diagnosis, including a number of neurologists. After their diagnosis, 
Miriam felt that even though the neurologists they were seeing were ‘nice’ enough for 
certain aspects of her child’s illness they weren’t mitochondrial specialists.  
“Well who do we need to see, who knows more about this condition?” ‘Cause 
obviously our doctor was a neurologist and he dealt more with like 
Parkinson’s, MS and this [mitochondrial disease] was off the radar  
(Miriam: 419-422) 
 
For Miriam attending an appointment with a regional neurologist that could only treat 
certain symptoms of her child’s phenotype was not good enough, an opinion shared 
by her husband and their then adult children. Upon receiving a diagnosis via their 
regional neurologist she and her family insisted that they saw a mitochondrial 
specialist together. What was key for Miriam was that she and her family were seen 
by an expert in mitochondrial disease, specifically with a focus on receiving 
treatment or participating in ‘clinical therapy trials’ (Miriam: 442). 
For these women, although they themselves did not experience a lengthy diagnostic 
pathway, I suggest that their diagnostic pathway was one of secondary complexity; 
and I have described this as the secondary complex diagnostic pathway of 
maternally inherited mitochondrial disease. For Jenny and Miriam, they considered 
their families complete and were not intending to add to their family, Sally was less 
certain of this and at different points of the interview she was less certain that she 
had completed her family than at other times. I will explore further how lived 
experience of family ill health, along with factors relating to concerns of safety for a 
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future child and maternal guilt and responsibility relating to inheritance impact upon 
reproductive decision-making in Chapter 8 section 8.7.2.   
5.5 Accounts of Diagnosis as a Result of a Family Members Symptoms  
Family accounts of noticing are seen in women whose parents or siblings exhibited 
symptoms that were later attributed to a mtDNA mutation or a posthumously 
suspected mtDNA mutation. These symptoms commonly presented over many 
years, including over decades. The accounts of noticing include their mothers 
experiencing deafness, seizures, organ failure, stroke like episodes and early 
dementia. One woman’s mother was thought to have been suffering from 
Creutzfeldt-Jakob disease, commonly known as mad cow’s disease or as they also 
described it, the one you get ‘from eating beef’ (Ashley: 30). Accounts relating to 
siblings included episodes of black outs, learning difficulties, blindness, seizures and 
deafness, some of which dated back to their siblings’ childhood or in the years 
preceding their diagnosis. It is interesting to note that many women’s families also 
included symptomatic maternal aunts and uncles who had also presented as early 
as childhood, most of whom were not aware of a genetic cause of illness, except in 
one case (see Chapter 8 section 8.7.2)   
For ten of the women interviewed, their family members diagnosis was what led 
them to receive their own diagnosis, five of whom were diagnosed as a result of their 
own mother’s experience of ill health and five women as a result of their siblings’ ill 
health (including both female and male siblings). Within this group of ten, four of 
these women had not experienced any signs of ill health that may have been related 
to their mitochondrial mutation before or after their diagnosis. Additionally, one 
woman, Ashley, offers a contradictory account. Ashley tells the interviewer that ‘I’m 
not really affected it’s kind of OK, cause you can’t change it anyways’ (Ashley: 44) 
but also that she was ‘handling the symptoms and hoping for the best’ (Ashley: 45). 
Ashley offered no additional information of what these were. For Ashley there may 
have been a potential appraisal and illness delay (Andersen et al., 1995). Dimond 
(2013) argues that asymptomatic individuals who live with the knowledge of a 
mtDNA mutation experience the phenomenon of being ‘a patient without symptoms’ 
like those with recessive disorders or late on set disorders such as Huntington’s 
disease. I too make this link to similarities experienced by patients with mtDNA 
mutations to those with known risk of HD in Chapter 8, with regards to the proposed 
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conceptual model of reproductive decision-making in maternally inherited 
mitochondrial disease.  
The remaining five women in this group had experienced symptoms that they had 
either deemed not worthy of visiting their GP for, or whose symptoms were treated 
but not investigated further. For Joanna, she had experienced fatigue levels that 
were of concern for her and noticeable to others, in particularly her partner, but had 
never sought medical advice. Alongside this Joanna, also had ‘few’ other health 
problems but did not provide any further information. It was clear that for Joanna her 
experience of fatigue was most notable. Upon receiving the news that she too had a 
mtDNA mutation like her mother, she felt relief in finding an explanation of her 
symptoms both for herself ‘so kind of things made sense a little bit’ (Joanna: 75) and 
others, in that the diagnosis had legitimised her fatigue ‘and he [her partner] realised 
that I’m not just lazy after all these years (Joanna: 84). Relatedly, this relief echoes 
the work of Clarke (2000) who writes of the sense of relief those with chronic fatigue 
syndrome experience upon receiving their diagnosis. The relative simplicity of 
Joanna’s diagnostic pathway compared to her mother’s is shown in Figure 5.2, 
highlighting the interventions and clinical referrals her mother experienced prior to 
diagnosis, that led to Joanna and her sibling being asked to consider a diagnostic 
test, whilst experiencing noticeable fatigue. 
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Figure 5.2 Example of secondary complex diagnostic pathway in maternally inherited mitochondrial disease. HCP: Health Care 
Professionals. DH: District Hospital. RH1: Regional Hospital. 
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Alice, had noticed extreme weight loss ‘I’m not, like, particularly big but I’d lost so 
much weight. People, I, I think people thought I was, like, anorexic’ (Alice: 943-945). 
It took 18 months for Alice to receive a diagnosis of diabetes given the complexities 
surrounding the presentation of the diabetes phenotype known to be associated with 
her mtDNA mutation (then undiagnosed). Interestingly Alice is medically trained. For 
Alice the then unexplained visible symptoms of illness caused concern not only with 
regards to the aetiology but that she was perceived to have an eating disorder by 
others. It can be deduced that Alice felt stigma associated with this perception, which 
is known to exist in eating disorders (Mond et al., 2006) as well as in rare disorders  
(Joachim & Acorn, 2003).  
As with the parental accounts of diagnosis delay I believe that these women also 
experience complex diagnostic pathways, secondary to their relative(s) lengthy 
diagnostic journeys, as they observed their family going through investigations but 
they themselves were also unwell. Women in this group also had the option if they 
had wanted to, to defer their diagnosis once armed with the knowledge of their 
relative’s diagnosis, which two women did after finding out their siblings diagnosis. 
They were not alone in this behaviour with many women describing other family 
members of theirs, who had at the time of the interview refused testing, including 
other siblings and extended family such as maternal aunts, nieces and nephews. 
When writing about genetic testing in families with a known risk of breast and ovarian 
cancers, d’Agincourt-Canning (2006) says that the decisions to have a genetic test is 
‘not made in isolation but is shaped by other life experiences, circumstances, 
responsibilities and commitments (p101).  
For the two women in this study who delayed testing, their reasons differed from one 
another, but both had waited a number of years before requesting a diagnostic test. 
For Wendy it was her decision to defer until she was actively considering starting a 
family (see Chapter 8) and for Alice it was because she struggled with knowing 
whether it was something she wanted to know because ‘once you know that’s it’ 
(Alice: 279). Alice made the decision to have the diagnostic test after finding out a 
younger member of her family had been found to have the mutation. This new 
information prompted Alice to be tested to enable her to contribute to research for 
the potential benefit of her family member and others. 
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And from then I checked, I, I wanted to go and get tested because I knew if, if 
I had it, that was it. But, like, I thought, “If [Family member] have got it, I’ve got 
to, like, contribute.” I’m not, I, I know that sounds a bit selfish, not just my 
[Family Member] - other people as well. But that was the deciding factor, I 
think, when I found out my [Family Member] [had it]‘ (Alice: 300-305) 
 
Both Wendy and Alice’s eventual desire to undergo genetic testing echoes work 
done by others in BRAC1 and BRAC2 testing, where known carriers wanted to be 
tested to benefit family members (Goelen et al, 1995). In addition to helping family, 
Alice’s motivation to help others who may be affected is described by d’Agincourt-
Canning (2006) as the ‘civic self’, where women at risk of BRAC1 and BRAC2 gene 
sought testing to help other families and advance medical knowledge, acting out of 
concern for ‘society at large’. For many women, experiencing their loved ones go 
through serious episodes of illness left lasting reminders of potential severity of their 
family’s mtDNA mutation. Lived experience of family ill health is shown within this 
study to be a factor of consideration with regards to reproductive decision-making 
(see Chapter 8 section 8.3).   
5.6 Summary    
Women with maternally inherited mitochondrial disease travel varied and often 
complicated pathways to diagnosis. In some instances, women delayed accessing a 
diagnosis, either to put off a suspected diagnosis or on the assumption that their 
illness was not too severe and did not warrant testing. However, some women had 
experienced symptoms from childhood that remained undiagnosed for a number of 
years devoid of the legitimisation offered by the sick role (Parsons, 1951), especially 
for women who were not afforded it by the health professionals they first 
encountered when seeking help with their symptoms. Women were sometimes left in 
a long term, medically unexplained or misdiagnosed state. Upon receiving their 
diagnoses these women described feeling relieved to receive an explanation for their 
illness. Similarly, data in this Chapter also shows how mothers of affected children 
experienced upset and frustration in obtaining a diagnosis for their child. This data 
contributes to, and supports literature that suggests that receiving a medical 
diagnosis can result in individuals feeling relieved (Dimond, 2013; Glenton, 2003) 
and in some instances enabled women to shed the stigmatised identities generated 
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from a misdiagnosis or lack of diagnosis (Huibers and Wessely, 2006; Picariello et 
al., 2015; Ashbring and Narvanen, 2002; Tucker, 2004; Barlow et al., 2007). 
Although relevant to some women at particular stages of their diagnostic journey, 
Andersen’s model of total patient delay has limited explanatory potential in the 
context of complex diagnostic pathways in mitochondrial disease. In part this can be 
explained in the design of the model, which was developed specifically in relation to 
how family units accessed health care (Andersen et al., 1995; Andersen & Newman, 
1973), with some researchers proposing disease specific adaptions or expansions 
(Walter et al., 2012). Because of the genetically inherited nature of mitochondrial 
disease, and the extensive variation in symptom manifestation, such a model is 
unlikely to deliver the scope necessary to satisfactorily incorporate the condition. 
However, as this chapter illustrates, it remains useful as a comparison point from 
which to develop understandings of alternative diagnostic pathways. 
I have shown that all women in this study have an experience of living with 
mitochondrial disease and that if they themselves have not been physically affected 
they have at least one family member that has as a result of a mtDNA mutation. I will 
go to explore the impact of this diagnosis in Chapter 6.
 134 
 
Chapter 6. The Social Implications of Diagnosis 
 
6.1 Introduction 
The previous chapter discussed the various routes to diagnosis travelled by 
women with mtDNA mutations who participated in this study. The effects of living 
with a rare disease have been shown to extend from the medical, biological and 
physical impacts into many areas of patients’ lives (Muir, 2016; Nunn, 2017). This 
chapter continues to explore the social impacts of being diagnosed with 
mitochondrial disease, which in turn provides additional context to the 
reproductive decision-making discussed in the following chapters. Data 
introduced in this chapter explains women’s experiences of being diagnosed, as 
well as their short-term responses to their diagnosis, which include fear of how 
the condition might progress and their attempt to seek further information. 
Women also had to navigate disclosure, and make decisions about who they 
would and would not share their diagnosis with. For example, decisions not to tell 
were largely informed by privacy or in the case of immediate family not wishing to 
be the bearers of bad news. Further the chapter goes on to examine the longer-
term disruptive implications of their illness on important relationships in their lives. 
This included navigating interactions with employment and educational 
organisations, which were ill equipped to manage the uncertainty posed by the 
women’s conditions. The last section reflects on how the dynamic of clinical 
relationships could change post diagnosis, as some non-specialist health 
professionals appeared to have difficulty in providing support appropriate to the 
uncertain nature of the women’s conditions. 
6.2 Receiving the Diagnosis 
6.2.1 Uncertainty and Fear 
Alongside relief of understanding what had caused their own or their family 
members’ ill health for many years came the uncertainty surrounding their or their 
family members’ future. The natural history of mtDNA mutations is still relatively 
unknown despite on-going research aimed at finding new associations and 
understanding all the potential phenotypes attributed to certain mitochondrial 
mutations (Mancuso et al., 2015; Nesbitt et al., 2013). As we have seen in 
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Chapter 5, some women were given their initial diagnosis by a non-mitochondrial 
specialist, the inability to provide specialised information at this appointment left 
some women extremely distressed ‘I just sort of panicked, and I thought, ‘“Oh no, 
I’m going to die” you know?’ (Maggie: 516-517). Maggie like many others actively 
sought a consultation with an expert in mitochondrial disease following her 
diagnosis and was told that: 
Maggie: ‘[They] just said, “Well, you know, we really don’t know what 
your prognosis is. We won’t know because it’s a fairly new 
area of medicine, and we don’t really know what the future is 
for” erm  
Int:   Yeah.  
Maggie: So, but I did feel, feel better 
Int:   Yeah.  
Maggie: You know, that [they] sort of, erm, because I [Laughter] I 
mean   that was one of the things I asked [them] what my life   
  expectancy would be. Erm, and [they] basically said, “Well  
  nobody can sort of tell you what that is, but he looked at like, 
  I mean my mam’s [XX years old]. My, my nana lived till she  
  was [XX years old] something, you know, so he says, you  
  know, “It’s obviously been passed through generations, and  
  it doesn’t seem to have caused any sort of shortening of your 
  life expectancy” (Maggie: 533- 551) 
 
Maggie’s specific concern was relating to life expectancy, which she deduced 
from the specialists advice unlikely to be adversely affected because of her 
mtDNA mutation. This had been based on the probability that her mother and 
grandmother had also carried the mutation. Although Maggie did not receive all 
the answers to her many questions at that appointment she did leave feeling 
more reassured.  
The initial fear of a threat to mortality was not uncommon, with many women’s 
first question being ‘will I die?’ and in reference to any children or family, ‘will they 
die?’ Many women who experienced strong emotions surrounding their diagnosis 
called for more psychological support to help them come to terms with their 
diagnosis, I explore this further in section 6.3.2. 
6.2.2 Seeking Information 
Information seeking relating to mitochondrial disease is intertwined in many areas 
of women’s lives from the moment they find out about their diagnosis or the 
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potential that they may have a mtDNA mutation. They seek information on a 
broad range of topics, including coping with their diagnosis, learning to adapt 
their lifestyle through to disclosing to others their diagnosis and for reproductive 
decision-making. Women relied on a number of sources of information prior to 
and when first diagnosed, most notably their mitochondrial specialist, other 
trusted health care professionals and the Internet to learn about the risk of 
mitochondrial disease. Awareness of mitochondrial disease and inheritance risk 
is a contributing factor to the proposed conceptual model of reproductive 
decision-making, with many women using these information seeking practices to 
inform their decision about reproduction (see Chapter 8 section 8.3.1).  
Information provision, especially during the initial phases of diagnosis is often 
key. Sally was shocked to receive the news that her daughter had a 
mitochondrial mutation after numerous hospital appointments, receiving at the 
same time the news that her child’s condition was maternally inherited.  
[they] gave us the information that what [they’ve] found I don’t think that 
anything else could have been given to me at the time to make me feel 
better erm unless you know cos I had to go away do my own research and 
come to terms with stuff’ (Sally: 278-280) 
 
For Sally it was important that she was able to do her ‘own research’ and she 
saw this as a way of ‘coming to terms’ with her child’s and eventually her own 
diagnosis, she did not feel more could have been done for her by her child’s 
clinical team initially. Noorda et al (2007) conducted interviews with parents of 
children with mitochondrial disease and found that the attitude and availability of 
the person providing information about their child’s condition was the most 
important item, that they wanted this person to be honest about what they did and 
did not know and that there should be resources available to allow them to ask 
questions.  
Like Sally many women conducted their own ‘research’ as to who were the 
experts in mitochondrial disease and who could help them further ‘it was me that 
kinda did further investigations and then I got in touch with [mitochondrial 
specialist]’ (Lucy: 19-20) and that the internet ‘opened the gate for me to speak to 
[mitochondrial specialist] (Sarah: 413-414). A common criticism on the 
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information available to women from sources linked to specialist centres was that 
stories featured did not represent their experiences of mitochondrial disease; 
where stories of severe phenotypes were more present than stories of those 
more mildly affected. This caused some women to feel anxious about their 
diagnosis. Sarah found this was this case during her initial investigations using a 
dedicated mitochondrial disease website, after having established that her 
diagnosis was not fatal.    
 Sarah: Their newsletter, their website for patient information  
   and it was all great I thought it was fab but also, I kept 
   thinking well this isn’t me, I’m not in a wheelchair  
 Int:  Yeah 
 Sarah: You know it doesn’t impact my daily life, yes it does  
   impact sort of the [Symptom] thing ermm but that not  
   really the mitochondria it was more starting to make  
   me worry about the future … I just kept thinking aw  
   these poor people  
 Int:  Yeah  
 Sarah: All these poor people but that’s not me but am I going  
   to be like that’ (Sarah: 405-417)  
 
For Sarah, she had been very relieved that her diagnosis was not fatal, she was 
also satisfied that the information she had was enough for her not to alter her 
plans to start a family (see Chapter 7 section 7.4.1). However, she felt that 
information published about living with a mitochondrial disorder was not tailored 
to her, aimed at those much more affected then her and so was not comparable 
to her current or possible future experience. The disparity has also been reported 
in bipolar disorders, with caregivers reporting that in contrast to the above, on 
evaluation of the usefulness and acceptability of an information website 
respondents felt information was directed at those with milder symptoms, with 
less provided in relation to those supporting family members or friends with 
chronic, severe or complex symptoms (Berk et al., 2013).  
Andi also felt this way with regards to the level of information available to adults 
in comparison to paediatric patients, where her experience of mitochondrial 
disease is of slow progression unlike that of severely affected adults and children: 
‘I don’t know, it doesn’t feel like it’s for me; (Andi: 523). Andi found that 
information available for patients when she was first diagnosed, the pamphlets 
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and website she found, was adequate enough for her at first. Over time no new 
information had become available via these routes or via dedicated social media 
platforms. Andi suggests many different areas of research that could be shared 
with patients, not just research centring on mitochondrial donation (which had just 
been voted on in the houses of parliament prior to her interview) but how 
mitochondria have been linked with other disorders and how this would be very 
interesting to mitochondrial patients to know. 
 Andi:   For instance I know there has been research in other  
   field’s erh connecting mitochondrial erm issues with  
   Parkinson’s or Alzheimer’s and there’s been research  
   into whether a lot of the other illnesses the cause is in 
   the mitochondria  
 Int:    Arh right yeah 
 Andi:   So that would be interesting to somebody who has  
   mitochondrial disease  
 Int:   Yeah  
 Andi:   Cause you think well there’s not a lot of research in  
   our field apart from this IVF thing (Andi: 544-550) 
 
Andi appears passionate about this subject and she feels that other mitochondrial 
patients would want to know about links to other conditions as well. There is little 
chance of people finding out about these advances ‘because it’s quite niche it’s 
not something that’s going to make the news unless it’s a slow day’ (Andi: 564).  
She feels that much of the relevant research is restricted to ‘medical journals or 
research journals which we don’t normally have access to’ (Andi: 473-474), that 
require ‘deciphering’ so that ‘ordinary’ people can read them. She, like some 
others, is seeking to further her understanding of the disease in terms that make 
sense to her. In practical terms, she is seeking a more open, accessible and 
democratic knowledge about her disease.  
Andi highlights that on-going information provision is important to her and could 
be to other patients, especially when research may go on to affect them in the 
future. The emergence of new knowledge from research and its communication 
to patients was also an issue for Miriam and her family; they felt that although 
there was lots of new information available she found it difficult to know what was 
relevant to her and her family. She describes that patient information days and 
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improved websites are helpful by that she feels that she does not receive 
answers to all ‘her’ questions. 
 Erm, so the last meeting we had was good information there. But 
 sometimes you find when you ask, I always have questions to ask 
 and I feel they’re not always answered. They’re kind of hmm, the 
 one says to me, that’s rubbish and that’s not gonna happen 
 (Miriam: 602-606)  
 
This is specifically relating to potential participation in a clinical trial, a central 
question for Miriam was ‘if the UK centres will not participate in the study then 
what else are they doing for patients?’ Miriam like many others is frustrated with 
the lack of therapeutic options available and would like more information about 
potential experimental therapies that her child may take part in.  
The receipt of a diagnosis led many women to seek further information about 
mitochondrial disease themselves, often online. Some women recounted that this 
was something they ‘had to go away do’ following their diagnosis, whilst others 
researched mitochondrial disease after a less then satisfactory consultation. 
Information seeking in this way has been said to be the start of the  ‘emotional 
work of grief and acceptance’ for parents of children affected with rare disorders 
and that the knowledge gained by this helped parents to address uncertainty and 
re-establish a life in which their child’s disorder can be managed (Gundersen, 
2011:p91). Searches often produced worse case scenarios, leading women to 
fear that they or their family members prognosis may be fatal. These feelings 
were alleviated once they or their family member received an individualised 
specialist assessment.  Factual awareness of mitochondrial disease and its role 
in reproductive decision-making is explored further in Chapter 8. Women felt that 
these search results did not mirror their experiences of the disorder, especially if 
they felt that they had mild symptoms; feeling sympathy for those more affected 
than themselves. Finally women wanted to be part of generating new knowledge, 
including recommendations for the dissemination of understandable science 
relating to mitochondria and its role in other diseases and participation in clinical 
research. This desire also mirrors Alice’s in Chapter 5, who wanted to be able to 
take part in research not only for her family members but also the wider 
community affected by mitochondrial disease.  
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6.2.3 Disclosure 
Following the receipt of information that they, their child or their family member 
had a possible mtDNA mutation or had already been diagnosed, came the 
process of deciding who in their lives became privy to this information. Sharing of 
genetic information within families, especially with at-risk relative(s), and its 
complexities has been written about extensively within the literature, with many 
clinical and ethical guidelines along with policies of best practice published 
(Forrest et al., 2007; reviewed in Gaff et al., 2007). The process of informing 
others of their potential or diagnosed mtDNA mutation was complex for many of 
the women. Issues faced by women included decisions as to whom to tell and 
whom not to tell, disclosure of the genetic cause and how this disclosure or non-
disclosure helped them in living with their disorder.  
a. ‘Telling others’ 
As we have seen in Chapter 5 a large majority of women were informed of their 
risk of having a mtDNA mutation from either a maternal family member or from 
their child’s clinician and so were therefore not the primary receiver of the family’s 
diagnosis of mtDNA mutation. For those informed this way they still found 
themselves faced with scenarios regarding further disclosure to other family 
members.  In this study women chose to tell those who were considered as 
socially significant that they might have ‘some kind of genetic condition’ relatively 
fast, even in circumstances when a diagnosis was not confirmed. Socially 
significant in this context was found to be their partners (if in a relationship), 
siblings, their parents, specifically their mothers and close friends. Many women 
also described telling their ‘in law’s’ but did not find it necessary to go into detail 
about their diagnosis as it was felt that they did not really understand. For those 
women who had strong relationships with in-laws, such as their sister-in-law, they 
were included in the socially significant group as both family and close friends.  
Providing information to others about their specific prognosis was important for 
women and their family members. As we’ve seen above, establishing if their 
diagnosis was life threatening was a main priority.  
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I think he was more concerned is it something terminal, “it’s not terminal is 
it?” something erm can’t remember what the other things could be but … it 
wasn’t something, I think once you rule out that it’s not terminal you sort of 
arh well I’ve I’ve had it’ (Andi:137-139) 
 
For Andi’s husband hearing that her diagnosis was not terminal was the most 
important thing to him, so much so that Andi cannot recall what other future 
potential symptoms she may have been told about at her diagnostic consultation. 
As for many women’s partners, friends and relatives, establishing the severity 
and prognosis of his wife’s diagnosis was Andi’s husband’s main concern.  
Many women chose to tell those who may also be at-risk, maternal family 
members ranged from siblings and their mothers as well as at-risk cousins and 
their children. This was seen primarily to be related to their feelings of guilt and 
responsibility (discussed further in Chapter 8, section 8.7.2) and supports the 
existing literature on ‘genetic responsibility’, in that individuals take on not only 
responsibility for themselves but responsibility for other at-risk biological relatives 
(Arribas-Ayllon et al., 2011; d'Agincourt-Canning, 2001; d’Agincourt-Canning, 
2006; Dimond, 2013; Hallowell et al., 2003; Novas & Rose, 2000).  
Women described sharing genetic information in family groups as a form of 
support, especially in those families in which there were multiple people affected. 
This echo’s work done on the key reason for communication of BRAC1 and 
BRAC2 genetic test results amongst sisters, which showed that 74% of their 
sample shared genetic information in order to obtain emotional support (Hughes 
et al., 2002). For Alice finding out her diagnosis meant she felt that she could 
better support her affected family members ‘I felt better once I knew, I could 
support my [family members] more’ (Alice: 407). Although Alice did consider this 
might seem ‘silly’ to say, she recalls telling a relative about her diagnosis via text 
message after her consultation. 
Alice:  As I said, we’re in the, we’re in the, we’re in the gang.   
  And, er, I can remember when I came out of the hospital  
  and I text [Family member X] because [Family member X]  
  and [Family member Y], I was-  
Int:  Yeah. 
Alice:  Only with [Family member Y] when I was diagnosed and,  
  erm, [Family member X] was, I don’t know, [Family   
  member X] might have been at work or something. And I  
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  text [Family member X] to say, “I’m in the gang.” And she  
  went, “I knew you would be,” type of thing  
  (Alice: 2869- 2879) 
 
For Alice, disclosure of her diagnosis to the family member who had first been 
diagnosed was relatively informal, via a text message following her appointment. 
Alice also wondered that had she not have tested positive for the family mutation, 
whether this would have somehow separated her from these relatives ‘It would 
have changed things a lot, wouldn’t it?’ (Alice: 2887). Alice tells us throughout the 
interview that those members of the family who are affected share together their 
experiences of their illness that she finds very comforting ‘I think we support each 
other a lot’ (Alice: 2894).   
Parental disclosure of illness and its aetiology to children varied depending on 
their ‘at-risk’ status and their age. For women whose children were affected, their 
child’s illness meant that siblings were aware of the struggle to find out what was 
wrong with their brother or sister, irrespective of age. Inheritance patterns were 
also not withheld from siblings. Sally discussed their family mutation with her 
children who were still of school age ‘I also want them to know that, about our 
condition and our gene and our family’ (Sally: 404-405). It was important to Sally 
that they grow up with an understanding of their family’s mutation - ‘our gene’ - 
but also that it affects people differently and to be empathetic to people with 
disabilities. Sally engages with social media to assist with this, included in more 
detail in Chapter 8 section 8.3.1. Johnson et al (2005) showed that parents of ill 
children shared their child’s medical diagnosis more often than affected adults 
disclosed their own diagnosis, and parents were also less likely to regret this 
disclosure (Johnson et al., 2005).  
Disclosure was complicated by women’s own lack of understanding of the 
complexities of maternally inherited mitochondrial disease. Frustrations arose 
when women found it difficult to understand their diagnosis and when they were 
unable to answer questions from others. Sally found it difficult to tell people about 
her family’s mutation because she did not believe her family showed typical signs 
expected from their mutation ‘so it’s a little bit complicated really, it’s not just a 
straight forward thing’ (Sally: 132-133). Lack of understanding was however 
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combated with the introduction of analogies used by mitochondrial specialists to 
explain mitochondrial disease to patients. Women found these helpful for their 
own understanding and went on to use these to tell others of their condition and 
how it affected them. 
Liza:    I didn’t really know what it meant just sort of had this   
  mutation erm in me you know DNA and at that point it was  
  very hard to try and tell somebody what it meant, what  
  [SYNDROME] meant erm you know it wasn’t until good  
  years later when they started using that term about the  
  batteries  
Int:    Right  
Liza:   So at the time it was kinda like arh yeah we’ve got this family 
  and were researching it through through the hospital but that 
  was it really  
Int:   And did you then tell that it might be carried through the  
  female line, through yourself or did you not 
Liza:   No no I don’t think I did 
Int:    Or did you not go into it       
Liza:    I didn’t really go into it no, I think it was just more because  
  there wasn’t much … for me like information for me to pass  
  on at that point  
Int:   Yeah 
Liza:   Erm so I kind of just just left it cause again it’s very hard for  
  other people to to understand when you’re fine  
  (Liza: 228-242) 
 
Liza found it difficult to tell others about her family’s diagnosis as she felt that 
there was not enough information available to help her do so. Liza showed signs 
of struggling to understand, as did other women, what the differences were 
between their family’s genetic mutation and the phenotypic syndrome that 
someone in their family had or were currently suffering from. For example, Ashley 
described herself as having a severe syndrome ‘I have [SYNDROME], if that 
helps, I am not sure’ (Ashley: 10) but also that ‘I’m not really affected’ (Ashley: 
11).  
Liza chose not to disclose to others that her condition was maternally inherited 
but was comfortable informing others that it was to do with ‘family DNA’, again 
because of the lack of information available to her. Disclosure was further 
complicated for Liza as she herself does not experience any signs of illness, 
she’s ‘fine’. Liza found the introduction of the analogy of batteries very helpful, 
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this being that mitochondria are the batteries of a cell that provide energy to 
enable the body to function, without these or ‘faulty batteries’ the body is unable 
to function how it should. Women also used their own scripts to ‘quicken’ up 
disclosing how their mtDNA mutation affected them to others. Sarah tells us that 
she is does not share information relating to her mtDNA mutation readily. When 
asked how Sarah had dealt with questions relating to her multiple hospital visits 
and time away from work, she tells us that she used a short script to explain her 
condition.  
Sarah: Oh gosh … well … I say that … it’s about an energy supply  
  that affects the cells in the DNA that makes muscles work  
  and fortunately for me … it’s only affecting my [X organ] but  
  they’ve got to keep an eye on me 
Int:  Yup 
Sarah: and that’s what I say ... now and that’s the shortest quickest  
Int:  Un hun 
Sarah:  But I don’t think that doesn’t that in any way explain the  
  severity of it ... at all (Sarah: 236-242)  
 
Although she prefers not to tell others when asked Sarah, like Liza, is 
comfortable disclosing that she has a genetic condition. She discusses ‘energy 
supply’ and how this affects her that she is ‘fortunate’ that it affects only one 
organ and that it requires a level of monitoring from health care professionals. For 
Sarah this provides enough information needed by others, but she recognises 
that this script does not represent the ‘severity of it at all’, which could be heard 
as both the severity that Sarah experiences as well as the severity of 
mitochondrial disease as a disorder.  
Difficulty in explaining to others about complex rare disorders and their 
implications has been reported in other conditions, scleroderma (Joachim & 
Acorn, 2003) and phenylketonuria (PKU) a disorder that has significant social 
implications due to diet restrictions (Diesen et al., 2015). Use of analogies is 
common practice in health care and can be used both to help patients to 
described their symptoms to their doctor and used by doctors to help patients 
understand and cope with symptoms (Fuller & Hughes, 2003). Most notably 
mitochondria as the ‘battery of the cell’ has been used extensively in ethical and 
legal scholarly debates, parliamentary consultation materials and in media 
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reports around the world during the UK parliamentary consultations and debates 
(see Chapter 2). Mitochondrial donation was explained by the analogy of  
‘changing the batteries in a camera or a laptop’ (Barber & Border, 2015 p22; 
Watts et al., 2012 p53 & p78). The use of such analogies or scripts were 
memorable to women and used by many to tell others of their condition, they also 
permitted women to modulate how much information they provided to others, in 
that it did not require them to specifically mention what organ or system was not 
functioning correctly.   
Close friends or the ‘inner circle’ (Wendy: 195), were included amongst the 
people informed of the illness. This was often as a form of emotional support for 
women. It provided an explanation as to why some woman had made lifestyle 
adaptions such as walking at a slower pace, taking naps, using walking aids and 
in one case explained a woman’s anxiety about looking after small children in the 
family. There was a mixture of those who provided either information regarding 
the maternal inheritance pattern, a ‘genetic condition’ or provided no specific 
information regarding either. This disclosure was based on trusted relationships 
with friends. For some women their diagnosis legitimised their experience of 
unexplained illness to others who may have questioned them, as we’ve seen in 
Chapter 5 in relation to Jenny’s childhood GP, Lucy’s PE teachers and Joanna’s 
partner.  For some this seemed to be experienced at a much more significant 
level, especially when prior comments had caused them lasting upset as we have 
seen with Lucy’s experience of being stigmatised as ‘lazy’.  
Some women also found it helpful to discuss their diagnosis and how it affected 
them with their employers and colleagues, this allowed them to tackle issues 
such as hearing impairments, ataxia, fatigue and mobility issues in the work 
place. Sometimes this disclosure upon diagnosis was due to concerns over 
employment contracts that required medical conditions that could affect their 
performance or pose a safety risk to be disclosed: ‘I’m contracted to tell them’ 
(Alice: 1528). It also emerged with regards to arranging working hours, a suitable 
office layout and helping colleagues to understand what they are living with.  
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 I was quite open about it. I believed that erm keeping it, like not  
 telling  people, erm, and having them kind of judge me based on  
 what they were seeing without understanding what was actually 
 wrong, erm was, wasn’t going to do anybody any favours. I thought 
 it was  better taking it out in the open and I actually printed off 
 sheets about mitochondrial disease and gave them to like my team 
 at work and my manager and things like that, to help them 
 understand a bit more about what I was dealing with (Holly: 612-
 621)  
 
Holly was the most proactive amongst the women who informed their employers, 
as well as providing medical letters or visiting occupational health as others had, 
Holly printed off information sheets for her managers and colleagues to enable 
them to understand more about her condition. For Holly, she had made a number 
of employment decisions in the past relating to symptoms that were later 
attributed to her mitochondrial disease, these had included leaving full time study 
and giving up a place on a workplace training scheme. She felt that being open 
about her diagnosis helped to prevent other people from judging her with regards 
to her working hours and patterns.  
Disclosure and confidentiality were synergistic for many women, however some 
women were faced with losing their anonymity either partially or completely when 
participating in charitable fundraising or via political engagements that involved 
local, national and international media. During parliamentary debates many 
women contacted their MP to vote on their behalf and as result were then known 
to them as an ‘affected family’. To prevent any possible identification, I have 
actively chosen not to include supportive quotes relating to personal media 
campaigning (available on request), however a proportion of women spoke about 
how their interaction with media at the time of debates meant that friends, 
acquaintances, employers and colleagues became aware of their diagnosis and 
their lived experience of mitochondrial disease if this was shared. This disclosure 
to those around them and to a broader public was not considered problematic by 
those women, but does raise awareness of what it means to be a ‘public patient’ 
and its impact on confidentiality and disclosure. 
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b. ‘Not telling’ 
For some women disclosure was problematic and included hesitancy to inform at-
risk female siblings or children and non-disclosure to elderly maternal 
grandparents and employers. Hesitancy to inform their adult at-risk siblings was 
seen when women wanted to delay their family members from experiencing the 
parental guilt that they felt toward their own children. Those women who had 
hesitated to tell their adolescent or young adult children did so because they 
believed them to be healthy and wanted to delay them informing them. For 
Maggie this included brief disclosure to her teenage children around the time of 
her diagnosis, but this was more to abate their concerns that their mother was 
very ill and may have been told she had a terminal illness.  
 so I sort of explained to them what it was, but I didn’t really sort of 
 say to them, “And yous have probably got it as well’” … I said 
 that it was a  genetic condition. That was all I sort of said (Maggie: 
 607-616) 
 
For Maggie ensuring that her children did not worry about her was the driving 
force behind telling her children; she did disclose that she had a genetic condition 
but did not explicitly tell them they may also be at-risk of having the same 
mutation. Maggie eventually went on to tell them when they were older after 
discussion with a mitochondrial specialist, although she was not entirely 
comfortable with doing so.  
Disclosure of a genetic condition was often withheld from elderly mothers or 
maternal grandmothers, with many women citing that this was to protect them 
from feeling the guilt that they themselves felt towards their own children. In 
addition to this, the complexities of mtDNA mutations also meant that their 
mothers or maternal grandmothers may not harbour a mtDNA mutation 
responsible for their child or grandchild’s illness and they may evoke distress for 
no reason. The role of guilt and responsibility is discussed in detail in Chapter 8 
section 8.7.2.  
Disclosure to employers however was seen, in comparison to examples above, 
as problematic for some women. For Wendy, concerns that knowledge of her 
diagnosis may negatively impact her employer’s perception of her ability to 
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perform at work. When discussing whom Wendy has chosen not to tell about her 
diagnosis, Wendy tells us that  
Well it’s not affecting my health and my work but also I don’t want it to in 
anyway sort of jeopardise my career (Wendy: 206-207) 
 
Wendy had two reasons as to why she had chose not to tell her employer, the 
first being that she did not experience any symptoms associated with her mtDNA 
mutation (having been diagnosed via a sibling) – and is in contrast to Holly (see 
above) who experienced significant disease burden and was very open with her 
employer. Secondly, Wendy felt strongly that it could jeopardise her career, in 
that knowledge of her diagnosis may in some way result in discrimination against 
her, not uncommon amongst patients with genetic disorders (Lapham et al., 
1996). Wendy sees this as a serious concern due to the nature of her work and 
the mental capacity that it requires.  
In summary we can see that disclosure is complex for women with mtDNA 
mutations and can affect every aspect of their life, including relationships with 
family members, friends, colleagues, employers and in some case the public.  
The role of ‘genetic responsibility’ and its impact on reproductive decision-making 
is explored in detail in Chapter 8 section 8.7.2.  
The receipt of diagnosis, either directly or indirectly meant that women were 
faced with decisions as to whom else to share this information with.  Women 
shared information of their diagnosis with socially significant individuals relatively 
fast, with news of their prognosis being the most important to these individuals. 
For those women who shared this information with family members, they felt a 
sense of support, where as some chose to withhold information either temporarily 
or indefinitely from family members whom they did not feel able to tell or who they 
felt it was unnecessary to tell due to the upset caused. These feelings of ‘genetic 
responsibility’ are closely linked with guilt and responsibility which is included as 
an influential factor in the proposed conceptual model of reproductive decision-
making (section 8.7.2) 
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6.3 The Long-Term Impacts of Diagnosis  
For a number of women in this study, the long-term impacts of their condition pre-
existed their diagnosis. In this section I discuss both these long-term symptom 
related experiences and if and how they were impacted on by receiving a 
diagnosis. This section is central to women’s experiential knowledge of 
mitochondrial disease and highlights its disruptive nature on their lives.  
For a proportion of women in the study their mitochondrial disease had become 
progressively worse over the years, requiring additional care and lifestyle 
adaptations (Garrino et al., 2015). Additional care often included being referred to 
other specialists and managing symptoms as well as possible, given that no 
specific mitochondrial treatments are known to date. Women discussed how their 
progressing symptoms affected them at home or work, more than they did their 
medical care. For Alice and her family, it was arranging for a hairdresser to come 
to their home as removing hearing aids in busy salons was distressing. For Andi 
it was using a walking stick to help her when out with the family on day trips. 
Some women however experienced more significant changes to their lives as a 
result of their or their child’s changing requirements including impact on social 
relationships, emotional needs, education and work, which I will discuss in turn. 
6.3.1 Social Relationships  
For those women physically affected by their mtDNA mutation they experience 
biographical disruption, as they undergo a ‘period of adaption’ to the emerging 
symptoms but have ‘access to periods of classic sick role behaviour’ when they 
experience symptom progression or exacerbation of existing symptoms (Bury, 
1982. p168). When discussing who knows of her diagnosis, Andi tells us that she 
had had to explain to others more as time goes on due to her disease 
progression. A sign of progression for Andi had meant that she had started to 
drop items but only noticing that she had when they hit the floor, due to lack of 
feeling in her fingertips, ‘there’s an adjustment period you adjust to that and then 
you’re fine again’ (Andi:168-169). For Andi, managing and adapting to her 
disease progression was central to her feeling ‘fine again’, a reaction also 
reported in other rare diseases (Garrino et al., 2015).  For Liza, she had grown up 
in a family affected by mitochondrial disease and was already aware of the 
potential disruptive impact of certain known symptoms. She therefore felt 
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prepared to deal with the symptoms associated with their family’s mtDNA 
mutation if her future child was to suffer from these.  
Liza:  I was like well we can cope with [Symptom A], [Symptom  
  A] fine, you know [Symptom B] yep its very rife now can  
  deal with that, you know other bits and bobs and so my  
  view was … even if I, I knew I was passing on I knew that  
  was the one thing 
Int:    OK 
Liza:   I knew I was passing onto my child but I thought whatever  
  I pass on …  is going to be fine it’s its manageable   
  millions of people manage it (Liza: 120-125) 
 
These ‘socially acceptable and manageable’ symptoms did not pose a 
concern to Liza when considering her reproductive decision-making she felt 
that society as well as her family would be able to help support a child if they 
were to experience these symptoms.  For Lisa her lived experience of 
mitochondrial disease did not impact her reproductive decision-making in her 
first pregnancy but a family fatality had a profound effect on Lisa feelings 
towards risk and uncertainty associated with their shared disorder (see 
Chapter 8 section 8.3.1). 
Experience of chronic illness is also said to lead to individuals retreating from 
social interactions because of the impact of their symptom (Jefferies & 
Clifford, 2011; Jeon et al., 2010). Strauss (1975) argues that although this can 
be seen as understandable it can become problematic. Uncertainty and 
unpredictability of symptoms have been linked to anxiety and depression due 
to lack of social contact and increased dependency on others (Barlow et al 
2007). For Holly she felt that relationships with some of her friends became 
strained both before and after her diagnosis, with many believing her 
symptoms were psychosomatic (see section 5.3). She describes incidents 
when she lost friendships she had had since childhood and that even recently 
she felt that some friends had been ‘really, really angry’ (Holly: 682) with her 
‘spoiling’ events. 
Erm, I lost a couple of friends because of it, because erm I had a, like 
because my symptoms were meaning that when I was going out I was 
having to, I was taken unwell and I was having to leave early, or I wasn’t, I 
was just going out and, or I just wasn’t able to go to things … And I think it 
 151 
 
got to the point that it was easier just to not invite me to things as to 
actually invite me and deal with the outcome of it, sort of thing, which was 
hard. It’s hard to (Holly: 622- 650) 
 
These losses and strained friendships had impacted on Holly quite 
considerably and she expressed feelings of selfishness for feeling like ‘I want 
to be like everybody else. I want to join in and have fun’ (Holly: 725-726). 
These feelings had led her to seek counselling to address this impact.  
Holly was not alone in feelings of isolation. Miriam describes how her child 
who is affected feels isolated from people their own age. There was a strong 
sense throughout Miriam’s interview that the lack of communities for affected 
mitochondrial patients was troublesome for her and her family. She was very 
upset when discussing this topic and returned to it as a major issue 
throughout the interview. Miriam’s feels that these communities exist in other 
conditions, notably Duchenne Muscular Dystrophy ‘they all keep in contact 
with each other, they all see each other’ (Miriam: 370-371) but that her family 
are unable to fit into any of these neuromuscular groups.   
Miriam would like to meet people with the same mutation as her family’s, she 
would like this because of how unpredictable her child’s phenotype can be. 
She ponders whether or not her family’s mitochondrial specialist team may be 
less forthcoming with details of similar patients to her child in order to protect 
them from witnessing how severely it can affect a person.  
 But all we want to know is because of this unpredictability we, we 
 should know of the people have got this condition. Maybe they’re 
 worse than they think they are. We don’t know whether they’re 
 [mitochondrial specialists] trying to protect us, we don’t know, but it 
 would be nice for [Child Y], who’s got something similar to [them]. 
 They truly understand each other. (Miriam 634-640) 
 
Throughout these segments of the interview, what is key to Miriam is that she 
wants to locate peer support for her child. Miriam had also exhausted 
symptom specific support groups but to no avail, ‘we always ask, well what 
kind of people go to the thing ‘cause we’ve had some really odd experiences’ 
(Miriam: 524-525). Many of these groups included elderly members only and 
when specifically asked if there were any younger members or groups known 
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to them, Miriam was told there was not. Given that Miriam’s affected child was 
a young adult these groups were not suitable to their requests for peer 
interaction and support.  
  Miriam: but [they] wants some people to understand and they  
    are [their] age 
  Int:  Yeah 
  Miriam: More fun for [them] rather than people our age, older  
    than us, what on earth [do they] want to be around  
    them for, “cause we’re older, we’ve lived our lives”  
    (Miriam: 536-543) 
 
It was distressing for Miriam that she was unable to find the peer support that her 
child had wanted. However, just before taking part in the interview, Miriam and 
her family had been approached by a stranger whilst in the park who ran a sailing 
club for people with disabilities. Miriam and the family were excited to go along to 
the club in the near future and were hoping that this would be what they had all 
been looking for.   
6.3.2 Emotional Support  
For some women, receiving news of their diagnosis and the diagnosis of their 
family members was a particularly emotional experience and continued to be for 
months and years afterwards. Two women specifically spoke about their desire to 
seek counselling for themselves and family members in relation to their 
diagnosis, with both women becoming very emotional when describing how they 
felt that they or their family member had not been offered or received any support 
such as counselling.   
Jenny had and is still struggling with her and her childs diagnosis, who at the time 
of this interview was a young adult. She tells us a number of times throughout the 
interview that she wished there was emotional support via a counselling service 
to help them come to terms with their diagnosis and to manage their disease 
progression, she feels that this is where the care provided to her and her child is 
lacking. 
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 Jenny: Yeah I think yeah that probably were the [service] falls 
   down  
 Int:  Right 
 Jenny: There is no counselling and there’s erm no   
   counselling for the kid either (Jenny: 299- 301) 
 
Jenny had hoped that there would have been more emotional help for her child 
as their disease burden had become, ‘worse and worse and worse’ (Jenny: 355-
356), she becomes emotional when recalling these memories. Jenny would like 
to have seen these services available to her child to deal with their changing 
body especially as this was occurring during their teenage years. Jenny had 
requested assistance from her child’s mitochondrial specialist but as this specific 
counselling service were not available via the team, it took many months for an 
appointment letter to arrive from what appeared to be a generic counselling 
department. This appointment was not attended, as it was felt by Jenny’s child 
that it was too late, ‘”it doesn’t matter”’(Jenny: 401). Jenny recognises that there 
is now more of an emphasis on talking therapies available via GP’s in primary 
care than there was at this time ‘I mean now they’re more into talking therapies 
and stuff like’ (Jenny: 404). Jenny also recognises that there are budgeting 
pressures that can prevent the level of care that she would have wanted ‘it all 
boils down to funding and money and stuff’ (Jenny: 312). Jenny feels that they 
would have also required a specialist counsellor with an awareness of 
mitochondrial disease.  
 Jenny: It’s changed a lot erm so probably even then even had 
   have went to see a counsellor the counsellor probably 
   wouldn’t have been …  able to deal with it you know  
   what I mean  
 Int:  Yeah 
 Jenny: Cos it’s like completely like, it’s not like just somebody 
   going in and going arhh I’m stressed and my work is  
   driving me mad where as you go what’s happening to  
   us and I don’t know what is happening to us 
   (Jenny: 406-412) 
 
For Jenny an ordinary counsellor would not have been able to help them, as she 
and her child weren’t like other people and their stressors were not ‘ordinary’. 
Jenny describes wanting to know more about what was happening to her and her 
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child’s bodies but less from a medical side and more in order for both her and her 
child to cope and understand these changes more. Jenny also struggles with the 
emotional burden of the maternal inheritance of their mutation (see Chapter 8 
section 8.7.2) and believes that, even after more than a decade of living with this 
knowledge, she would like the opportunity to discuss this with a trained 
counsellor.  
6.3.3 Education and Work  
Uncertainty features in the lives of women with mitochondrial disease in relation 
to the education including mandatory and higher education and women’s 
employment. Women provided a number of varied accounts of both educational 
and employment institutions failing in their ability to cope with the uncertainty and 
unpredictability of mitochondrial disease, both pre and post diagnosis. As a 
result, some women found themselves needing to leave university courses and 
employment training schemes as well as seeking roles that offered flexible 
working to accommodate in most circumstances, feelings of fatigue. These 
experiences contributed to women’s lived experience of mitochondrial disease, 
which is discussed in Chapter 8 in relation to reproductive decision-making. The 
long-term effects of restricted access to education and employment and their 
associated negative financial implications have not been assessed in 
mitochondrial disease. Although outside the scope of this thesis it is evident that 
mitochondrial disease impacts upon these areas, leaving some women (and their 
children) navigating complex relationships with societal institutions.  
Jenny offers an insight into her child’s experience in compulsory education and 
how having mitochondrial disease affected their schooling. Jenny was a fierce 
advocate for her child during their time at school, particularly in relation to their 
time at secondary school, which she describes as not being equipped to 
accommodate someone with the needs that her child had or making an attempt 
to after they were advised by a specialised physiotherapists, citing that 
adaptations ‘never got done’ (Jenny: 367-368). This unwillingness or inability to 
address the needs of Jenny’s child highlights an area of society that is ill adapted 
to accommodate the needs of mitochondrial patients, which in this case resulted 
in not only frustration but also restricted GCSE options due to physical access to 
classrooms and excursions. 
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For Maggie, her employers and colleagues were initially very compassionate and 
accommodating to her symptoms and news of her diagnosis. Over time and in 
conjunction with an increasing number of symptoms such as stumbling and loss 
of balance, Maggie’s employers became frustrated with her unspecified disease 
prognosis. Maggie felt that this was due to their anxiety that a serious incident 
may occur whilst at work. As symptoms progressed Maggie changed job roles 
within the same company, retrained and secured a promotion. For some time this 
was suitable, until additional symptoms meant that Maggie needed to reduce her 
hours. Unfortunately, this request was not suitable and Maggie felt that she had 
‘had enough’ and that she had ‘no support’. After some time off work, Maggie 
returned to a new part time role in another company that offered flexibility around 
her symptoms.  
Living with unpredictable and uncertain symptoms has been reported in those 
living with blood clotting disorders, who reported that their disorder had had a 
negative impact on their education and their employment, with some losing their 
job or retiring on health grounds (Barlow et al 2007). As a result these individuals 
also suffered from ‘severely reduced’ incomes (Barlow et al 2007:p238). When 
exploring the impact of symptoms on women and their education and 
employment it is key to not underestimate the societal and individual value of 
‘work’ and the potential impact of being labelled as ‘disabled’ at work can have on 
a person’s identity. Fryers (2006) discusses how those workers with disabilities 
may suffer ‘discrimination as non-workers’ and loss of their identity (p4). In the 
accounts provided from women within this study, this could include the loss of 
their identity as departmental managers, employment training program 
candidates and as university students.   
6.4 On-going Clinical Relationships 
Being diagnosed with a mtDNA mutation generated new clinical relationships with 
mitochondrial specialists for the women in this study. However, they also had to 
continue to negotiate pre-existing relationships with health care professionals 
with their new diagnosis. This section provides context by reflecting on women’s 
negative encounters with health care professionals prior to being diagnosed, 
before exploring their accounts of these relationships after being diagnosed as 
well as detailing women’s positive experiences of engaging with specialist care.  
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6.4.1 Negative Encounters with Non-Specialist Healthcare Professionals 
In Chapter 5 we saw multiple examples of women who struggled to convince their 
GP that their symptoms were ‘not in their head’, with many waiting until further 
symptoms appeared to seek further medical advice. Some women however 
struggled to be ‘believed’ even when under specialist review. Holly experienced 
personal ill health for a number of years before her diagnosis with ever increasing 
disease burden over these years. When referred for further investigations Holly 
tells us that she was made to feel that her symptoms were ‘all in my head’ until 
the point where her examination showed that something was not right. 
Holly:   When I went to the [Symptom Specialist] the first time he  
  erm, I  left that appointment in tears because he basically told 
  me that erm, like he, before I went on the treadmill he initially 
  was saying you know, “Your medical file is massive for  
  somebody your age. Is your family supportive of you getting  
  all these tests?” And he pretty much accused me of having,  
  of it all being psychological and said 
Int:  That’s not helpful. 
Holly:  You know, there’s this great psychosomatic disorder that can 
  be if you’re, you know, it can be like to do with stress and  
  different psychological factors, and it can present itself and  
  cause  physical symptoms. I left that appointment thinking,  
  “God, is this all in my head?” Like, he had me sort of   
  believing that, right up until I went on the treadmill and then  
  he totally changed his tune when he seen the reaction that I  
  had on that. 
Int:  Yes. 
Holly:  But it was hard. But yeah, having a name for it made a  
  difference. It, it kind of validated basically everything that I  
  had said, and the fact that I had had all these symptoms, and 
  really that it wasn’t in my head, and they were all real.   
  (Holly: 319-333) 
 
Like previous examples, Holly experienced an accusation that her illness had no 
physical cause. This encounter and how she was made to feel after seeing this 
specialist is clearly very memorable for her. As discussed previously, for her and 
many others in the study, validation of their illness from a medical professional 
was a very important milestone for them.  
Unfortunately for Holly, negative experiences with health care services have 
continued since her diagnosis, with more than one incident relating to the 
provision of emergency care via the ambulance service in her region. The events 
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described by Holly were in relation to the ambulance services call handler’s lack 
of knowledge of mitochondrial disease and how serious Holly’s symptoms were. 
Holly describes falling very ill at a friend’s house party 
 
Holly:  And then there was in issue because I had mitochondrial  
  disease, erm there was nobody there that could run me, like  
  to drive me to the hospital, so they said well the best thing  
  would  just be to phone an ambulance, but when we phoned  
  the ambulance they had never, they didn’t know what   
  mitochondrial disease was. They couldn’t understand the  
  need for me to have an ambulance because they were like,  
  “Well, just put her in a taxi, why do you need an ambulance?” 
  Erm, and it took three hours for them to actually put a, get an 
  ambulance out’ (Holly: 689-698) 
 
Holly stayed in hospital for two days after this event, and went on to experience 
many more episodes of hospitalisation during the course of that year.  Lack of 
knowledge in the wider medical community of the potential dangers of 
mitochondrial disorders meant that even with a diagnosis, Holly’s symptoms and 
the seriousness of them was overlooked by emergency call handlers. Holly’s 
experience not only reiterates the unpredictability of the disorder and how 
uncertainty affects social relationships and can lead to isolation, but also how 
lack of knowledge in the wider medical community causes practical, emotional 
and health problems.  
Distress from not receiving the appropriate care even after diagnosis due to lack 
of medical knowledge of mitochondrial disease was not uncommon. Miriam found 
that because her symptoms were different from her child’s presentation that her 
GP did not believe that she was actually affected. When discussing how she had 
tried to seek help from her GP regarding her concern for herself and her family, 
Miriam tells that: 
Miriam: But you mention mitochondrial, you mention the word   
  [SYNDROME] they just laugh at you, what on earth and they 
  describe what [Child Y] got and they want to look for   
  [SYNDROME]. Well for goodness sake, it’s just sounds like a 
  made up name, ‘cause they’re all made up like that. They  
  sound a bit weird and I think [GP] for my doctor I see, he’s  
  great with [Child Y]. He doesn’t understand the condition  
  affects us all, you know. So when I go down I said - he said,  
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  “You haven’t got that condition.” I say, “Well, I have.” … So  
  when we go with [Child Y] and I go, he doesn’t really   
  associate it as us all having it. He doesn’t really understand  
  it. Erm, so one day I think I went to see him, erm, and I said,  
  “My [Child X] made this appointment, I’ve not made it. They  
  think I’m depressed, I’m not depressed, I’m just concerned.”  
  And, erm, he just goes, “Oh I understand, you’ll be okay.” I’m 
  thinking, “You don’t …” 
Int:  He can’t say that. 
Miriam: You know, he can’t, that’s kind of annoying (Miriam: 663- 
  698) 
 
Miriam finds that the complexities of the sub-types of mitochondrial disease make 
understanding mitochondrial disease even harder for her GP and other health 
professionals. Miriam feels that her GP is unable to associate the genetic 
condition to her and other family members, that he does not understand their 
mitochondrial mutation and as a result is unable to offer the level of care she and 
her family believe that she needs. Like Miriam, other women experience similar 
encounters with their GP post diagnosis, recalling events when they have been 
told by their GP that “’I actually don’t know anything about it’ (Maggie: 3232) and 
that ‘he says “I really must read up on it”’ (Maggie: 3255). This results in many 
women choosing to bypass their GP and instead directing all their clinical queries 
to their mitochondrial specialist, or to their trusted symptom specialist, which I will 
now go on to discuss. 
The impact of being diagnosed for women who had negative experiences of 
health care provision prior to diagnosis, was not an improvement in their 
experience, but a change. Non-specialist health care professionals were ill 
equipped to manage the uncertainty and unknowns of mitochondrial disease. 
Whereas previously women felt that their symptoms were not necessarily 
believed, having been diagnosed, they now felt that non-specialist health care 
professionals did not know and were unwilling to learn how to support them 
adequately with their condition.  
6.4.2 Recognition and Referral 
Persistent negative encounters in primary care and misdiagnosis in other 
specialities meant that for some women their relationship with the person who 
signposted or referred them to mitochondrial specialists or mitochondrial 
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specialists themselves become very important to them. In addition to being the 
ones who initiated or confirmed their diagnosis, these specialist have assisted 
them in accessing various types of support since, which as we’ve seen above is 
not always easy for patients with mitochondrial disease. This translates to them 
seeing these health professionals as those they can really trust.  
Specialists who signpost or referred women (or their family members) for 
diagnostic testing are seen to be the person that if they had they not met, they 
would have never received their diagnosis. In these circumstances women speak 
highly of these individuals and subsequently return to them not only for symptom 
specific care but to also discuss information provided by other clinicians who 
were unable to provide the level of clarity they required. When discussing how 
she received her diagnosis, Sarah tells us that: 
Sarah: It was quick, during my appointment there was a fire alarm,  
  so we all had to go outside so that was all interrupted erm … 
  so I had about 10 minutes with him that was it  
Int:  OK 
Sarah: Where [Regional Neurologist] told me not to really worry  
  about  anything, then did [Investigative test] which obviously  
  made me worry, but then I was seeing my [Symptom   
  Specialist] … erm about 3 weeks later 
Int:  OK 
Sarah: So that was actually really quite helpful because it allowed  
  me to  go away 
Int:  Absolutely 
Sarah: Think about the diagnosis, think about all the questions I had 
  erm and come back to appointment my with [Symptom  
  Specialist] prepared (Sarah: 112-121) 
 
For Sarah returning to her symptom specialist after her diagnosis allowed her 
time to think of all her questions surrounding the news of her mtDNA mutation 
and was able to ask them at her appointment with them. Sarah speaks very 
highly of this individual many times during her interview ‘amazing, absolutely 
amazing’ (Sarah: 175-176) and when describing the care received at their clinic  
‘it’s been a really good experience and their care has been amazing’ (Sarah: 183-
184). They were not only the person who prevented drastic measures being 
taken (a symptom related operation that would have left Sarah with sight in one 
eye only) but they were also the specialist with whom she discussed her 
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reproductive decision-making with. Sarah recalls discussing ideas of what is ‘a 
normal life’ and her symptom specialist’s giving her anecdotes from earlier in their 
career about people living with disabilities and how everyone’s normal is different. 
We will see in Chapter 7 that advice from experts was an important factor for 
Sarah in deciding to start a family.  
Seventeen of the 18 women in the study had received their diagnosis from 
laboratories based in one mitochondrial specialist centre, and as we know not all 
received their diagnosis from a mitochondrial specialist. Eleven women were 
informed of their diagnosis from a mitochondrial specialist at the same specialist 
centre, where as seven women were informed by either their general neurologist, 
symptom specialist or via a mitochondrial specialist located elsewhere. For those 
that did not receive a diagnosis at a specialist centre, consultations in which 
these women were informed of their diagnosis were often seen as somehow 
flawed, with not enough specific information being provided or simply being 
conducted via a letter or telephone. This resulted in women feeling distressed, 
confused and in some cases angry; anger which persisted to the day of the 
interview when recalling their diagnosis. The one exception to this is a woman 
who received her diagnosis from a mitochondrial specialist whilst living in another 
country.  
All seven of these women went onto to actively seek a consultation with a 
mitochondrial specialist at the specialist centre, either immediately upon 
diagnosis, when they moved into the region or when they sought specific advice 
regarding their reproductive options. This was often through an Internet search 
and initial email contact directly to the mitochondrial specialists that their 
searches had found. Women recall receiving fast responses to these initial 
enquires ‘from the first time I googled and then just sent [them] an email and 
[they] responded within 12 hours’ (Sarah: 354-355). For those women who had 
themselves experienced symptoms they describe how important it had been for 
them to have met doctors that believed them and that there was a sense that 
these doctors ‘were on our side’, that they could be trusted with their care or the 
care of their family members.  
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Hmm, but as I say this was where I think [Dr X] I trust him, ‘cause he 
knows about the condition and I know he specialises in [SYNDROME X] 
and [SYNDROME Y] and [SYNDROME Z] and that (Miriam: 854-856) 
 
For Miriam she tells us explicitly that she trusts the mitochondrial specialist that 
she and her family members see, she trusts him because he specialises in many 
of the potential syndromes caused by mtDNA mutations. As we have seen 
earlier, ensuring that her affected child receives the most appropriate and up to 
date care is very important for Miriam. This trust extends to the wider specialist 
team, including specialised nurses and physiotherapists who make up an even 
larger clinical team that includes a speech and language therapist, dietician and 
benefit advisor all specialising in mitochondrial disease.   
Women feel able to directly contact these individuals, bypassing their GP and 
those symptom specialists whom they have not found particularly helpful or 
understanding in the past. Maggie’s direct contact with the mitochondrial 
specialist team is as a result of not trusting her GP. Maggie describes a ‘horrible’ 
incident in which she lost feeling in her fingers and toes and was asked during 
her appointment with her GP whether or not she thought it was related to her 
mitochondrial diagnosis, when she replied that’s what she had hoped they could 
help her with, her GP responded: ‘ “Well really you know I put, I hold my hands 
up,” he says, “I hold my hands up and tell you. I don’t really understand anything 
about it.” ‘(Maggie: 1415-1416). Maggie experienced what seems to be a similar 
response on many occasions and as directed by her GP, she now contacts her 
mitochondrial specialist team in the first instance. The GP is reported as saying to 
her ‘ “I’m not really sure whether I should do anything. I think you need to speak 
to the, the [mitochondrial specialists] first”’ (Maggie: 1439-1441). Maggie tells us 
with an air of humour that she feels able to discuss any medical concern that she 
has with specialist mitochondrial nursing staff ‘I mean they’re so approachable, 
and I don’t even feel embarrassed asking them daft questions’ (Maggie: 2846-
2845). Maggie receives quick responses to emails and she and her family 
members have been seen for clinical reviews promptly when they had concerns.  
The majority of women in the study felt the same way as Maggie and have many 
positive comments on the level of care and availability of their mitochondrial 
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specialists and the wider team. Women benefited from being able to contact the 
mitochondrial specialist team via email if they had hearing impairments and via 
tele- health clinics that allowed them to stay in regular contact when living far 
from the centre. Although not common, some women comment on the speed of 
receiving results of tests back and how they felt the speed of communication 
could have been quicker. Positive comments were given with regards to how they 
felt that their mitochondrial specialist had been an advocate on their behalf with 
other health care professionals. This included staying in regular contact with their 
local specialist clinicians, communicating with and providing support letters to 
local funding commissioners around required care packages, home adaptions 
and access to funding for assisted reproductive techniques such as PGD. When 
discussing how their mitochondrial specialist was helping them to access funding 
from their local clinical commissioning group, Joanna tells us on more than one 
occasion that she feels the team are ‘on our side’ (Joanna: 293) and that the 
team were ‘gonna do all they can to help us’ (Joanna: 293).  
These attributes described by women concur with those described by Mechanic 
& Meyer (2000) as integral to trust between a patient and doctor, interpersonal 
competencies such as compassion and concern, listening and ‘fighting’ for 
patients access to health care. Trust in medical encounters has been defined and 
conceptualised by a number of researchers, see Hall et al (2001) for review. 
Trust between a patient and doctor has also been discussed in decision-making 
(Charles et al., 1999; Schildmann et al., 2013). Charles et al (1999) reported the 
importance of finding a clinician whom women felt they could not only trust but 
who would also treat them as individuals, was an importance aspect of decision-
making (p:655). Trust is also invoked when individuals believe in their doctor’s 
expertise and when they feel that they have been provided with all the relevant 
information to their diagnosis (Coulter, 2002; Wright, 2004). As we have seen 
above, for patients who feel as though they have been misled by their doctor loss 
of trust can be ‘irretrievable’ (Wright, 2004:p3). Lack of trust between a doctor 
and patient may also prevent active patient participation in decision-making 
(Belcher et al., 2006).  
Positive and trusting relationships with their mitochondrial specialist team meant 
that for those women who were considering their reproductive options they felt 
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able to discuss these with their care team. These discussions took place in either 
a patient requested consultation or later, specially designated reproductive 
choices clinics where women felt at ease, ‘the clinic was lovely and they were 
really supportive’ (Ashley: 90) and ‘their approach was really nice and it was like 
don’t worry we’re here for you’ (Zoe: 135-136). Even Sally, who thought she may 
have completed her family, noted that if she were to want another child in the 
future ‘I would definitely discuss it with them if I did’ (Sally: 295). Mandy was still 
some years away from starting a family but had felt able to ask for a specific 
reproductive information session with a member of the mitochondrial specialist 
team and reproductive medicine specialist.   
Mandy: It was information based but then obviously I got a chance to 
  ask any questions or I said obviously how I was confused as  
  to where it was going erm and that’s where they both kind of  
  got together and said kind of obviously they can’t give you  
  what your gonna do but  
Int:  Yeah 
Mandy: But it’s given you the kind of wise option as to what they  
  would  advise (Mandy: 306-310)   
 
Mandy describes this meeting, attended with her by a close friend as being 
extremely helpful, that she was able to discuss how she felt confused by the 
options that she thought were available to her. Mandy tells us that although the 
specialists were unable to tell her what options she should choose they were able 
to tell her the ‘wise option’. For Mandy this relationship of trust meant that was 
able to request this consultation at a time when she felt she needed more 
individualised information and she also felt that she had been given the most 
appropriate advice for her and her mtDNA mutation. 
6.5 Summary 
Data presented in this chapter show some of the short and long term social 
impacts of women’s diagnoses of maternally inherited mitochondrial disorders. 
Women responded to their diagnoses in different ways, though a number of 
women were concerned and fearful about the potential progression of their 
condition, or the condition of their child/children. This is comparable to literature 
on other chronic conditions, which explores people’s fears of dying (Cinar et al., 
2012; Jeon et al., 2010), illness recurrence (Koch et al., 2013; Oxlad et al., 2008) 
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or progression (Herschbach et al., 2005; Kwakkenbos et al., 2012), To allay 
these concerns, women sought information from varied sources. However, those 
that conducted research on the Internet found that it largely exacerbated their 
fears, (a finding supported by research in relation to a number of health 
conditions Ziebland et al., 2004; Ziebland & Wyke, 2012) whereas those that 
accessed information via mitochondrial specialists were more reassured, despite 
the uncertainty fundamental to their condition. 
Experiences of illness are inherently social (Nettleton, 2006), and there are clear 
parallels between aspects of the women’s accounts and Bury’s (1982) notion of 
biographical disruption. Often their symptoms had a disruptive impact on their life 
that preceded being diagnosed, and the process of diagnosis brought with it a 
renegotiation of a number of important social relationships including with family 
and employers. Issues included disclosure of their or their family members 
diagnosis to other family members including those who may also be at-risk. This 
disclosure can be seen in the context of a spectrum from full, partial, delayed or 
none at all. Women quoted reasons for disclosure as establishing a social 
support, a sense of responsibility and openness. Being diagnosed with a rare 
disorder also affected the nature of some women’s relationships with health care 
professionals. Their accounts featured disappointment in their pre-diagnosis 
interactions with (mostly) non-specialist healthcare professionals, suspecting that 
they were not believed or their symptoms inadequately understood (Glenton, 
2003; Jeon et al., 2010; Muir, 2016). Having been diagnosed, these interactions 
did not necessarily improve, though they were subject to change. After diagnosis 
some women felt that non-specialist healthcare could no longer address their 
general health needs and so approached mitochondrial specialists directly, 
whereas others were encouraged to do so. Recognition of either the symptoms or 
aetiology of their condition and consequent referral or signposting to suitable 
services was also important to women in this study. Not only did it offer the 
legitimisation discussed in the previous chapter, it also resulted in the subsequent 
return of women to the ‘referrer’ as a trusted professional (Hall et al., 2001; 
Mechanic & Meyer, 2000). These trusting relationships with mitochondrial 
specialist team members meant that women felt not only comfortable in 
discussing their reproductive options but also requesting specific reproductive 
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consultations, sometimes years in advance. We can see from Mandy’s 
description of her consultation that principals of shared decision-making were 
applied by her specialist team, in that she received high quality information from 
those with expertise and that she was supported in her deliberation of her options 
(Elwyn et al., 2012). Mandy’s description of her consultation supports Elwyn and 
colleagues (2012) process of ‘doing shared decision making’ in that there was 
Choice talk, where Mandy’s reproductive options were presented, Option talk in 
which more detailed information was provided and Decision talk where Mandy’s 
preferences were sought. Providing this specific care to women can be seen to 
be very beneficial in helping them to decide amongst the many reproductive 
options available women, enabling a space in which to discuss their own 
individual inheritance risk, assisting women in understanding what some of the 
more complex options are and offering reassurance that the clinical team are 
available to answer questions now and in the future.  
Insight into lives of women with maternally inherited mitochondrial disease helps 
provide the necessary context for the following two chapters, which specifically 
focus on women’s ideas and preferences of reproductive options and the 
proposed conceptual model of reproductive decision-making. This chapter 
provides women’s accounts of lived experiences of mitochondrial disease on a 
social spectrum, highlights the types of clinical relationships that exist between 
women and medical professionals and how trust is fundamental to these 
relationships. I will now move on to explore women’s ideas and preference of 
available reproductive options in Chapter 7.  
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Chapter 7. Reproductive Options: Searching for the Healthy and 
Biologically Authentic Child  
7.1 Introduction 
The previous chapter explored some of the social implications of receiving a 
mtDNA mutation diagnosis, in combination with the social impacts of having 
symptoms that pre-existed being diagnosed. This chapter focuses explicitly on 
women’s ideas and preferences for their reproductive options in the context of 
being diagnosed with harbouring a pathogenic mtDNA mutation. The initial 
section of this chapter explains how women first came to know of their 
inheritance risk through reproductive guidance and/or genetic counselling, whilst 
also providing a distinction between the two. The women’s accounts 
demonstrated strong preferences for having children that were both healthy and 
genetically related to them. Whereas the preference for health is undermined by 
the uncertainty that features throughout experiences of mitochondrial disease, 
the preference for genetic relatedness represents an outcome women can be 
certain of, and could be constrained or enabled by the nature of the reproductive 
pathway the women took, or would consider taking. This chapter opens up 
discussions and understandings about kinship, as options such as raising 
‘someone else’s child’ or voluntary childlessness were largely problematised by 
women in this study. However alternate accounts are also explored. 
7.2 Reproductive Guidance and Genetic Counselling  
In Chapter 3 I outlined that clinical professionals offering reproductive guidance to 
women with maternally inherited mitochondrial disease would consider 
reproductive options as a list of options to be presented to women. One of those 
within the list of options is ‘genetic counselling’. Within this dataset we see that 
most women understand genetic counselling as part of the overarching process. 
For them, genetic counselling covers the period of time in which their 
reproductive options were being discussed. The women did not make the 
distinction between general discussions of reproductive options within a clinic 
from a meeting with a separate genetic counsellor. 
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For the women, genetic counselling – what health professionals would see as 
outlining reproductive options within consultation - is described as helping them 
(and their partner, when applicable) to choose between the options. When asked 
if she recalls being told about the risk of inheritance to future children, Emma 
says that 
you know what the different options were and the things like for us to, to 
consider if starting family was something that we wanted to do and erm 
explained how you know it’s females that kinda pass down that man carry 
and but they don’t pass it down and those sort of things  
(Emma: 65-67) 
 
Emma attended the clinic with her husband following her diagnosis via a relative, 
where they were told that her mtDNA mutation was passed down the maternal 
line and that men were unable to pass on the mutation. For her, the central issue 
is understanding that the disease is inherited, and inherited through the female 
line, and that, should they choose to have a family, they have different options.  
For women in the retrospective group they recall being told about the maternal 
inheritance and in the specific context relating to the potential risk to their 
child/children. Pauline tells us about the analogy used by the specialist 
mitochondrial team to describe maternal inheritance - snooker balls in a bag.  
This is not to dissimilar to the use of analogies used to explain mitochondrial 
disorders to patients and then later used by patients to tell others discussed in 
Chapter 5. 
 
Pauline:  “And this is like, if, if you were gonna have children now,” he 
said, “and I kind of picked three, and two are red, and one's 
black”  
Int:  Yeah  
Pauline: “That one black might be the one mutation. But you might be 
really lucky, and get all red” (958-965) 
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Pauline recalls being told that there was, what would equate to, a one in three 
chance that if she had children now that they would inherit her mtDNA mutation, 
but that there was two in three chance that she would be ‘really lucky’ and a 
future child would not inherit the mutation. The presentation of inheritance as a 
game of chance is influenced by the classical decision-making theory of 
subjectively expected utility maximisation (SEU) theory (Edwards, 1961). 
Bonoma and Johnston (1979) define SEU as a 
 case in which both the probabilities of decision outcomes and the worth or 
 utility of each consequence to the decision maker cannot be objectively 
 determined, but must be estimated in a subjective fashion by each 
 individual (Bonoma and Johnston 1979:p177) 
 
Shiloh et al (2006) notes that this approach has led to those practicing genetic 
counselling believing that providing accurate probabilities is the most important 
piece of information that a decision maker requires. Clearly, in Pauline’s case, the 
analogy of the snooker balls in the bag is still memorable to her after all this time.   
For those in the current and prospective groups the approach and methods of 
discussing genetic inheritance and reproductive options lead to a combination of 
feeling supported but not influenced or having made joint reproductive decisions 
with the clinical professionals, seen also in Chapter 5. Joanna, when asked if she 
felt influenced by clinicians, responded that 
Joanna: Erm no  
Gary:  No, absolutely 
Joanna: I’d say no, totally left to make our own decisions 
Gary:  Yeah  
 Joanna: And they have given us lots of information about all our  
   options and things like that and you know the implications  
   erm for that (297-303) 
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Joanna and her partner Gary had attended specific reproductive guidance 
appointments with both mitochondrial and reproductive medicine specialists prior 
to the study interview. Both Joanna and Gary work together to show the 
interviewer how they reject any idea that they felt influenced. She notes that the 
clinicians only provided ‘lots of information’ and that they were ‘left to make their 
own decision’. This style of decision-making, where the patient is offered the 
information, yet the clinician does not offer their preference, is known as 
‘informed’ or ‘consumerist’ (Charles et al., 1997; Charles et al., 2000; Emanuel 
and Emanuel, 1992) 
Within the data set, three women discussed seeing professionals they described 
as ‘genetic counsellors’. Two of the women, Zoe and Holly, had been referred to 
this service via their regional reproductive centre prior to a mitochondrial 
specialist consultation. The third woman, Joanna, had been assigned a genetic 
counsellor nearer to her home whilst also at the same time receiving 
mitochondrial specific genetic counselling at a mitochondrial specialist centre.  
Holly and her family visited a genetic councillor soon after receiving her 
diagnosis, in part to discuss risks to her nieces and nephews. Zoe outlined that 
her appointment had covered what she and her husband already knew about her 
mtDNA mutation and she remembers specifically being told about PGD at a 
private healthcare clinic outside the region. When Zoe and husband returned for 
a second visit to the genetic counsellor they were told that that private fertility 
centre did not hold a licence for Zoe’s mutation and it would not be possible to 
conduct PGD there.  For Joanna, her genetic counselling sessions complimented 
those provided by her specialist mitochondrial and reproductive medicine team.  
If I’ve been [mitochondrial specialist centre] and gone away and forgotten 
things then when I go see them then I can speak about things yeah, so 
that is really good (Joanna: 306-309) 
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The combination of seeing different services assisted with her recollection of 
inheritance risk information previously given and offered a dedicated space to 
consider inheritance. This was a positive experience for Joanna because she 
was able to further discuss inheritance risk. The approach of repeat follow up 
counselling dates back to Emery et al (1979), who recommended that it should 
be routine to conduct follow up genetic counselling. Especially in cases when the 
counsellor suspects the patient has had difficulty in comprehending complicated 
inheritance patterns (such a X-linked disorders) and where the chances of having 
an affected child are considerable.  
Over the dataset, only one woman raised specific objections to genetic 
counselling from mitochondrial specialists. Andi tells us that had she been offered 
genetic counselling during the consideration of her two post diagnosis 
pregnancies she ‘would have turned it down’ (Andi: 599). Although she does not 
outline the direct reasoning, she tells us later in the interview that the decision to 
have more children was a family-based decision. Issues under consideration 
included her health and abilities whilst pregnant and the degree of support from 
her husband and elder children around the house if a new child was to arrive. 
She outlines that ‘So our best would be to to have a family that we wanted and to 
do our best when they got here whatever’ (Andi: 684-685). Concerns relating to 
pregnancy complications and parenting ability in women’s reproductive decision-
making is discussed further in Chapter 8 section 8.5 and 8.6.  
Women’s understanding of the inheritance of their mtDNA mutation and 
reproductive options available to them or other women allowed them to form 
ideas and preferences on current and future reproductive options that they were 
aware of. This study sought to investigate these preferences and to seek 
information on all current and potential reproductive options. Their ideas and 
preferences have been developed into four areas: having a healthy child and 
keeping them safe; raising a child of my own; raising some else’s child; and 
voluntary childlessness. I will now present them each in turn.  
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7.3 Having a Healthy Child and Keeping Them Safe  
This topic is further divided into two areas, which include having a healthy child 
now and in future generations and keeping their children safe, especially in 
relation to women’s ideas and preferences regarding prenatal testing. I will 
discuss these in turn. 
7.3.1 Having a Healthy Child Now and for Future Generations  
Throughout the project, the majority of women favoured mitochondrial donation 
as the most favourable reproductive option for women with maternally inherited 
mitochondrial disorders. This includes women from the current and prospective 
group considering their own options and from women in the retrospective group 
who were considering their younger sisters or daughters’ future reproductive 
options. For women and their partners who were hoping to be able to access 
mitochondrial donation they described the technique as a ‘real sort of lifeline, 
lifeline, you know’ (Mark: 578). Whilst women in the retrospective group talk 
about mitochondrial donation as the only real option for their daughters, 
‘[daughter] couldn’t really have a baby anyway apart from trying this new 
syndrome method [mitochondrial donation]’ (Miriam: 2118-2219).  
Mitochondrial donation’s popularity as the best option available to women was 
centred on their understanding that it would allow them (or other women 
considering the technique) the ability to not only reduce the level of uncertainty 
they faced with the knowledge of their mtDNA inheritance but potentially rid them 
of any burdens associated with inheritance and allow them to have a ‘healthy 
child’. Liza had completed her family at the time of the study interview (Round 1- 
pre-parliamentary debates). When asked if she would support women choosing 
mitochondrial donation as an option in the future Liza says:  
 Liza:  Yes definitely yeah cause I totally back it you know I’ve seen 
   what it can do and I can see what it does erm and I just think 
   ... why wouldn’t you, why, if you had that opportunity and  
   someone said that I can do this for you to make sure that you 
   have a healthy baby then why wouldn’t ya   
 Int:  Yeah 
 Liza:  Why wouldn’t you do it, you know and so yeah for me it’s  
   totally  a total positive thing 
 Int:  And if it had been available to you might have considered  
   that   
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 Liza:  Yeah I would have if it had been passed sorted, available  
   then, yes I would have I would have probably gone for it erm  
   yeah so (Liza: 710-717)  
 
Liza tells us that she has seen what mitochondrial donation can do and if it had 
been available to her then she would have ‘gone for it’. For Liza the key issue 
was the potential to be offered the chance to ‘make sure’ she would have a 
healthy baby.  
Mitochondrial donation offered hope to women of not only having a healthy child 
as a result of the technique but also that future mitochondrial disease would ‘be 
gone’, as mitochondrial donation is germ line technique, in which it is hoped that 
female children born of the technique would no longer risk passing the disorder 
onto their children. When asked which options she would chose, Lesley 
discounted them all but mitochondrial donation: 
Lesley:    I would go straight for that en [mitochondrial donation]  
Int:   Yeah 
Lesley:  Um hu 
Int:   And is that 
Lesley:  And that is basically because then I would know that I would 
   have a healthy baby 
 Int:   Yeah 
 Lesley:  Um hu, and it would it wouldn’t be there anymore  
    (Lesley: 633-639) 
 
Similarly to Liza, Lesley’s support of mitochondrial donation was the ability to 
know in advance that you would have a healthy child but also that ‘it’ - 
mitochondrial disease - would no longer be part of the next generations’ lives. 
The importance of this inheritance link being broken by the introduction of 
mitochondrial donation is the significant factor for Lesley.    
For Liza a motivation for her to support mitochondrial donation was centred on 
the chance that she may have had a daughter who could benefit from 
mitochondrial donation in the future: ‘I want to be able to say well I fought and 
helped for you to be able to have this’ (Liza: 604-605). Mitochondrial donation 
would have gone on to have enabled a daughter to have children who would not 
be affected by a mtDNA mutation, that the children would be ‘normal and happy’. 
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When recalling her motivation to support mitochondrial donation and what she 
would have said to a daughter:  
Erm you know so that you you can go on to have children that are 
perfectly normal and happy erm so that was my main motivation it was 
future.  As it  happens I’ve had [X] son’s it’s fine, it’s great [Laughs]. Erm 
you know I’ve wiped it out in my family kind of thing but yeah that was the 
main sort of focus  on yeah I’l I’l I wana get it out there and people need 
to understand that you know because of the thrown this three parent IVF 
thing around (Liza: 607-612) 
 
 
Women talked about their mitochondrial disease ‘ending’ when they had either 
not had children or if they or their relatives had had male children. For Alice she 
wonders if fate had been the reason why she and her husband had not been able 
to have children and that her family members had all had sons, ‘because it’s 
stopped now’ (Alice: 3722). For Alice the end to the inheritance of the family’s 
mtDNA mutation was poignant and seemed to offer a potential reasoning as to 
why she and her husband had not conceived a child. The notion of hope and the 
potential for mitochondrial donation to prevent inheritance has been reported by 
Herbrand and Dimond (2017), who described women’s accounts of hope for 
themselves, their children and society. 
Although there was overwhelming support for mitochondrial donation for the 
reasons outlined above, Miriam had concerns that mothers may still be faced with 
the uncertainty as to whether their child may develop symptoms even if 
mitochondrial donation was successful.  
Miriam:  You’ll always be watching your child, saying, “Is that a mi- a  
  mitochondrial … there?” Could they see?  
Int:  Yeah 
Miriam: And not to have this worry in the back of your mind. It won’t 
be   much fun for the mother having a baby with this new, new  
  method. (Miriam: 5552-5556) 
 
Miriam is supportive of both the mitochondrial donation as a technique and the 
prospect that her children may be able to opt for it in the future. She does not 
express concerns of risk(s) associated with the technique but she does question 
whether it would be enough to prevent women from worrying in the future as to 
whether their child may develop symptoms and how this worry would not be 
 174 
 
‘much fun’. We see here that for Miriam the uncertainty of a child’s future 
affectedness is central to her view of mitochondrial donation. This can be likened 
to the experience of uncertainty reported by childhood cancer survivors (Zebrack 
& Chesler, 2002) and fears of recurrence in serious illness (Koch et al., 2013). 
7.3.2 Keeping Them Safe  
All women interviewed expressed a strong desire to keep their developing child 
safe during a pregnancy and as a result prenatal testing was not considered an 
option for the majority of them. The reluctance to undergo prenatal testing was 
related to the risk to the unborn child as a result of the technique ‘I was told was 
that prenatal diagnosis is kind of risky for the child’ (Ashley: 155-156). However, 
the dominant objection was to the potential decision that may need to be made 
following a result, terminating their pregnancy. Uncertainty about what 
percentage mtDNA mutation load would result in an affected child and the 
severity, as well as objections to termination of an established pregnancy or 
moral objections to termination made this option even more complicated and 
dictated how women formed opinions on prenatal testing.  
 
For some women being potentially placed in this situation led to immediately 
discounting the option. When asked which options Wendy would discount, 
Wendy quickly discounts prenatal testing:  
 
 we’ve ruled out ... because you’ve then got to make a decision about 
 whether you abort and we don’t really want to do that (Wendy: 518-519)  
 
For Wendy and her husband being presented with the decision to terminate was 
something that they were not willing to consider. Similarly Maggie discounts 
prenatal testing as an option immediately from the lists as she considers ‘it must 
be awful to actually be pregnant and then have to have a termination, decide 
whether you want a termination’ (Maggie: 2667-2669). For both women the 
central objection was finding themselves in the situation where they would have 
to make a decision to terminate an established pregnancy. This supports 
women’s and couples accounts of termination following prenatal testing in other 
genetic disorders (Boardman, 2017; Kelly, 2009; Myring et al., 2011; Rapp, 
1998). 
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Prenatal testing for particular mtDNA mutations was not thought to be of any 
benefit for one woman as she foresaw knowing that their child would have a 
percentage mutation load. Zoe believed that her genetic mutation meant that any 
child she would conceive naturally would be affected ‘I think they said that all my 
mitochondrials will be, they know that obviously it’s, be affected’ (Zoe: 201-202). 
Whereas for Mandy the ambiguity surrounding mutation load percentages and 
predicting the affectedness of a child was more troublesome.  Knowing the value 
of a prenatal result would not be helpful to Mandy, especially if she was then to 
be faced with the decision to continue or to terminate an established pregnancy. 
When asked which reproductive options she would discount Mandy says:  
 
 Mandy: I think you would, I think it would be too hard of decision to  
   make  to whether to go through with the pregnancy or to not  
   and I think knowing that the difference between the   
   percentages and the symptoms I don’t think I could make  
   that decision  
 Int:   Right 
 Mandy:   On for example if it came back … that kind of if it had a  
   percentage of ... I don’t know [X] cent or something erm  
   I know I’m sitting here and I’ve got [X + 10] and I’m very well  
 Int:   Yeah 
 Mandy:   And I think that’s but then I know there are other children  
   who are born with even less than that percentage and have a 
   massive range of symptoms and are really complex  
 Int:   Yeah 
 Mandy:   So I just think that decision is just … too hard (overlapping) 
 Int:   Too difficult (overlapping) yeah 
 Mandy:  I just don’t think I could do that (Mandy: 503-515) 
 
For Mandy the key issue is the uncertainty surrounding any result from a prenatal 
test – given different ways that the symptoms can express themselves - and that 
making a decision about the future of her pregnancy based on a result would be 
too difficult.  
 
For one woman interviewed, engaging in any prenatal testing over and above 
standard clinical procedures was not an option ‘You know I’ve never done the 
amnio-gesis or whatever tests’ (Andi: 388). The reasons given for not engaging in 
any additional testing was that the outcome of the testing would not have no 
impact on her decision to continue with the pregnancy ‘we’d have the baby 
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whatever it was’ (Andi: 391) and that she would not terminate a pregnancy ‘Yeah 
well we wouldn’t go “well I’d abort”, I would never abort’ (Andi: 386). For Andi 
prenatal testing was not a reproductive option as it provided no relevant 
information that she and her husband would act upon and was therefore 
unnecessary.  
 
For a small number of women, they saw prenatal testing as a benefit in that it 
would allow them time to prepare for a potential difficult pregnancy and the arrival 
of an affected child. Ashley tells us that ‘it might have been important for us to 
know erm where the levels are’ (Ashley: 155) but that even considering this 
advantage ‘I am not sure if we have gone through with it to be honest’ (Ashley: 
156).  This was echoed by Pauline who would not consider a termination of a 
pregnancy but ‘I suppose then you could prepare, that it might be a difficult birth 
or it might be’ (Pauline: 1185-1186) or that there may be ‘something wrong with 
the baby at the end of it’ (Pauline: 1190). However, for these women the 
advantage of ‘being prepared’ for potential difficulties ahead did not mean that 
they themselves would have chosen prenatal testing as an option. 
 
At the time of the interview many women had not considered prenatal testing as 
an option let alone experienced undergoing a prenatal test, with the exception of 
two women. Miriam had been offered and accepted amniocentesis testing in her 
three pregnancies, 20-30 years prior to the interview because ‘it was just done, 
you’re meant to have it’ (Miriam: 2110-2111). Miriam describes how she had 
considered the potential outcome that she might receive a positive result for 
Down syndrome and what this would have meant for her ‘I would still keep the 
baby’ (Miriam: 2120-21021). Miriam did not discuss knowing of any risks 
associated with an amniocentesis test at the time. For Liza, she and her husband 
had been unable to access PGD via the NHS as they already had one child and 
private treatment was not an option ‘I would have to pay for any treatment 
through IVF [PGD] … upfront and obviously it just wasn’t an option’ (Liza: 264-
266). Liza and her husband deferred starting a family for a number of years after 
receiving the news that they were not eligible for NHS treatment and that prenatal 
testing was the only other option available to them ‘then after that it was the CVB 
or you do nothing just go ahead and don’t know’ (Liza: 484). Not knowing the 
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potential risk to her child was not an option for Liza, so after finding out that she 
was pregnant she requested a test, although she didn’t ‘fully realise what exactly 
it mean’ (Liza: 270-274). Liza had two pregnancies and underwent two prenatal 
tests and both experiences were very difficult for Liza and her husband. Lisa and 
her husband made the difficult decision to terminate her second pregnancy after 
much consideration with not only the mitochondrial specialist team but with 
extensive consultation with her extended family. Based on this and the 
percentage mutation load Liza and her husband decided that their baby ‘wouldn’t 
have had a very nice life so erm we terminated the pregnancy based on that 
information’ (Liza: 278-279). The option to undergo a second prenatal testing was 
because ‘nothing really else available to me’ (Liza: 285) but that this meant that 
Liza was undergoing another emotional ‘CVBS gamble’ (Liza: 287). Liza felt that 
she had no other option but to undergo prenatal testing to ensure that she was 
able to make the best decision possible for her future child based on the mutation 
load and how the child may be affected by their family’s specific mtDNA mutation. 
We see from interviews that women wanted to be able to combat the uncertainty 
that exists with the inheritance of mtDNA mutations to ensure, as best as 
possible, that their future child would be healthy and free from the burden of 
mitochondrial disease both in their generation and future generations. We see 
that some women were unwilling to risk the safety of their unborn child to 
undergo prenatal testing when they would not terminate a pregnancy whilst 
others used prenatal testing results to assess future risks to their unborn child 
and made decisions based on preventing future suffering. Having a healthy child 
is a central finding in this study as well as the idea of having a ‘child of my own’.  
7.4 Raising A Child of My Own   
Frequently seen across the reproductive options was the idea of a ‘child of my 
own’ and that some reproductive options restricted or enabled women to achieve 
this goal. I have chosen to specifically distinguish between restricting and 
preventing this goal as the women set different parameters to what a ‘child of my 
own’ meant. In those cases where women spoke of ‘their child’ they seemed to 
be speaking specifically of the genetic link to themselves as mothers whereas the 
genetic link to their partner or future partner only was specified in relation to 
options such as ovum donation and surrogacy (with or without a donor ovum). In 
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the following sections I will discuss issues that applied to options that enabled or 
restricted genetic relatedness.  
7.4.1 Reproductive Options that Enable Genetic Relatedness  
Reproductive options that enable women to have a genetic link to their child or 
future child include conception without medical intervention, prenatal testing, 
PGD and mitochondrial donation. Women discussed all of these options across 
the three interview rounds, with the introduction of the interview aid facilitating 
more detailed discussions. Over the course of the interviews, the women offered 
four different responses to these options. They were: lack of knowledge, 
awareness and understanding; not concerned; not an option and that such an 
option was to be used as an interim option. I will discuss each of these in turn. 
7.4.1.a Lack of Knowledge, Awareness and Understanding  
For some women interviewed, lack of knowledge of their mtDNA mutation or 
naivety regarding potential risk(s) to a future child featured when discussing 
conception without medical intervention. For the purpose of this study I define 
conception without medical intervention as, natural conception without prenatal 
testing (CVS/CVB or Amniocentesis). 
For example, Maggie had ‘completed’ her family before her diagnosis and she 
reflected on the position she was in then and how she had conceived naturally ‘in 
ignorance’: 
 And if I had known that I had, had this when I was younger, whether 
 I would have even, whether I would have had any kids. I don’t know 
 (Maggie: 1705-1707). 
 
 
Maggie questions whether she would have had children had she known of her 
diagnosis early. In contrast, Liza had known of her diagnosis for a number of 
years beforehand and had considered the potential inheritance risk. She was 
aware of symptoms including deafness, diabetes and gastrointestinal symptoms 
but she deemed these as socially acceptable symptoms. She conceived her first 
child without medical intervention. Liza tells us that she did not consider the 
seriousness of the symptoms arising as a result of their family mutation before 
her first pregnancy.  
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I was sort of before my mam died I was actually very naïve about what 
could potentially happen so with [first child] I never did anything, I never 
spoke to anyone about it, I think I remember going … well when I was 
pregnant they knew I was pregnant but you know I and I do remember 
being offered a erm CBV test. And I just kinda said “arhh no it fine dur dur” 
and again very naïve at the time erm and so it was offered to me but … I 
just had [first child] sort of normal, everything fine you know, erm left it at 
that 
(Liza: 91-97) 
  
Liza describes herself as naive a number of times when discussing her first 
pregnancy. She also tells us that she did not discuss her pregnancy or any 
inheritance concerns with the mitochondrial specialist team in detail. Liza’s 
reflections on her first pregnancy and the actions she chose in her future 
pregnancies after her mothers death can be seen in relation to her experiential 
knowledge of their families mutation and a change in risk perception  (Boardman, 
2017), discussed further in Chapter 8 section 8.3.1. 
7.4.1.b Not Concerned  
For some women, after receiving genetic counselling and expert assessment of 
their individual inheritance risk they were not overly concerned to either continue 
trying to become pregnant or to plan to become pregnant without medical 
intervention in the future. Sarah fell pregnant with her first child soon after her 
diagnosis and declined prenatal testing. She relied on the information from her 
regional neurologist who had informed her of her diagnosis to assess the risk of 
inheritance to a future child. When asked if she felt she was informed enough to 
make her decision Sarah tells us that: 
the first thing that I said “well what does this mean for my decision to start 
a family?” And he said “I really think that it is low risk and that I don’t think 
that it should let you, it should affect your decision; continue as you are” 
(Sarah: 390-392) 
 
 
For Sarah this level of information from ‘an expert’ (Sarah: 400) was enough to 
not deter her from continuing to try to conceive naturally, although she 
acknowledges that this was not very scientific ‘That was helpful, how scientific it 
was, he’s an expert so that was all I need to hear to not stop’ (Sarah: 392-392). 
However, it provided her with the reassurance she needed at the time. It was 
 180 
 
important for Sarah that her child not be affected by the mutation more than she 
was: 
Sarah:  Nobody would choose to have, to put, to have a child and put 
  them at that risk so for me it was just incredibly hard cos I  
  just kept clinging onto all I need to hear from somebody is  
  that (0.2) that if I had a baby with mitochondrial disease it  
  wouldn’t be any more severe then what I’ve got 
Int:  Right OK 
Sarah: And that would been enough for me (Sarah: 273-276) 
 
Information from a trusted expert about the risk factors to her child was important 
to Sarah in managing her uncertainty and knowing that her child would not be 
more severely affected then herself the key factor.  
Emma had previously considered her reproductive options in more depth. She 
recalls that her mitochondrial specialist at the time was not encouraging couples 
to seek alternative options to establish a pregnancy: 
 I think what erm what he was saying at that time was that he, you know he 
 wasn’t strongly encouraging that we, we erm you know that we took up 
 any of the alternate options and was saying that you know “a lot of people 
 just make the decision to kinda of go ahead naturally”, I think that was 
 quite quite reassuring erm and he did offer us an appointment erm with 
 one of the specialists (Emma: 76-81)  
 
 
Again, we see how advice from a trusted expert is central to decision-making. 
The advice was reassuring for Emma and her partner at the time as conceiving 
naturally was a ‘sanctioned’ option, a norm that she was told many others like her 
already undertook.  
Finally, Andi offers a different perspective, one where advice and trust is still 
central, but that advice and trust is based on religious faith.  Andi went on to have 
two further pregnancies after her diagnosis. For her conception without 
intervention was the only option that would permit her to have a biologically 
related child. Andi tells us earlier that she believes that she would have turned 
down the offer of genetic counselling but that she did receive information on 
inheritance ‘I think it was mentioned at the very beginning erm’ (Andi: 419) and 
that she hadn’t needed any additional information. Therefore, for Andi and her 
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husband, they did not require an expert opinion on risk to inform their future 
reproductive choices.  
Well being [religious] has affected all my decisions to do with it because 
it’s just been … it’s just something that we accept, you know everybody 
has got. You know it’s a progressive disease but you don’t know what the 
future is, you don’t know where you’re going to be, you don’t know what 
your kids, you don’t know anything about the future, so I don’t dwell on it 
and when it comes to so when it comes to family and things making a 
decision whether to have a family or not it doesn’t really affect it, we’d we’d 
want, you try you’re best  
 (Andi: 675-682) 
For Andi and her husband their religious beliefs were central in informing their 
views on having a potentially affected child. If this were to occur then they would 
accept and work with the emergent situation. As a family all they could do would 
be to try their best: ‘so our best would be to to have a family that we wanted and 
to do our best when they got here whatever’ (Andi: 844-845). In this way, a 
doctrine of predestination means that such information is unnecessary and 
therefore of no concern.  
Relatedly, Andi also told us that she has not actually ‘had to consider’ 
mitochondrial donation as an option. She noted that she was unsure as to where 
she stands in relation to it. In response as to whether her uncertainty was 
because she had not considered it previously, she outlines that:   
 Andi:  I’ve not had to consider, I’m not sure whether it would be  
   from a religious point of view 
 Int:  Ok  
 Andi:  Erm but I don’t have to consider that, that my kids will have  
   to think about that one [slight laugh] (Andi: 641-644) 
 
It is not that her religious faith directs her reasoning, but rather such an option is 
not a concern for her, as she has already completed her family. She notes, albeit 
with a tone of humour, such considerations, including those of how such a 
technique could be understood from a religious perspective, is for the next 
generation of her family. 
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7.4.1.c Not an Option  
Reproductive options that enabled genetic relatedness that women framed as not 
an option to them included conception without medical intervention, prenatal 
testing, PGD and mitochondrial donation, which were related to their perception 
of inheritance risk and risk of having an affected child.  
For some women in both the retrospective and current and prospective arm, 
conception without medical intervention was defined as ‘not an option’ as soon as 
they were informed of their diagnosis. Multiple accounts from women and their 
partners show that ‘to conceive naturally has never really been an option to start 
with’ (Joanna: 383-384) and ‘you couldn’t do it with our condition, I would not 
recommend that with this condition, no, absolutely not, no’ (Miriam: 1866-1876).  
For Holly, at the time of the interview, natural conception was not an option after 
receiving her diagnosis. In addition to receiving her mitochondrial diagnosis she 
had also received medical advice that as a result of her specific phenotype she 
would not be physically fit enough to carry a child to full term safely. When asked 
Holly tells us that: 
 Holly:  But it was never, once I knew I had mitochondrial disease  
   and like erm the fact that it had got so bad, erm especially as 
   the years went on, it was never something that I would have  
   wanted to 
 Int:  Considered since the diagnosis 
 Holly:  Consider doing, no. (Holly: 1856-1861) 
 
For these women, and in some cases their partners, knowledge of a 
mitochondrial diagnosis would reconfigure beliefs and expectations, such that the 
‘natural’ birth would become too risky to begin to consider.  
7.4.1.d Interim Option  
For some women reproductive options that enabled biological relatedness were 
actively considered when their preferred option was not available. In the majority 
of cases this was women and their partners who had sought specific advice 
about PGD because their preferred option of mitochondrial donation was not yet 
available. This is complicated further by the assumption that PGD is suitable for 
all mtDNA mutations and that all women would be considered candidates for the 
procedure. PGD is dependant on the type of mtDNA mutation that a woman has 
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as well as typical IVF screening factors such as ovarian reserve and age which 
can significantly influence the chance of a live birth (Craven et al., 2017; Sallevelt 
et al., 2013).  
A number of women in the study had sought or were actively seeking advice 
regarding PGD as a reproductive option. For all of these women their preferred 
option at the time of the interview was mitochondrial donation. For example, 
Joanna and her partner Gary were pursuing PGD as an option and had attended 
a joint mitochondrial and reproductive medicine consultation prior to the interview. 
For both Joanna and her partner, PGD was their chosen option:  
Joanna:  since the very first time we were sort of told you know we  
  would, we could go through IVF and this is you know this is  
  the implication, we’ve both sort of, before we even knew too  
  much information I think that we would go 
Gary:  yeah I think we’ve already made owa minds up  
Joanna: I think that we would go with (Joanna: 386-392) 
 
 
Since they first found out about PGD (described by them as IVF) and with only 
brief information on the technique, they had already decided that it was what they 
wanted to try as their first choice. However when asked – pre the parliamentary 
debates - if they knew anything about mitochondrial donation both Joanna and 
Gary tell us how mitochondrial donation would be their preferred option: 
 Joanna:  I think it be fantastic  
 Gary:    Yeah I think it [overlapping] 
 Joanna:   And if we could go for that then 
 Gary:    Then I’d rather 
 Int:    Really would you? 
 Gary:    Yeah (overlapping) 
 Joanna:   We’d both rather go for that if that could eradicate the  
    mitochondrial disease almost completely or   
    completely 
 Int:    Yeah  
 Joanna:   Then I think it’s you know  
 Gary:   Fantastic  
 Joanna:   Really good yeah, fantastic (Joanna: 350-361) 
 
 
They work together enthusiastically to tell the interviewer how ‘fantastic’ 
mitochondrial donation is and if it were now ‘we’d try it yeah’ (overlapping: 377). 
Their belief that mitochondrial donation will be able to eradicate mitochondrial 
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disease ‘almost completely or completely’ was the primary factor for it’s 
preferential status.  
Wendy and her husband Mark took part in the study interview shortly after the 
favourable parliamentary debates and up until these debates were considering 
PGD as their only option ‘we thought that we we may want to do PGD cause that 
was all that was available then’ (Wendy: 143-144). As a result of the 
parliamentary debates, Wendy and her husband had contacted specialists to 
request a mitochondrial and reproductive medicine consultation. This consultation 
was to specifically discuss mitochondrial donation as an option, as they had 
changed their minds about undergoing PGD at their local mitochondrial specialist 
centre. When telling us why PGD was no longer their preferred option they 
outline that:  
 Wendy:  But because my percentage is so high that the advice that  
   we’ve  received is that the kind of best-case scenario is that  
   we’d probably have fifty per cent an embryo with about fifty  
   per cent which is still is at the lower end of the grey category  
   of risk  
 Int:    OK  
 Wendy:   So ... because I’ve got [XX percent] PGD … PGD isn’t a  
   perfect solution  
 Int:    Right ok  
 Wendy:   Because we could ... we could have a child ... that’s in the  
   kind of ... probably  gona be OK but it’s still in the grey area 
 Mark:   Yeah  
 Wendy:  In the lower end of the grey area (Wendy: 526-533)  
 
Their understanding is that the probability that an embryo created through PGD 
would still have at least 50% mutation load. For Wendy and Mark the uncertainty 
that PGD brings with regards to the possible mutation percentage load of the 
embryos created and the possible ‘grey area’ of affectedness for a future child 
has meant that they now would now prefer to explore mitochondrial donation. 
Wendy tells us that her and Mark had spoken to the mitochondrial specialist team 
via telephone and email prior to their specialist mitochondrial and reproductive 
medicine appointment. They had also received a counselling session and that 
they had all their questions about mitochondrial donation answered:  
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 our assessment of the risk is that we want to have our own biological child 
 ... ideally erm and this is a way to get a very very low percentage of 
 mutational load like the studies are showing it’s could that the carry over 
 is likely to be should be less then sort of five per cent (Wendy: 544-546) 
 
For them, having a biological child with the lowest inheritance risk is key to their 
reproductive decision-making and their preference for mitochondrial donation and 
the reason why PGD is no longer an option.  
Ashley is another woman, who’s preferred reproductive option was mitochondrial 
donation and had been for a number of years prior to the interview:  
 so our hopes were already really high up to get it developed in time kind of 
 for us to have a chance to have a child of ours without it being affected in 
 the end (Ashley: 63-65) 
 
 
Ashley and her husband has spent a number of years tracking the progression of 
mitochondrial donation through parliamentary and regulatory approval in the hope 
that they would be able to undergo the technique. Their preference for 
mitochondrial donation was the chance to have a ‘child of ours’ who would not be 
affected by an mtDNA mutation. Ashley recalls being advised that mitochondrial 
donation may not be approved in the time frame that her and her husband would 
wish and that they should consider other potential options. She was told by a 
mitochondrial specialist that:  
 well it is an option, he can’t promises us it’s going through in time for us, 
 possible for us to go through with the treatment and we should already 
 look into other options, he told us that’ (Ashley: 70-72) 
 
They had been trying to conceive without medical intervention for a number of 
years prior to the licencing of mitochondrial donation. It seems that for this period 
of time Ashley was able to accept the potential risk.  
Even though Ashley and her husband were trying to conceive naturally she stills 
describes this period of time as waiting for mitochondrial donation ‘we took our 
chances’ to wait (Ashley: 73) and ‘hoped’ it would be approved before she 
reached an age that she believed would prevent her from accessing 
mitochondrial donation. Over time Ashley’s perception of risk associated with 
‘natural’ conception as an option changed: 
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 Ashley: but within me it developed kind of that I don’t want to bear  
   the responsibility of having a child that is getting really sick,  
   either as a child or later on in life depending on how severe it 
   is  
 Int:  yeah and that’s a common thing that’s been said yeah  
 Ashley  so it did change over time and I am taking now the   
   contraceptive pill again until we can figure out what were  
   gonna do about egg donation (Ashley: 126-130) 
 
Over time, her perception of the potential impact of her mutation on a future child 
and the potential burden of guilt and responsibility shifted their preferences and 
practices (see Chapter 8 section 8.9). Ashley and her husband had hoped to be 
candidates for mitochondrial donation or PGD but after an assessment at their 
regional reproductive centre they were informed that Ashley did not meet the 
requirements to be considered a candidate for either of the techniques and as a 
result they were now considering egg donation (see section 7.4.2.b). We see 
from the response given to the options that enable genetic relatedness that 
having a biological child with the lowest inheritance risk is high priority for the 
women interviewed in this study. 
7.4.2 Reproductive Options that Restrict Genetic Relatedness  
Options that women considered restrictive to genetic relatedness included ovum 
donation and surrogacy (with or without a donor ovum). It should be noted that 
women in Round One did not discuss either of these options. However, with the 
introduction of an interview aid in Round Two and Three I was able to initiate a 
conversation about them as potential reproductive options (see Appendix B2). 
This itself could be seen to denote their almost irrelevance to women in their 
consideration of reproductive options, despite the potential of ovum donation 
ability to provide certainty of preventing transmission of mtDNA mutation and 
allowing for the embodied experience of pregnancy. Over the interviews, the 
women offered two types of responses to options that restricted genetic 
relatedness to a child. They were that they were ‘not an option’ or that such an 
option would only be used as ‘a last resort’. I will discuss these in turn.  
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7.4.2.a Not an Option  
Ovum donation was also considered as a non-option for some women in relation 
to the child not having the genetic link to the mother or carrying the family’s 
genetic lineage down through the generations. Opinions of surrogacy were also 
often included with options to ovum donate or pitted against ovum donation. For 
Lucy her objection to both ovum donation and surrogacy were formed from the 
desire to carry her own genetically related child ‘I would want to carry my own 
baby. I want it to be related to me. I want to carry it myself’ (Lucy: 71-72).  
Such ideas about genetic lineage are central to some women. Holly‘s account 
centres on a continuation of ‘my family line’:  
 Holly:  I would want a baby that was linked to me genetically. I  
  wouldn’t want to use like a donor egg because I, I know for  
  some people it doesn’t matter and being genetically linked  
  doesn’t make you the mother sort of thing. 
 Int:  Right, so that is important. 
 Holly:  But for me it was important to feel that it was like a   
  continuation of like my family line as well, sort of thing. So I  
  wanted to, I wanted to feel as though it was a part of me sort 
  of thing, like my baby was going to be a part of me and  
  obviously [partner]. And if it was a donor egg I would almost  
  feel like I wasn’t part of that. So I think it would be harder  
  (Holly: 1171-1184) 
 
For Holly, and others, ideas about family and belonging are centred on ideas 
about genetics. A donor egg would remove a key link between herself and her 
child, as she feels that that child would not be ‘a part of me’.  
Miriam thinks about ovum donation in comparison to surrogacy and believes that 
ovum donation is ‘probably a better option in some ways’ (Miriam: 2030) but that 
‘it’s still somebody’s egg you’re carrying’ (Miriam: 2033). Additionally, with 
surrogacy she envisages potential complications, including the surrogate 
unwilling to give up the child once born, as well as the potential of bonding 
between the surrogate and the biological father.  
 If it’s going to work, if if it’s going to be that the mother will give up the 
baby that she is carrying for nine months, if they don’t change their 
feeling, if the father doesn’t get involved with the woman carrying his 
eggs (Miriam: 1962-1965) 
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Miriam considers that the ‘there’s too many complications, too many emotions’ 
(Miriam: 1975) with surrogacy. Miriam also considers that if resemblance was to 
exist between the surrogate and the intending mother, the father may feel 
somewhat conflicted by this. 
 She’s going to be a young, healthy woman, probably looking like his wife, 
hav- the same hair colour and the same eyes; all the kind of- he’ll think 
about that (Miriam: 1981-1983) 
 
For Miriam, concerns about not ‘receiving’ the child that the couple had planned 
together and the emotional burden were central to her objection of surrogacy. 
Objections to options that women saw as restricting genetic relatedness seem to 
raise questions about what it means to be a member of a family. The sharing of 
genetic material with a child was important for them to ensure feelings of 
belonging and a core requirement to ensure insider status in a family.  
7.4.2.b Last Resort  
For some women reproductive options that restrict genetic relatedness would be 
considered but only after other avenues had been fully explored. As Wendy 
outlines:  
 if our preferred option didn’t work then we would consider them, so we’ve 
 not eliminated them they’re just not at the top of the list (Wendy: 487-491) 
 
When considering ovum donation, Wendy and her husband tell us that they 
‘haven’t really spoken that much about just using a donor egg in its entirety’ 
(Wendy: 477-478). Ovum donation would permit the child to be related to her 
husband Mark as well as providing her the chance to carry the child. On reflection 
Wendy finds it interesting that they hadn’t considered ovum donation more:  
Wendy: Erm and interestingly that’s probably one that we haven’t 
really   discussed (0.5) Yeah and I suppose the difference between  
  [adoption] and [ovum donation] is that is would be your  
  biological child but not mine cause we would use a donor  
  egg 
Mark:  Arh right yeah of course 
Wendy: Erm but then I would carry the baby (Wendy: 433-484) 
 
Wendy and Mark talk through ovum donation together in the interview and begin 
to see that it would result in a child genetically linked to Mark and that Wendy 
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would be able to carry the baby. Both of the mitochondrial specialist teams that 
Wendy and Mark had discussed their options with had not yet spoken to them 
about ovum donation and only in the interview do they seem to consider the 
potential benefits. For Zoe ‘egg donation would be another option to the 
mitochondrial donation as well’ (Zoe: 194-196). This is because she believes that 
her mutation would not be suitable for PGD and has been to date putting on hold 
having a family in the fear of passing on her mutation to a child.  
For Ashley and her husband, Ashley describes having already reached their ‘last 
resort’ after receiving the news that she would not be a suitable candidate for 
either of the IVF technologies, her preferred method being mitochondrial 
donation. She and her husband had already initiated their own investigations into 
ovum donation from private clinics. They had chosen to search for private clinics 
as they were conscious of her age and long waiting times on the NHS. Ashley 
and her husband had expanded their search across Europe for a clinic that would 
permit them to review characteristics of a potential donor to enable them to try to 
match the potential physical features of the potential future child to their family. 
 Ashley:  if possible we would love to have a child of our own again  
   erm and if it’s just half [laughter] with the egg donation  
   process we would move forward with that 
 Int:  is it more the genetic link with your husband or is that you  
   would want to carry the baby? 
 Ashley: I think it is more the genetic link for my husband erm yeah it’s 
   kind of important for him I think… ‘it’s a closer link then  
   adoption but no it’s not that important for me to be pregnant  
   (Ashley: 138-144) 
 
Having ‘our’ child, even if ‘it’s just half’ our child is seen as a good outcome. 
Ashley tells us that the genetic link to her husband is important to him, as it 
provides a closer ‘link’ to the child than adoption. Ashley had experienced 
complications in her previous pregnancy that required emergency surgery, a 
number of months in hospital and the eventual early arrival of their first child, 
which may account for lack of importance of carrying her child. Although Ashley 
does not specify whether the genetic link to her husband is important for her, she 
does tell us that it is important that the child resembles both her and her husband 
‘that the child would hopefully look a bit alike’ (Ashley: 110-111). It could be 
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argued that having a child that could be perceived by others as not genetically 
related such as ‘having dark hair’ (Ashley: 112) is central to her concern of ovum 
donation and the reason why choosing a clinic that permits this matching is of 
importance to Ashley and her husband.  
Holly and Edward were unique to the study in that at the time of the interview 
they were actively pursuing PGD with Holly’s eggs (although like others their 
preferred option was mitochondrial donation) with a proposed plan to use a 
surrogate to carry their biological child to term. This was thought to be a 
requirement due to severity of Holly’s mtDNA mutation ‘I’ve been told that I 
should find a surrogate rather than carrying the baby myself’ (Holly: 828). As we 
have seen above (section 7.4.2.a) a biological link to Holly was important and 
that surrogacy would allow for this genetic link to be possible, as she believed 
that ‘I don’t think I’ve got another option’ (Holly: 1167). To enable this, Holly 
would need to freeze her eggs until they can find a surrogate. However finding a 
surrogate had a number of barriers. Holly and Edward described facing practical 
issues of costs of upwards of £20,000 to accommodate the surrogates medical 
care including a £1000 registration fee to the leading UK not-for-profit surrogacy 
organisation (www.surrogacyuk.org). Other pressing issues were around the 
legal aspects of the surrogate mother being the legal mother at birth who did not 
have to ‘handover’ the child to the ‘biological mother’ if they did not wish. 
However the main issue for Holly was concern relating to bonding or the lack of 
bonding if she were to not carry her child. When talking about whether surrogacy 
was an easy option to understand, Holly talks about her sister’s pregnancies:  
 Because even like the kicks and like, like she’d say, “Put your hand here 
and you can feel the baby kicking,” and I thought, “Oh it must be 
amazing to feel that,” and you’ve, like that’s a bond you just can’t 
replace. And like I just think, “How hard is it going to be to watch 
another female carrying my baby?” And then just try and pick up almost 
where they’ve left off, I just think it’ll be really like, I think it will be 
difficult, erm like the bonding side of it. (Holly: 1158-1166) 
 
Clearly, for Holly the emotional issues that emerge out of not having an inter-
embodied experience of pregnancy are central, especially around issues she 
describes as bonding. Holly and Edward were at the time of the interview 
prepared to accept surrogacy as their option of last resort, to enable them to have 
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a child that was biologically related to them both. Interestingly Holly took part in a 
second interview, outlining that she and Edward had conceived a child without 
medical intervention, had chosen not to undergo any prenatal testing and had a 
healthy child who was approaching their first birthday. This notion of change over 
time in reproductive decision making is explored in Chapter 8 section 8.9.  
In conclusion, ‘raising a child of my own’ was important to women and 
reproductive options that enabled genetic relatedness were favoured over 
reproductive options that restricted a woman’s biological link to the child. Women 
who conceive naturally without medical intervention were often those who had no 
prior knowledge of their mtDNA mutation and who had no reason to consider 
other avenues of having children. Whereas those who made their decision after 
receiving information did so either through self-proclaimed lack of awareness and 
understanding of risk or who were not concerned either after receiving expert 
guidance or because they did not consider there to be any risk. Conception 
without medical intervention was for a proportion of women too risky due to the 
uncertainty that surrounds predicting the affectedness of a future child. Whilst 
mitochondrial donation was the preferred choice of the majority of women, PGD 
was regarded by many as the interim option, due to concerns that mitochondrial 
donation may not receive approval or not be available in time for them. PGD 
provided women the biological link but still presented uncertainty, a ‘grey zone’ 
whereby children may still be at-risk of affectedness. For those reproductive 
options that restricted genetic relatedness, these were seen as less favourable, 
and either not an option or as a last resort. Ovum donation was considered not 
an option for women who placed importance in their biological link to a future 
child, for those women considering ovum donation as a last resort this link was 
less important, but interestingly genetic relatedness to the father was reported as 
important to one woman’s husband. Surrogacy was considered problematic for 
concerns commonly cited, which included concerns that the intending parents 
may not ‘receive’ their child at birth and concerns relating to missing out on the 
inter-bodied experience of pregnancy and notion of maternal bonding (Teman, 
2009). I will now move on to discuss women’s ideas and preferences that centred 
on ‘raising someone else’s child’.   
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7.5 Raising Someone Else’s Child  
The idea of raising a child that was ‘not their own’ was in most cases problematic 
for the women interviewed, there were some women who may have considered 
raising a child that was not in any way biologically related to themselves or their 
partner given no other options and only one woman who had already decided 
that she would raise ‘another woman’s’ child if she could not conceive.  
7.5.1 Not an Option  
For Alice to whom adoption was described as not being an option, her reasoning 
had centred around the desire for her and her husband to have their ‘own baby’. 
Alice had experienced fertility issues for over 20 years at the time of the interview 
and as result she did not have any children. She and her husband had discussed 
adoption in the context of childlessness but not within the context of a known 
mitochondrial disease diagnosis. Alice recalls the information sheet on adoption 
she was given by a reproductive medicine specialist after approximately 5 years 
of trying to become pregnant, she remembers ‘it was saying that that could take, 
like, four or five years’ (Alice: 2062-2063). Sandelowski et al (1991) has outlined 
that the experience of long waiting times for adoption can cause distress to 
couples by disrupting the couple’s social lives, creating prolonged transitions to 
parenthood and the stages of imagination. For Alice, like others, given the 
temporal uncertainty, adoption was not an option.  
Alongside information on adoption, Alice was also provided with a leaflet about 
the then new IVF procedure ‘the test tube baby’. At the time Alice, describes 
reading what she though was science fiction ‘it was like science fiction and I was 
like, “Oh my God.”’ (Alice: 2079-2080). She outlined how ‘I s- I was scared, the 
two of us were scared stiff, right? And I read it qu- the stuff quite a lot’ (Alice: 
2091-2093). Alice and her husband discussed their available options and 
decided:   
 We’ve got a good marriage and we talk about things and we decided that 
 adoption wasn’t what we wanted to do. And if we wanted to have a baby it 
 was going to be our baby (Alice: 2125-2139) 
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For Alice and her husband the central issue was one of genetics. Despite the 
possibility that the new techniques of IVF offered a child with a genetic link, Alice 
and her husband continued to try to conceive ‘naturally’. 
Miriam offers a range of accounts as to why she would discount adoption. When 
discussing what options she would not consider she says that:  
 
 Miriam:  Not have, no. That one adoption, of course, but it’s not the  
   same  
 Int:  yeah 
 Miriam: I’ve not adopted so I can’t really say, for that but I if I   
   desperately wanted a family and I couldn’t have   
   mitochondrial donation I still don’t think I could adopt. I don’t  
   think I could,  ‘cause you don’t really know, it sounds awful, I  
   don’t think anybody I know has ever adopted’ (Miriam: 1893- 
   1905) 
 
Even if she ‘desperately wanted a family’ adoption could not really be considered. 
It is ‘not the same’. She alludes to the preference for genetic relatedness by 
contrasting adoption with mitochondrial donation. With a non-genetic child via 
adoption you are left with uncertainty ‘cause you don’t really know’ about aspects 
of that child. She is aware that such a position is hearable as problematic by 
some. She comments that it ‘sounds awful’ and offers a range of justifications for 
her opinion: she has no experience and does not know anyone with experience. 
In response to adoption as an option on the interview aid another woman, Lucy 
tells us ‘no I don’t think that would be for me’ (Lucy: 68) and when asked which 
options she would not consider ‘probably adoption it sounds horrible but erm 
adoption’ (Lucy: 69). However, unlike Miriam, Lucy did not unpack further as to 
the reasons why adoption was not for her.  
Miriam then tells us that her daughter and son and law had discussed adoption 
as a possible option but that her son in law in a similar fashion to her was not in 
favour. 
 ‘But [daughter] and [son in law], have said they might adopt but [son in  
 law] said “no”. If they can’t have their own children he doesn’t want to have 
 somebody else’s children’ (Miriam: 1909-1911) 
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Again we see a preference for genetic relatedness, that adoption means that you 
are having ‘somebody else’s child’. Miriam also offers concerns, as adoption may 
not ‘bring a family closer’ if someone then had a biological child.   
 Miriam: Mmhmm and what if they do then have another baby? How  
   would it feel to be, you see so many programmes and films  
   about that and you think “How would it be to have your own  
   child and an adopted child?” (Miriam: 1924-1935) 
 
 
Such a blended family, of ‘your own child’ and someone else’s is not for Miriam. 
Similarly, Ashley acknowledges adoption as an abstract option but feels that it is 
not an option for her and her husband as 
 we are already having one child, were really happy with it, and we  
 probably wouldn’t adopt another child (Ashley: 132-133) 
 
Ashley and her husband had been trying for a number of years to become 
pregnant. However, they would consider ovum donation (see above section 
7.4.2), which we have seen can be linked to genetic relatedness to her husband 
and a preference to having a child that physically resembles them both.   
7.5.2 Never Considered  
For women in the retrospective group who had completed their families before 
their diagnosis they recall never considering or had hoped to never have to 
consider reproductive options other than natural conception (without 
intervention). Pauline had not struggled to fall pregnant with three children. 
 I would hope not to have to adopt. I would still want, I think, to, to carry me 
own baby, so not to have to adopt (Pauline: 1134-1136) 
 
Pauline like others does not discount adoption as an option but she tells us that 
her preference would always be to carry her own baby.  
7.5.3 Last Resort  
For some women adoption would be considered but only when other avenues 
had been explored first, albeit is a ‘last resort’ (Zoe: 193). Holly and her partner 
had previously discussed adoption prior to the study interview as an option if their 
preferred methods of PGD with combined surrogacy were not successful. 
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 Holly:  It would be the last resort but it’s certainly not something we  
  would rule out. We, we definitely would look at adoption.  
  Erm, we’ve also looked at, because of the issues with  
  actually looking after a new baby erm, if we were doing  
  adoption we would maybe look at adopting a slightly older  
  child who is past that kind of really demanding stage where  
  you are doing. You’ve got the sleepless nights and you really 
  do need to have a lot of energy to kind of keep up with them  
  and look after them 
 Int:  So like an older toddler? 
 Holly:  Yeah, yeah like somebody that is maybe past those, that  
  kind of stage. But we haven’t really talked about it in great  
  depth 
 Edward: Not yet, no. We still, that would be our last thing once, if we  
  had to decide then we would probably talk about it. But I  
  think we will obviously go down that route I think, if we have  
  to 
 Holly:  Yes. It’s really important for both of us to have a baby, so  
  erm if, if what we are going to do isn’t going to be possible  
  and we end up then we’ll certainly look at that option (Holly:  
  1868-1889) 
 
 
As they note, they have not yet ‘talked about it in great depth’, but they have 
clearly thought through some of the implications, given their discussions about 
the age of the child that they would try to adopt. Adopting a child who was slightly 
older and not as dependent as a newborn may be more practical for them given 
that fatigue is a prominent symptom for Holly. However, centrally for them, 
adoption is only something that they would do ‘if we have to’, ‘it would be the last 
resort’, it would be ‘our last thing’.  
7.5.4 Definite Option 
In contrast to the above outlooks Andi and her husband had discussed adoption 
prior to getting married in the event that once married they might find themselves 
unable to conceive.  When discussing adoption as an option Andi tells us that:  
 Andi:  No I wouldn’t you know if I can’t have a child I’m not meant to 
   have a child I’ll adopt, I’ll look after somebody else’s child  
 Int:  Yeah, yeah erm and so if you, so the decision not to have a  
   family wouldn’t have happened you would have just gone on  
   to have children via adoption? 
 Andi:  Probably yes, yes adopt’ (Andi: 666-671) 
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Again we see, the impact of her religious faith on her choices (see above 7.4.1). 
For Andi, a doctrine of predestination is central, if she had been unable to 
conceive then it must mean that it was not meant to be.  In such circumstances 
she would care for ‘somebody else’s child’ – note here how again, issues of 
ownership and belonging, tied to genetics is still central to these accounts.  
Over all these accounts having a child is centred around ideas of genetic lineage 
and inheritance over, say, ideas of belonging emerging through the day-to-day 
practices of caring for a child. Raisings someone else’s child through adoption 
was primarily considered as a non-option or not even one at all.  Those women in 
whom adoption had never been a consideration were those women who had not 
known of their diagnosis prior to having children and who had not experienced 
any issues in conceiving. Adoption was considered by some women to be 
problematic due to the lack of genetic relatedness and pre-existing beliefs that 
adoption can be a lengthy and disruptive process, resulting in it mainly being 
considered not an option. One exception was Andi and her husband, both of 
whom were in agreement that if they were unable to conceive naturally, they 
would care for someone else’s child. For Andi and her husband, parenthood was 
founded on their actions of caring, and reflects Schinder (1984) definition of 
social kinship. Finally, I will discuss voluntary childlessness as an available option 
to women.  
7.6 Voluntary Childlessness  
The reproductive option to decide to not have children was first introduced into 
the study by Wendy who upon seeing version one of the interview aid (see 
Appendix B2) suggested an addition; ‘or seven don’t have any children’ (Wendy: 
443).  For the majority of women interviewed having a family was very important 
to them and had been since they were young, having a child/children was central 
to this imagined family. Individuals who are said to have always known that they 
wanted a child have been referred to as ‘predetermined parents’ (Murphy, 2013). 
We have seen above in section 6.4 that some women may have re-considered 
whether or not they would have had children had they known their mtDNA 
mutation and others who had actively been taking measures to not become 
pregnant whilst waiting for their preferred option to become available to them. 
The women who had spent time waiting for their options could be seen to be 
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practicing temporary voluntary childlessness in the hope that they could in the 
future have access to mitochondrial donation. As we have seen above, many 
women believed that having access to mitochondrial donation enabled them to 
reduce or eradicate the uncertainty of affectedness risk and offer them a greater 
chance of a healthy child genetically related to both them and their partner. For 
one woman interviewed, she believed that, had she had known of her mtDNA 
mutation she would have chose to not have children. For Jenny the primary 
reasoning behind this is linked to the perception of the inheritance risk being too 
high for her to feel comfortable having a child (see Chapter 8 section 8.3.1). 
Interestingly she tells that she had never been very maternal and that having 
children had ‘never really (0.2) really bothered me you know’ (Jenny: 79) however 
she supports mitochondrial donation for women who are both desperate for a 
child and for that child to not be affected by ‘anything mitochondrial’.  
 Jenny: I, if it’s going to help people who want to have normal  
   kids, healthy kids, go for it you know, if your that, if  
   you really are desperate for a child and (0.2) and you  
   would  rather it not have.anything.mitochondrial  
   related wrong with it 
 Int:   Yeah 
 Jenny: go for it (Jenny: 226-230)  
 
Jenny supported women whom would want to undergo mitochondrial donation in 
order to have a child who would not be affected by a mtDNA mutation. 
7.7 Summary   
This chapter shows the ways in which women with maternally inherited 
mitochondrial disease formed ideas and preferences based on current and future 
reproductive options available. These ideas and preferences were formed after 
receiving information from trusted experts regarding how mtDNA mutations are 
inherited and their own personal inheritance risk.   
As we have seen in Chapter 6, receiving information on their individual prognosis 
and inheritance risk was especially important to women. Some women report 
their understanding of inheritance as chance, and that having an unaffected child 
would be ‘really lucky’, mirroring existing literature on beating the odds in CF 
(Myring et al., 2011) and luck in HD (Klitzman et al., 2007). Attending 
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appointments with both mitochondrial specialists and genetic counsellors meant 
that women were able to seek assistance in understanding and recalling risk. 
Retention of genetic risk is difficult for some couples due to the amount of 
information presented to them (Dommering et al., 2010) with it being reported 
that many people’s perceptions of risk are said to be inaccurate follow 
counselling (Timmermans, 2005). Retention of genetic risk has also been 
reported to decrease over time (Hallowell et al., 1997; Michie et al.,1997) with 
genetic counselling assisting individuals with accurate perceptions of their risk 
(Bish et al., 2002; Evans et al.,1999). However, for Zoe, her experience includes 
being given inaccurate or out of date information in regards to a private PGD 
clinic, highlighting the possibility non-mitochondrial specialist genetic counselling 
could lead to inaccurate guidance provided to women. We have also seen 
previously in Chapter 6, that Joanna described aspects of SDM (Charles et al., 
1997; Elwyn et al., 2012) in relation to her specific reproductive options 
consultation. Emma and Joanna and Gary presented their experiences of genetic 
counselling as informed or consumerist decision-making, whereby they were 
provided with detailed information but did not feel that the views of their 
mitochondrial or reproductive specialist was pressed upon them (Charles et al., 
1997; Charles et al., 2000; Emanuel and Emanuel, 1992). Encounters relating to 
specific reproductive options consultations are described as positive, with women 
recalling feeling supported in making or planning future reproductive decisions. 
However, for one woman, genetic counselling was not a necessary requirement, 
this being that information about inheritance risk was irrelevant to her and her 
family’s decisions.  
We see that the core preference for most, but not all women was for ‘my healthy 
child’ with the focus first on the health of the child. As a result, mitochondrial 
donation is considered the most favourable reproductive option. In the face of 
uncertainty regarding possible affectedness of children, mitochondrial donation 
offers women and their partners both biological parenthood as well as a 
significantly reduced risk of having an affected child. Mitochondrial donation 
offers this hope to not only women making the decision in the present, but to 
maternal family members and future generations, echoing reports that 
mitochondrial donation provides hope to women, their children and society 
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(Herbrand and Dimond 2017). Women, whom considered prenatal testing as too 
risky, commonly described the importance of keeping their unborn child safe. In 
addition to this, prenatal testing was discounted by many women as receiving 
information about their unborn child’s mutation load would then put them in a 
position of considering a termination, in which many did not want to find 
themselves.  
After this we see a clear preference that women wanted ‘my own child’, which 
equated to a child that was genetically related to them, a child biologically 
connected to their wider family and one whom they had carried physically. There 
is a preference for maximising genetic relatedness to both parents provided by 
mitochondrial donation as the most favoured option whilst those options offering 
a partial biological link such as ovum donation or no biological link at all such as 
adoption were either never seen as relevant, never even considered or 
considered as a last resort.  
This chapter shows the importance of women’s ideas and preferences for certain 
reproductive options in the decision-making process. However, findings from this 
study show that these idea and preferences are set within a larger framework of 
reproductive decision making with other influencing factors and elements, which I 
will now go on to discuss in Chapter 8. 
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Chapter 8. Reproductive Decision-Making in Maternally Inherited 
Mitochondrial Disease: Conceptual Model 
 
8.1 Introduction 
In preceding chapters I have discussed how uncertainty features in the lives on 
women diagnosed with mtDNA mutations and their ideas and preferences 
towards available reproductive options. This chapter brings together these 
findings and organises them into influential factors and elements of reproductive 
decision-making. This chapter continues to explore each of these factors and 
elements providing justification for their status in the conceptual model proposed.  
Data presented shows that reproductive decision-making is influenced by 
women’s awareness of inheritance risk, which can be further divided into lived 
awareness and factual awareness. Women consider a number of risks in the 
process of decision-making, which are primarily centred on the potential health 
risk to a future child. Some women consider the parenting risk associated with 
their ability to parent if their own disease burden were to increase and pregnancy 
itself, which can pose risks to both mother and baby. Women’s values are 
intrinsic to reproductive decision-making, which have been shown in the data to 
comprise of their ideas and preferences surrounding the available reproductive 
options discussed in Chapter 7, their feelings of guilt and responsibility of 
transmitting a mtDNA mutation and for some, their religious beliefs. The 
conceptual model shows a number of influential factors or elements, however for 
some women their decision-making may be influenced by only one of these, 
whereas other women may consider a combination. These considerations enable 
women to reach a state of a risk acceptance, modification or avoidance, which in 
turn informs their decision-making relating to available reproductive options. 
Finally, the last section shows how the model accounts for decision-making as 
temporal and how women’s perceptions of risk may change over time, based on 
new information or a change in personal circumstances, which can lead to a re-
evaluation of available options.   
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8.2 Conceptual Model  
In Chapter 4 I showed how the below conceptual model  was both initially 
developed and later superimposed into an adapted ‘model of responsibilities’ 
from Downing (2005) to provide a conceptual model of reproductive decision-
making in maternally inherited mitochondrial disease. In this section I will discuss 
each of the influential factors and elements in detail, showing their importance in 
the model and the lives of women with maternally inherited mitochondrial 
disorders.  
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Figure 8.1 Conceptual Model of Reproductive Decision Making In Maternally Inherited Mitochondrial Disease (adapted from 
Downing (2005)) 
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8.3 Awareness of Inheritance Risk   
For the majority of women included in this study, reproduction was not defined as 
problematic prior to their or their family members diagnoses of mitochondrial 
disease. I have termed this time point in the lives of women interviewed as ‘time 
point Zero’ (or T0). During this time, women were not aware of the potential risk 
factors associated with the diagnosis of a genetically inherited disorder that would 
require deliberation as ‘at any time in the last 15 years I could have made that 
decision and been completely ignorant to having mitochondrial disease’ (Sarah: 
214-215). However, during this time, women lived with the effects of 
mitochondrial disease, be it their own experience of ill health or that of a family 
member without knowledge of the actual cause. This experience is described in 
the literature on chronic illness, rare disease and reproductive decision making as 
lived experience (Barlow et al., 2007; Boardman, 2014; Christensen et al., 2016; 
Dimond, 2013; Downing, 2005; Frank et al., 2007; Garrino et al., 2015; Grinyer, 
2007; Jefferies & Clifford, 2011; Jeon et al., 2010; Kelly, 2009).  Although one 
woman in the study, Alice, she did have an experience of reproduction that was a 
cause for consideration prior to a mitochondrial diagnosis, and this was 
understood as being related to infertility issues (see Chapter 7 section 7.5).  
Upon receiving a diagnosis and with the knowledge that they carry a genetic 
disorder that is maternally inherited, women enter a position in time whereby they 
consider one or a number of influential factors and elements, ‘time point One’ (or 
T1). Factors contributing to awareness of inheritance risk, either individually or in 
combination lead women to define reproduction as a cause for consideration and 
ultimately their reproductive decision to accept, modify or avoid risk. These 
factors included: factual awareness, lived awareness, child centred risk, 
parenting risk and pregnancy risk. I will discuss these each in turn.  
8.3.1 Factual Awareness  
Women discussed a number of different sources of information that have been 
defined as ‘factual awareness’ in the proposed conceptual model. These sources 
were either provided to or accessed by women at varying time points including: 
on receipt of their own or a family members diagnosis, whilst seeking strategies 
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of coping with their mitochondrial disease and in relation to their active 
consideration of reproductive options.   
As discussed in Chapters 5 and 6, women sought information to help them 
understand their or their family members diagnosis, its potential impacts and to 
follow research updates specifically in relation to mitochondrial donation. 
Receiving information from ‘a mitochondrial expert’ in a clinical consultation 
scenario for many women was necessary to enable them to process their 
diagnosis and understand further their individual inheritance risk. Women 
described other ‘factual’ sources of information as the Internet or ‘Google’, 
research organisations, patient organisations, mitochondrial patient newsletters, 
mitochondrial or neuromuscular patient information days, and traditional and 
social media platforms. Information sources including clinical experts and the 
information provided were scrutinised by women with regards to trustworthiness, 
resulting in a personal scale of usefulness for some women.  
Many women described searching the Internet or ‘I started googling it 
[mitochondrial disease]’ (Sarah: 92) when they or their family member were told 
of the potential or actual diagnosis of mitochondrial disease. In Chapter 6 we see 
that diagnosis coupled with information seeking led to the majority of women 
being scared by what they found online, describing finding information relating to 
limited life expectancy and that they were concerned that they and their children 
may die prematurely from their diagnosis. 
In Chapter 6 we see that Maggie’s fears for her family were alleviated after she 
sought advice from a mitochondrial specialist as opposed to the symptom 
specialist who had informed her of her diagnosis. This non-specialist doctor was 
unable to offer much information other than that she had mitochondrial disease. 
This led Maggie to start ‘looking on the Internet as you do’ (Maggie: 393-394). 
Whilst awaiting an appointment with a mitochondrial specialist, Maggie cried 
nearly every day worrying about what she had read online and cried when 
retelling her story. 
Er, people sort of dying. It’s not, not sort of unusual for children to die from 
it, and then of course I mean I have got [X number of children], like [X 
children], and I was just thinking like, “What if they’re gonna die?” (Maggie: 
448-451) 
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For Maggie her experience of researching mitochondrial disease online was 
extremely distressing and that it led her to believe that both she and her children 
were at serious risk. Maggie, like other women interviewed who had researched 
mitochondrial disease online found a sense of relief when receiving more specific 
information relating to her mtDNA mutation and her inheritance risk. For women 
in the current and prospective group this factual awareness from an expert was 
an important factor to their reproductive decision-making, especially in Sarah’s 
decision to continue to try for a baby (Chapter 7 section 7.4.1). 
As discussed in Chapter 6 the variability in phenotypes associated with 
mitochondrial disease led to the common criticism that the multiple sources of 
information did not reflect their specific experiences of their disease. This made 
reflecting on their inheritance risk complicated as not all children were affected in 
the same way or with the same severity (especially when women may have 
unknowingly compared nDNA and mtDNA mutations). Sally was part of the 
retrospective group and tells us during the interview that she had completed her 
family but also that she would not rule out having another child in the future. Sally 
was diagnosed via her youngest child who had shown symptoms from a young 
age. When considering if what she had seen or read about mitochondrial disease 
online and via social media platforms had influenced how she felt about the 
inheritance of her mitochondrial mutation Sally tells us that: 
Sally:  I think that when I first ermm heard about mitochondrial  
  disease before [Child Z] I never heard about it before   
  ever, erm when I did hear about it and I looked into it, and  
  when you first type in mitochondrial disease it looks   
  horrible and it is terrible ermm but there are different   
  scales of terrible  
Int:  Yeah 
Sally:  Errm so for me, that’s what I found when I first when   
  heard about mitochondrial disease it just looks dreadful  
  and ermm looks like it looks like it has a poor prognosis  
  but like I said in our case were actually hopefully one of  
  the lucky families that it can ermm if it does (0.3) if it does  
  give us symptoms it won’t be as bad  
  (Sally: 305-313) 
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Sally tells us that after researching mitochondrial disease online and in 
connection with the main UK patient charity there is a ‘scale of terrible’ in 
mitochondrial disease. Although Sally is concerned about the possibility that 
symptoms will present in her other children, particularly in one child whom she 
believes to be at greater risk, she is hopeful that it will not be to the extent of 
other families who are affected more severely. Sally does a lot of work throughout 
the interview to tell us that she feels her family are ‘lucky’ to have escaped the 
‘horrible’ mitochondrial disease. For Sally the key issue was knowing that her 
family would not be affected as severely as others. Sally appears to exhibit what 
is known as downward social comparison, which can be applied to those living 
with a medical condition. This is the process in which people compare 
themselves to individuals whose experience of the same condition appears to be 
much worse than their own or who seem to be less fortunate. This then allows for 
them to form a more positive outlook on their experience (Standing et al 2017 in 
press) (Festinger, 1954; Taylor & Lobel, 1989; Wills, 1981).  
Some women actively engaged in patient communities via the main UK patient 
charity or ‘private’ mitochondrial patient only social media groups where access 
and debates are controlled by appointed patient administrators/moderators. 
Some women used these groups for support in caring for affected relatives or as 
support to manage their own disease burden. These platforms were also used to 
raise awareness, inform family members, friends and co-workers of mitochondrial 
disease and for some to show their support in lobbying for the approval of 
mitochondrial donation in parliament. In one instance, these online communities 
were used as a direct source of information and support relating to reproductive 
options. Women who were not aware of these groups, expressed a wish to have 
an ‘online forum so if you wanted to speak to other people who were going 
through it you could’ (Wendy: 408-409).  
Holly described being part of a global community of adult mitochondrial patients 
via a social media platform, which she described as offering peer support and a 
place ‘that they can be totally open and honest about whatever feelings and 
whatever issues they are going through’ (Holly: 1538-1540). In particular Holly 
was also able to connect with other ‘mitochondrial mums’ in America who had 
been through surrogacy to have their child/children and who were parenting with 
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a disability. When discussing how helpful this connection with other mums was to 
Holly she tells us: 
Holly:  Yes, they helped answer a lot of questions that I had   
  about it, and even just the bonding side of it, and how,  
  what they did and how because erm this, this lady is   
  confined to a wheelchair and how she was able to just do  
  things like, that you would expect a mum to do with her  
  child. And how, what other types of things. So she told  
  me about the things that she could do rather than   
  focussing on all the things she couldn’t do, sort of thing.  
  And just trying to like turn it on its head and there are so  
  many more things that you, you, you- 
Int:  Positive. 
Holly:  That you’re not even aware of, that you can do with your  
  child. Like you, you, until you actually sit and think about  
  it. Whereas because people who are able bodied are   
  running about and doing all these kinds of things, it   
  doesn’t mean to say that you can’t do things just like   
  sitting down. You don’t have to be on the go constantly  
  sort of thing (Holly: 1984-2002) 
 
Holly used the social media platform to gain practical and experiential information 
from others, which helped shape her knowledge, hopes and expectations. Holly 
tells us that they discussed issues surrounding bonding with a child planned 
through surrogacy, recommendations on how to care for child when in a 
wheelchair and thinking positively about what can be achieved in spite of 
limitations caused by their mitochondrial disease. Engaging with other patient’s 
experience (Ziebland & Wyke, 2012), their experiential expertise (Boling et al., 
2015; Moreira, 2006; Ziebland et al., 2004; Ziebland & Herxheimer, 2008) is a 
central resource that helps to inform and support Holly’s reproductive decision-
making.  
8.3.2 Lived Awareness  
Downing's (2005) model of responsibilities in reproductive decision making 
(Figure 4.13) in HD showed that lived awareness was an important factor in the 
awareness of risk, this was described in relation to the participant’s experiences 
of HD in family members. Amongst women interviewed in this project we see that 
women’s lived awareness of mitochondrial disease can consist of their 
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experience of family ill health and experience of their own personal ill health as a 
result of a mtDNA mutation. I will discuss both these in turn.  
8.3.1.a Experience of Personal Ill Health  
Chapter 5 highlighted that for some women their personal experiences of ill 
health as a result of their mtDNA mutation dated back to their childhood. For 
Jenny, she had experienced over 40 years of symptoms at the time of the 
interview, that once diagnosed were attributed to her mtDNA mutation. Jenny had 
experienced severe fatigue from approximately 7 or 8 years old and despite 
being taken to see health professionals on a number of occasions she was not 
diagnosed with any illness other than being ‘just lazy’ (Jenny: 80-81). Jenny 
finally received a diagnosis when her only child presented with the same 
symptoms at approximately the same age, which led to the diagnosis of a mtDNA 
mutation in both Jenny and her child. 
Jenny tells us that had she been aware of the inheritance risk associated with her 
mtDNA mutation she would have decided to not have any children. 
Jenny: If I’d had had been diagnosed .... I wouldn’t have had   
  kids  
Int:  You wouldn’t have done? 
Jenny: No way  
Int:  You have chosen not to? 
Jenny: Wey the risk is too great ain’t it (Jenny: 290-295) 
 
For Jenny the inheritance risk would have been too great. Jenny can be seen to 
have made this assessment of risk in part due to her lived experience of 
mitochondrial disease. Her decision therefore can be translated to the model as 
avoiding risk, resulting in the decision to not have children.  
For others the uncertainty of being unable to predict the risk of affectedness of a 
child made it difficult for them to compare their own experience of ill health as a 
result of their mtDNA mutation to that of a future child’s. Joanna struggled with 
not knowing what mutation percentage a future child may have and if they would 
have a percentage more or less than her own percentage. As we have seen in 
Chapter 5 section 5.5, Joanna was diagnosed via her mother whom she 
describes as having a ‘really complex like medical history and things’ (Joanna: 
33) and she herself experiences bouts of chronic fatigue and other ‘health 
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complications’ that affect her daily living. At the end of the interview and when 
asked if there is anything that she wished to add Joanna adds: 
Joanna: I have you know a few health complications and   
  things like that and so it’s the not knowing with    
  mitochondrial disease  
Int:  Yeah 
Joanna: I‘ve got [XX] per cent, baby could have like [XX+11] –   
  [XX+21], do you know the not knowing  
Gary:  Umm 
Joanna:  There is nothing to say that it would have less than me  
  and you know  
Gary:      Yeah 
Joanna:  Cos it affects people in just different ways  
  (Joanna: 398-405) 
 
For Joanna the fact that there was no way of knowing what percentage mutation 
load her future child may have makes it difficult for her to compare her mutation 
percentage load with that of a future child. She tells us that a future child may 
have 11 per cent or 21 per cent more than her and that it may be more like her 
mother’s percentage mutation load. The uncertainty described by Joanna and her 
partner Gary can be broken down to the unpredictability of mutation percentage, 
the lack of information relating to their specific risk due to the complexities of 
inheritance and unfamiliarity with the potential phenotype their future child may 
experience. We see that for both Joanna and Gary, this uncertainty is key to 
them seeking ways in which to modify risk by engaging with PGD (Chapter 7 
section 7.4.1).  
8.3.1.b Experience of Family Ill Health  
As seen in Chapter 5 it is often the case that some women with mitochondrial 
mutations do not experience any symptoms or experience low levels of 
symptoms that they deem to not require medical review until after they have had 
a child or children. A number of women interviewed had however experienced 
family ill health associated with undiagnosed mitochondrial disease for decades, 
which in some case included multi-generational experiences. Some women had 
witnessed their family members’ health decline after a diagnosis of a mtDNA 
mutation, in line with the known natural history of these disorders. Both scenarios 
influenced how the women framed their own reproductive decisions. 
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For Wendy she had witnessed her sibling become seriously ill over 10-15 years, 
which was diagnosed as a mtDNA mutation after exhausting neurology services 
at their district and regional hospitals. Her mother who also experiences 
symptoms of the mutation, and her father, are her siblings’ sole carers. When 
talking about how mitochondrial disease impacts their life as a family, Wendy tells 
us that  
Wendy: Yeah [she] is severely disabled so [she] can’t walk,   
  [she] need’s [she] can’t [she] can’t shower by    
  [herself], [she] can’t go to the toilet by     
  [herself], [she] can’t dress [herself]  
Int:  Right so  
Wendy:  Erm so yes so severely impacts my parent’s life cause  
  they’re [her] main carers  
Int:   Right OK 
Wendy:  Well sole carers (Wendy: 259-264) 
 
Wendy’s sibling has a severe phenotype associated with the family’s mtDNA 
mutation that requires both of Wendy’s parents to care for them. The impact that 
her sibling’s disability has had on both her and her husband’s consideration of 
their options has led them to feel that they ‘would rather not have a child, than 
have a child that’s … severely disabled like my [sibling]’ (Wendy: 279-280). This 
strong desire to avoid having an affected child is in correlation with experiences 
of siblings with X-linked genetic disorders reported by (Kay & Kingston, 2002).  
For Wendy it was important for her to tell her husband Mark of the possibility that 
she may also carry a mtDNA mutation before they were engaged. Although she 
had not wanted to take a genetic test to find out previously, she would have taken 
the test if Mark had wanted her to ‘I offered to have the test (0.2) before before 
you’d even proposed to me and you were like “I don’t care it doesn’t matter”’ 
(Wendy: 179-180). As discussed briefly in Chapter 5, Wendy had delayed 
undergoing a genetic test to find out if she too was affected by the family’s 
mtDNA mutation for a number of years. The decision to have the test was as a 
result of her and Mark’s discussions about having a family and how they wanted 
to know in advance Wendy’s mtDNA mutation load. Upon receiving her result, 
Wendy and Mark considered Wendy’s siblings quality of life, utilising their lived 
experience of mitochondrial disease. As a result of these considerations the 
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couple opted to seek guidance on PGD initially and then mitochondrial donation, 
with their preferred option being mitochondrial donation (Chapter 7). Both of 
these options would therefore allow for Wendy and Mark to modify the risk of 
having an affected child.   
Awareness of the impact of mitochondrial disease could also impact on the 
reproductive decisions in other ways. For example, Lesley had grown up knowing 
that both her parents were ill, she attributes this firstly to the ages her mother and 
father were when she was born, describing her mother as ‘in her forties’. Later 
she describes how her mother had started to experience serious health 
complications whilst she was still at school, including deafness, seizure episodes 
and dementia by the time Lesley was in her early twenties. For Lesley her older 
sister was ‘more like wa mam than what my mam was actually like’ (Lesley: 234). 
As a result of this lived experience of her families ill health Lesley decided, prior 
to any knowledge of the genetic condition, at an early age that if she were to 
have a family that she had to have a child before twenty six:  
Lesley: No, no had me reasons  
Int:  Is that related? 
Lesley: Yeah 
Int:  To the diagnosis? 
Lesley: Erm even before that going back to when I was young all I 
can remember is illness … I always said that if I didn't have a 
child by twenty six year old I’l never ever have a family and 
that’s the way it worked out (Lesley: 211-214)  
 
This was in order to reduce the chance that she too would become an ill parent, 
like her mother. Fortunately for Lesley she had a child by this age who was also 
the gender that she had always wanted and her husband was also in agreement 
that one child was enough for their family.  
Lesley and her family believe that her mother’s declining health over decades 
and early death was attributed to the severe phenotype associated with their 
family’s mtDNA mutation, although they were unable to confirm this with any 
genetic testing. For Lesley becoming pregnant at an age that would allow her to 
parent without illness can been seen as central to shaping her and her partners 
reproductive decision making. She had initially decided this course of action prior 
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to the diagnosis of mitochondrial disease within the family, so her reasoning at 
that time point, was only informed by her lived experience.  
Mandy had also experienced family ill health relating to her families then 
undiagnosed mitochondrial mutation. Mandy’s mother was diagnosed when 
undergoing screening for a multi organ transplant, which was later found out to 
be have been a requirement due to her mtDNA mutation. Subsequently the rest 
of her maternal family was diagnosed, including aunts, uncles and her older 
sibling. When discussing factors that have influenced Mandy’s reproductive 
decisions she tells us that: 
it kinda was in the way that I wouldn’t like to put my child through two 
transplants like what my mum has been through do you know what I mean 
erm and I wouldn’t like to put them through just generally feeling weak and 
things like that erm (Mandy: 252-255) 
 
Mandy tells us that she is not only concerned that her future child may require 
serious medical interventions as a result of the families mtDNA mutation but that 
she would want to avoid having a child that is affected by general weakness ‘and 
things like that’.  
In addition to her experience of family ill health, uncertainty as to what 
percentage mutation load would result in an affected child confused Mandy, as 
her mother’s organ transplants had prevented clinicians from being able to 
accurately test her percentage mutation load. When discussing how 
mitochondrial disease affects her family Mandy tells us: 
I mean my obviously my mum is more symptomatic than me so you would 
think her percentage would be higher or the same but then again it could 
be lower’ (Mandy: 180-181)  
 
The ambiguity of inheritance risk and the potential that her mother may have a 
percentage mutation load lower than her own but still be symptomatic was a real 
possibility to Mandy. We see that for Mandy both the uncertainty of inheritance 
risk and family experience of ill health are central to her desire to modify risk and 
her preference for mitochondrial donation as a future reproductive option 
(Chapter 7.4.1).   
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For women interviewed their lived experience of mitochondrial disease both 
personal and through family members impacted upon their reproductive decision-
making (Decruyenaere et al., 2007; Dommering et al., 2010; Henneman et al., 
2001; Klitzman et al., 2007; Myring et al., 2011). This experience, alongside 
women’s concerns for their future child (child centred risk) as a result of the 
inability to predict inheritance risk accurately, impacted on their reproductive 
decision-making.  
8.4 Child Centred Risk  
We have seen in Chapter 7, and again above that women considered their future 
child’s health and development as one of the most important factors in their 
reproductive decision-making. Sarah had considered the possibility of having a 
child whose mutation may have manifested in symptoms worse than her own but 
upon receiving advice from an ‘expert’, a regional neurologist, decided to 
continue with trying to become pregnant. When discussing how she made the 
decision to become pregnant following her diagnosis she tells us: 
Sarah:  I just think the world and life is hard enough as it is   
  without proactively making a decision to bring a child into  
  the world that is going to suffer 
Int:  yeah 
Sarah: or is going to have problem (Sarah: 619-622) 
 
Sarah believes that life is hard enough for what can be presumed as the ‘average 
person’. Knowingly deciding to have a child who was going to ‘suffer’ or have 
‘problems’ was not something that she would have wanted to do. For Sarah is 
was important for her child to be as healthy as possible.  
As described in Chapter 7 section 7.3, women also considered the wellbeing of 
future generations, specifically relating to their daughters - living or imagined - 
who would be faced with reproductive decisions and the possibility of an affected 
child in the future. A number of women interviewed had been politically active in 
voicing their support of mitochondrial donation. For these women, this was in 
relation to not their own reproductive options but that of their female family 
members, predominantly their daughters. Sally was one of these women. At the 
time of Sally’s interview, mitochondrial donation had not yet been discussed in 
parliament and the timeframe for debates relating to the technique were not yet 
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known. However, it was Sally’s wish that mitochondrial donation be approved so 
that her daughters would be able to consider it as an option. When talking about 
how she will have passed on her mtDNA mutation to her children Sally says: 
Sally:  Obviously my … girls will have the gene and will pass it  
  and they have to make choice when they’re older ermm  
  especially with all the … things happening at the   
  moment with the ermm you know the IVF treatment that  
  they are trying to do so erm I definitely keep up to date  
  with that cos   hopefully in another 20 years’ time when  
  my children decide to have it, that might be an option for  
  them    
Int:  OK 
Sally:  I think I know that if I had the option that would make me  
  feel a lot better that I could have that rather   than take the  
  chance and passing the gene on (Sally: 318-325) 
 
Sally has kept ‘up to date’ with the progressing parliamentary campaign, including 
emailing her member of parliament to lobby in favour of the amendment to the 
2008 Human Fertilisation and Embryology Act. Sally supported the new 
technique as she hoped that this would enable her daughters to be given the 
choice, one that she did not have, to prevent them ‘passing the gene on’.  What is 
central to Sally, and others, is preventing further inheritance to subsequent 
generations.  
8.5 Parenting Risk  
Concerns over risk with regards to parenting ability is a factor in establishing 
ones self as a responsible decision maker in Downing (2005) model. With HD, 
the complexities of disease can manifest later in life and possibly after 
childbearing decisions have been made. As we have seen in Chapters 5 and 6, 
the onset of symptoms for some mtDNA mutations is the same, with many 
women interviewed not experiencing symptoms until after they had started or 
completed their families.  
Women with mtDNA mutations also face the same predicament as patients with 
HD in that there is a lack of effective treatments to combat disease progression, 
which can lead to uncertainty regarding future parenting ability. We have seen 
previously in Chapter 7 section 7.4.1 that the risk of passing on her mitochondrial 
mutation was not a concern for Andi, however having a mitochondrial diagnosis 
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did impact on Andi in relation to whether she would be physically able to care for 
the new child, her other children and manage their home ‘so in that way the mito 
affected it’ (Andi: 383).  
Andi experienced combinations of symptoms including chronic fatigue, visual 
disturbances including double vision, peripheral neuropathy and sometimes 
required the use of a walking aid. Andi and her husband discussed together the 
practicalities of having another child in relation to her mitochondrial disease.  
Andi: No it was erm shared but he he did make sure that I wanted 
this because I was the one with the mitochondrial so it was 
going to be hard on me so with [Child Z] I said “yeah it would 
be nice for [them] to have a, with [Child Y] it would be nice 
for [them] to have erm to have a companion but I’m going to 
need a lot of help with this one so if were doing this”, if we’re 
getting pregnant then with another one he has to understand 
that he has got to put more work in  
Int:  Um hu 
Andi:  With me and around the house and everything so and he  
  understood that and he was fine with that  
  (Andi: 354-361)  
 
Central to her decision-making was her husband agreeing to put ‘more work in’ to 
their family, to help her ‘around the home and everything’. She also tells us that 
her elder children were involved in the decision, understanding that they would 
need to help their mum ‘because I couldn’t do it alone (Andi: 380) and so that it 
had been a ‘family decision to have [Child Z]’ (Andi: 381). For Andi, the practical 
support of her immediate family to help her through her pregnancy and raising 
her children in the future was important. For Andi and her family although her 
symptoms were taken into consideration when planning to have another child, 
any future parenting risks were alleviated with the extra input promised by her 
husband and older children. Therefore Andi can be seen to have accepted this 
risk.  
Holly and her partner Edward had also discussed the possible affect that Holly’s 
mtDNA mutation would have on both Holly’s ability to parent in the future as well 
as Edward’s ability to parent alongside, fulfilling the role of carer for Holly. When 
discussing how important it was to them both to have a child who would not be 
affected by a mtDNA mutation Holly tells us that: 
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I certainly wouldn’t want to have a child that would potentially have a 
serious condition based on the fact that I’ve also got, like I’ve, I really 
struggle just every day, like generally, living day to day, without the added 
pressure of having to look after a child who has also got like complex 
needs as well, sort of thing (Holly: 944-950) 
 
Holly was very aware the impact of her mitochondrial disease on her day-to-day 
life and that caring for an affected child with ‘complex needs’ would be added 
pressure and be ‘extremely difficult’ (Holly: 954). In Chapter 7 we also see that 
when considering adoption, Holly discusses adopting an older child who would be 
less demanding than a newborn and may be more suited to their family, given her 
specific disease burden.  
Holly also considers the potential impact of her disease progression on Edward 
and how she would not want him to have to care for her and their child ‘because 
that’s not fair either’ (Holly: 2262-2264). Edward tells us that his parents had 
discussed the issue.  
I think my parents are concerned about having the baby and the pressure 
of it, so having to look after Holly with her condition and then also having a 
baby. So that adds a lot onto me (Edward: 2030-2033)  
 
It is notable that Edward does report his parents being concerned about the 
health of the child. Edwards’s parents are not alone in their concerns for Edward 
looking after Holly and their future child. Holly’s family had also expressed similar 
viewpoints relating to the ‘amount pressure that we will be under’ (Edward: 2037-
2038). It is evident that for both Holly and Edward a key issue to their decision-
making is related to Holly’s future parenting ability and the added ‘pressure’ of 
having a child may exert on them as a couple. Caring for a child with a 
mitochondrial disorder was reported by Read (2003) to be significantly more 
stressful and worrying compared to parents of another rare disease (PKU), with 
mothers experiencing dissatisfaction with social support and having multiple 
impacts on their personal lives. Parenting as a ‘disabled parent’ is of noticeable 
concern for Holly, and draws on the wider social studies of parenthood and 
disability and disabled parents raising children with a disability also (Olsen & 
Clarke, 2003). 
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8.6 Pregnancy Risk   
Pregnancy complications in maternally inherited mitochondrial disease are varied 
and can be very dependent on the phenotype of the expectant mother. The 
majority of the women interviewed had not experienced difficult or traumatic 
births, although certain conditions of pre-eclampsia, appendix rupture, 
emergency caesarean sections, low birth weights of children, periods of 
hospitalisation and early deliveries were reported by women, concurrent with 
reports of pregnancy in mitochondria disease (Say et al., 2011). 
For some women becoming pregnant when also being affected by a mtDNA 
mutation is however an issue. For one woman the potential that she may 
experience severe and possibly life threating complications played a significant 
role in her reproductive decision-making. Holly had been told a number of years 
prior to the interview that her body would be unable to support the additional 
stress of pregnancy, due to symptoms associated with her mtDNA mutation. 
Holly had received this information in a consultation with her mother and before 
meeting her partner Edward, at this appointment Holly was told that she should 
find a surrogate to have a baby in the future. Holly goes in to detail about what 
was said to her during this appointment with a local doctor.  
 Yeah, so that was, that was erm, I’d went to the fertility one at the [local 
 hospital] and then I’d seen like the obstetrician person. Erm, it was my 
 mum that went to that appointment and [they], [they] basically went 
 through it and, and like put the, like the absolute dread into me; the 
 thought of actually carrying a baby. Because [they] said about how the rest 
 of, erm like [organ] problems and there was a whole list of things, was 
 much, much higher  because obviously of having the mitochondrial
 disease, and just the added pressure in your body of carrying 
 another, like carrying a child. Erm, plus the [symptom], I could 
 potentially become [symptom] and [symptom] right through my 
 pregnancy; I might end up having to spend most of it in hospital and it 
 just, it scared the, it really scared me (Holly: 828-239) 
 
For Holly finding out about the considerable risks to her health if she were to fall 
pregnant and carry a baby put the ‘absolute dread’ into her and ‘really scared’ 
her. Holly tells us that because of ‘how much it kind of affected me’ (Holly: 857) 
she was referred to a fertility counsellor, who she had continued to see at the 
time of the interview who had helped her ‘come to terms with the fact that I wasn’t 
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going to be able to carry’ (Holly: 862-863). For Holly, finding out that she would 
have to seek an alternative option to have a child irrespective of inheritance risk 
influenced her reproductive decision-making before she had even met her partner 
Edward. As a result, Holly and Edward were actively seeking advice regarding 
options that would modify risk to both Holly and their future child, this being both 
PGD and surrogacy.  
For Jenny the concern over the potential risk of complications during pregnancy 
was not for herself but for a female relative of hers. When asked if she felt that 
mitochondrial donation may be a suitable to her or her family members in the 
future, Jenny tells us that because of her female relative’s symptoms and how 
they sometimes restrict her to a wheelchair she feels that ‘Erm and you know, 
just, yeah I don’t think it would, I don’t think her body would cope … you know’ 
(Jenny: 252-253). For Jenny she did not feel that her female relative should risk 
becoming pregnant out of concern for her physical wellbeing.  
As we have seen previously, some women do not experience any symptoms of 
their mtDNA mutation, are affected mildly (in their opinion) or who don’t 
experience symptoms until after they have completed their family. However, for 
some women their individual experience of the disease and the complications 
that could potentially arise from a pregnancy do need to be considered when 
assessing their reproductive options, options that modify the risk of pregnancy 
complications would include surrogacy, adoption or voluntary childlessness.  
We see that the factors identified in Downings (2005) model of responsibility in 
relation to awareness of inheritance risk also apply to women with maternally 
inherited mitochondrial disease. I have expanded upon these factors to include 
further detail relating to women’s lived experiences of mitochondrial disease and 
inclusion of pregnancy risk that presents to some women as a result of their 
phenotype. I have shown that these factors either alone or in combination result 
in women defining reproduction as a cause for consideration. I have purposively 
chosen to assign these as ‘cause for consideration’ as opposed to problematic as 
the Downing (2005) model has defined them as we have seen that not all women 
describe them as problematic per se but rather a necessary consideration. I will 
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now continue to outline what I have termed ‘elements of consideration’ and how 
these play a role in the reproductive decisions made by the women interviewed.  
8.7 Elements of Consideration  
Downing (2005) showed that once reproduction was defined as problematic 
participants went on to ‘redefine certain elements of their situation’ (p221). They 
argued that although some factors covering response to risk may be similar, 
responses are not consistent and that the process of redefining reflects elements 
that can be modified, therefore enabling people to tell different stories about risk 
acceptance, avoidance or modification. In her paper Downing (2005) outlines 
these elements as: values; concept of future; perceived social support; risk; self-
relationships and reproduction. Emergent categories from interviews with women 
in this project support the inclusions of some of these elements into the 
mitochondrial specific model, whereas others were found to not be relevant as 
well as being difficult to define from their model and so therefore have not been 
included. In addition to those elements carried over, novel elements discovered 
within the data set have been added. These elements include values 
encompassing religion, inheritance guilt and responsibility and women’s ideas 
and preferences surround reproductive options. I will discuss these each in turn.  
8.7.1 Values  
Women’s values were shown to be a major contributor in reproductive decision-
making. Intrinsic to their values, were women’s ideas and preferences 
surrounding available reproductive options. Chapter 7 showed how preference 
was placed on having a healthy and biologically authentic child, linked to women 
genetically. For the majority of women, mitochondrial donation was the most 
favoured reproductive option, as it enabled not only a genetic link but also 
maximised the opportunity to have a healthy child, either for themselves or for 
other female family members (real or imagined). Mitochondrial donation directly 
tackled the uncertainty of predicting the clinical affectedness of a future child, 
therefore significantly reducing the child-centred risk and feelings of guilt and 
responsibility (see section 8.7.2). 
Other reproductive options that offered certainty in relation to having a child free 
of a mtDNA mutation included ovum/egg donation and adoption were problematic 
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to some women due to the lack of biological link and ideas of bringing up 
‘someone else’s child’, rendering them either a non-option or a last resort. 
Surrogacy for those women who had no reason to consider a potential pregnancy 
risk was primarily discounted, whereas in the one instance whereby pregnancy 
raised the potential of life threating complications, it was seen as an option that 
would permit a genetically related child to be born. Issues pertaining to embodied 
experience of pregnancy and missing out on this experience were raised as a 
potential challenge to be overcome in surrogacy. PGD was often considered as 
an interim option for women and their partners who would have, given the chance 
opted for mitochondrial donation, with many couples believing that PGD still 
presented uncertainty in regards to its ability to reduce child centred risk, the 
‘potential grey zone’. Prenatal testing was in principal discounted by women, with 
women unwilling to take the risk of these procedures and their desire to avoid 
being place in a situation in which they may have to consider the termination of 
an established pregnancy. These accounts were supported by one woman’s 
experiences of how difficult decision-making was when presented with 
information that her unborn child may be affected. Some women reflected on not 
having any children/more children as a way to avoid transmission in both the 
retrospective and current and prospective groups. Although many women 
expressed that fulfilling the mothering role was something they had felt strongly 
about since they were young and therefore complete childlessness was not an 
option   
8.7.2 Guilt and Responsibility  
Notions of guilt and responsibility were present throughout the majority of 
interviews and these radiated out to not only real or imagined children but also to 
other family members. Chapter 6 explored how women had feelings of guilt when 
discussing their children or when faced with telling other family members about 
the diagnosis (see section 6.2.3). Women who deliberately sought to prevent 
their own mothers or grandmothers from feeling maternal guilt chose not to 
disclose that they had a genetic disorder and especially in relation to its maternal 
inheritance. Preventing their own imagined feelings of future guilt led to women 
seeking options that could modify inheritance risk to future children. Women also 
felt responsible to future children to do their best to reduce or prevent inheritance 
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and ill health as well as feeling responsible to disclose to family members ‘at risk’ 
of a mtDNA mutation (Arribas-Ayllon et al., 2011; d’Agincourt-Canning, 2001; 
d’Agincourt-Canning, 2006; Dimond, 2013; Hallowell et al., 2003; Novas & Rose, 
2000). The realisation that their genetic disorder was passed down from mothers 
magnified these feelings.  
For the women in the retrospective group who received their diagnosis after their 
children were born, they described feelings of guilt towards known affected 
children but also towards children whose risk of affectedness was unknown. They 
described feeling almost immediate guilt when initially learning about the 
inheritance pathway. For example, Sally’s youngest child was diagnosed after 
almost two years of investigations at district and regional hospitals. Sally had 
assumed the visit when  she found about her child’s diagnosis was going to be 
yet another appointment where they were told the cause was still unknown. 
cos we weren’t expecting it erm but at first when he said that he had found 
it and that it’s came from me I felt really guilty and responsible for [Child 
Z’s] conditions straight away, as soon as I came out of the room I was just 
in tears for a few days afterwards (Sally: 82-84)  
 
For Sally, discovering that her child’s problems had ‘came from’ her, led to an 
immediate emotional response. Sally’s mother echoed her daughter’s feelings 
later that same day.  
my mum (0.2) didn’t really take it on board until she got home but then she 
rang me a few hours later to say that she had been crying, upset because 
now she feels that now she is responsible (Sally:147-148)  
 
Sally’s mother had been looking after her other children whilst she attended the 
consultation with her husband. In this way, each generation felt guilt and 
responsibility towards the next generation.  
Sally also felt the burden of responsibility towards her other two children who at 
the time of the interview showed no signs or symptoms, describing feeling ‘really 
concerned’, ‘really responsible’ and ‘I didn’t feel good at all’ (Sally: 89). Clearly, 
she cannot change her past, but she can take responsibility for future actions. For 
Sally these feelings where central in her considerations around having more 
children.  
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Cos I did feel that immense guilt and I think that I would carry that on again 
if I had more children (Sally: 187-188)  
 
Receiving her child’s and her own diagnosis had ‘put her off’ thinking of having 
more children. Given her new knowledge, she now felt responsible to minimise 
the potential suffering of future generations. In this way, a desire to avoid any 
potential complications for future generations resulted in her avoiding this risk 
and believing, at the time of the interview, that she would have no future children.  
For Sally it was also important at the time of finding out about the inheritance 
pattern that she disclosed her and her child’s mtDNA mutation to her family as 
she felt ‘I had this responsibility to tell the family’ (Sally: 121). This disclosure to 
the family included a female sibling and cousins. Interestingly within Sally’s family 
her maternal uncle had been diagnosed with a mtDNA mutation many years 
beforehand.  
 
Yeah but I felt responsible again because I got to erm tell my family 
because because obviously my uncle has got this disease and we didn’t 
know about it, he’s had it for about [XX-XX] years (Sally: 115-116)  
 
Unlike in other families in this study, Sally’s uncle had known the reason why he 
had lost his vision after receiving a diagnosis of mitochondrial disease about the 
time when Sally would have been a teenager. Sally felt frustrated by this prior 
family knowledge because she felt that had she known her child could have 
received care sooner as opposed to taking over two years to be diagnosed. She 
also felt that through telling others in the family, they could then also have been 
tested or been able to seek an explanation for why they or their children might be 
unwell. It was important to Sally that this silence, the lack of collective knowledge 
about the condition, did not continue within the family.   
We have seen in Chapter 7 and above that Jenny would not have had children 
had she been aware of her mtDNA mutation because of the risk relating to 
affectedness to a child. Jenny had had a child before her diagnosis and she 
describes very emotionally throughout the interview the feelings she experienced 
when she was first told of the inheritance pathway ‘absolutely horrendous the 
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guilt’ (Jenny: 55-56). When discussing how she had told others about feeling this 
way Jenny tells us through tears that:  
 Jenny:  you sort of say you feel guilty, but you told that   
   ridiculous cause like yeah it’s ridiculous [inaudible]  
 Int:  Yeah 
 Jenny: It’s crazy yeah, you know, I mean I know (0.2) it’s  
   not me fault (Jenny) 323 
 Int:  Yeah 
 Jenny: But it’s still there (0.4) yeah (Jenny: 319-327) 
 
She still feels this guilt, which she knows, in rational terms, is ‘ridiculous’, even 
after more than a decade since her and her child’s diagnosis. Jenny talks 
throughout her interview as acting as an advocate for her child as they have 
grown to become an adult. As we have seen in Chapter 6, Jenny still feels that 
what was lacking throughout both her and her child’s diagnostic process was 
access to appropriate counselling services that could help her come to terms with 
the diagnosis and the feelings of guilt she suffers from.  
For women in the current and prospective group, they considered the potential 
health of their future child and for them to be as healthy as possible. As we have 
seen in Chapter 7 (section 7.4.2), Ashley and her husband were actively 
considering ovum donation as an option to have another child at the time of the 
interview. They had made this decision after finding out that they would not be 
suitable candidates for PGD or mitochondrial donation. For some time before 
seeking interventional reproductive options she and her husband had tried to 
conceive without medical intervention, over time this was no longer an option. 
When discussing why this was the case Ashley says that:  
I don’t want to bear the responsibility of having a child that is getting really 
sick, either as a child or later on in life depending on how severe it is 
(Ashley: 126-128) 
 
Specifically for Ashley her decision to no longer continue with ‘natural’ conception 
was driven by the feeling that she no longer wanted to risk bearing the 
responsibility for an ill child or a child who may grow up to have complications 
later in life. A key issue for Ashley was to avoid this responsibility and to try to 
reduce the probability that she would have an affected child. This resulted in her 
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seeking to modify her risk by actively inquiring about interventional reproductive 
options.  
For some women interviewed they were worried about how their own mothers or 
grandmothers may have felt when receiving the news of the maternal inheritance 
pathway. They were worrying that they may feel the burden of guilt that Sally’s 
mother had. To prevent their mothers or grandmothers from feeling they were 
somehow to blame for their or other family members symptoms, some families 
had collectively agreed to not disclose the news of a genetic condition, especially 
that it was maternally inherited, to their mothers or grandmothers, raised earlier in 
section 6.2.3. This decision to not disclose this information seems to be led by 
the women’s own feelings of guilt towards their own children, even if they did not 
know if their children were affected. This was further complicated by the 
ambiguity as to whether their mothers or grandmothers were affected, reporting 
that some of these women were in good health. There was also the potential that 
their mtDNA mutation may have been sporadic (Gorman et al., 2015) and had not 
originated in their mothers or grandmothers, such that disclosure could therefore 
cause unnecessary suffering. 
As we have seen in Chapter 5, Joanna had received her diagnosis via her mother 
who had a complex medical history (section 5.5). Joanna’s mother had made the 
decision to not tell her own mother, Joanna’s grandmother, about their mtDNA 
mutation or the maternal inheritance pathway. When asked if there was anyone 
that Joanna had not told about her diagnosis she tells us that her grandmother 
did not know and that this had been because:  
Erm she, you know my mum didn’t want her to blame (0.2) to blame 
herself but now they say they think that it just started in my mum anyway 
not from my grandma (Joanna: 137-138) 
 
Joanna’s mother was herself struggling with the knowledge of inheritance and 
was often ‘really emotional about it cos she blames herself’ (Joanna: 91). Joanna 
herself found it quite hard to ‘talk to my mum about it because (0.2) she feels like 
it’s her fault’ (Joanna: 96). Joanna therefore avoids talking about inheritance to 
prevent her mother from feeling ‘terrible’ or as if it were ‘her fault’ because the 
inheritance of their mtDNA mutation is ‘just one of them things’ (Joanna: 99). 
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What was central to Joanna and her mother was avoiding situations where their 
own mothers may feel guilt or blame themselves for the inheritance of their 
mtDNA mutation.  
Maggie describes her mother being aware that she and her siblings were all 
unwell in similar ways and that she believed her mother may have thought it was 
a genetic condition but that she may be in ‘denial’ or may think that their 
symptoms may have come from either her or Maggie’s father.  
Maggie struggled with the idea of telling her mother that her symptoms were 
likely to have been inherited from her, she therefore decided to not tell her 
mother.  
 Maggie: It, it would only be something else for her to worry  
   about. 
 Int:  Worry about.  
Maggie: And have the guilt to think that she’s passed it on to 
her [X children], and that in turn that has been passed 
onto all of her grandchildren (Maggie: 1127-1134) 
 
For Maggie she did not feel that her mother knowing about her mtDNA mutation 
would be of any ‘benefit’ to her and that this would only cause feelings of guilt for 
passing on the mutation to Maggie, her siblings as well as her grandchildren. 
Maggie also struggled with disclosing inheritance to a cousin who would be at 
risk along with her children. When discussing who Maggie has discussed her 
diagnosis with she tells us that she was slightly hesitant in discussing her 
diagnosis and inheritance pathway with a cousin. 
But I was sort of thinking my [cousin] got [X] kids, and I thought it’s a 
horrible thing to have to tell her if she’s got it, that she’s going to have the 
same horrible feelings as I’ve got, that she might have passed it onto her 
kids as well (Maggie: 1040-1043) 
 
Maggie was also concerned that telling her cousin would induce the same 
feelings of guilt that she had on to another person who also had children who 
were potentially at risk. What was central to Maggie was trying to prevent 
unnecessary feelings of guilt where possible but also being responsible to inform 
other family members of the potential risk.  
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Zoe was diagnosed via her older sibling, they were both teenagers at the time of 
their diagnosis. At the time Zoe was concerned about what her diagnosis meant 
for her in the future but has remained asymptomatic. Her sibling struggled with 
many aspects of their diagnosis, where symptoms had resulted in the loss of their 
job, driving licence, social life and independence. Zoe described them as feeling 
‘devastated, absolutely devastated cause I think at the time [they] felt that [their] 
life had been took away from [them]’ (Zoe: 38-39). Zoe believes that for some 
time after her sibling’s diagnosis they felt ‘resentment’ toward their mother and 
that ‘l think [they] blamed me mam like a little’ (Zoe: 48-49). This period of time 
was especially difficult for Zoe’s whole immediate and extended family and that 
her mother ‘was absolutely devastated [by the diagnosis] cause they didn’t know’ 
(Zoe: 77-78). Interestingly Zoe’s maternal uncle was also affected by the family’s 
mtDNA mutation prior to her diagnosis, similar to Sally, but Zoe’s uncle had never 
received a diagnosis or explanation as to why he too experienced the same 
symptoms as Zoe’s sibling. Like Sally, Zoe’s mother struggled with knowing that 
the diagnosis was maternally inherited and felt a responsibility to tell her wider 
family, who along with their children may be at risk of the family mtDNA mutation. 
Zoe’s account of her sibling’s initial reactions to their diagnosis is the only 
account in the study of a ‘child’ being perceived as ‘blaming’ their mother for the 
inheritance of their mtDNA mutation.  
All of the women who discussed their mothers described how they did not blame 
their mothers and how they wanted to prevent their mothers from feeling any guilt 
for the transmission, but that they had feelings of guilt towards their children. Only 
one woman described not having any feelings of guilt towards her children ‘I don’t 
feel guilty if my kids get it off me’ (Andi: 117), as Andi believes that if her children 
were meant to inherit her mtDNA mutation there was nothing that could be done 
other than to care for them and look after them as best as possible (see section 
7.2)  
We see that a large proportion of women feel a sense of guilt when thinking 
about their children irrespective of whether they were known to be affected or not. 
For those women in the current and prospective group they felt a sense of 
responsibility to prevent transmitting their mtDNA mutation to future children. 
Women also felt a combination of responsibility to tell other family members who 
 227 
 
may be at risk as well as hesitancy or avoidance regarding the disclosure of the 
maternal inheritance of their mtDNA mutation. 
8.7.3 Religion   
All women were asked at the start of the interviews whether they followed a 
particular faith, in most circumstance women replied that they had been raised in 
a certain religion, christened or baptised for example but that they did not class 
themselves as religious. Three women within the study however answer that they 
had a faith, whilst one woman said she was not religious but believed there was a 
‘bigger force’. We see in Chapter 7 that Andi’s religious beliefs impacted directly 
on how she both perceived inheritance risk and opinions of reproductive 
techniques including IVF technologies.   
For Andi her beliefs affect ‘all my decisions’ (Andi: 675). When discussing how 
she and her husband considered future risk to their child and if they were to be 
affected by inheriting her mtDNA mutation, she tells us that: 
religion affected it in that way, we don’t, we would never have gone aw 
“I’ve got this illness, I can’t, I’m going to stop now” (Andi: 698-690) 
 
For Andi her religious views meant that she could accept and support any future 
children who were affected by a mtDNA mutation and that ‘religions affected it 
more than science [laughter]’ (Andi: 699). For her and her husband, faith was the 
central mediator through which they made sense of their life. For them, this 
meant that they accepted the potential risk and continued to add to their family 
without engaging in interventional reproductive options. Rapp (1998) reports that 
women with strong religious affiliations (as well as strong kinship and social 
communities) were ‘most likely to decide against the biomedical information’ 
provided by prenatal testing in their consideration of accepting or rejecting a 
pregnancy with known serious fetal abnormality (p67).    
For the two women that described themselves as religious at the start of the 
interview they did not describe their faith as a mediator to their reproductive 
decision-making or their ideas or preferences of reproductive options. For Alice 
who believed in ‘something greater’ she spoke of her beliefs with regards to her 
and her husbands struggle with infertility and that perhaps she was not meant to 
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have children, to prevent having any affected children and from passing on her 
mtDNA mutation. When discussing how there were no younger females in her 
family who would be at risk of passing on the family’s mtDNA mutation Alice tells 
us that: 
Alice:  This is the other thing I find funny. 
Int:  Right. 
Alice:  Because it’s a maternal link and what you were saying  
  about before, “Are you religious and do you believe in  
  anything?” I’ve got [female family members] who’ve been  
  diagnosed and they’ve got [X] sons  
Int:  Yeah. 
Alice:  The mitochondrial disorder …and I don’t    
  have any children, so it’s stopped. 
Int:  Yeah. 
Alice:  It’s stopped now. 
Int:  It’s all stopped now. 
Alice:  Hmmhmm. Isn’t that funny? 
Int:  Yeah. 
Alice:   Hmm (Alice: 1276-1298) 
 
Alice tells us that all the females at-risk of passing on their mitochondrial disease 
in their family had had sons who would not transmit the disorder to their offspring 
(but may still experience symptoms themselves). Alice finds it funny that this in 
combination with her being unable to have children has meant that their family 
mutation is no longer a risk to future generations, ‘its stopped now’. Alice talks 
about this as fate through the interview and it seems to have provided a 
comforting explanation of her and her husbands infertility and is supported by 
Tennen et al (1991) who showed that attributing an existential reason for infertility 
helped women make sense of ‘what might otherwise seem like meaningless 
victimisation’ (p110). 
8.8 Establishing a ‘Responsible’ Viewpoint  
We have seen above how women or women and their partners reach a position 
that Downing (2005) states as a responsible decision maker, where women or 
couples have assessed all of the necessary factors and elements that apply to 
them. When women or couples have reached this stage they can then be seen to 
make a reproductive decision, which centres on accepting, modifying or avoiding 
risk. For those who can be seen to accept risk, they continue with planning or 
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adding to their family without engaging in interventional reproductive options, 
conceiving ‘naturally’. For women that want to avoid risk, they opt to avoid 
becoming pregnant or to have no future pregnancies. Those women who want to 
modify risk are seen to seek information on or have already started the process 
of engaging with options that allow for risk to be modified such as egg donation, 
surrogacy, PGD and mitochondrial donation. However, not specifically explored 
in the model presented by Downing (2005) was the temporality of reproductive 
decisions, I will therefore explore how change over time was important in the lives 
of women in this study in relation to their reproductive decision-making and how 
this was incorporated into the proposed conceptual model.  
8.9 Change Over Time  
The notion of time and change over time in relation to reproductive decision-
making has been explored in other genetic disorders as well as in consideration 
of PGD as a reproductive option. Hershberger et al's (2012) model of decision-
making in couples considering PGD described a decision type entitled oscillating, 
whereby couples where neither for or against PGD. Whilst Myring et al (2011) 
described decision making as dynamic and not fixed in CF. Dommering et al 
(2010) reported that parents of children whose treatment for retinoblastoma had 
ended no longer wished to avoid having more children. For some women in this 
study, change over time was an important influencer of their perception of risk 
and subsequent reproductive decision-making, and has been presented in the 
conceptual model as time point two (T2). The altered perception of risk meant 
that women could be seen to return back to the stage in the model where 
reproduction was defined as a cause for consideration. Using this new 
information alongside existing factors and elements women reached a new 
viewpoint regarding risk and acted according to this new perception of risk. This 
new information was either in relation to a family experience or a change in 
personal circumstances. Family experiences ranged from witnessing the impact 
of progressing disease burden or suffering the loss of a family member due to 
their mitochondrial disease. Changes in personal circumstances seen in the 
study included, women being made aware of new reproductive options, becoming 
pregnant unexpectantly or a relationship change that saw them view their prior 
options differently.  
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We have seen previously in Chapter 7, section 4.1 that Liza considered herself 
naive when she fell pregnant with her first child after she and a number of her 
family members were diagnosed with a mtDNA mutation. During the time of 
planning her first pregnancy Liza can be seen to have considered the potential 
child centred risks to a future child. Liza relied on her lived experience (Kelly, 
2009) and experiential knowledge (Boardman, 2017) of the possible symptoms of 
which a future child may be at-risk of. Within her family these had included 
deafness, diabetes or gastrointestinal symptoms. For Liza she believed that she 
and society were able to accommodate these symptoms fairly easily. Liza 
conceived her first child ‘naturally’ and turned down prenatal testing. However 
Liza’s perception of child- centred risk changed after her mother died from 
complications associated with a severe phenotype of their mtDNA mutation. 
When telling us about how her view of risk changed after the death of her mother, 
Liza tells us that:  
Erm and I say it was when my mam died that aw hold on a second I 
maybe should be taking more interest in this and what’s going on, erm I 
know my mam was very poorly with it but I never expected her to die kind 
of (Liza: 105-107)  
 
For Liza the death of her mother made her stop and consider what having a 
mtDNA mutation may result in, she had known her mother was very unwell but 
‘never’ expected her to die as a result of the mutation. Following her mother’s 
death Liza started to learn more about inheritance risk ‘so it was from that point 
really that I started to get involved with it’ (Liza: 109). We’ve seen in section 7.3.2 
that Liza and her husband went on to explore PGD as their preferred option 
followed by prenatal testing when denied access due to NHS funding criteria. 
Liza can be seen to have received new information that alerted her perception of 
risk resulting in her and her husband seeking ways in which to modify risk by 
engaging in interventional reproductive options.  
Ashley acts in a similar way upon receiving new information, in her case this was 
the declining health of her sibling who had been diagnosed at the same time as 
her, just a number of weeks before the death of their mother. Ashley’s mothers 
health had declined over 20 years with symptoms classically associated with their 
mtDNA mutation, later going onto to develop the severe phenotype associated 
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with the mutation. Ashley tells us that she is ‘pretty much alright’ (Ashley: 44-45) 
but also that she handles the symptoms and hopes for the best. At the time of her 
diagnosis Ashley did not live in the UK and received her result and information 
about inheritance from mitochondrial experts in two separate countries. Ashley 
and her husband had had their first child before becoming aware of her 
diagnosis, which she tells us was not easy, she had undergone a period of time 
on hormone injections, eventually conceiving her child after these interventions 
had ended. As we have seen in section 7.4.1, Ashley and her husband had been 
trying for a child naturally for ‘quite some time now’ (Ashley: 123-124) they could 
be seen to have considered risk and had chosen to accept risk by conceiving 
naturally. 
However Ashley tells us that ‘it changed over time and I got more scared’ 
(Ashley: 162-163) and that she was no longer willing to take the risk of having a 
potentially sick child.  Ashley tells us that this was because she has ‘more time to 
think about it and seeing my sibling suffering’ (Ashley: 166). Ashley’s sibling 
experienced symptoms before they were diagnosed which were first identified 
when undergoing a medical examination as part of a job application, she also 
described them as suffering from short stature and mild learning disabilities. Over 
time they have experienced increased complications involving major organs and 
they have required intense and invasive medical treatments, she described them 
as ‘really badly affected’ (Ashley: 35) and ‘very severely ill’ (Ashley: 50). This new 
information altered Ashley’s perception of risk and as a result she and her 
husband chose to prevent the chance of conceiving naturally by starting 
contraception and by actively seeking ways in which to modify their risk. 
Specifically enquiring about mitochondrial donation, PGD and ovum donation.  
For Zoe her perception of risk changed when she and her husband saw on 
breakfast telly one morning that there was a new IVF technique approved that 
could prevent the transmission of mitochondrial disease. When telling us about 
how she had first heard about mitochondrial donation Zoe tells us that  
so that’s when me and my husband had seen, it was about a year and half 
ago I think or year, last year and we’d seen it on breakfast telly erm and 
that when we thought here’s our chance, so it was like someone giving 
you a chance for something (Zoe: 100-103) 
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Zoe describes how finding out about mitochondrial donation was like being 
offered a chance, the chance to have a child who may not be affected. Prior to 
finding out about the ‘3 parent family thing’ (Zoe: 118) Zoe had avoided becoming 
pregnant and had been practicing temporary childlessness to avoid the risk that 
she may have a child who could be affected like her sibling. When telling us 
about the potential risk to a future child she tells us that: 
its not definite that they could… get it but there is a chance that they will 
you know and I, for me, its been hard to know that you want a family and 
physically able you can have a family but you’ve got that bit that pulls you 
back that says no (Zoe: 100-103) 
 
For Zoe she had spent many years wanting to start a family with her husband but 
even with ‘expert’ advice regarding inheritance risk and knowing that ‘it’s not 
definite’ that a child would be affected she had felt that something had pulled her 
back. During this time Zoe had assessed both factual and lived awareness of risk 
and can been seen to have chosen to avoid it, by actively preventing becoming 
pregnant. The new information for Zoe that led to alter her perception of risk was 
learning about mitochondrial donation, which had led to Zoe and her husband 
actively seeking advice on reproductive options that would modify the risk to a 
future child, specifically mitochondrial donation. 
To further test the conceptual model for rigour after its development in relation to 
change over time, an amendment was made to the study protocol which allowed 
for those women who had been interviewed in the current and prospective group 
to be approached to take part in a follow up interview (see Chapter 4 section 
4.3.5). Four women were approached; two women took part in a follow up 
interview. In both of these cases women had experienced a change in personal 
circumstances that had led to a change in reproductive decision-making.  
At the time of her first interview Emma was unsure if she wanted to have children 
‘I don’t know in the future as to whether I whether I will want them’ (Emma: 169), 
but that she and her previous partner had had been given brief advice about their 
reproductive options when they were considering starting a family. At the time of 
her initial interview Emma’s reasonings for potentially not having children was 
based on other factors including at the time the relationship she was in, ‘it’s not 
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something were looking at’ (Emma: 189) and ‘no it’s nothing to do with 
mitochondrial diagnosis’ (Emma: 192). Emma took part in the follow up interview, 
which centred on asking women if anything had changed with regards to their 
reproductive journeys since their previous interview. Emma responded that she 
was currently pregnant and in a new relationship. After congratulating her on the 
news Emma tells us immediately that:  
Emma: But no we went ahead naturally, we didn’t take up any  
  of the options that were offered by the clinic, erm again  
  we kind of looked at it before we made a decision and  
  erm we were quite happy that we should go ahead   
  naturally. We met up with the [mitochondrial specialist]  
  from the clinic and sought some advice about that 
Int:   Was that Dr X was it?  
Emma:  Yeah, yeah  
Int:   Aw wow, that’s brilliant, so did you were your kinds of   
  discussions were they brief or did you go into any depth  
  or  
Emma:  Erm no I think we did go into quite a bit of depth  
  (Emma repeat interview: 11-19) 
 
Before becoming pregnant, Emma and her new partner had contacted her 
mitochondrial specialist team, where they had an in-depth discussion about the 
reproductive options that were available to them. Emma was very aware of 
mitochondrial donation via the previous parliamentary campaigns. Emma and her 
partner ‘looked at it’ before making any decision and after considering their 
position they decided that they were happy with the information provided to them 
and opted to conceive naturally without any intervention. For Emma she tells us 
that she was ‘aware of everything that [the clinic] could do and I’ve spoken to 
them quite a few times since erm to make sure everything is OK’ (Emma: 27-29). 
Emma recalls being offered prenatal testing but like many women in the study 
declined this ‘on balance’ and that they did not think it ‘necessary’. Emma has 
been offered additional care during her pregnancy from the mitochondrial 
specialist team but declined as she was already being monitored more closely for 
a condition that she describes as being linked to increased risk of other 
chromosomal abnormalities. Emma is relatively confident that this issue will right 
itself and she will be discharged back to standard pre-natal care. For Emma her 
change in personal circumstance has resulted in a change to her reproductive 
 234 
 
decision-making, whereby she and her partner can be seen to have considered 
factual awareness and the reproductive options available to them and reached a 
viewpoint, which can been seen as accepting risk and conceiving their child 
without medical intervention.  
8.10 Summary   
Data presented in this chapter supports the proposed conceptual model of 
reproductive decision-making in maternally inherited mitochondrial disorders. The 
decision-making model shows that for many women their lived experience of 
mitochondrial disease precedes their awareness of inheritance risk, be it personal 
or via a family member (T0). These experiences can be influential in women’s 
assessment of risk including most commonly child centred risk and in some 
cases relating to parenting ability. Upon receiving a diagnosis, women are 
informed that their disorder is maternally inherited and that due to complexities of 
mitochondrial inheritance there is an unknown and difficult to predict risk to their 
current or future children. Women seek and receive information from a number of 
sources that can aid in the decision-making, with information from mitochondrial 
specialists being a trusted source of information relating to an individual’s 
inheritance risk. Social communities including those made via charitable, political 
and online connections can be helpful to women as a source of information, 
whereas other women believe more could be done to represent the spectrum of 
mitochondrial disease and provide more information on on-going research.   
Risks to a future child’s health, risks surrounding future parenting ability and for 
some women potential risk of pregnancy are influential factors, alongside factual 
and lived awareness, that can see reproduction defined as a cause for 
consideration. Additional elements of consideration for women include their 
individual preference for reproductive options, their thoughts of guilt and 
responsibility in the context of a maternally inherited genetic disorder and for 
some their religious beliefs. These factors and elements allow for women to 
establish themselves as a responsible decision-maker, whereby they reach a 
decision to accept, modify or avoid risks. Acceptance of risk can be seen as 
continuing to have a child without engaging in interventional reproductive options, 
modification of risk included women or couples that chose to engage with an 
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interventional reproductive option and those who wish to avoid risk are those who 
would choose to have no future pregnancies.  
The proposed conceptual model also takes into account the temporal nature of 
decision-making, accounting for change over time. The model accommodates the 
change in personal circumstances for women and their experiences of 
mitochondrial disease that can alter their perception of risk. This altered risk 
perception can then lead women acting/consider acting differently to their 
previous choice of accept, modify or avoid risk.  
Through robust investigation of women’s retrospective and current and 
prospective accounts of decision-making the proposed conceptual model is able 
to support discussions of reproductive decision-making with women and 
specialist clinicians, offering visual representation of the factors and elements 
that have been considered by a subsection of women with mtDNA mutations. The 
implications, strengths and limitations of the study and future evaluation of model 
are discussed further in Chapter 9.
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Chapter 9. Discussion, Recommendations and Conclusion 
 
9.1 Introduction 
This study sought to understand the process of reproductive decision-making in 
maternally inherited mitochondrial disease, but also revealed the broader 
experiences of uncertainty faced by women with mtDNA mutations. Existing 
literature is dominated by ideas around the biomedical uncertainty of predicting 
the risk of transmission of mtDNA mutations, whilst the broader experience of 
social uncertainty in reproductive decision-making is under represented. In 
addition to this there is scarce empirical research exploring patients’ experiences 
of living with mitochondrial disease and of women’s experiences of reproductive 
decision-making. 
Primary objectives of this study included exploring women’s experiences of living 
with a diagnosis of maternally inherited mitochondrial disease, their knowledge 
about the risk of transmission, genetic testing and reproductive options, the 
impact of health professionals on the process of reproductive decision-making 
and their information needs. The primary outcome of this study was to inform the 
development of a patient pathway and provide a conceptual model of decision-
making to support discussions of reproduction with women with maternally 
inherited mitochondrial disease.  
This chapter brings together the findings from the empirical chapters presented in 
this thesis, by summarising the key issues and outlining the implications for 
women with maternally inherited mitochondrial disorders, clinicians and the 
broader social science literature. I will examine these findings in relation to the 
study objectives, existing literature and highlight the unique contribution that this 
thesis offers. I will critically assess the limitations of the study, reflect on its 
strengths and conclude with recommendations for future research and the clinic.  
9.2 Main Findings  
This thesis shows that uncertainty is fundamental to the experiences of women 
with mtDNA mutations, manifesting in personal accounts of their condition and in 
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reproductive decision-making. It demonstrates how reproductive decision-making 
is necessarily social and advocates for a more sociological understanding of 
uncertainty within the reproductive advice clinic. In taking this approach I have 
adapted an existing sociological conceptual model, developed in HD  by Downing 
(2005) to develop the first disease-specific conceptual model of reproductive 
decision-making in maternally inherited mitochondrial disease. This model 
includes influential factors and elements of reproductive decision-making specific 
to women interviewed in the study, but which may also be applicable to decision-
making for women with nDNA mutations.   
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Figure 9.1 Conceptual Model of Reproductive Decision Making In Maternally Inherited Mitochondrial Disease (adapted from 
Downing (2005))
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9.3 Implications for Women with mtDNA Mutations   
This study used qualitative interviews to investigate women’s experiences of 
reproductive decision-making and included women who had already made 
reproductive decisions and those currently or prospectively making reproductive 
decisions. This thesis was particular centred on understanding reproductive 
decision-making from women’s perspectives, but it highlighted that uncertainty as 
a predominant feature in the lives of women with mtDNA mutations. I therefore 
divide this section into implications of this study for women on their reproductive 
decision-making and the wider social implications of mitochondrial disease.  
9.3.1 Reproductive Decision-Making  
Reproductive decision-making in maternally inherited mitochondrial disease is 
commonly reported as complex and reported in relation to the inability for 
clinicians to predicted inheritance risk to a future child (Poulton et al, 2017; 
Thorburn and Dahl, 2001; Smeets et al., 2015; Nesbitt et al., 2014; Poulton et al., 
2010; Gorman et al., 2016; Vento and Pappa, 2013; White et al., 1999; Craven et 
al., 2017). As a result, providing genetic counselling to this group of women and 
their partners (if applicable) is difficult (Vento and Pappa, 2013) and can also 
result in distress experienced by clinicians (Bredenoord et al., 2010). Supporting 
women with mtDNA mutations in making reproductive decisions has been at the 
centre of discussions surrounding their reproductive options.  
The conceptual model illustrates the factors and elements that are considered by 
women in this study, either in isolation or in combination. It provides a tool to 
assist clinicians in discussions with women to comprehensively explore decision-
making in the face of uncertainty. The conceptual model enables discussions 
around women’s lived and factual experience of mitochondrial disease, their 
concerns over child-centred risk, pregnancy risk and risks surrounding their ability 
to parent with respect to their own disease burden, women’s values and the 
possibility of change over time in relation to their risk perception.  
The model builds upon Downing's (2005) model of responsible decision-making 
in HD, by highlighting that lived experience of mitochondrial disease can be a 
personal experience of ill health or experienced via an affected family member(s).  
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For some women this lived experience is translated in to experiential or 
empathetic knowledge, which directly informs their reproductive decision-making, 
supporting Boardman who writes about experiential and empathetic knowledge 
and their role in decision-making in spinal muscular atrophy (SMA) (Boardman, 
2017; Boardman et al., 2017). 
The primary concern expressed by women was uncertainty with regards to the 
potential affectedness of a future child, with many women fearing that their future 
child may be more affected than themselves. Women feared that their child may 
be affected in similar ways to that of their affected family member or like those 
individuals they had seen as a result of their own information seeking activities. 
This particular concern surrounding the unpredictability of affectedness is directly 
related to complexities of mtDNA mutations. In contrast, Mendelian genetic 
disorders are able to predict probabilities of affected, carrier and unaffected, 
although the retention of these probabilities is not always accurate (Hallowell et 
al., 1997; Parsons & Clarke, 1993; Sivell et al., 2008). It is important to note that 
some X-linked conditions can affect carriers mildly, due to the deactivation of one 
of the X chromosomes (Puck & Willard, 1998).  
Although less common, some women were concerned about their future 
parenting ability, with these women considering their disease burden currently 
and in the future. Although understanding of the natural history of mtDNA 
mutations has greatly increased in recent years (Nesbitt et al., 2013; Mancuso et 
al., 2015; Gorman et al., 2016) and recent developments in the identification of 
potential therapeutic targets (Gorman et al., 2016; Parikh et al., 2009), uncertain 
futures still featured prominently in women’s accounts. With their understanding 
that their condition was progressive, their ability to look after a child, or more 
children, featured in accounts of women’s deliberation over having a child/more 
children. These concerns were noted by Downing (2005) with regards to the late 
onset of HD, but are also supported in other rare disorders (Barlow et al., 2007) 
and chronic illness (Barlow et al., 1999). 
The risk of pregnancy complications was of major concern for one woman 
included in this study and in direct relation to her phenotype. Pregnancy 
complications in mitochondrial disease have been reported to range from severe 
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to mild (Say et al., 2011), although further explorations of these has been called 
for. Multi-disciplinary clinical care is therefore recommended for women on an 
individual basis in an attempt to minimise potential pregnancy complications. 
Experiencing pregnancy complications can have a number of psychological 
effects on women (Morrison et al., 2014; Heaman, 1998), including uncertainty as 
to whether they will attain motherhood (Heaman, 1998). High levels of uncertainty 
have been reported in women hospitalised due to their high-risk pregnancy, 
which correlated with high levels of stress (Clauson, 1996). Uncertainty also 
features in parental accounts of children born prematurely (Lu et al, 2013), with 
threatened pre-labour a reported complication in mitochondrial disease. Providing 
advice on prenatal coping strategies and advocating for social support networks 
have been reported as ways in which to mediate the effects of uncertainty in high 
risk pregnancies (Giurgescu et al., 2006), with emotion based strategies advised 
over problem focused strategies (Lu et al, 2013). The provision of up to date 
information on potential risks posed by women’s pre-existing conditions prior to 
conception and as early as their teenage years has also been called for to enable 
informed decision-making around pregnancy and possible risks (Crawford & 
Hudson, 2003).  
Critics of debates surrounding the approval and introduction of mitochondrial 
donation centred on the lack of information and discussions on other available 
reproductive options (Haimes & Taylor, 2017; Herbrand, 2017) This thesis 
addresses this by presenting women’s ideas and preferences in relation to the 
range of available reproductive options. This study shows that for the majority of 
women their preference is for their ‘own healthy child’, one that is biologically 
related to them and who will not suffer from a mitochondrial disease related 
illness. This finding is supported by US survey of women with a known mtDNA 
mutation, whereby 95% (20 of 21) of those considering childbearing placed 
biological relatedness as somewhat (43%) or very important (52%) (Engelstad et 
al., 2016). Mitochondrial donation allows for this biological link and significantly 
reduces, with the potential to eradicate, the uncertainty faced by women and their 
partners as to whether their child and future generations will be affected by 
mitochondrial disease. As a result, mitochondrial donation is the most favoured of 
the reproductive options in this study. 
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Findings showed that prenatal testing was problematic for women due to the 
perceived risks of the procedures and their reluctance to be placed in a scenario 
of deciding between continuing with or terminating an establish pregnancy.  
These accounts are supported by others including Boardman (2017),  Myring et 
al (2011), Kelly (2009) and Rapp (1998).  
Ovum donation has been cited as the most obvious option to women who wish to 
prevent transmission of their mtDNA mutation (Thorburn and Dahl, 2001; 
Burgstaller et al.,2015). However, for the majority of the women this option has 
never been considered. For those women who would consider the technique this 
was as a last resort and if in the event they were ineligible for their preferred 
options (mitochondrial donation followed by PGD) and for those that had already 
received news that they would not be candidates for either. Lack of biological 
relatedness was the main objection to ovum donation, with the couple actively 
pursuing ovum donation specifically seeking a clinic that would allow for matching 
of physical characteristics to resemble both parents. The significance of 
resemblance between a parent and child can be related back to cultural 
ideologies of what family is (Becker, 2000), and how a physical ‘resemblance is 
seen as the outward bodily expression of biological relationships’ (Becker et al., 
2005:p1301).  
Surrogacy is an option for symptomatic women whose presenting phenotype may 
pose a significant risk to mother and baby. Surrogacy in this study was 
specifically viewed as the way in which to have a genetically related child, this 
biological link and carrying on of the family lineage was of particular importance. 
In addition, concerns relating to the use of a surrogate in this study are supported 
by the literature and included legal status of the biological mother (Fenton-Glynn, 
2016), relinquishment of the child to the intending parents (Teman, 2008), 
financial costs (MacCallum et al., 2003) and negotiating pregnant embodiment 
and maternal identity (Teman, 2009).  
Adoption was viewed by a number of women as not an option due to their 
preference for a genetically related child and corresponds with accounts of the 
‘prioritisation of biology’ in women who experienced infertility but decided against 
adoption (Slauson-Blevins and Park, 2016:p248). Women who offered additional 
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explanations as to why adoption would not be suitable for them centred on pre-
existing beliefs of the lengthy and disruptive processes associated with adoption 
(Sandelowski et al., 1991). For those women who did not discount adoption, it 
was considered as a last option and only after other medical options had failed, 
and support van Balen et al's (1997) report of couples choosing medical 
interventions for infertility before considering adoption or fostering. A deviant 
account existed in the study sample, whereby the couple had discussed the 
possibility of infertility prior to their marriage and were both in agreement that they 
would parent ‘someone else’s’ child in the event they could not have their own 
biological child. This couple can be seen to view parenthood as a collection of 
caring activities for a child and not contingent on a biological link and this is 
supported by Miall (1996) whose respondents reported a ‘sameness of maternal 
and paternal’ feelings’ between adoptive and biological parents (p315).  
For the majority of women in this study, fulfilling the role of mother was an 
intrinsic desire experienced since childhood, referred to by Murphy (2013) as a 
‘predestined parent’. Women’s accounts of having their ‘own child’ or raising 
‘someone else’s child’ concurs with theories of parenthood as a form of 
possession (Berman, 2014), as well as western ideologies of family that 
prioritises biological kinship (genetically related children) over socially 
constructed parental relationships (adopted child) (Suter et al., 2011).  
Health professionals that signposted, referred or diagnosed women were 
considered trusted individuals, whom women felt comfortable in approaching for 
expert advice relating to reproductive decision-making. Women described 
consultations that utilised shared decision-making (Charles et al., 1997, 1999; 
Elwyn et al., 2012) and informed/constructivist decision-making (Emanuel and 
Emanuel, 1992; Charles et al., 1999; Charles et al., 2000). Both approaches were 
received positively by women and their partners (if applicable) and reported 
feeling supported in their autonomous decision-making. Rapley (2008) notes that 
decision-making is distributed and is an activity that includes a number of people 
as well as being on-going in nature and evolutionary, supporting the need for 
continued review of women (and their partner’s) current perceptions of risk. It was 
particularly important to women that they received individual assessment of their 
inheritance risk, at diagnosis and when considering their reproductive options and 
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this is supported by Durand et al (2010) who highlighted women’s needs for 
personalised information when considering prenatal testing, along with their 
request for this to be ‘presented in multiple ways, remaining simple and unbiased’ 
(p125). I advocate that the conceptual model can aid decision-making 
discussions by providing visual representation of the potential considerations for 
women, their partners and family members.   
9.3.2 Wider Social Implications   
Diagnostic delay is a common experience shared by patients suffering from a 
rare disease (Dharssi et al., 2017; Elliott & Zurynski, 2015; Zurynski et al., 2017).  
Delay in diagnosis meant that some women were devoid of the legitimisation that 
is offered by the ‘sick role’ (Parsons,1951) with accusations that ‘it was all in their 
head’. This supports Dimond's (2013) account that diagnosis allowed 
mitochondrial patients a ‘legitimate patient identity, treatment and support’ (p3), 
as well as other accounts of delay in diagnosis in rare disease (Nunn, 2017) and 
chronic illness (Glenton, 2003). These findings were also reflected in parents of 
children presenting with symptoms, with women describing complications at their 
GP surgeries and multiple repeat visits, reinforcing Muir's (2016) description of 
parents being branded as hypochondriacs or neurotic. This study showed that for 
women who had experienced symptoms for decades or even since their 
childhood, their diagnosis helped them to address feelings of stigmatisation which 
had resulted from symptoms that went undiagnosed or misdiagnosed. This is 
particularly apparent when they experienced severe fatigue and so were 
categorised as lazy. This echoes researchers investigating delayed or 
misdiagnosis of Chronic Fatigue Syndrome (CFS) and Myalgic Encephalomyelitis 
(ME) (Ashbring & Narvanen, 2002; Huibers & Wessely, 2006; Picariello et al., 
2015; Tucker, 2004).   
A large proportion of women recalled negative experiences with medical 
professionals who did not recognise or explore the potential reasoning for their or 
their family members symptoms. Noticeably, this was often directed to primary  
health care professionals as well as some symptom specialists. Experiences like 
these have been documented in other rare diseases where, alongside diagnostic 
delay, lack of knowledge in primary care was attributed to mistreatment (Barlow 
et al 2007), delayed access to social care (Grut & Kvam, 2013), conflicting 
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information (Frank., 2007) and inadequate or missing information (von der Lippe 
et al., 2016). Upon receiving recognition that there may be an underlying cause 
for their symptoms, subsequent referral and eventual diagnosis, can create 
positive and trusting relationships between women and those who had sign-
posted or diagnosed them or their family member. These were formed out of the 
feeling of being ‘believed’ and ‘listened to’, that they were being looked after by 
experts with the most up to date knowledge and that these professionals were ‘on 
their side’. This has also been reported in rare disease by Garrino et al (2015) 
and in relation to serious illness by Mechanic and Meyer (2000). These new 
relationships of trust resulted in women bypassing their GP or other neurologists 
when seeking advice on presenting health complaints of all severities and non-
health related issues, such as assistance with home adaptations and funding for 
reproductive techniques (PGD).  
An objective of this study was to explore the information needs of women with 
mtDNA mutations in relation to reproductive decision-making. In addition to this, 
the findings show that women also desired more varied information about 
mitochondrial disease. Women felt that sources of information, in particular 
results of Internet searches were not representative of some women’s 
experiences, especially those who considered themselves to be mildly affected or 
somehow different to others with their mutation. With the tendency for searches 
to show extreme cases or information of the life-limiting and potential fatal 
consequences of mitochondrial disease many women were left in fear and panic 
following their diagnosis, more so when informed by a non-mitochondrial 
specialist. These fears were alleviated for women when receiving advice from 
mitochondrial specialists who were able to provide a more individually specific 
assessment of their own and/or their family members prognosis. In addition to 
this some women found online communities via social media platforms helpful in 
terms of support from other patients around the world, particular in relation to 
having a ‘safe place’ in which to share their frustrations, whilst other women were 
unaware of these. For one woman in particular, she felt that information provided 
by the main mitochondrial patient charity was irrelevant, as they did not consider 
adult patients experiences of disease and that mitochondrial research 
organisations provided limited and repeated information. A request for research 
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into the wider role of mitochondria in other disorders, written in a way that is 
accessible to patients, was desired.    
For some women the initial emotional impact of their diagnosis remained for 
months and years following. For these women, they expressed the centrality of 
emotional support, specifically in relation to their diagnosis, feelings of guilt and 
responsibility and managing changing or progressing symptoms. At the end of 
one interview, the on-going distress experienced by one woman resulted in her 
permission being given to discuss this with her clinician in the hope of seeking 
specialised counselling. The lack of counselling support for people diagnosed 
with a rare disease was recognised in the UK Strategy for Rare Disease (2013) 
with commitment number 45 addressing the need to provide support to specialist 
centres to enable the provision of local counselling for patients (Department of 
Health & UK Government, 2013, p35).   
Uncertain futures and unpredictability of mitochondrial disease resulted in women 
and their family members experiencing biographical disruption (Bury,1982). 
Periods of illness and disease progression had educational, financial and social 
implications for women. This included experiences of mainstream and higher 
education and employment being interrupted or terminated, renegotiation of 
important social relationships along with feelings of isolation. These findings 
show that educational and employment institutions were also unable to adjust to 
the uncertainty of mitochondrial disease, with some institutions incapable of 
accommodating a flexible working approach or physical access. Relationships 
with family and friends were impacted as a result of disclosure of their diagnosis, 
especially in families where others may be at risk, with feelings of guilt and 
responsibility at their core that determined the level of disclosure in families. 
Some women’s experiences were positive, where a collective family diagnosis 
offered a sense of a shared or mutual understanding of what it was to have 
mitochondrial disease. For one woman this experiential knowledge of certain 
symptoms directly influenced her reproductive decision-making. Disclosure of 
illness was further complicated by the complexities of mitochondrial diagnosis, 
which proved difficult for some women to fully understand and then in part to 
others. This was combatted with the use of analogies and scripts as tools to help 
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others understand what caused their symptoms and how in particular they were 
affected. 
The thesis has shown that uncertainty is fundamental to the lived experiences of 
women with mitochondrial disease, and encroaches into many areas of their 
lives. In turn this then impacts upon their reproductive decision-making. 
9.4 Study Limitations and Strengths  
In this section I critically review the study and discuss its limitations and reflect on 
its strengths.  
9.4.1 Methodology   
Utilising qualitative methodologies to explore the experiences of women and 
reproductive decision-making is a strength of this study as it has allowed for the 
collection of rich and varied data. Without this approach it would not have been 
possible to create the proposed conceptual model of reproductive decision 
making, as data collected allowed unique insight into uncertainty in reproductive 
decision-making and more broadly the lives of women with mtDNA mutations.  
Data collected within this study allowed for a very specific knowledge of women’s 
experiences to be highlighted, an area that is currently lacking in the existing 
literature.   
Qualitative research allows for in-depth illumination of a phenomenon and is 
especially useful in understanding the experiences of individuals (Atieno, 2009).  
It is particularly useful in exploring ‘complex, new and relatively unexplored areas’ 
(Clarke and Jack, 1998:p845). In taking this approach to explore the experiences 
of women and reproductive decision-making I have been able to gather rich and 
varied data that has shown how uncertainty features across the lives of women. 
Limitations commonly associated with qualitative research however include 
restriction of generalisability, as qualitative research does not seek to be 
‘statistical generalisability and representativeness’ but ‘aims to reflect diversity’ 
(Barbour, 2001:p1115). Purposive sampling was used to identify a range of 
experiences of reproductive decision-making.  
A key consideration in qualitative research is reflexivity, evaluating my role as 
researcher and my influence on the data – and in return its influence on me 
(Finlay & Gough, 2008). I discuss in Chapter 4 my position as a researcher, 
 248 
 
reflecting on my previous research experience and personal background. 
Throughout the conduct of this study, reflections on data were included in field 
notes and patient and theme specific memos, as well as discussions with peers 
and supervisors. Researchers are said to gravitate to research areas that explore 
their own experiences, however this may make them more sensitive to data 
(Dickson-Swift et al., 2008). Some stories shared by women resonated with my 
own family’s experience of prenatal testing, genetic disease and uncertain 
futures, which at times were emotionally challenging. By undertaking self-
reflection, I was able to pay close attention to how my own experiences and pre-
existing beliefs and values could shape the process of the research.   
9.4.2 Longitudinal Interviews and Changing Political Landscape  
This study was initiated prior to parliamentary debates relating to the introduction 
mitochondrial donation as a reproductive option and continued until after the first 
centre licence to perform the technique was granted. A strength of the study is 
that it captures pre-parliamentary debate, post parliamentary approval and post 
licencing perspectives of reproductive options whereby mitochondrial donation 
transitioned from a research technique to a clinically available option. This was in 
part strengthened by the study design, informed by constructivist grounded 
theory. This permitted data to be collected and analysed throughout the course of 
the study. This enabled emergent categories and key areas within the data to be 
explored in future interviews. A criticism of this approach is that it can be 
exhausting, especially for novice researchers like myself who may become 
preoccupied with coding of data (Hussein et al., 2014). To ensure that that was 
not the case, data was discussed with supervisors and in a confidential peer 
setting that allowed for further exchange and interpretation of key issues 
emerging from the data (Rapley, 2010).  
9.4.3 Recruitment   
Recruitment into this study was dependent on clinical gatekeepers with prior 
knowledge of the women who took part. This approach had a number of 
strengths but could also be considered a limitation. Research in rare disease is 
inherently difficult, however to address this problem in research into mitochondrial 
disease, mitochondrial experts from across the UK developed the MRC 
Mitochondrial Patient Registry and Natural History Study (MitoCohort) for the 
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purpose of rapid identification of eligible patients for research. This resource 
enabled potential participants for this study to be pre-screened by the 
department’s mitochondrial research nurse more easily and that these women 
could be approached to consider participation at their next clinical review. This 
approach was especially helpful in regards to the purposive sampling 
methodology employed within the study, as I was able to enquire and request 
contact with women who matched certain criteria. Women who believed that their 
family members might also be willing to take part communicated this to the 
mitochondrial research nurse, often after reading the study information. If these 
women had previously consented to the MitoCohort to be contacted for research 
the mitochondrial research nurse was then able to approach them and provide 
study information if willing. For the one participant who was not identified by the 
MitoCohort, their mitochondrial specialist informed them of the research project in 
advance of their clinical visit. Although approved, mailing study information 
sheets to women identified via the MitoCohort only and not seen in the clinic was 
not tested, as those women that fulfilled the purposive sampling strategy were 
identified as attending upcoming clinics. It is an unknown as to whether a mail 
shot approach would have yielded different accounts from women.  
Clinical gatekeepers were an important step in identifying women they believe to 
be suitable to take part in the study. This took into account women who may be 
known to have experienced a recent bereavement, be it experiencing their own or 
a family members declining health or those who may be struggling with issues 
such as their recent diagnosis. Without this up to date personal and medical 
knowledge of women there may have been occasions whereby women who 
received an invitation to the study and the study information sheet in the post 
may have been left distressed by its arrival. These considerations occurred twice 
within this study, whereby two women were not approached to take part in the 
study due to their own disease progression and that they were still processing 
their own diagnosis.  
A strength of having a connection with the clinical specialist team meant that - as 
described above - with patient’s permission, their clinical team could be informed 
of any distress and assist women with seeking additional support. Without this 
link I would have been unable to refer women to specific mitochondrial support, 
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due to the current lack of adult based support networks outside specialist clinical 
care teams.  
The limitation of using gatekeepers in identification of research participants is that 
there may be additional screening criteria consciously, or sub-consciously, 
applied to the sample or even disagreements between gatekeepers as to the 
appropriateness of participants. In this study there was one incident were the 
clinical team discussed between one another as to whether a certain woman 
should be contacted, with concerns from some that an approach to take part 
would cause distress. To avoid this potential, that particular woman was not 
contacted. A limitation of recruiting women by their association with the 
MitoCohort was that these were women who had previously expressed a wish to 
be contacted to take part in research associated with their diagnosis and 
therefore may not have been entirely representative of the wider population of 
women, who may have previously declined participation in the MitoCohort.  
The rarity of mitochondrial disease coupled with some women’s confusion 
regarding the aetiology of their mitochondrial disease would have meant that 
general advertisement for women with mtDNA mutations willing to discuss their 
reproductive decision-making would have been extremely difficult, most likely 
receiving little response and may have led to a mixed sample of mitochondrial 
and nuclear mutations. Although general advertisement of the study would have 
been impractical, utilising the main mitochondrial patient charity may have 
enabled a mitochondrial specific population to be targeted (however this may not 
have addressed the potential to recruit women with nDNA mutations). This 
recruitment strategy was utilised by another study, identified in Chapter 4, it 
therefore may not have been feasible to approach this charity for their assistance.  
During the course of the study I was informed of a large online social media 
group for mitochondrial patients, maintained and administered by patients 
themselves. It is possible that connections with this group could have been made, 
to post an advertisement for the women in the UK to contact myself directly. This 
approach may have permitted a geographically wider and therefore diverse 
sample, as the sample included in this study represents women - with the 
exception of one woman - living predominantly in the North of England and 
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Scotland. It is possible that recruitment of women in other regions of the UK and 
the Republic of Ireland may have led to different experiences of mitochondrial 
disease and reproductive decision-making. This recruitment approach may be 
suitable for future qualitative studies into the array of experiences of 
mitochondrial disease, which are currently missing from the literature (see section 
9.5).  
9.4.4 Insider Research  
As discussed in Chapter 4, there were concerns that women would associate me 
with their clinical care team and perceive me as someone with medical training 
and/or feel unable to critique the clinical service provided to them and their family 
members. Study information sheets declared that the study was for the purpose 
of my PhD, although some participants had met me or seen me previously in my 
role as clinical research manager at patient engagement events, patient focus 
groups or study steering group activities. I also went on to see participants at 
future events following their interview. In addition to these encounters, my staff 
profile was also present on Data Collection Centre 1’s website, further reinforcing 
my role as a member of staff. It is therefore possible that some women may have 
consciously decided to refrain from criticisms or alternatively over complimented 
the service out of concern of possible identification and potential negative 
repercussions in their relationships with clinical team members. A strength of my 
sometimes-known status may have meant that women knew I had a level of 
understanding about mitochondrial disease, how it presented and its potential 
clinical implications. This may have been beneficial to establishing a relationship 
at start of the interview as opposed to feeling as though I had no insight into what 
mitochondrial disease was.  
9.4.5 Couples Perspectives of Decision-Making   
This study was designed to specifically explore women’s experiences of 
reproductive decision-making.  Although interviewing couples was considered 
during study design it was thought not possible to accommodate, with a possible 
negative impact on recruitment. However, the study allowed for an attendee of 
the woman’s choice to be present and contribute to the interview if they wished, 
which led to the inclusion of three couples. This approach was taken to allow 
women the opportunity to feel as comfortable as possible during the interview, 
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with support from an individual of their choosing. Interviews that included partners 
were those that took place before or following clinical reviews and were 
conducted in an outpatient clinic or research facility. Therefore, their participation 
may have been purely coincidental as opposed to purposeful attendance. Upon 
noticing this, I asked future women if there was a reason as to why their partners 
were not present. Reasons centred around availability as opposed to declining to 
take part. Existing research into reproductive decision-making has included both 
women’s accounts (Raspberry and Skinner, 2011; Herbrand and Dimond, 2017; 
Kay and Kingston, 2002; Rapp, 1998; Dudding et al., 2000; Donnelly et al., 2013) 
and accounts of couples and families (Dommering et al., 2010; Downing, 2005; 
Frets et al., 1991; Helbig et al., 2010; Hershberger et al., 2012; Kelly, 2009; 
Myring et al., 2011; Snowdon & Green, 1997).   
Myring et al (2011) reported that couples in their study believed women had the 
‘final say’ in decision making, in part due to their role in primary care giving and 
pregnancy implications. Women (and partners where applicable) in this study 
reported their decision-making to be joint decision between couples and that they 
were not made in isolation, with some women discussing their options at length 
with family members. Interviewing couples can offer insight into their relationship 
and their shared realities, in this case their experience of reproductive decision-
making (Valentine 1999). It is reasonable to assume that the presence of a 
partner may have limited or directed responses from women or vice-versa. To 
combat this, interviews could have been conducted with women and partners 
separately, followed by a combined interview, enabling viewpoints to be 
discussed that they may have felt unable to in front of their partner. This 
methodology would have added a layer of practical complexity to the study that 
may have negatively affected recruitment and the timely completion of the study.  
9.4.6 Multiple Perspectives of Decision-Making 
This study utilised retrospective and current and prospective accounts of 
decision-making. When discussing which options women would consider and 
those they would discount. For those in the retrospective group these were 
largely hypothetical, as the majority of the women had completed their families. 
Hypothetical lines of questioning have been criticised for the potential to cause 
confusion for the participant, which can interrupt the interview and therefore the 
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quality of the data (King & Horrocks, 2010). The approach taken in this study can 
also be related to the technique of imagined variation, which is essentially a 
thought experiment used in interviews. This is the process whereby the 
interviewer encourages interviewees to reflect further on their experience of the 
specific area of study and then tell the interviewer how they think their experience 
would differ (King & Horrocks, 2010) if for example in this study, they had 
received their diagnosis prior to having completed their family. King and Horrocks 
(2010) advise caution when approaching this question, with recommendations 
that variations in the directions of questions be made. In the example of this study 
I asked women in the retrospective group which options they thought they may 
have been more likely to have chosen and those they would have discounted. I 
believe however that including multiple perspectives of decision-making was a 
strength of the study; especially as it uncovered a key area, change over time. 
This was then followed up by the inclusion of a repeat interview in Round Three 
to examine further.  
9.4.7 Conceptual Model  
A key strength of the proposed conceptual model is that it is the first proposed 
model of reproductive decision-making in maternally inherited mitochondrial 
disease. As Hunink et al (2014) noted, decision models or balance sheets allow 
for the individuals to assess the impact of multiple factors that present at varying 
times, which most people would be unable to do unaided. A strength of the model 
has been its rigorous development, which occurred over a number of versions 
before being superimposed into Downing's (2005) model and then further 
adapted to reflect the women’s accounts. The conceptual model was presented 
to the local mitochondrial specialist team to permit content review and feasibility. 
The conceptual model also aligns with influential factors reported in other genetic 
conditions (Myring et al., 2011) and considerations of PGD as an option 
(Hershberger et al., 2012 ).  
9.5 Areas of Future Research  
Further evaluation of the conceptual model needs to be conducted with women, 
their partners and health professionals. Accessible, user-friendly versions need to 
be developed, prototyped and evaluated. These could take the form of decision-
aids, either for women (and their partners) to use alone, or to use within clinical 
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consultations. A more formal, long term, development process would need to be 
undertaken in light of the International Patient Decision Aids Standards (IPDAS).  
Such formal evaluation often occurs in the context of randomized controlled trials 
(RCTs) or via user-centred acceptability and feasibility testing. 
The IPDAS collaboration outlines four criteria for the development and evaluation 
of patient decision making aids: 1) provide information in sufficient detail for 
decision making 2) present probabilities of outcomes (where/if available) 3) 
include methods for clarifying and expressing patient values 4) include structured 
guidance in deliberation and communication (Elwyn et al., 2009).  The proposed 
conceptual model, and the information used to develop it, currently offers a lot of 
detailed information about the reproductive options that women face.  This would 
need to be further refined and tailored, so as to be clear and accessible to 
women.  Additionally, as outlined throughout the thesis, given the rare disease 
status, probabilities of outcomes are not yet available.  Finally, in relation to the 
third and fourth criteria, there are to date, only a relatively limited number of ways 
that people design these features into decision aids, and these would need to be 
reviewed and then discussed and evaluated with women.  The IPDAS 
collaboration also recommend that following the development of a decision-
making aid with patients and specialsied clinicians, ‘beta’ testing in real life 
scenarios should then take place (Coutler et al., 2012; Elwyn et al., 2006). This 
should include critical appraisal by those not involved in the developmental 
process and such a review could be conducted those with expertise in shared 
decision-making and clinicians not involved with the development to date. Not 
only would the inclusion of additional stakeholders enable further validation of the 
model in accordance with these recommendations but may also offer new areas 
of interest to explore, including its relevance for nDNA mutations. 
Findings from this study also showed that mitochondrial disease impacts on the 
lives of women and their family members in a multitude of ways, which is largely 
missing from the literature. Feelings of guilt, responsibility and concern for 
maternal family members has been discussed in this thesis surrounding 
disclosure of genetic risk and reproductive decision-making, but uncovered also 
were impacts of mitochondrial disease on social relationships including those 
between partners, mothers, children, affected siblings, aunts, uncles, 
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grandparents and friends. For women who experienced symptoms, they spoke of 
their partners acting or potentially acting’s as caregivers in the future. 
Investigation of this role in relation to partners/primary caregivers could provide 
further understanding of disease burden - uncover unknown emotional and 
financial costs for patients and caregivers (Awad and Voruganti, 2008 in 
reference to mental illness) - identify the needs of caregivers (Houldin, 2007 in 
reference to cancer; Cameron and Gignac, 2008 in reference to stroke) and 
develop caregiver specific information (Given et al., 2008) and support networks  
(McCabe et al., 2016 in relation to dementia). 
Some women described feeling a sense of support when more than one person 
in their family was diagnosed with mitochondrial disease. Research into these 
existing support networks could provide further understanding as to what it is like 
to live in ‘family of affected people’ and how these families negotiate varied 
symptom presentation and severity. Feelings of isolation arose out of the 
unpredictability of symptoms and their impacts of social life as well as the lack of 
peer support. Further work on this could lead to understanding of how to address 
these and possibly implement future interventions.   
This study primarily examines clinical relationships in relation to reproductive 
decision-making, however it is evident that women’s experiences of these 
relationships in relation to mitochondrial disease can pre-exist diagnosis for 
sometimes decades. This study highlights the lack of awareness of mitochondrial 
disease in the wider medical community, in particular the GP setting, which 
continues after diagnosis. Specific investigation into the wider experiences of 
patients and health professionals may allow for the development of targeted 
information portals, accessible to these health professionals. In addition to further 
exploring patients perspectives of clinical relationship, there is little qualitative 
exploration on health care professionals perspectives of caring for patients with 
mitochondrial disorders (Bredenoord et al., 2010; Read & Calnan, 2000). Insights 
into these individuals’ experiences of caring for patients could assist with 
understanding the emotional, practical and financial implications of providing care 
to patients, all of which could support appeals for increased funding to 
commissioners.   
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Uncertainty of mitochondrial disease affected some women’s education from 
compulsory through to higher education and work place training schemes. The 
long-term impact of being unable complete education for patients with 
mitochondrial disorders may have emotional (Barrera et al., 2005 in relation to 
childhood cancer), and financial implications (Smith, 2009 relation to childhood 
illness) as well as potential implications on identity. This also highlights wider 
topics of the understandings of rare disease in education sectors and disability 
rights of access to education (Bines & Lei, 2011). Findings also showed that 
some women who experienced symptoms, commonly fatigue sought flexible 
working arrangements, reduced working hours and community commitments or 
left their jobs. None of the women who modified their working patterns to fit 
around their symptoms spoke about personally accessing any governmental 
support such as the previous disability support allowance or the newer personal 
independence payment (PIP). It is arguable to say that these women experienced 
a negative impact on their earnings or potential earnings due to reduced hours 
and interruptions to career development opportunities as a result of navigating 
work around their symptoms.  
The cost of illness in mitochondrial disease has been reviewed in relation to the 
cost of treatment, in an impact assessment report of mitochondrial donation 
(HFEA, 2014) with an estimated lifetime cost of between  £100,000 and £300,000 
for patients with serious mitochondrial disease. A specific case study of one 
patient’s treatment costs showed that of the estimated treatment cost of £222,906 
over a ten-year period, £212,443 was attributed to their inpatient care in their final 
year of their life, highlighting the drastic decline of health some patients suffer as 
a result of their serious mitochondrial disease (HFEA, 2014). No investigation of 
cost of illness has been conducted in patients with mitochondrial disease on a 
microeconomic level (individuals and households). Investigations in other rare 
disease and chronic illness have shown a significant correlation between financial 
stress, disability and poor physical and mental health (Jeon et al., 2009). Rare 
disease and chronic illness can not only incur significant financial loss (Barlow et 
al., 2007) for sufferers but also psychosocial losses (Meenan et al., 1981), effects 
on social relationships (Cohen, 2004) and impacts on identity (Fryers, 2006). 
Women’s experience in the workplace highlights the broader issues of disability 
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and work (Shier et al. 2009). Specific investigations of the impact of mitochondrial 
disease and employment would be required to support this claim further.   
Finally, women described feeling as though their experiences of mitochondrial 
disease were not portrayed when searching online. Patients requested lay 
summaries of new and on-going research that could be easily accessed, with 
information shared to interested patients via patient engagement events, 
websites and social media platforms. I also propose that carrying out some of the 
above suggested research may address these feelings of under-representation, 
with qualitative investigations providing a mechanism to document the diverse 
spectrum of experiences in individuals and families affected by mitochondrial 
disease. Future work could also aim to explore the phenomenon of the ‘patient 
without symptoms’ (Dimond, 2013) which would allow for the experiences of 
these women to feature in the wider narrative of mitochondrial disease.  
9.6 Recommendations for Clinical Practice and Policy  
Based on the findings of this thesis, I suggest the following recommendations to 
clinical practice and policy in relation to reproductive decision-making.  
9.6.1 Considerations of Lived Experience 
Findings from this study have shown that women are influenced by their personal 
and family experience of ill health associated with mitochondrial disease (in some 
case more general ill health). Discussions with women about their experiences of 
mitochondrial disease are encouraged to understand how these experiences and 
experiential and empathetic knowledge gained as result may potentially impact 
on decision-making.  
9.6.2 Reflections of Normality and Socially Acceptable Symptoms  
Findings from this study have shown that for some women, perceptions of 
disease severity and symptom management and acceptability in modern day 
society impact upon reproductive decision-making. Understanding of symptoms 
or phenotypes women are accepting of may assist with discussion around 
negotiating child-centred risk.  
9.6.3 Factual Awareness and Representation  
Findings from this study have shown that during both diagnosis and reproductive 
decision-making, women used Internet searches to seek information relating to 
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mitochondrial disease. Women reported that the information available reflected 
more severe accounts of mitochondrial disease and that they felt their 
experiences were not relatable. Providing more readily accessible accounts of 
the varied experiences of mitochondrial disease may assist women who 
undertake information-seeking activities as part of their factual awareness during 
decision-making. 
9.6.4 Change Over Time   
A specific influential factor in the proposed conceptual model of decision-making 
is the potential for women’s perceptions of risk to change over time, based on 
new information or personal circumstances. For some women in this study, this 
change in risk perception led to women considering reproductive options they 
had not considered previously. Mindfulness of this potential and discussions with 
women surrounding awareness of this change may support women further in 
their reproductive decision-making.  
9.6.5 Emotional and Psychological Support    
Findings from this study have shown the role of guilt and responsibility in 
women’s reproductive decision-making and its impact on women many months 
and years following their diagnosis. I recommend that specialised counselling be 
provided to women who are considering their reproductive decisions as part of 
their reproductive decision-making patient pathway and in addition offered to all 
women who attend the clinic who may be struggling with feelings of guilt and 
responsibility since receiving their diagnosis.  
9.6.6 Central and Local Funding of Reproductive Options 
Findings from this study highlight that some women and their partners were 
prevented access to PGD as a reproductive option or where in the process of 
appealing a decision to prevent access. These funding barriers were in relation to 
the couple or one parent (father) already having a child or as an issued of 
devolution and access to NHS services. I recommend that central and local 
commissioners should be informed of health and social implications of 
mitochondrial disease and a request a review of the current funding criteria in 
relation to access to PGD.  
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9.6.7 Implementation of Recommendations  
One aspect of the recommendations is that extended discussions could be 
offered to women.  These would, ideally, focus on their lived experiences, 
reflections of normality, change over time and emotional and psychological 
support dedicated mitochondrial disease reproductive advice clinics should be 
offered to women. Such discussion would need to be incorporated into the patient 
care pathway for women and their families who wish to explore the multiple 
reproductive options available to them now and in the future. However, with 
specialties in both mitochondrial disease and associated reproductive options 
limited (on a global level as well as in the UK) offering these services locally to 
women and their families could prove challenging, resulting in attendance being 
restricted due to travel costs. Advances in tele-health clinics (Armfield et al., 
2015; Langenau et al., 2014 Hommel et al., 2003) may address the uneven 
distribution of services routinely seen in rare disease, with regards to accessing 
appropriate care (Department of Health and UK Government, 2013; Cialone et 
al., 2011), providing personalised support to patients (Dorsey et al.,2013) to 
those patients living long distances for specialist’s centers.   
Clearly, such extended discussions would also take up additional health 
professional time, whether undertaken face-to-face within clinics or remotely, 
through tele-health clinics. In part, women’s desire for more accessible 
information about mitochondrial disease could also be supported by a dedicated 
website. Such a dedicated website, with easily accessible information in multiple 
formats, may offer both additional support to women and families before, during 
and after reproductive decision-making and those wishing to have access to 
more varied accounts of other’s experiences of disease. Women and their family 
members could be directed to it prior to any extended discussion to both provide 
important information to them as well as, potentially, focus the discussion on 
specific topics most relevant to them. 
9.7 Conclusion  
In summary, this study adds to the limited qualitative literature of reproductive 
decision-making in maternally inherited mitochondrial disease. This study was 
conducted during intense global interest of mitochondrial donation from clinical, 
biomedical, social, ethical, religious, legal and policy researchers and offers 
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valuable insight into women’s perspectives of their available options. It centres 
women’s narratives of reproductive decision-making at its core and offers a 
unique contribution to scholarly debates.  
This study demonstrates the uncertainty fundamental to the experience of women 
with mtDNA mutations which manifests in both their personal accounts of the 
condition and in reproductive decision-making. Women with mtDNA mutations 
harbour the desire for a healthy biologically authentic child and decision-making 
is essentially the process in which women consolidate their desire for healthy 
children and how they negotiate risk.  
Qualitative research in mitochondrial disease is relatively novel, this study 
explores women’s experiences of reproductive decision-making as well as 
highlighting the impact of mitochondrial disease in everyday life. It makes 
suggestions of further research to explore how uncertainty posed by 
mitochondrial disease affects the lives of patients and their interactions with 
society.  
The outcome of the study has been the adaptation of an existing sociological 
model to support reproductive discussions between clinicians and women 
regarding decision-making in the face of uncertainty. The central finding of this 
thesis is the women with mtDNA mutation live an uncertain existence and 
highlights the importance of sociological understanding of this uncertainty in the 
mitochondrial reproductive advice clinic. 
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Appendices 
Appendix A - Recruitment 
A.1 Invitation Letter and Expression of Interest Forms 
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To be on Hospital Headed Paper 
Dear [Patient] 
 
Reproductive Decision Making in Mitochondrial Patients: A Qualitative Investigation of 
Women’s Experience  
I am contacting you to invite you to consider taking part in a research study being done at 
Newcastle looking into how women with mitochondrial disease or carry a mitochondrial 
DNA mutation make reproductive decisions.  
 
I have enclosed an information sheet, which explains the study in greater detail and it 
also contains contact details for the research team should you wish to ask any further 
questions about the study. 
 
If you would like to take part in this research, I would be grateful if you could complete 
the enclosed expression of interest form and post this back to us in the pre-paid envelope 
provided. Alternatively you can contact Julia Maddison on 0191 208 5982 
(julia.maddison@ncl.ac.uk) to express your interest. 
 
Many thanks for taking the time to read this information.    
 
Yours sincerely 
[Research team member] 
 
 
 
 
 
 
Reproductive Decision Making  
Invitation Letter  Version 1 28/03/2014 
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Expression of interest  
We would be grateful if you could return this reply slip within 6 weeks of receipt. Please 
return to  
Julia Maddison  
Clinical Research Office – M4.008 
Mitochondrial Research Group 
 
I would be interested/not interested (please delete as appropriate) in finding out more 
about participant in Reproductive Decision Making in Mitochondrial Patients study  
 
My name is ………………………………………………………………………………….. 
My date of birth is…………………………………………………………………………… 
My address is ……………………………………………………………………………….. 
My phone number is ………………………………………………………………………... 
My email address is ………………………………………………………………………… 
The best way to contact me is by phone/email (please delete as appropriate) 
The most convenient time for me to be contacted (if I wish to be contacted by phone) is: 
Mornings  (9am-12pm)  
Afternoons  (12pm-5pm) 
Early evenings  (5pm-8pm) 
Late evenings  (8pm-11pm) 
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To be on Hospital Headed Paper  
Dear [Patient] 
 
Reproductive Decision Making in Mitochondrial Patients: A Qualitative Investigation of 
Women’s Experience  
Repeat Interview Arm  
 
I am contacting you to invite you to consider taking part in an extension to a study that 
you participated in, in the past. This previous study looked into how women with 
mitochondrial disease or carry a mitochondrial DNA mutation make reproductive 
decisions.  
 
I have enclosed an information sheet about the extension study, which explains why this 
being done in greater detail and it also contains contact details for the research team 
should you wish to ask any further questions about the study. 
 
If you would like to take part in this research project again, I would be grateful if you 
could complete the enclosed expression of interest form and post this back to us in the 
pre-paid envelope provided. Alternatively you can contact Julia Maddison on 0191 XXX 
XXXX (xxx xxxx@ncl.ac.uk) to express your interest. 
 
Many thanks for taking the time to read this information.    
 
Yours sincerely 
[Research team member] 
 
 
 
Reproductive Decision Making  
Invitation Letter- Repeat Interview Arm   Version 1 11/03/2016 
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Expression of interest  
 
We would be grateful if you could return this reply slip within 6 weeks of receipt. Please 
return to  
Julia Maddison  
Clinical Research Office – M4.008 
Mitochondrial Research Group 
 
I would be interested/not interested (please delete as appropriate) in finding out more about 
participating in the extension of the above study 
My name is ………………………………………………………………………………….. 
My date of birth is…………………………………………………………………………… 
My address is ……………………………………………………………………………….. 
My phone number is ………………………………………………………………………... 
My email address is ………………………………………………………………………… 
The best way to contact me is by phone/email (please delete as appropriate) 
The most convenient time for me to be contacted (if I wish to be contacted by phone) is: 
Mornings  (9am-12pm)  
Afternoons  (12pm-5pm) 
Early evenings  (5pm-8pm) 
Late evenings  (8pm-11pm) 
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A.2 Participant and Attendee Study Information Sheets  
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To be on Hospital Headed Paper 
 
 
 
 
 
You are being invited to take part in a research study. Before you accept or decline the 
invitation, it is important for you for to understand why the research is being done and 
what it will involve. Please read the following information and discuss it with relatives, 
friends and your GP, if you wish. If there is anything that is not clear, or if you have any 
further questions, please ask us (our contact details are printed on page 3).  
Why are we asking you to take part?  
You are being invited to take part in this research because you have mitochondrial disease 
or carry a mitochondrial DNA mutation and you have made a reproductive decision in the 
last 16 years  
Do I have to participate? 
It is up to you to decide whether you want to join the study. If you agree to take part, we 
will then ask you to complete a consent form. You are free to withdraw at any time, 
without giving any reason. This would not affect the standard of care you receive. 
What is the purpose of this study? 
Approximately 1 in 3,500 women are affected by a mitochondrial DNA mutation, many of 
whom are of childbearing age.  
Reproductive Decision Making  
Women who have made a decision Patient Information Sheet Version 1 28/03/2014 
 
 
   
 
 Reproductive Decision Making in Mitochondrial Patients: A qualitative investigation of 
women’s experiences 
Patient Information Sheet for  
Women who have made a decision  
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The study aims to look at how women diagnosed with mitochondrial disease, or 
carrying a mitochondrial DNA mutation have made reproductive decisions in the past 
and how they make decisions now. Reproductive decisions to some woman may 
mean, deciding to try to become pregnant or deciding not to become pregnant. Little 
is known about how patients with mitochondrial disease make these important and 
complex decisions.  
We would like to conduct interviews with two groups of women, women who have 
made reproductive decision/decisions in the past 16 years (Retrospective Group) and 
those women who are making decisions now (Current/Prospective Group).  
We are interested in learning about topics like: 
• how you made this decision (or multiple decisions),  
• what was important to you at the time,  
• what information you received or did not receive at the time that would have 
helped you to make a decision  
• and how you feel about new reproductive techniques.  
 
This study is part of a PhD project for Julia Maddison, who is part of the 
Mitochondrial Research Group; results from this study will form part of her thesis. 
What happens if I agree to take part? 
The study will involve a one to one interview with the researcher. Interviews will last 
between 45-90 minutes; they can be paused or stopped at any time. There will be 
some areas we are keen to discuss but you are free to talk about anything you think is 
important about how you made your reproductive decision/decisions.  
If you are interested in taking part in this study, a member of the research team will 
contact you to arrange a time and date for your interview; you will be asked to sign a 
consent form before the interview starts.  
The interview will take place at a time convenient to you, usually coinciding with your 
planned clinic visit. If this is not possible we will make an appointment at a time most 
convenient for you to attend the Clinical Research Facility at the xxx.xxxxx, xxx.xxxxx 
or the researcher will visit you at your home or a location that you feel the most 
comfortable.  
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If you prefer, someone else, like a partner, a member of your family or a close friend, can 
also take part in the interview with you. Any travel / parking costs for helping with this 
research will be refunded. 
Taking part in this study is voluntary; you can decline to take part at any time. Not taking 
part in this study will not affect the standard of care you receive. If you decide after the 
interview has taken place that you would like collected data to be destroyed and not used, 
this will be done at your request. 
Will information about me be kept confidential? 
All information we receive from you will be treated confidentially. Your personal details and 
replies will be kept safe and secure. The interview will be audio-recorded so that the 
researcher can transcribe the information accurately. The audio-recording will be 
destroyed six months after we have finished analysing and writing up the data. Written 
information will be kept secure in a locked office and only members of 
XXXX XXXX team will be given permission to look at this information. Your personal details 
will be converted into a code and stored on a secure computer located at Newcastle 
University. If we publish any research, we ask your permission to use direct quotes; this will 
not identify you in any way. 
Research records and data may also be inspected by regulatory bodies for audit purposes. 
This is a normal part of research and it is just to make sure that we are doing everything 
right. 
Are there any benefits to taking part? 
We cannot promise the study will help you personally, but we hope that the information 
we get from this study will help to improve the way we discuss and support patients who 
will be faced with making reproductive decisions in the future.  
Are there any disadvantages to taking part? 
Giving up your time to take part in this project has to be considered. We also recognise that 
the topic of this interview is sensitive and may cause some distress.  
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Taking part in this study is voluntary and you do not have to take part if you feel that 
you would be too upset discussing this topic. We will do our best to make you feel as 
comfortable as possible. If you feel on the day of the planned interview that you 
would like to rearrange, this would not be a problem. If you feel before or during your 
interview you would like to take some time out, or stop the interview it is completely 
acceptable to do so. 
We would like to support you as much as possible. Approximately 7-10 days following 
your interview the research team will contact you to make sure that you have not 
been left feeling upset or distressed. If you feel that after taking part in the interview 
(either immediately or in the weeks/months following) you would like to discuss 
things further, the research team can make a referral to your doctor or other 
appropriate NHS services and can also provide you with details of counselling 
services. This will only be done with your consent to do so.  
The only time we will disclose your personal information without your prior consent 
would be   if during the interview you disclose any information that could be deemed 
related to your safety or safety of others. We would then contact your health care 
team or other appropriate services.  
What happens at the end of the research study? 
We hope to interview 15 women from each group, a total of 30 women over 1 to 2 
years. At the end of the study, we will be able to inform you of the outcomes of the 
study in a newsletter. You will not be made identifiable in the newsletter or any 
published work.  You will be welcome to have a copy of the results once they are 
published. 
Who has reviewed this project? 
All research conducted within the NHS has to be reviewed by an ethics committee to 
make sure we are not doing anything harmful to you or your personal information in 
this project.  
This research has been reviewed by NRES Committee xxxxxxxxxx who have decided 
they are happy for us to go ahead with the study. 
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Who has funded this project? 
The project is being funded by the Medical Research Council who has allocated funds to 
Newcastle team for research into Mitochondrial Diseases. None of the research team will 
receive any direct (or indirect) payment for you entering this study.  
What if I have any concerns?  
 
If you have any concerns or other questions about this study or the way it has been carried 
out, you can contact either xxxxxxxxx xxxxxx on 0191 XXX XXXX (xxx.xxxx@ncl.ac.uk) or the 
Principal Investigator xxxx xxxxx on 0191 XXX XXXX 
You may also contact the xxx.xxxxx Hospitals Patient Advice Liaison Services department on 
telephone xxx xxxxx.  
If you feel that you have been treated unfairly throughout the research, or would like to 
make comment about the conduct of any aspect of this research, please contact the 
xxx.xxxxx NHS Foundation Trust complaints department on 0191 XXX XXXX. 
 
Thank you for reading this information sheet  
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To be on Hospital Headed Paper 
 
 
 
 
 
 
 
You are being invited to take part in a research study. Before you accept or decline the 
invitation, it is important for you for to understand why the research is being done and 
what it will involve. Please read the following information and discuss it with relatives, 
friends and your GP, if you wish. If there is anything that is not clear, or if you have any 
further questions, please ask us (our contact details are printed on page 4).  
Why are we asking you to take part? 
You are being invited to take part in this research because you have mitochondrial 
disease or carry a mitochondrial DNA mutation and you have expressed an interest in 
discussing your reproductive options for the future with your doctor. 
Do I have to participate? 
It is up to you to decide whether you want to join the study. If you agree to take part, we 
will then ask you to complete a consent form. You are free to withdraw at any time, 
without giving any reason. This would not affect the standard of care you receive. 
 
Reproductive Decision Making  
Women who may be faced with a decision Patient Information Sheet  Version 1 28/03/2014 
   
 
Reproductive Decision Making in Mitochondrial Patients: A Qualitative Investigation of 
Women’s Experience  
 
Patient Information Sheet for  
Women who may be faced with a decision 
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What is the purpose of this study? 
Approximately 1 in 3,500 women are affected by a mitochondrial DNA mutation, many of 
whom are of childbearing age. The study aims to look at how women diagnosed with 
mitochondrial disease, or carrying a mitochondrial DNA mutation have made reproductive 
decisions in the past and how they make decisions now. Reproductive decisions to some 
woman may mean, deciding to try to become pregnant or deciding not to become pregnant. 
Little is known about how patients with mitochondrial disease make these important and 
complex decisions.  
We would like to conduct interviews with two groups of women, women who have made 
reproductive decision/decisions in the past 16 years (Retrospective Group) and those women 
who are making decisions now or in the future (Current/Prospective Group). 
We are interested in learning about topics: 
• what is important to you at this time, 
• what information you have received or have not received at this time that would 
help 
      you to make a decision 
• and how you feel about new reproductive techniques.  
 
 This study is part of a PhD project for Julia Maddison, who is part of the Mitochondrial 
Research Group; results from this study will form part of her thesis.  
What happens if I agree to take part? 
The study will involve a one to one interview with the researcher. Interviews will last between 
45-90 minutes; they can be paused or stopped at any time. There will be some areas we are 
keen to discuss but you are free to talk about anything you think is important about the 
decision you are making now or in future.  
If you are interested in taking part in this study, a member of the research team will contact 
you to arrange a time and date for your interview; you will be asked to sign a consent form 
before the interview starts.  
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The interview will take place at a time convenient to you, usually coinciding with your 
planned clinic visit. If this is not possible we will make an appointment at a time most 
convenient for you to attend the Clinical Research Facility at the xxxx.xxxx , xxxx xxxx or 
the researcher will visit you at your home or a location that you feel the most 
comfortable.  
If you prefer, someone else, like a partner, a member of your family or a close friend, can 
also take part in the interview with you. Any travel / parking costs for helping with this 
research will be refunded. 
Taking part in this study is voluntary; you can decline to take part at any time. Not taking 
part in this study will not affect the standard of care you receive. If you decide after the 
interview has taken place that you would like collected data to be destroyed and not 
used, this will be done at your request. 
Will information about me be kept confidential? 
All information we receive from you will be treated confidentially. Your personal details 
and replies will be kept safe and secure. The interview will be audio-recorded so that the 
researcher can transcribe the information accurately. The audio-recording will be 
destroyed six months after we have finished analysing and writing up the data. Written 
information will be kept secure in a locked office and only members of  XXXX XXXX team 
will be given permission to look at this information. Your personal details will be 
converted into a code and stored on a secure computer located at Newcastle University. If 
we publish any research, we ask your permission to use direct quotes; this will not 
identify you in any way.  
Research records and data may also be inspected by regulatory bodies for audit purposes. 
This is a normal part of research and it is just to make sure that we are doing everything 
right. 
Are there any benefits to taking part? 
We cannot promise the study will help you personally, but we hope that the information 
we get from this study will help to improve the way we discuss and support patients who 
will be faced with making reproductive decisions in the future.  
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Are there any disadvantages to taking part? 
Giving up your time to take part in this project has to be considered. We also recognise that 
the topic of this interview is sensitive and may cause some distress. Taking part in this study is 
voluntary and you do not have to take part if you feel that you would be too upset discussing 
this topic. We will do our best to make you feel as comfortable as possible.  
If you feel on the day of the planned interview that you would like to rearrange, this would not 
be a problem. If you feel before or during your interview you would like to take some time 
out, or stop the interview it is completely acceptable to do so. 
We would like to support you as much as possible. Approximately 7-10 days following your 
interview the research team will contact you to make sure that you have not been left feeling 
upset or distressed. If you feel that after taking part in the interview (either immediately or in 
the weeks/months following) you would like to discuss things further, the research team can 
make a referral to your doctor or other appropriate NHS services and can also provide you 
with details of counselling services. This will only be done with your consent to do so.  
The only time we will disclose your personal information without your prior consent would be   
if during the interview you disclose any information that could be deemed related to your 
safety or safety of others. We would then contact your health care team or other appropriate 
services.  
What happens at the end of the research study? 
We hope to interview up to 15 women from each group, a total of up to 30 women over 1-2 
years. At the end of the study, we will be able to inform you of the outcomes of the study in a 
newsletter. You will not be made identifiable in the newsletter or any published work.  You 
will be welcome to have a copy of the results once they are published. 
Who has reviewed this project? 
All research conducted within the NHS has to be reviewed by an ethics committee to make 
sure we are not doing anything harmful to you or your personal information in this project. 
This research has been reviewed by NRES Committee xxxxxxxxxx who have decided they are 
happy for us to go ahead with the study. 
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Who has funded this project? 
The project is being funded by the Medical Research Council who has allocated funds to 
Newcastle team for research into Mitochondrial Diseases. None of the team will receive 
any direct (or indirect) payment for you entering this study.  
What if I have any concerns?  
If you have any concerns or other questions about this study or the way it has been 
carried out, you can contact either xxxxxxxxx xxxxxx on 0191 XXX XXXX 
(xxx.xxxx@ncl.ac.uk) or the Principal Investigator XXXX XXXX on 0191 XXX XXXX. You may 
also contact the xxxx.xxxx Hospitals Patient Advice Liaison Services department on 
telephone xxxx.xxxx  
If you feel that you have been treated unfairly throughout the research, or would like to 
make comment about the conduct of any aspect of this research, please contact the 
xxxx.xxxxx NHS Foundation Trust complaints department on 0191 xxxx.xxxx. 
 
Thank you for reading this information sheet  
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To be on Hospital Headed Paper 
 
 
 
 
 
 
Your partner, family member or close friend has been invited to take part in a research 
study. If you choose to accompany them it is important for you for to understand why the 
research is being done and what it will involve. Please read the following information and 
discuss it with your partner, family member or close friend. If there is anything that is not 
clear, or if you have any further questions, please ask us (our contact details are printed on 
page 4).  
Why are we asking you to take part? 
Your partner, family member or close friend has been invited to take part in this research 
because they have mitochondrial disease or carries a mitochondrial DNA mutation and they 
have made a reproductive decision in the past. 
Do I have to participate? 
It is up to you to decide whether you want to join the study. If you agree to take part, we 
will then ask you to complete a consent form. You are free to withdraw at any time, 
without giving any reason. This would not affect the standard of care your partner, family 
member or close friend receives. 
Partner/Family Member/Close Friend Information Sheet 
Women who have made a decision   Version 2 05/06/2014 
 
  
 
Reproductive Decision Making in Mitochondrial Patients: A Qualitative Investigation of 
Women’s Experience  
Partner/Family Member/Close Friend Information Sheet for 
Women who have made a decision  
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What is the purpose of this study? 
Approximately 1 in 3,500 women are affected by a mitochondrial DNA mutation, many 
of whom are of childbearing age. The study aims to look at how women diagnosed 
with mitochondrial disease, or carrying a mitochondrial DNA mutation have made 
reproductive decisions in the past and how they make decisions now. Reproductive 
decisions to some woman may mean, deciding to try to become pregnant or deciding 
not to become pregnant. Little is known about how patients with mitochondrial 
disease make these important and complex decisions. 
We would like to conduct interviews with two groups of women, women who have 
made reproductive decision/decisions in the past 16 years (Retrospective Group) and 
those women who are making decisions now (Current/Prospective Group).  
We are interested in learning about topics like: 
• how they made this decision (or multiple decisions),  
• what was important to them at the time,  
• what information they received or did not receive at the time that would have 
helped them to make a decision  
• and how they feel about new reproductive techniques.  
 
This study is part of a PhD project for Julia Maddison, who is part of the Mitochondrial 
Research Group; results from this study will form part of her thesis. 
What happens if I agree to take part? 
The study will involve a one to one interview with the researcher and your partner, 
family member or close friend. Interviews will last between 45-90 minutes; they can be 
paused or stopped at any time. There will be some areas we are keen to discuss but 
your partner, family member or close friend are free to talk about anything they think 
is important about how they made your reproductive decision/decisions. We will not 
be asking questions to you directly, but if you want to add anything that is fine  
If your partner, family member or close friend is interested in taking part in this study, 
a member of the research team will contact them to arrange a time and date for their 
interview.  
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If you choose to attend the interview both yourself and your partner, family member or 
close friend will be asked to sign a consent form before the interview starts.  
The interview will take place at a time convenient to your partner, family member or close 
friend, usually coinciding with their planned clinic visit. If this is not possible we will make 
an appointment at a time most convenient for them to attend the Clinical Research Facility 
at the xxx xxxx, xxxxx xxxx or the researcher will visit them at their home or a location that 
they feel the most comfortable. Any travel / parking costs for helping with this research will 
be refunded. 
Taking part in this study is voluntary; yourself and your partner, family member or close 
friend can decline to take part at any time. Not taking part in this study will not affect the 
standard of care your partner, family member or close friend will receive. If your partner, 
family member or close friend decide after the interview has taken place that they would 
like their collected data to be destroyed and not used, this will be done at their request. 
This is also the case if you wish that your collected data to be destroyed (if you choose to 
add anything to the interview).  
Will information about me be kept confidential? 
All information we receive from your partner, family member or close friend and yourself 
will be treated confidentially. Your personal details and replies will be kept safe and secure. 
The interview will be audio-recorded so that the researcher can transcribe the information 
accurately. The audio-recording will be destroyed six months after we have finished 
analysing and writing up the data. Written information will be kept secure in a locked office 
and only members of XXXX XXXX team will be given permission to look at this information. 
Your personal details will be converted into a code and stored on a secure computer 
located at Newcastle University. If we publish any research, we ask your permission to use 
direct quotes; this will not identify you in any way.  
Research records and data may also be inspected by regulatory bodies for audit purposes. 
This is a normal part of research and it is just to make sure that we are doing everything 
right. 
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Are there any benefits to taking part? 
We cannot promise the study will help you or your partner, family member or close 
friend personally, but we hope that the information we get from this study will help to 
improve the way we discuss and support patients who will be faced with making 
reproductive decisions in the future.  
Are there any disadvantages to taking part? 
Giving up your time to take part in this project has to be considered. We also recognise 
that the topic of this interview is sensitive and may cause some distress. Taking part in 
this study is voluntary and yourself and your partner, family member or close friend do 
not have to take part if you feel that it would be too upset discussing this topic. We will 
do our best to make yourself and your partner, family member or close friend feel as 
comfortable as possible. If your partner, family member or close friend feel on the day 
of the planned interview that they would like to rearrange, this would not be a 
problem. If they feel before or during the interview they would like to take some time 
out, or stop the interview that is completely acceptable to do so. 
We would like to support your partner, family member or close friend as much as 
possible. Approximately 7-10 days following your interview the research team will 
contact them to make sure that they have not been left feeling upset or distressed. If 
they feel that after taking part in the interview (either immediately or in the 
weeks/months following) they would like to discuss things further, the research team 
can make a referral to their doctor or other appropriate NHS services and can also 
provide them with details of counselling services. This will only be done with their 
consent to do so.  
The only time we will disclose personal information without your partner, family 
member or close friend or your prior consent would be if during the interview any 
information is disclosed that could be deemed related to the safety of you both or the 
safety of others. We would then contact their health care team or other appropriate 
services.  
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What happens at the end of the research study? 
We hope to interview 15 women from each group, a total of 30 women over 1- 2 years. 
At the end of the study, we will be able to inform your partner, family member or close 
friend of the outcomes of the study in a newsletter. Your partner, family member or 
close friend and yourself will not be made identifiable in the newsletter or any 
published work.  You will be welcome to have a copy of the results once they are 
published. 
Who has reviewed this project? 
All research conducted within the NHS has to be reviewed by an ethics committee to 
make sure we are not doing anything harmful to you or your personal information in 
this project. This research has been reviewed by NRES xxx xxxxx who have decided they 
are happy for us to go ahead with the study. 
Who has funded this project? 
The project is being funded by the Medical Research Council who has allocated funds 
to Newcastle team for research into Mitochondrial Diseases. None of the research 
team will receive any direct (or indirect) payment for entering your partner, family 
member or close friend or yourself into this study.  
What if I have any concerns?  
If you have any concerns or other questions about this study or the way it has been 
carried out, you can contact either Julia Maddison on 0191 XXXX. XXXX 
(xxx.xxxx@ncl.ac.uk) or the Principal Investigator XXXX XXXX on 0191 XXXX XXXYou 
may also contact the xxxx xxx x Patient Advice Liaison Services department on 
telephone XXXX.  
If you feel that your partner, family member or close friend or yourself have been 
treated unfairly throughout the research, or would like to make comment about the 
conduct of any aspect of this research, please contact the XXX XXXX NHS Foundation 
Trust complaints department on 0191 XXX XXXX. 
Thank you for reading this information sheet 
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To be on Hospital Headed Paper 
 
 
 
 
 
 
Your partner, family member or close friend has been invited to take part in a research 
study. If you choose to accompany them it is important for you for to understand why 
the research is being done and what it will involve. Please read the following information 
and discuss it with your partner, family member or close friend. If there is anything that 
is not clear, or if you have any further questions, please ask us (our contact details are 
printed on page 4).  
Why are we asking you to take part? 
Your partner, family member or close friend has been invited to take part in this 
research because they have mitochondrial disease or carry a mitochondrial DNA 
mutation and have expressed an interest in discussing their reproductive options for the 
future with their doctor. 
Do I have to participate? 
It is up to you to decide whether you want to join the study. If you agree to take part, we 
will then ask you to complete a consent form. You are free to withdraw at any time, 
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without giving any reason. This would not affect the standard of care your partner, 
family member or close friend receives. 
What is the purpose of this study? 
Approximately 1 in 3,500 women are affected by a mitochondrial DNA mutation, many 
of whom are of childbearing age. The study aims to look at how women diagnosed with 
mitochondrial disease, or carrying a mitochondrial DNA mutation have made 
reproductive decisions in the past and how they make decisions now. Reproductive 
decisions to some woman may mean, deciding to try to become pregnant or deciding 
not to become pregnant. Little is known about how patients with mitochondrial disease 
make these important and complex decisions.  
 We would like to conduct interviews with two groups of women, women who have 
made reproductive decision/decisions in the past 16 years (Retrospective Group) and 
those women who are making decisions now or in the future (Current/ Prospective 
Group).  
 We are interested in learning about topics: 
• what is important to them at this time, 
• what information they have received or have not received at this time that would 
help them to make a decision 
• and how they feel about new reproductive techniques.  
 
This study is part of a PhD project for Julia Maddison, who is part of the Mitochondrial 
Research Group; results from this study will form part of her thesis.  
What happens if I agree to take part? 
The study will involve a one to one interview with the researcher and your partner, 
family member or close friend. Interviews will last between 45-90 minutes; they can be 
paused or stopped at any time. There will be some areas we are keen to discuss but your 
partner, family member or close friend are free to talk about anything they think is 
important about how they made your reproductive decision/decisions. We will not be 
asking questions to you directly, but if you want to add anything that is fine  
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If your partner, family member or close friend is interested in taking part in this study, a 
member of the research team will contact them to arrange a time and date for their 
interview; if you choose to attend the interview both yourself and your partner, family 
member or close friend will be asked to sign a consent form before the interview starts.  
The interview will take place at a time convenient to your partner, family member or 
close friend, usually coinciding with their planned clinic visit. If this is not possible we will 
make an appointment at a time most convenient for them to attend the Clinical 
Research Facility at the xxxx xxxx , xxx xxxx or the researcher will visit them at their 
home or a location that they feel the most comfortable. Any travel / parking costs for 
helping with this research will be refunded. 
Taking part in this study is voluntary; yourself and your partner, family member or close 
friend can decline to take part at any time. Not taking part in this study will not affect 
the standard of care your partner, family member or close friend will receive. If your 
partner, family member or close friend decide after the interview has taken place that 
they would like their collected data to be destroyed and not used, this will be done at 
their request. This is also the case if you wish that your collected data to be destroyed (if 
you choose to add anything to the interview).  
Will information about me be kept confidential? 
All information we receive from your partner, family member or close friend and 
yourself will be treated confidentially. Your personal details and replies will be kept safe 
and secure. The interview will be audio-recorded so that the researcher can transcribe 
the information accurately. The audio-recording will be destroyed six months after we 
have finished analysing and writing up the data. Written information will be kept secure 
in a locked office and only members of XXXX XXXX team will be given permission to look 
at this information. Your personal details will be converted into a code and stored on a 
secure computer located at Newcastle University. If we publish any research, we ask 
your permission to use direct quotes; this will not identify you in any way.  
Research records and data may also be inspected by regulatory bodies for audit 
purposes. This is a normal part of research and it is just to make sure that we are doing 
everything right. 
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Are there any benefits to taking part? 
We cannot promise the study will help you or your partner, family member or close friend 
personally, but we hope that the information we get from this study will help to improve 
the way we discuss and support patients who will be faced with making reproductive 
decisions in the future.  
Are there any disadvantages to taking part? 
Giving up your time to take part in this project has to be considered. We also recognise that 
the topic of this interview is sensitive and may cause some distress. Taking part in this study 
is voluntary and yourself and your partner, family member or close friend do not have to 
take part if you feel that it would be too upset discussing this topic. We will do our best to 
make yourself and your partner, family member or close friend feel as comfortable as 
possible.  
If your partner, family member or close friend feel on the day of the planned interview that 
they would like to rearrange, this would not be a problem. If they feel before or during the 
interview they would like to take some time out, or stop the interview that is completely 
acceptable to do so. 
We would like to support your partner, family member or close friend as much as possible. 
Approximately 7-10 days following your interview the research team will contact them to 
make sure that they have not been left feeling upset or distressed. If they feel that after 
taking part in the interview (either immediately or in the weeks/months following) they 
would like to discuss things further, the research team can make a referral to their doctor 
or other appropriate NHS services and can also provide them with details of counselling 
services. This will only be done with their consent to do so.  
The only time we will disclose personal information without your partner, family member 
or close friend or your prior consent would be if during the interview any information is 
disclosed that could be deemed related to the safety of you both or the safety of others. 
We would then contact their health care team or other appropriate services.  
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What happens at the end of the research study? 
We hope to interview 15 women from each group, a total of 30 women over 1- 2 years. At 
the end of the study, we will be able to inform your partner, family member or close friend 
of the outcomes of the study in a newsletter. Your partner, family member or close friend 
and yourself will not be made identifiable in the newsletter or any published work.  You will 
be welcome to have a copy of the results once they are published. 
Who has reviewed this project? 
All research conducted within the NHS has to be reviewed by an ethics committee to make 
sure we are not doing anything harmful to you or your personal information in this project.  
This research has been reviewed by NRES  xxxx xxxx who have decided they are happy for us 
to go ahead with the study. 
Who has funded this project? 
The project is being funded by the Medical Research Council who has allocated funds to 
Newcastle team for research into Mitochondrial Diseases.  
None of the research team will receive any direct (or indirect) payment for entering your 
partner, family member or close friend or yourself into this study.  
What if I have any concerns?  
 If you have any concerns or other questions about this study or the way it has been carried 
out, you can contact either Julia Maddison on 0191 XXX XXXX (xxxx.xxxx@ncl.ac.uk) or the 
Principal Investigator XXXX XXXX on 0191 XXX XXXX 
 You may also contact the xxxxx xxxxx Advice Liaison Services department on telephone 
xxxx.xxxxx  
 If you feel that you have been treated unfairly throughout the research, or would like to 
make comment about the conduct of any aspect of this research, please contact the xxxxx 
xxxxx  NHS Foundation Trust complaints department on 0191 XXX XXXX. 
Thank you for reading this information sheet  
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To be on Hospital Headed Paper 
 
 
 
 
 
 
 
You are being invited to take part in a research study. Before you accept or decline the 
invitation, it is important for you for to understand why the research is being done and what it 
will involve. Please read the following information and discuss it with relatives, friends and 
your GP, if you wish. If there is anything that is not clear, or if you have any further questions, 
please ask us (our contact details are printed on page 4).  
Why are we asking you to take part? 
You are being invited to take part in this research because you have mitochondrial disease or 
carry a mitochondrial DNA mutation and you have expressed an interest in discussing your 
reproductive options for the future with your doctor. 
Do I have to participate? 
It is up to you to decide whether you want to join the study. If you agree to take part, we will 
then ask you to complete a consent form. You are free to withdraw at any time, without giving 
any reason. This would not affect the standard of care you receive. 
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What is the purpose of this study? 
Approximately 1 in 3,500 women are affected by a mitochondrial DNA mutation, many 
of whom are of childbearing age. The study aims to look at how women diagnosed with 
mitochondrial disease, or carrying a mitochondrial DNA mutation have made 
reproductive decisions in the past and how  they make decisions now. Reproductive 
decisions to some woman may mean, deciding to try  to become pregnant or 
deciding not to become pregnant. Little is known about how patients  with 
mitochondrial disease make these important and complex decisions.  
We would like to conduct interviews with two groups of women, women who have 
made reproductive decision/decisions in the past 21 years (Retrospective Group) and 
those women who are making decisions now or in the future (Current/Prospective 
Group).  
We are interested in learning about topics: 
• what is important to you at this time, 
• what information you have received or have not received at this time that would 
help you to make a decision 
• and how you feel about new reproductive techniques.  
 
This study is part of a PhD project for Julia Maddison, who is part of the Mitochondrial 
Research Group; results from this study will form part of her thesis.  
What happens if I agree to take part? 
The study will involve a one to one interview with the researcher. Interviews will last 
between 45-90 minutes; they can be paused or stopped at any time. If you would 
prefer, a telephone interview can be arranged. There will be some areas we are keen to 
discuss but you are free to talk about anything you think is important about the decision 
you are making now or in future.  
If you are interested in taking part in this study, a member of the research team will 
contact you to arrange a time and date for your interview; you will be asked to sign a 
consent form before the interview starts. If you have a telephone interview verbal 
consent will be taken over the phone and documented. 
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The interview will take place at a time convenient to you, usually coinciding with your 
planned clinic visit. If this is not possible we will make an appointment at a time most 
convenient for you to attend the Clinical Research Facility at the xxx xxxxxx or the researcher 
will visit you at your home or a location that you feel the most comfortable. If you would 
wish to take part over the telephone the researcher will ring you at a time most 
convenient for you.  
If you prefer, someone else, like a partner, a member of your family or a close friend, can 
also take part in the interview with you. Any travel / parking costs for helping with this 
research will be refunded. 
Taking part in this study is voluntary; you can decline to take part at any time. Not taking part 
in this study will not affect the standard of care you receive. If you decide after the interview 
has taken place that you would like collected data to be destroyed and not used, this will be 
done at your request 
Will information about me be kept confidential? 
All information we receive from you will be treated confidentially. Your personal details and 
replies will be kept safe and secure. The interview will be audio-recorded so that the 
researcher can transcribe the information accurately. The audio-recording will be destroyed 
six months after we have finished analysing and writing up the data. Written information will 
be kept secure in a locked office and only members of XXXX XXXX team will be given 
permission to look at this information.  
Your personal details will be converted into a code and stored on a secure computer located 
at Newcastle University. If we publish any research, we ask your permission to use direct 
quotes; this will not identify you in any way.  
Research records and data may also be inspected by regulatory bodies for audit purposes. 
This is a normal part of research and it is just to make sure that we are doing everything 
right. 
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Are there any benefits to taking part? 
We cannot promise the study will help you personally, but we hope that the information we 
get from this study will help to improve the way we discuss and support patients who will be 
faced with making reproductive decisions in the future.  
Are there any disadvantages to taking part? 
Giving up your time to take part in this project has to be considered. We also recognise that 
the topic of this interview is sensitive and may cause some distress. Taking part in this study 
is voluntary and you do not have to take part if you feel that you would be too upset 
discussing this topic. We will do our best to make you feel as comfortable as possible. 
 If you feel on the day of the planned interview that you would like to rearrange, this would 
not be a problem. If you feel before or during your interview you would like to take some 
time out, or stop the interview it is completely acceptable to do so. 
We would like to support you as much as possible. Approximately 7-10 days following your 
interview the research team will contact you to make sure that you have not been left 
feeling upset or distressed. If you feel that after taking part in the interview (either 
immediately or in the weeks/months following) you would like to discuss things further, the 
research team can make a referral to your doctor or other appropriate NHS services and can 
also provide you with details of counselling services. This will only be done with your consent 
to do so.  
The only time we will disclose your personal information without your prior consent would 
be   if during the interview you disclose any information that could be deemed related to 
your safety or safety of others. We would then contact your health care team or other 
appropriate services.  
What happens at the end of the research study? 
We hope to interview up to 15 women from each group, a total of up to 30 women over 1-2 
years. At the end of the study, we will be able to inform you of the outcomes of the study in 
a newsletter. You will not be made identifiable in the newsletter or any published work.  You 
will be welcome to have a copy of the results once they are published. 
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Who has reviewed this project? 
All research conducted within the NHS has to be reviewed by an ethics committee to 
make sure we are not doing anything harmful to you or your personal information in this 
project.  
This research has been reviewed by NRES Committee xxxx.xxxxx  who have decided they 
are happy for us to go ahead with the study. 
Who has funded this project? 
The project is being funded by the Medical Research Council who has allocated funds to 
Newcastle team for research into Mitochondrial Diseases. None of the team will receive 
any direct (or indirect) payment for you entering this study.  
What if I have any concerns?  
If you have any concerns or other questions about this study or the way it has been 
carried out, you can contact either Julia Maddison on 0191 XXX XXXX 
(xxx.xxxx@ncl.ac.uk) or the Principal Investigator XXXX XXXX on 0191 XXX XXXX 
You may also contact the xxx.xxxxx. Patient Advice Liaison Services department on 
telephone xxxx xxxx   
If you feel that you have been treated unfairly throughout the research, or would like to 
make comment about the conduct of any aspect of this research, please contact the xxx 
xxxxx NHS Foundation Trust complaints department on 0191 XXX XXXX. 
Thank you for reading this information sheet  
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To be on Hospital Headed Paper  
 
 
 
 
 
 
You are being invited to take part in a research study. Before you accept or decline the 
invitation, it is important for you for to understand why the research is being done and what it 
will involve. Please read the following information and discuss it with relatives, friends and your 
GP, if you wish. If there is anything that is not clear, or if you have any further questions, please 
ask us (our contact details are printed on page 4).  
Why are we asking you to take part? 
You are being invited to take part in this research because you have mitochondrial disease 
or carry a mitochondrial DNA mutation and you have made a reproductive decision in the 
last 16 years  
Do I have to participate? 
It is up to you to decide whether you want to join the study. If you agree to take part, we 
will then ask you to complete a consent form. You are free to withdraw at any time, 
without giving any reason. This would not affect the standard of care you receive. 
What is the purpose of this study? 
Approximately 1 in 3,500 women are affected by a mitochondrial DNA mutation, many of 
whom are of childbearing age.  
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The study aims to look at how women diagnosed with mitochondrial disease, or carrying a 
mitochondrial DNA mutation have made reproductive decisions in the past and how they 
make decisions now.  
Reproductive decisions to some woman may mean, deciding to try to become pregnant or 
deciding not to become pregnant. Little is known about how patients with mitochondrial 
disease make these important and complex decisions.  
We would like to conduct interviews with two groups of women, women who have made 
reproductive decision/decisions in the past 21 years (Retrospective Group) and those women 
who are making decisions now (Current/Prospective Group).  
We are interested in learning about topics like: 
• how you made this decision (or multiple decisions),  
• what was important to you at the time,  
• what information you received or did not receive at the time that would have helped 
you to make a decision  
• and how you feel about new reproductive techniques.  
 
This study is part of a PhD project for Julia Maddison, who is part of the Mitochondrial 
Research Group; results from this study will form part of her thesis. 
What happens if I agree to take part? 
The study will involve a one to one interview with the researcher. Interviews will last between 
45-90 minutes; they can be paused or stopped at any time. If you would prefer, a telephone 
interview can be arranged. There will be some areas we are keen to discuss but you are free 
to talk about anything you think is important about how you made your reproductive 
decision/decisions.  
If you are interested in taking part in this study, a member of the research team will contact 
you to arrange a time and date for your interview; you will be asked to sign a consent form 
before the interview starts. If you have a telephone interview verbal consent will be taken 
over the phone and documented.  
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The interview will take place at a time convenient to you, usually coinciding with your 
planned clinic visit. If this is not possible we will make an appointment at a time most 
convenient for you to attend the Clinical Research Facility at the xxxx xxxxx xxxxx  or the 
researcher will visit you at your home or a location that you feel the most comfortable. 
If you would wish to take part over the telephone the researcher will ring you at a 
time most convenient for you. If you prefer, someone else, like a partner, a member of 
your family or a close friend, can also take part in the interview with you. Any travel / 
parking costs for helping with this research will be refunded. 
Taking part in this study is voluntary; you can decline to take part at any time. Not taking 
part in this study will not affect the standard of care you receive. If you decide after the 
interview has taken place that you would like collected data to be destroyed and not 
used, this will be done at your request. 
Will information about me be kept confidential? 
All information we receive from you will be treated confidentially. Your personal details 
and replies will be kept safe and secure. The interview will be audio-recorded so that the 
researcher can transcribe the information accurately. The audio-recording will be 
destroyed six months after we have finished analysing and writing up the data. Written 
information will be kept secure in a locked office and only members of XXXX XXXX team 
will be given permission to look at this information. Your personal details will be 
converted into a code and stored on a secure computer located at Newcastle University. 
If we publish any research, we ask your permission to use direct quotes; this will not 
identify you in any way.  
Research records and data may also be inspected by regulatory bodies for audit 
purposes. This is a normal part of research and it is just to make sure that we are doing 
everything right. 
Are there any benefits to taking part? 
We cannot promise the study will help you personally, but we hope that the information 
we get from this study will help to improve the way we discuss and support patients 
who will be faced with making reproductive decisions in the future.  
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Are there any disadvantages to taking part? 
Giving up your time to take part in this project has to be considered. We also recognise 
that the topic of this interview is sensitive and may cause some distress. Taking part in 
this study is voluntary and you do not have to take part if you feel that you would be too 
upset discussing this topic. We will do our best to make you feel as comfortable as 
possible. If you feel on the day of the planned interview that you would like to 
rearrange, this would not be a problem. If you feel before or during your interview you 
would like to take some time out, or stop the interview it is completely acceptable to do 
so. 
We would like to support you as much as possible. Approximately 7-10 days following 
your interview the research team will contact you to make sure that you have not been 
left feeling upset or distressed.  
If you feel that after taking part in the interview (either immediately or in the 
weeks/months following) you would like to discuss things further, the research team can 
make a referral to your doctor or other appropriate NHS services and can also provide 
you with details of counselling services. This will only be done with your consent to do 
so.  
The only time we will disclose your personal information without your prior consent 
would be   if during the interview you disclose any information that could be deemed 
related to your safety or safety of others. We would then contact your health care team 
or other appropriate services.  
What happens at the end of the research study? 
We hope to interview 15 women from each group, a total of 30 women over 1 to 2 
years. At the end of the study, we will be able to inform you of the outcomes of the 
study in a newsletter. You will not be made identifiable in the newsletter or any 
published work.  You will be welcome to have a copy of the results once they are 
published. 
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Who has reviewed this project? 
All research conducted within the NHS has to be reviewed by an ethics committee to make 
sure we are not doing anything harmful to you or your personal information in this project.  
This research has been reviewed by NRES Committee xxxx xxxx who have decided they are 
happy for us to go ahead with the study. 
Who has funded this project? 
The project is being funded by the Medical Research Council who has allocated funds to 
Newcastle team for research into Mitochondrial Diseases. None of the research team will 
receive any direct (or indirect) payment for you entering this study.  
What if I have any concerns?  
If you have any concerns or other questions about this study or the way it has been carried 
out, you can contact either Julia Maddison on 0191 XXX XXXX (xxxx.xxxx@ncl.ac.uk) or the 
Principal Investigator XXXX XXXX on 0191 XXX XXX  
You may also contact the xxxx xxxxx Hospitals Patient Advice Liaison Services department on 
telephone xxxx xxxxx 
If you feel that you have been treated unfairly throughout the research, or would like to 
make comment about the conduct of any aspect of this research, please contact the xxxx 
xxxxx NHS Foundation Trust complaints department on 0191 XXX XXXX. 
 
Thank you for reading this information sheet  
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To be on Hospital Headed Paper 
 
 
 
 
 
Your partner, family member or close friend has been invited to take part in a research 
study. If you choose to accompany them it is important for you for to understand why the 
research is being done and what it will involve. Please read the following information and 
discuss it with your partner, family member or close friend. If there is anything that is not 
clear, or if you have any further questions, please ask us (our contact details are printed on 
page 4).  
Why are we asking you to take part? 
Your partner, family member or close friend has been invited to take part in this research 
because they have mitochondrial disease or carry a mitochondrial DNA mutation and have 
expressed an interest in discussing their reproductive options for the future with their 
doctor. 
Do I have to participate? 
It is up to you to decide whether you want to join the study. If you agree to take part, we will 
then ask you to complete a consent form. You are free to withdraw at any time, without 
giving any reason. This would not affect the standard of care your partner, family member or 
close friend receives. 
 
Partner/Family Member /Close Friend Information Sheet 
Women who may be faced with a decision    Version 3 08/04/2015 
 
 
297 
 
 
Reproductive Decision Making  
Women who have made a decision Patient Information Sheet Version 2 08/04/2015 
   
 
Reproductive Decision Making in Mitochondrial Patients: A Qualitative Investigation of 
Women’s Experience  
Partner/Family Member/Close Friend Information Sheet for 
Women who may be faced with a decision 
 298 
 
What is the purpose of this study? 
Approximately 1 in 3,500 women are affected by a mitochondrial DNA mutation, many of 
whom are of childbearing age. The study aims to look at how women diagnosed with 
mitochondrial disease, or carrying a mitochondrial DNA mutation have made reproductive 
decisions in the past and how they make decisions now.  
Reproductive decisions to some woman may mean, deciding to try to become pregnant or 
deciding not to become pregnant. Little is known about how patients with mitochondrial 
disease make these important and complex decisions.  
We would like to conduct interviews with two groups of women, women who have made 
reproductive decision/decisions in the past 21 years (Retrospective Group) and those 
women who are making decisions now or in the future (Current/ Prospective Group).  
We are interested in learning about topics: 
• what is important to them at this time, 
• what information they have received or have not received at this time that would 
help them to make a decision 
•  and how they feel about new reproductive techniques.  
 
This study is part of a PhD project for Julia Maddison, who is part of the Mitochondrial 
Research Group; results from this study will form part of her thesis.  
What happens if I agree to take part? 
The study will involve a one to one interview with the researcher and your partner, family 
member or close friend. Interviews will last between 45-90 minutes; they can be paused or 
stopped at any time. If they prefer, a telephone interview can be arranged. There will be 
some areas we are keen to discuss but your partner, family member or close friend are free 
to talk about anything they think is important about how they made your reproductive 
decision/decisions. We will not be asking questions to you directly, but if you want to add 
anything that is fine  
If your partner, family member or close friend is interested in taking part in this study, a 
member of the research team will contact them to arrange a time and date for their 
interview; if you choose to attend the interview both yourself and your partner, family 
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member or close friend will be asked to sign a consent form before the interview starts. If 
your partner, family member or close friend takes part in a telephone interview verbal 
consent with be taken from you both over the phone and documented.  
The interview will take place at a time convenient to your partner, family member or close 
friend, usually coinciding with their planned clinic visit.  
If this is not possible we will make an appointment at a time most convenient for them to 
attend the Clinical Research Facility at the xxxx xxxx xxxxx or the researcher will visit them at 
their home or a location that they feel the most comfortable. If your partner, family 
member or close friend wishes to take part over the telephone the researcher will ring 
them at time most convenient to them. Any travel / parking costs for helping with this 
research will be refunded. 
Taking part in this study is voluntary; yourself and your partner, family member or close 
friend can decline to take part at any time. Not taking part in this study will not affect the 
standard of care your partner, family member or close friend will receive. If your partner, 
family member or close friend decide after the interview has taken place that they would like 
their collected data to be destroyed and not used, this will be done at their request. This is 
also the case if you wish that your collected data to be destroyed (if you choose to add 
anything to the interview).  
Will information about me be kept confidential? 
All information we receive from your partner, family member or close friend and yourself will 
be treated confidentially. Your personal details and replies will be kept safe and secure. The 
interview will be audio-recorded so that the researcher can transcribe the information 
accurately. The audio-recording will be destroyed six months after we have finished 
analysing and writing up the data. Written information will be kept secure in a locked office 
and only members of XXXX XXXX team will be given permission to look at this information. 
Your personal details will be converted into a code and stored on a secure computer located 
at Newcastle University. If we publish any research, we ask your permission to use direct 
quotes; this will not identify you in any way.  
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Research records and data may also be inspected by regulatory bodies for audit purposes. 
This is a normal part of research and it is just to make sure that we are doing everything 
right. 
Are there any benefits to taking part? 
We cannot promise the study will help you or your partner, family member or close friend 
personally, but we hope that the information we get from this study will help to improve the 
way we discuss and support patients who will be faced with making reproductive decisions in 
the future.  
Are there any disadvantages to taking part? 
Giving up your time to take part in this project has to be considered. We also recognise that 
the topic of this interview is sensitive and may cause some distress.  
Taking part in this study is voluntary and yourself and your partner, family member or close 
friend do not have to take part if you feel that it would be too upset discussing this topic. We 
will do our best to make yourself and your partner, family member or close friend feel as 
comfortable as possible. If your partner, family member or close friend feel on the day of the 
planned interview that they would like to rearrange, this would not be a problem. If they feel 
before or during the interview they would like to take some time out, or stop the interview 
that is completely acceptable to do so. 
We would like to support your partner, family member or close friend as much as possible. 
Approximately 7-10 days following your interview the research team will contact them to 
make sure that they have not been left feeling upset or distressed. If they feel that after 
taking part in the interview (either immediately or in the weeks/months following) they 
would like to discuss things further, the research team can make a referral to their doctor or 
other appropriate NHS services and can also provide them with details of counselling 
services. This will only be done with their consent to do so.  
The only time we will disclose personal information without your partner, family member or 
close friend or your prior consent would be if during the interview any information is 
disclosed that could be deemed related to the safety of you both or the safety of others. We 
would then contact their health care team or other appropriate services.  
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What happens at the end of the research study? 
We hope to interview 15 women from each group, a total of 30 women over 1- 2 years. At 
the end of the study, we will be able to inform your partner, family member or close friend 
of the outcomes of the study in a newsletter. Your partner, family member or close friend 
and yourself will not be made identifiable in the newsletter or any published work.  You will 
be welcome to have a copy of the results once they are published. 
Who has reviewed this project? 
All research conducted within the NHS has to be reviewed by an ethics committee to make 
sure we are not doing anything harmful to you or your personal information in this project.  
This research has been reviewed by NRES Committee xxxx xxxxx who have decided they are 
happy for us to go ahead with the study. 
Who has funded this project? 
The project is being funded by the Medical Research Council who has allocated funds to 
Newcastle team for research into Mitochondrial Diseases. None of the research team will 
receive any direct (or indirect) payment for entering your partner, family member or close 
friend or yourself into this study.  
What if I have any concerns?  
If you have any concerns or other questions about this study or the way it has been carried 
out, you can contact either Julia Maddison on 0191 XXX XXXX (xxxx xxxxx @ncl.ac.uk) or the 
Principal Investigator XXXX XXXX on 0191 XXX XXXX 
You may also contact the xxxx xxxxx Patient Advice Liaison Services department on 
telephone xxxx xxxx 
If you feel that you have been treated unfairly throughout the research, or would like to 
make comment about the conduct of any aspect of this research, please contact the xxxx 
xxxx NHS Foundation Trust complaints department on 0191 XXX XXXXX. 
Thank you for reading this information sheet 
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To be on hospital headed paper 
 
 
 
 
 
Your partner, family member or close friend has been invited to take part in a research 
study. If you choose to accompany them it is important for you for to understand why 
the research is being done and what it will involve. Please read the following information 
and discuss it with your partner, family member or close friend. If there is anything that 
is not clear, or if you have any further questions, please ask us (our contact details are 
printed on page 4).  
Why are we asking you to take part? 
Your partner, family member or close friend has been invited to take part in this 
research because they have mitochondrial disease or carry a mitochondrial DNA 
mutation and have expressed an interest in discussing their reproductive options for the 
future with their doctor. 
Do I have to participate? 
It is up to you to decide whether you want to join the study. If you agree to take part, we 
will then ask you to complete a consent form. You are free to withdraw at any time, 
without giving any reason. This would not affect the standard of care your partner, 
family member or close friend receives. 
Partner/Family Member /Close Friend Information Sheet 
Women who may be faced with a decision    Version 3 08/04/2015 
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What is the purpose of this study? 
Approximately 1 in 3,500 women are affected by a mitochondrial DNA mutation, many 
of whom are of childbearing age. The study aims to look at how women diagnosed with 
mitochondrial disease, or carrying a mitochondrial DNA mutation have made 
reproductive decisions in the past and how they make decisions now. Reproductive 
decisions to some woman may mean, deciding to try to become pregnant or deciding 
not to become pregnant. Little is known about how patients with mitochondrial disease 
make these important and complex decisions.  
We would like to conduct interviews with two groups of women, women who have 
made reproductive decision/decisions in the past 21 years (Retrospective Group) and 
those women who are making decisions now or in the future (Current/ Prospective 
Group).  
We are interested in learning about topics: 
• what is important to them at this time, 
• what information they have received or have not received at this time that 
would help 
       them to make a decision 
•  and how they feel about new reproductive techniques.  
 
This study is part of a PhD project for Julia Maddison, who is part of the Mitochondrial 
Research Group; results from this study will form part of her thesis.  
What happens if I agree to take part? 
The study will involve a one to one interview with the researcher and your partner, 
family member or close friend. Interviews will last between 45-90 minutes; they can be 
paused or stopped at any time. If they prefer, a telephone interview can be arranged. 
There will be some areas we are keen to discuss but your partner, family member or 
close friend are free to talk about anything they think is important about how they made 
your reproductive decision/decisions. We will not be asking questions to you directly, 
but if you want to add anything that is fine  
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If your partner, family member or close friend is interested in taking part in this study, a 
member of the research team will contact them to arrange a time and date for their 
interview; if you choose to attend the interview both yourself and your partner, family 
member or close friend will be asked to sign a consent form before the interview starts. 
If your partner, family member or close friend takes part in a telephone interview 
verbal consent with be taken from you both over the phone and documented.  
The interview will take place at a time convenient to your partner, family member or 
close friend, usually coinciding with their planned clinic visit. If this is not possible we will 
make an appointment at a time most convenient for them to attend the Clinical 
Research Facility at the xxxx xxxxx or the researcher will visit them at their home or a 
location that they feel the most comfortable. If your partner, family member or close 
friend wishes to take part over the telephone the researcher will ring them at time 
most convenient to them. Any travel / parking costs for helping with this research will 
be refunded. 
Taking part in this study is voluntary; yourself and your partner, family member or close 
friend can decline to take part at any time. Not taking part in this study will not affect 
the standard of care your partner, family member or close friend will receive. If your 
partner, family member or close friend decide after the interview has taken place that 
they would like their collected data to be destroyed and not used, this will be done at 
their request. This is also the case if you wish that your collected data to be destroyed (if 
you choose to add anything to the interview).  
Will information about me be kept confidential? 
All information we receive from your partner, family member or close friend and 
yourself will be treated confidentially. Your personal details and replies will be kept safe 
and secure. The interview will be audio-recorded so that the researcher can transcribe 
the information accurately. The audio-recording will be destroyed six months after we 
have finished analysing and writing up the data. Written information will be kept secure 
in a locked office and only members of XXXX XXXX team will be given permission to look 
at this information. Your personal details will be converted into a code and stored on a 
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secure computer located at Newcastle University. If we publish any research, we ask 
your permission to use direct quotes; this will not identify you in any way.  
Research records and data may also be inspected by regulatory bodies for audit 
purposes. This is a normal part of research and it is just to make sure that we are doing 
everything right. 
Are there any benefits to taking part? 
We cannot promise the study will help you or your partner, family member or close 
friend personally, but we hope that the information we get from this study will help to 
improve the way we discuss and support patients who will be faced with making 
reproductive decisions in the future.  
Are there any disadvantages to taking part? 
Giving up your time to take part in this project has to be considered. We also recognise 
that the topic of this interview is sensitive and may cause some distress. Taking part in 
this study is voluntary and yourself and your partner, family member or close friend do 
not have to take part if you feel that it would be too upset discussing this topic. We will 
do our best to make yourself and your partner, family member or close friend feel as 
comfortable as possible. If your partner, family member or close friend feel on the day 
of the planned interview that they would like to rearrange, this would not be a problem. 
If they feel before or during the interview they would like to take some time out, or stop 
the interview that is completely acceptable to do so. 
We would like to support your partner, family member or close friend as much as 
possible. Approximately 7-10 days following your interview the research team will 
contact them to make sure that they have not been left feeling upset or distressed. If 
they feel that after taking part in the interview (either immediately or in the 
weeks/months following) they would like to discuss things further, the research team 
can make a referral to their doctor or other appropriate NHS services and can also 
provide them with details of counselling services. This will only be done with their 
consent to do so.  
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The only time we will disclose personal information without your partner, family 
member or close friend or your prior consent would be if during the interview any 
information is disclosed that could be deemed related to the safety of you both or the 
safety of others. We would then contact their health care team or other appropriate 
services.  
What happens at the end of the research study? 
We hope to interview 15 women from each group, a total of 30 women over 1- 2 years. 
At the end of the study, we will be able to inform your partner, family member or close 
friend of the outcomes of the study in a newsletter. Your partner, family member or 
close friend and yourself will not be made identifiable in the newsletter or any published 
work.  You will be welcome to have a copy of the results once they are published. 
Who has reviewed this project? 
All research conducted within the NHS has to be reviewed by an ethics committee to 
make sure we are not doing anything harmful to you or your personal information in this 
project.  
This research has been reviewed by NRES Committee xxxx xxxx who have decided they 
are happy for us to go ahead with the study. 
Who has funded this project? 
The project is being funded by the Medical Research Council who has allocated funds to 
Newcastle team for research into Mitochondrial Diseases. None of the research team 
will receive any direct (or indirect) payment for entering your partner, family member or 
close friend or yourself into this study.  
What if I have any concerns?  
If you have any concerns or other questions about this study or the way it has been 
carried out, you can contact either Julia Maddison on 0191 XXX XXXX 
(xxx.xxxx@ncl.ac.uk) or the Principal Investigator XXXX XXXX on 0191 XXX XXXX 
You may also contact the xxxx xxxxx Patient Advice Liaison Services department on 
telephone xxx xxxx 
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If you feel that you have been treated unfairly throughout the research, or would like to 
make comment about the conduct of any aspect of this research, please contact the  
xxxx xxxxx NHS Foundation Trust complaints department on 0191 XXX XXXX  
 
Thank you for reading this information sheet  
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To be on hospital headed paper 
 
 
 
 
 
You are being invited to take part in an extension to a study that you participated in, in 
the past. Before you accept or decline the invitation, it is important for you for to 
understand why the extension to this research is being done and what it will involve. 
Please read the following information and discuss it with relatives, friends and your GP, 
if you wish. If there is anything that is not clear, or if you have any further questions, 
please ask us (our contact details are printed on page 4).  
Why are we asking you to take part? 
You are being invited to take part in the extension of a previous project that you took 
part in, in the past. You were previously invited to take part in the past because you 
have mitochondrial disease or carry a mitochondrial DNA mutation and you had 
expressed an interest in discussing your reproductive options for the future with your 
doctor. 
Do I have to participate? 
It is up to you to decide whether or not you want to participate in this extension. If you 
agree to take part, we will then ask you to complete another consent form. You are free 
Reproductive Decision Making  
Patient Information Sheet –Repeat Interview Arm Version 1 11/03/2016 
 
 
 
308 
 
 
Reproductive Decision Making  
Women who have made a decision Patient Information Sheet Version 2 08/04/2015 
   
 
Reproductive Decision Making in Mitochondrial Patients: A Qualitative Investigation 
of Women’s Experience  
Patient Information Sheet for  
Repeat Interview Arm 
 309 
 
to withdraw at any time, without giving any reason. This would not affect the standard 
of care you receive. 
What is the purpose of this study? 
Approximately 1 in 3,500 women are affected by a mitochondrial DNA mutation, many 
of whom are of childbearing age. The study aims to look at how women diagnosed with 
mitochondrial disease, or carrying a mitochondrial DNA mutation have made 
reproductive decisions in the past and how they make decisions now. Reproductive 
decisions to some women may mean, deciding to try to become pregnant or deciding 
not to become pregnant. Little is known about how patients with mitochondrial disease 
make these important and complex decisions.  
We have been conducting interviews in two groups of women, women who have made 
reproductive decision/decisions in the past 21 years (Retrospective Group) and those 
women who are making decisions now or in the future (Current/Prospective Group).  
We are interested in learning about topics: 
• what is important to women at this time, 
• what information women have received or have not received at this time that 
would help them to make a decision 
• and how women feel about new reproductive techniques.  
 
This study is part of a PhD project for Julia Maddison, who is part of the Mitochondrial 
Research Group; results from this study will form part of her thesis.  
What is the purpose of the extension to the study? 
A number of months or even years have elapsed since you were originally interviewed. 
Since the study was originally approved, changes in regulation have permitted the new 
reproductive technique, Mitochondrial Donation, to be considered by patients as a 
reproductive option. We have also been able to look at the data collected in interviews 
and we would like to gather more data on issues raised by patients. We would also like 
to see if your experiences or opinions on reproduction options are the same or different 
since your first interview. 
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What happens if I agree to take part? 
The study will involve another one to one interview with the researcher. Interviews will 
last between 30-45 minutes; they can be paused or stopped at any time. If you would 
prefer, a telephone interview can be arranged. There will be some areas we are keen to 
discuss but you are free to talk about anything you think is important about the decision 
you are making now, in future or may have made since your last interview.  
If you are interested in taking part in the extension of this study, a member of the 
research team will contact you to arrange a time and date for your interview; you will be 
asked to sign a new consent form before the interview starts. If you have a telephone 
interview verbal consent will be taken over the phone and documented. 
The interview will take place at a time convenient to you, usually coinciding with your 
planned clinic visit. If this is not possible, we will make an appointment at a time most 
convenient for you to attend the Clinical Research Facility at the xxxx xxxxx or the 
researcher will visit you at your home or a location that you feel the most comfortable. If 
you wish to take part over the telephone the researcher will ring you at a time most 
convenient for you. If you prefer, someone else, like a partner, a member of your family 
or a close friend, can also take part in the interview with you. Any travel / parking costs 
for helping with this research will be refunded. 
Taking part in this study is voluntary; you can decline to take part at any time. Not taking 
part in this study will not affect the standard of care you receive. If you decide after the 
interview has taken place that you would like collected data to be destroyed and not 
used, this will be done at your request. 
Will information about me be kept confidential? 
All information we receive from you will be treated confidentially. Your personal details 
and replies will be kept safe and secure. The interview, like your last interview, will be 
audio-recorded so that the researcher can transcribe the information accurately. The 
audio-recording will be destroyed six months after we have finished analysing and 
writing up the data. Written information will be kept secure in a locked office and only 
members of XXXX XXXX team will be given permission to look at this information. Your 
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personal details will be converted into a code and stored on a secure computer located 
at Newcastle University. If we publish any research, we ask your permission to use direct 
quotes; this will not identify you in any way. Research records and data may also be 
inspected by regulatory bodies for audit purposes. This is a normal part of research and 
it is just to make sure that we are doing everything right. 
Are there any benefits to taking part in the extension? 
We cannot promise that taking part in study and the extension to the study will help you 
personally, but we hope that the information we get from this study as a whole will help 
to improve the way we discuss and support patients who will be faced with making 
reproductive decisions in the future.  
Are there any disadvantages to taking part in the extension? 
Just like your first interview, giving up your time to take part in this project has to be 
considered. We also recognise that the topic of this repeat interview is sensitive and 
may cause some distress. Taking part in the study extension is voluntary and you do not 
have to take part if you feel that you would be too upset discussing this topic. We will do 
our best to make you feel as comfortable as possible. If you feel on the day of the 
planned interview that you would like to rearrange, this would not be a problem. If you 
feel before or during your interview you would like to take some time out, or stop the 
interview it is completely acceptable to do so. 
We would like to support you as much as possible. Approximately 7-10 days following 
your interview the research team will contact you to make sure that you have not been 
left feeling upset or distressed. If you feel that after taking part in the interview (either 
immediately or in the weeks/months following) you would like to discuss things further, 
the research team can make a referral to your doctor or other appropriate NHS services 
and can also provide you with details of counselling services. This will only be done with 
your consent to do so. The only time we will disclose your personal information without 
your prior consent would be   if during the interview you disclose any information that 
could be deemed related to your safety or safety of others. We would then contact your 
health care team or other appropriate services.  
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What happens at the end of the research study? 
We have been interviewing women from each group since August 2014 with a pause in 
conducting interviews to analyse data. At the end of the study (including the 
extension/repeated interviews), we will be able to inform you of the outcomes of the 
study in a newsletter. You will not be made identifiable in the newsletter or any 
published work.  You will be welcome to have a copy of the results once they are 
published. 
Who has reviewed this project? 
All research conducted within the NHS has to be reviewed by an ethics committee to 
make sure we are not doing anything harmful to you or your personal information in this 
project. This research and the extension has been reviewed by NRES Committee xxxx 
xxxx who have decided they are happy for us to go ahead with the study. 
Who has funded this project? 
The project is being funded by the Medical Research Council who has allocated funds to 
Newcastle team for research into Mitochondrial Diseases. None of the team will receive 
any direct (or indirect) payment for you entering this study. 
What if I have any concerns?  
If you have any concerns or other questions about this study or the way it has been 
carried out, you can contact either Julia Maddison on 0191 XXX XXXX (xxxx 
xxxxx@ncl.ac.uk) or the Principal Investigator XXXX XXXX on 0191 XXX XXXXYou may also 
contact the xxx xxxxx Patient Advice Liaison Services department on telephone XXXX 
XXXXX 
If you feel that you have been treated unfairly throughout the research, or would like to 
make comment about the conduct of any aspect of this research, please contact the 
xxxxx xxxxx NHS Foundation Trust complaints department on 0191 XXX XXXX 
 
Thank you for reading this information sheet  
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Your partner, family member or close friend has been invited to take part in the 
extension to a research study that they participated in the past. If you choose to 
accompany them it is important for you for to understand why the extension to the 
research is being done and what it will involve. Please read the following information 
and discuss it with your partner, family member or close friend. If there is anything that 
is not clear, or if you have any further questions, please ask us (our contact details are 
printed on page 4).  
Why are we asking you to take part? 
Your partner, family member or close friend has been invited to take part in the 
extension to a previous research project that they took part in the past. They were 
invited to take part because they have mitochondrial disease or carry a mitochondrial 
DNA mutation and had expressed an interest in discussing their reproductive options for 
the future with their doctor. 
Do I have to participate? 
It is up to you to decide whether you want to participate in the extension study. If you 
agree to take part, we will then ask you to complete a consent form. You are free to 
Reproductive Decision Making  
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withdraw at any time, without giving any reason. This would not affect the standard of 
care your partner, family member or close friend receives. 
What is the purpose of this study? 
Approximately 1 in 3,500 women are affected by a mitochondrial DNA mutation, many 
of whom are of childbearing age. The study aims to look at how women diagnosed with 
mitochondrial disease, or carrying a mitochondrial DNA mutation have made 
reproductive decisions in the past and how they make decisions now. Reproductive 
decisions to some women may mean, deciding to try to become pregnant or deciding 
not to become pregnant. Little is known about how patients with mitochondrial disease 
make these important and complex decisions.  
We have been conducting interviews with two groups of women, women who have 
made reproductive decision/decisions in the past 21 years (Retrospective Group) and 
those women who are making decisions now or in the future (Current/ Prospective 
Group).  
We are interested in learning about topics: 
• what is important to them at this time, 
• what information they have received or have not received at this time that 
would help 
       them to make a decision 
•  and how they feel about new reproductive techniques.  
 
This study is part of a PhD project for Julia Maddison, who is part of the Mitochondrial 
Research Group; results from this study will form part of her thesis.  
What is the purpose of the extension to the study? 
A number of months or even years have elapsed since your partner/family member or 
close friend were originally interviewed. Since the study was originally approved, 
changes in regulation have permitted the new reproductive technique Mitochondrial 
Donation to be considered by patients as a reproductive option. We have also been able 
to look at the data collected in interviews and we would like to gather more data on 
issues raised by patients. We would also like to see if patient experiences or opinions on 
reproduction options are the same or different since they were first interviewed. 
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What happens if I agree to take part? 
The study will involve a one to one interview with the researcher and your partner, 
family member or close friend. Interviews will last between 30-45 minutes; they can be 
paused or stopped at any time. It they prefer, a telephone interview can be arranged. 
There will be some areas we are keen to discuss but your partner, family member or 
close friend is free to talk about anything they think is important about the decisions 
they are making now, in the future or may have made since their last interview. We will 
not be asking questions to you directly, but if you want to add anything that is fine  
If your partner, family member or close friend is interested in taking part in the 
extension to this study, a member of the research team will contact them to arrange a 
time and date for their interview; if you choose to attend the interview both yourself 
and your partner, family member or close friend will be asked to sign a consent form 
before the interview starts. If your partner, family member or close friend takes part in a 
telephone interview verbal consent with be taken from you both over the phone and 
documented.  
The interview will take place at a time convenient to your partner, family member or 
close friend, usually coinciding with their planned clinic visit. If this is not possible we will 
make an appointment at a time most convenient for them to attend the Clinical 
Research Facility at the xxx xxxxx or the researcher will visit them at their home or a 
location that they feel the most comfortable. If your partner, family member or close 
friend wishes to take part over the telephone, the researcher will ring them at a time 
most convenient to them. Any travel / parking costs for helping with this research will be 
refunded. 
Taking part in this study is voluntary; yourself and your partner, family member or close 
friend can decline to take part at any time. Not taking part in this study will not affect 
the standard of care your partner, family member or close friend will receive. If your 
partner, family member or close friend decide after the interview has taken place that 
they would like their collected data to be destroyed and not used, this will be done at 
their request. This is also the case if you wish that your collected data to be destroyed (if 
you choose to add anything to the interview).  
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Will information about me be kept confidential? 
All information we receive from your partner, family member or close friend and 
yourself will be treated confidentially. Your personal details and replies will be kept safe 
and secure. The interview will be audio-recorded so that the researcher can transcribe 
the information accurately. The audio-recording will be destroyed six months after we 
have finished analysing and writing up the data. Written information will be kept secure 
in a locked office and only members of XXXX XXXX team will be given permission to look 
at this information. Your personal details will be converted into a code and stored on a 
secure computer located at Newcastle University. If we publish any research, we ask 
your permission to use direct quotes; this will not identify you in any way.  
Research records and data may also be inspected by regulatory bodies for audit 
purposes. This is a normal part of research and it is just to make sure that we are doing 
everything right. 
Are there any benefits to taking part in the extension? 
We cannot promise the study and the extension will help you or your partner, family 
member or close friend personally, but we hope that the information we get from this 
study will help to improve the way we discuss and support patients who will be faced 
with making reproductive decisions in the future.  
Are there any disadvantages to taking part? 
Just like in their first interview, giving up your time to take part in this project has to be 
considered. We also recognise that the topic of this repeat interview is sensitive and 
may cause some distress. Taking part in the study extension is voluntary and yourself 
and your partner, family member or close friend do not have to take part if you feel that 
it would be too upset discussing this topic. We will do our best to make yourself and 
your partner, family member or close friend feel as comfortable as possible. If your 
partner, family member or close friend feel on the day of the planned interview that 
they would like to rearrange, this would not be a problem. If they feel, before or during 
the interview, they would like to take some time out or stop the interview that is 
completely acceptable to do so. 
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We would like to support your partner, family member or close friend as much as 
possible. Approximately 7-10 days following their interview the research team will 
contact them to make sure that they have not been left feeling upset or distressed. If 
they feel that after taking part in the interview (either immediately or in the 
weeks/months following) they would like to discuss things further, the research team 
can make a referral to their doctor or other appropriate NHS services and can also 
provide them with details of counselling services. This will only be done with their 
consent to do so.  
The only time we will disclose personal information without your partner, family 
member or close friend or your prior consent would be if during the interview any 
information is disclosed that could be deemed related to the safety of you both or the 
safety of others. We would then contact their health care team or other appropriate 
services. 
What happens at the end of the research study? 
We have been interviewing women from each group since August 2014 with a pause in 
conducting interviews to analyse data. At the end of the study (including the 
extension/repeated interviews), we will be able to inform your partner, family member 
or close friend of the outcomes of the study in a newsletter. Your partner, family 
member or close friend and yourself will not be made identifiable in the newsletter or 
any published work.  You will be welcome to have a copy of the results once they are 
published. 
Who has reviewed this project? 
All research conducted within the NHS has to be reviewed by an ethics committee to 
make sure we are not doing anything harmful to you or your personal information in this 
project. This research and extension has been reviewed by NRES Committee xxx xxxx 
who have decided they are happy for us to go ahead with the study. 
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Who has funded this project? 
The project is being funded by the Medical Research Council who has allocated funds to 
Newcastle team for research into Mitochondrial Diseases. None of the research team 
will receive any direct (or indirect) payment for entering your partner, family member or 
close friend or yourself into this study.  
What if I have any concerns?  
If you have any concerns or other questions about this study or the way it has been 
carried out, you can contact either Julia Maddison on 0191 XXX XXXX (xxxx xxxxx 
@ncl.ac.uk) or the Principal Investigator XXXX XXXX on 0191 XXX XXXX 
You may also contact the xxxx xxxxx  Patient Advice Liaison Services department on 
telephone xxx xxxx  If you feel that you have been treated unfairly throughout the 
research, or would like to make comment about the conduct of any aspect of this 
research, please contact the xxxx xxxx  NHS Foundation Trust complaints department on 
0191 XXX XXXX . 
Thank you for reading this information sheet 
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A.3 Participant and Attendee Informed Consent Forms  
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To be on Hospital Headed Paper 
REC reference number: 14/NE/0144 
Committee: NRES Committee XXXX XXXXX  
Chief Investigator: XXXX XXXX Mitochondrial Research Group, Newcastle University, NE2 4HH 
Sponsor: Newcastle Upon Tyne Hospitals NHS Foundation Trust  
 
 
 
 
Please write your initials in the box 
 
1. I confirm that I have read and understand the information sheet 
dated ……………………… (version …………..) for the above study.  I have had the 
opportunity to consider the information, ask questions and have had these 
answered satisfactorily. 
 
 
2. I understand that my participation is voluntary and that I am free to withdraw at 
any time, without giving any reason, without my medical care or legal rights 
being affected.  
 
 
3. By signing this document, I understand that I give consent for the study interview 
to be audio recorded and transcribed. 
 
 
 
 
4.  I understand that direct quotations from my interview may be used in published 
results, but that I will remain non identifiable.  
 
 
Reproductive Decision Making  
Patient Consent Form  Version 1 28/03/2014 
     
 
Reproductive Decision Making in Mitochondrial Patients: A Qualitative Investigation of 
Women’s Experience  
Consent Form  
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5. I understand that relevant sections of my medical notes and data collected 
during the study may be looked at by individuals from: the study team; the 
Sponsor (Newcastle Upon Tyne Hospitals NHS Foundation Trust) or their 
representatives; and from regulatory authorities, where it’s relevant to taking 
part in this research. I give permission for these individuals to have access to the 
records and I understand that the records will only be reviewed for information 
related to my participation in the study.  
 
 
 
 
6. I understand that any information will be stored confidentially and identified by 
code rather than by name.   
 
 
 
 
7. I understand that the results from this research will not have any direct 
implications for me or my family.   
 
 
8. I agree to participate in this research. 
 
 
 
    
   Name of Patient         Date         Signature 
 
  
   Name of Researcher         Date         Signature 
 
 Original to be kept in medical notes;  1 copy for the researcher;  1 copy to be given 
to the patient  
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To be on Hospital Headed Paper 
REC reference number: 14/NE/0144 
Committee: NRES Committee XXXX XXXXX  
Chief Investigator: XXXX XXXX Mitochondrial Research Group, Newcastle University, NE2 4HH 
Sponsor: Newcastle Upon Tyne Hospitals NHS Foundation Trust  
 
 
 
 
 
Please write your initials in the box 
 
1. I confirm that I have read and understand the information sheet 
dated ……………………… (version …………..) for the above study.  I have had the 
opportunity to consider the information, ask questions and have had these 
answered satisfactorily. 
 
 
2. I understand that my participation is voluntary and that I am free to withdraw at 
any time, without giving any reason, without my medical care or legal rights 
being affected.  
 
 
3. By signing this document, I understand that I give consent for the study interview 
to be audio recorded and transcribed. 
 
Reproductive Decision Making  
Partner/Family Member/Close Friend Consent Form Version 1 28/03/2014 
  
    
 
Reproductive Decision Making in Mitochondrial Patients: A Qualitative Investigation of 
Women’s Experience  
Partner/ Family Member / Close Friend  
Consent Form  
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4.  I understand that direct quotations from my interview may be used in published 
results, but that I will remain non identifiable.  
 
 
 
5. I understand that relevant sections of data collected during the study may be 
looked at by individuals from: the study team; the Sponsor (Newcastle Upon 
Tyne Hospitals NHS Foundation Trust) or their representatives; and from 
regulatory authorities, where it’s relevant to taking part in this research. I give 
permission for these individuals to have access to the records and I understand 
that the records will only be reviewed for information related to my participation 
in the study.  
 
 
 
6. I understand that any information will be stored confidentially and identified by 
code rather than by name.   
 
 
 
7. I understand that the results from this research will not have any direct 
implications for me or my family.   
 
 
8. I agree to participate in this research. 
 
 
 
    
   Name of Participant         Date         Signature 
 
    
   Name of Researcher         Date         Signature 
 
 Original to be kept in medical notes of patient interviewed;  1 copy for the 
researcher;  1 copy to be given to the participant 
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Appendix B Interview Documentation   
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B.1 Interview Topic Guides (Retrospective and Current & Prospective 
Groups) 
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Semi Scheduled Interview Schedule 
Reproductive Decision Making in Mitochondrial Patients: A Qualitative Investigation of 
Women’s Experience  
Women who may be faced with a decision 
Note: The interview schedule is developmental.   The questions will need to be 
tailored to the specific answers of each interviewee.   It is designed to facilitate 
the addition of emerging topics and so is subject to change throughout the 
lifetime of the study  
*Thanks will be given to participants before the interview commences, the 
purpose, intended duration and the voluntary nature of the study will be 
reiterated, along with the option to suspend or terminate the interview at any time. 
A general information gathering set of questions will be asked at the start 
Can you tell me a bit about yourself? 
• Age, work life, education, religion relationship status etcetera.  
• Do you know if you have a nuclear or mitochondrial mutation?  
 
First learning about risks: 
Do you remember the time when you were first told about the potential risk of 
passing on your condition to a child?  
• Was this by a doctor, nurse or genetic counsellor? 
• Was this person someone you had regular contact with? 
• Can you remember what it was that they told you? 
• How did if feel at the time? 
 
 
Women who may be faced with a decision Interview Schedule    Version 1 28.03.2014 
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Talking about risks with others: 
Did you talk about these risks with your family/ close friends?  
• What members of family/close friends did you discuss this with?  
• How did they take the news?  
• Was there anyone close who you did not tell?  
• Why was this?  
Do you think the people you chose to tell or not to tell could possibly influence any 
decision you are facing currently or in the future? 
Impact of diagnosis 
How do you feel your diagnosis has affected your life and reproductive decisions?  
• How important is becoming pregnant to you at this time?   
o If relevant, how important is becoming pregnant to your partner? 
• What are your thoughts about becoming or not becoming pregnant? 
• What are your reasons for becoming pregnant or reasons for not becoming 
pregnant? 
Family History: 
Does anyone else in your family suffer from mitochondrial disease?  
If relevant, what was your mother’s or siblings (or other) experiences of pregnancy?  
• Did you discuss their experiences at any great length? 
• Do you think their experiences have affected you and the decisions you are 
facing?  
Relationships with healthcare team: 
Do you feel that the risk of complications of pregnancy with mitochondrial disease have 
been explained to you enough?  
• Have you had enough on-going support from your health care professional at 
this time? 
• What support have they offered? 
• What has worked well?  
• Is there anything you feel could be said or done differently?  
• Do you feel you have a good relationship with your doctors (or others) 
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Do you feel that you are able to play an active role in your current decision-making or 
will do in the future?  
Information: 
Has information given to you so far impacted on any decision you may make to 
become or not to become pregnant?   
• Have you had enough information each stage so far?  
• What sort of information do you think would be helpful to you at this time?   
• Would any specific format, leaflets, information days, someone to 
talk to   face-to-face help?  
Have things like the media, social media and the internet had any influence?  
New techniques: 
Do you know anything about the new techniques available to women with 
mitochondrial disease?  
• How did you learn about these techniques? 
• How do you feel about these techniques?  
• Do you feel that these techniques may be of any benefit to you? 
• Would you choose any of these techniques if they had been 
available/ suitable to you? 
Closing questions: 
Finally, we need to understand whether the kinds of questions we are asking actually 
relate to the issues that you think are important? 
• Are we asking the right questions? 
• Did these questions allow you to talk about what was important for you? 
• Is there anything else you would like to say? 
Thank you for taking part 
Remind them that you will be contacting them in 7-10 days 
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Semi Scheduled Interview Schedule 
Reproductive Decision Making in Mitochondrial Patients: A qualitative investigation of 
women’s experiences 
Patient Information Sheet for  
Women who have made a decision  
Note: The interview schedule is developmental.   The questions will need to be tailored 
to the specific answers of each interviewee.   It is designed to facilitate the addition of 
emerging topics and so is subject to change throughout the lifetime of the study  
*Thanks will be given to participants before the interview commences, the purpose, 
intended duration and the voluntary nature of the study will be reiterated, along with 
the option to suspend or terminate the interview at any time. A general information 
gathering set of questions will be asked at the start 
Can you tell me a bit about yourself? 
• Age, work life, education, religion relationship status etcetera.  
• Do you know if you have a nuclear or mitochondrial mutation?  
 
First learning about risks: 
Do you remember where you were when you were told about the potential risk of 
passing on your condition to a child?  
• Were you told by a doctor, nurse or genetic counsellor?  
• Was this person someone you have had a regular contact with?  
• Can you remember exactly what it was that they told you?  
• How did it feel at the time? 
Talking about risks with others: 
Did you talk about these results with your family/ close friends?  
• What members of family/ close friends did you discuss this with?  
• How did they take the news?  
Women who have made a decision Interview Schedule    Version 1 28.03.2014 
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• Was there anyone close you did not tell?  
• Why was this?  
Do you think the people you chose to tell or not to tell influenced your decision? 
Impact of diagnosis:  
How do you feel your diagnosis has affected your life and reproductive 
decisions? 
• How important was becoming pregnant to you when you were making your 
reproductive choices?  
o If relevant, how important is becoming pregnant to your partner? 
• What were your thoughts about becoming or not becoming pregnant? 
• What was your reason for becoming pregnant or reasons for not becoming 
pregnant?  
Family History: 
Does anyone else in your family suffer from mitochondrial disease?  
 If relevant, what was your mother’s or siblings (or other) experiences of 
pregnancy?  
• Did you discuss their experiences at any great length?  
• Do you think their experiences affected you and your decisions about 
pregnancy? (All)  
Relationships with healthcare team: 
Do you feel that the risk of complications of pregnancy with mitochondrial disease 
was explained to you enough?  
• Have you had enough on-going support from health care professional at 
this time? 
• What support have they offered? 
• What has worked well? 
• Is there anything you feel could be said or done differently? 
• Do you feel you have a good relationship with your doctors (or others) 
Do you feel that you are able to play an active role in your decision-making or will 
do in the future?  
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Information:  
Did the information given to you at the time impact any decision you made to 
become or not to become pregnant?  
• Did you feel you had enough information at each stage? 
• What sort of information do you think would have been helpful to you at 
that time? 
• Would any specific format, leaflets, information days, someone to talk to 
 face to face helped? 
Have things like the media, social media and the internet had any influences? 
New techniques: 
Do you know anything about the new techniques available to women with 
mitochondrial disease?  
• How did you learn about these techniques? 
• How do you feel about these techniques? 
• Do you feel that these techniques may have been of any benefit to you? 
• Would you choose any of these techniques if they had been available/ 
suitable for you? 
Closing Question  
Finally, we need to understand whether the kinds of questions we are asking 
relate to the issue that you think are important? 
• Are we asking the right questions? 
• Did these questions allow you to talk about what was important for you? 
• Is there anything else you would like to say? 
Thank you for taking part 
Remind them that you will be contacting them in 7-10 days 
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B.2 Interview Aid (Version 1 and 2)  
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Reproductive Decision Making – Topic Guide /Interview Aid 
 
 
1. Genetic Counselling  
Healthcare professionals who have been specifically trained in human genetics 
provide information, advice and support to individuals and families. 
 
2. Conception without medical intervention   
 
 
3. Adoption  
 
 
4. Surrogacy and Ovum Donation  
 
Surrogacy – When a woman carries a baby for a woman who is unable carry a 
child. Using the woman’s egg or an egg donated by another women  
Ovum Donation- Using an egg donated by another woman (known or unknown) 
for IVF treatment  
 
 
 
Interview Aid Reproductive Decision Making        Version 1 
1208.02.2015 
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5. Prenatal Diagnosis Testing  
There are two commonly offered prenatal tests. They can assess the level of 
risk to the unborn baby. 
Chorionic villus sampling -involves removing and testing a sample of cells 
from the placenta (the organ linking the mother’s blood supply with her 
unborn baby’s) 
Amniocentesis – involves removing and testing a sample of the amniotic 
fluid that surrounds the unborn baby in the womb. 
 
6. Pre-Implantation Genetic Diagnosis (PGD) 
 
Involves checking the genes and/or chromosomes of embryos created 
through IVF. After a discussion with the clinical team and the family the 
embryo that is least affected can then be transferred to the womb to allow it 
to develop. 
 
7. Mitochondrial Donation  
 
Faulty mitochondrial DNA from a mother’s egg can be replaced with healthy 
mitochondrial DNA from a donor egg 
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Reproductive Decision Making – Topic Guide /Interview Aid 
 
 
1. Genetic Counselling  
Healthcare professionals who have been specifically trained in human genetics 
provide information, advice and support to individuals and families. 
 
2. Conception without medical intervention   
 
3. Adoption  
 
4. Surrogacy and Ovum Donation  
 
Surrogacy – When a woman carries a baby for a woman who is unable carry a 
child. Using the woman’s egg or an egg donated by another women  
Ovum Donation- Using an egg donated by another woman (known or unknown) 
for IVF treatment  
 
 
 
 
 
 
Interview Aid Reproductive Decision Making        Version 2 
208.02.2015 
 
   
 
 336 
 
5. Prenatal Diagnosis Testing  
There are two commonly offered prenatal tests. They can assess the level 
of risk to the unborn baby. 
Chorionic Villus Sampling -involves removing and testing a sample of 
cells from the placenta (the organ linking the mother’s blood supply with her 
unborn baby’s) 
Amniocentesis – involves removing and testing a sample of the amniotic 
fluid that surrounds the unborn baby in the womb. 
 
6. Pre-Implantation Genetic Diagnosis (PGD) 
Involves checking the genes and/or chromosomes of embryos created 
through IVF. After a discussion with the clinical team and the family the 
embryo that is least affected can then be transferred to the womb to allow it 
to develop. 
 
7. Mitochondrial Donation  
Faulty mitochondrial DNA from a mother’s egg can be replaced with healthy 
mitochondrial DNA from a donor egg 
 
8. Decision not to have a family  
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Appendix C – Conference Proceedings and Presentations 
 
• Invited Speaker  
Tonge,J. (2017). ‘The Implication of Clinical Relationships in Making 
Reproductive Decisions’. MitoSoc Symposium 2017. London, May 5th  
 
• Selected Abstract 
Tonge,J. (2016). ‘Making Sense’ of Reproductive Options: A Qualitative 
Examination of Reproductive Decision Making in Maternally Inherited 
Mitochondrial Disease’. British Sociological Association Medical Sociology 48th 
Annual Conference, Aston University, September 9th 
 
Tonge,J. (2016). ‘Exploring Factors Influencing Reproductive Decision Making in 
Women with Maternally Inherited Mitochondrial Disease’. British Sociological 
Association Annual Human Reproduction Conference 2016. De Montfort 
University, June 10th 
 
• Poster Presentations  
Tonge,J. (2017). ‘Making Sense’ of Reproductive Options: A Qualitative 
Examination of Reproductive Decision Making in Maternally Inherited 
Mitochondrial Disease’. Neuromuscular Translational Research Conference 10th 
Annual Conference, University College London, March 22nd-23rd  
 
Tonge,J. (2016). ‘Reproductive Decision Making in Mitochondrial Disease. A 
Qualitative Examination of Women’s Experiences’. Neuromuscular Translational 
Research Conference 9th Annual Conference, Oxford University, March 22nd-23rd  
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Tonge,J. (2015). ‘Reproductive Decision Making in Mitochondrial Disease. A 
Qualitative Examination of Women’s Experiences’. Neuromuscular 
Translational Research Conference 8th Annual Conference, Newcastle 
University, March 19th-20th  
 
• Internal Presentations 
Tonge, J. (2017). ‘Making Sense’ of Reproductive Options: A Qualitative 
Examination of Reproductive Decision Making in Maternally Inherited 
Mitochondrial Disease’. Mitochondrial Research Group Journal Club, 
Newcastle University Feb 15th  
 
 Tonge, J. (2015). ‘Reproductive Decision Making in Mitochondrial Disease’. 
 Mitochondrial Research Group Journal Club, Newcastle University Nov 11th   
 
Tonge,J. (2015). ‘Reproductive Decision Making in Mitochondrial Disease. A 
Qualitative Examination of Women’s Experiences’. Institute of Neuroscience 
Postgraduate Poster Session, Newcastle University, Nov 5th  
 
Tonge, J. (2015). ‘Reproductive Decision Making in Mitochondrial Disease. 
A Qualitative Examination of Women’s Experiences’.  Applied Qualitative 
Health Research Session, Newcastle University, March 11th  
 
Tonge, J. (2015). ‘Reproductive Decision Making in Mitochondrial Disease’. 
Mitochondrial Research Group Journal Club, Newcastle University, Feb 
2015   
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